0001144204-12-067267.txt : 20121210 0001144204-12-067267.hdr.sgml : 20121210 20121210172026 ACCESSION NUMBER: 0001144204-12-067267 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20121031 FILED AS OF DATE: 20121210 DATE AS OF CHANGE: 20121210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-25169 FILM NUMBER: 121254181 BUSINESS ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CANADA STATE: A1 ZIP: M5J 2G2 BUSINESS PHONE: 4163642551 MAIL ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CA STATE: A1 ZIP: M5J 2G2 10-Q 1 v328917_10q.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2012

¨ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from _________________ to ________________

COMMISSION FILE NUMBER: 0-25169

GENEREX BIOTECHNOLOGY CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

98-0178636

(State or other jurisdiction of

incorporation or organization)

(IRS Employer Identification No.)

555 RICHMOND STREET WEST, SUITE 604

TORONTO, ONTARIO

CANADA M5V 3B1

(Address of principal executive offices)

(416) 364-2551

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨ Accelerated filer x

Non-accelerated filer ¨ Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes x No

The number of outstanding shares of the registrant's common stock, par value $.001, was 372,059,685 as of December 7, 2012.

GENEREX BIOTECHNOLOGY CORPORATION

INDEX

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)

Consolidated Balance Sheets - October 31, 2012 (unaudited) and July 31, 2012	1

Consolidated Statements of Operations — For the three-month periods ended October 31, 2012 and 2011, and cumulative from November 2, 1995 to October 31, 2012 (unaudited)	2

Consolidated Statements of Cash Flows — For the three-month periods ended October 31, 2012 and 2011, and cumulative from November 2, 1995 to October 31, 2012 (unaudited)	3

Notes to Consolidated Financial Statements (unaudited)	5

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3. Quantitative and Qualitative Disclosures About Market Risk	29

Item 4. Controls and Procedures	30

PART II: OTHER INFORMATION

Item 1. Legal Proceedings	31

Item 1A. Risk Factors	31

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	34

Item 3. Defaults Upon Senior Securities	34

[Item 4. Removed and Reserved.]	-

Item 5. Other Information	34

Item 6. Exhibits	34

Signatures	34

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED BALANCE SHEETS

	October 31, 2012			July 31, 2012
	(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	37,031		$	246,309
Other current assets		116,256			200,552
Total Current Assets		153,287			446,861

Property and Equipment, Net		118,776			704,678
Assets Held for Investment, Net		852,832			858,377
Patents, Net		2,561,090			2,634,458

TOTAL ASSETS	$	3,685,985		$	4,644,374


LIABILITIES AND STOCKHOLDERS’ DEFICIENCY
Current Liabilities:
Accounts payable and accrued expenses (Note 5)	$	7,777,732		$	7,015,652
Deferred revenue		242,356			263,125
Current maturities of long-term debt		156,596			1,222,746
Total Current Liabilities		8,176,684			8,501,523

Long-Term Debt, Net		—			441,415

Derivative Warrant Liability (Note 10)		4,347,710			4,081,627

Total Liabilities		12,524,394			13,024,565

Commitments and Contingencies (Notes 6 and 7)

Stockholders’ Deficiency (Note 9):
Series A 9% Convertible Preferred Stock, $1,000 par value; authorized 5,500 shares at October 31, 2012 and July 31, 2012, respectively ; 0 shares issued and outstanding at October 31, 2012 and July 31, 2012, respectively		—			—
Series B 9% Convertible Preferred Stock, $1,000 par value; authorized 2,000 shares at October 31, 2012 and July 31, 2012, respectively ; 792 and 1,490 shares issued and outstanding at October 31, 2012 and July 31, 2012, respectively		—			—
Series C 9% Convertible Preferred Stock, $1,000 par value; authorized 750 and 0 shares at October 31, 2012 and July 31, 2012, respectively ; 750 and 0 shares issued and outstanding at October 31, 2012 and July 31, 2012, respectively		—			—
Common stock, $.001 par value; authorized 750,000,000 shares at October 31, 2012 and July 31, 2012, respectively; 370,260,904 and 354,161,297 shares issued and outstanding at October 31, 2012 and July 31, 2012, respectively		370,261			354,161
Additional paid-in capital		348,396,471			348,099,813
Deficit accumulated during the development stage		(358,370,276	)		(357,611,780	)
Accumulated other comprehensive income		765,135			777,615
Total Stockholders’ Deficiency		(8,838,409	)		(8,380,191	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	$	3,685,985		$	4,644,374

The Notes to the Consolidated Financial Statements are an integral part of these statements.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF OPERATIONS

							Cumulative From
	For the Three Months Ended October 31,						November 2, 1995 (Date of Inception)
	2012			2011			to October 31, 2012
	(Unaudited)			(Unaudited)			(Unaudited)

Revenues, net	$	—		$	9,931		$	5,110,784

Cost of Goods Sold		—			3,262			1,620,375

Gross profit		—			6,669			3,490,409

Operating Expenses:
Research and development		653,395			1,979,502			132,629,359
Research and development - related party		—			—			220,218
Selling and marketing		—			75,661			9,333,214
General and administrative		1,286,636			1,421,284			149,088,792
General and administrative - related party		—			—			314,328
Total Operating Expenses		1,940,031			3,476,447			291,585,911

Operating Loss		(1,940,031	)		(3,469,778	)		(288,095,502	)

Other Income (Expense):
Miscellaneous income		—			—			686,303
Income from assets held for investment, net (Note 11)		1,042,868			712,075			5,377,125
Interest income		225			519			7,782,118
Interest expense		(117,975	)		(34,921	)		(69,126,657	)
Change in fair value of derivative liabilities (Note 10)		358,714			3,128,459			(357,263	)(1)
Loss on extinguishment of debt		—			—			(14,134,068	)

Net Income/(Loss) Before Undernoted		(656,199	)		336,354			(357,867,944	)

Minority Interest Share of Loss		—			—			3,038,185

Net Income/(Loss)		(656,199	)		336,354			(354,829,759	)

Preferred Stock Dividend (Note 9)		102,297			—			3,540,517

Net Income/(Loss) Available to Common Stockholders	$	(758,496	)	$	336,354		$	(358,370,276	)

Net Income/(Loss) Per Common Share (Note 8)
Basic	$	(.002	)	$	.001
Diluted	$	(.002	)	$	.001

Shares used in computing earnings/(loss) per share (Note 8)
Basic		364,310,359			313,342,608
Diluted		364,310,359			313,348,032

(1) - includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to October 31, 2012" column. See Note 10 - Derivative Liabilities.

The Notes to the Consolidated Financial Statements are an integral part of these statements.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF CASH FLOWS

							Cumulative From
	For the Three Months						November 2, 1995
	Ended October 31,						(Date of Inception)
	2012			2011			to October 31, 2012
	(Unaudited)			(Unaudited)			(Unaudited)
Cash Flows From Operating Activities:
Net income/(loss)	$	(656,199	)	$	336,354		$	(354,829,759	)
Adjustments to reconcile net income/(loss) to net cash used in operating activities:
Depreciation and amortization		117,027			163,703			10,025,567
Minority interest share of loss		—			—			(3,038,185	)
Reduction of notes receivable - common stock in exchange for services rendered		—			—			423,882
Write-off of uncollectible notes receivable - common stock		—			—			391,103
Write-off of deferred offering costs		—			—			3,406,196
Write-off of abandoned patents		—			88,582			1,353,976
(Gain)/Loss on disposal of property and equipment		(994,125	)		(639,680	)		(2,985,275	)
Loss on extinguishment of debt		—			—			14,134,069
Common stock issued as employee compensation		—			11,783			4,011,938
Amortization of options and option modifications as stock compensation		9,993			22,690			3,421,219
Common stock issued for services rendered		114,250			48,195			14,621,529
Amortization of prepaid services in conjunction with common stock issuance		—			—			138,375
Non-cash compensation expense		—			—			45,390
Stock options and warrants issued for services rendered		—			—			7,956,723
Issuance of warrants as additional exercise right inducement		—			—			21,437,909
Preferred stock issued for services rendered		—			—			100
Treasury stock redeemed for non-performance of services		—			—			(138,000	)
Amortization of deferred debt issuance costs and loan origination fees		—			—			2,405,629
Amortization of discount on convertible debentures		—			—			38,345,592
Common stock issued for interest on convertible debentures & preferred stock		188,514			212,490			1,431,218
Interest on short-term advance		—			—			22,190
Founders’ shares transferred for services rendered		—			—			353,506
Fees in connection with refinancing of debt		—			—			113,274
Warrant repricing costs		—			—			3,198,604
Change in fair value of derivative liabilities		(358,714	)		(3,128,459	)		357,263	(1)
Changes in operating assets and liabilities (excluding the effects of acquisition):
Accounts receivable		—			6,774			(15,047	)
Miscellaneous receivables		—			—			43,812
Inventory		—			216,011			(20,091	)
Other current assets		85,452			28,949			(97,496	)
Accounts payable and accrued expenses		559,973			(13,908	)		15,583,913
Deferred revenue		(20,769	)		(6,471	)		236,563
Other, net		—			—			110,317
Net Cash Used in Operating Activities		(954,598	)		(2,652,987	)		(217,553,996	)

Cash Flows From Investing Activities:
Purchase of property and equipment		—			(2,416	)		(4,809,439	)
Proceeds from sale of property and equipment		1,579,189			1,669,115			6,532,514
Costs incurred for patents		(23,475	)		(39,621	)		(2,863,521	)
Change in restricted cash		—			—			512,539
Proceeds from maturity of short term investments		—			—			195,242,918
Purchases of short-term investments		—			—			(195,242,918	)
Cash received in conjunction with merger		—			—			82,232
Advances to Antigen Express, Inc.		—			—			(32,000	)
Increase in officers’ loans receivable		—			—			(1,126,157	)
Change in deposits		—			—			(652,071	)
Change in notes receivable - common stock		—			—			(91,103	)
Change in due from related parties		—			—			(2,222,390	)
Other, net		—			—			89,683
Net Cash Provided by/(Used in) Investing Activities		1,555,714			1,627,078			(4,579,713	)

The Notes to the Consolidated Financial Statements are an integral part of these statements.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF CASH FLOWS

							Cumulative From
	For the Three Months						November 2, 1995
	Ended October 31,						(Date of Inception)
	2012			2011			to October 31, 2012
	(Unaudited)			(Unaudited)			(Unaudited)

Cash Flows From Financing Activities:
Proceeds from short-term advance		—			—			325,179
Repayment of short-term advance		—			—			(347,369	)
Proceeds from issuance of long-term debt		—			—			5,567,297
Repayment of long-term debt		(1,534,577	)		(684,673	)		(8,597,276	)
Repayment of obligations under capital lease		—			—			(83,002	)
Change in due to related parties		—			—			154,541
Proceeds from exercise of warrants		—			—			45,728,281
Proceeds from exercise of stock options		—			—			5,003,793
Proceeds from minority interest investment		—			—			3,038,185
Proceeds from issuance of preferred stock		725,000			—			17,030,000
Redemption of SVR preferred stock		—			—			(100	)
Proceeds from issuance of convertible debentures, net		—			—			40,704,930
Payment of costs associated with convertible debentures		—			—			(722,750	)
Repayments of convertible debentures		—			—			(5,142,424	)
Purchase of treasury stock		—			—			(483,869	)
Proceeds from issuance of common stock, net		—			—			120,576,242
Purchase and retirement of common stock		—			—			(497,522	)
Net Cash (Used in)/Provided by Financing Activities		(809,577	)		(684,673	)		222,254,136

Effect of Exchange Rates on Cash		(817	)		(18,712	)		(83,396	)

Net (Decrease)/Increase in Cash and Cash Equivalents		(209,278	)		(1,729,294	)		37,031

Cash and Cash Equivalents, Beginning of Period		246,309			2,798,797			—

Cash and Cash Equivalents, End of Period	$	37,031		$	1,069,503		$	37,031

Supplemental Disclosure of Cash Flow Information:
Cash paid during the period for:
Interest	$	117,975	$	34,921
Income taxes	$	—	$	—

The Notes to the Consolidated Financial Statements are an integral part of these statements.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1 – Basis of Presentation:

The accompanying unaudited interim consolidated financial statements (“interim statements”) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by generally accepted accounting principles for complete financial statements are not included herein. The interim statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s latest Annual Report on Form 10-K. The results for the three months ended October 31, 2012 may not be indicative of the results for the entire year.

Interim statements are subject to possible adjustments in connection with the annual audit of the Company’s accounts for fiscal year 2013. In the Company’s opinion, all adjustments necessary for a fair presentation of these interim statements have been included and are of a normal and recurring nature.

The Company is a development stage company, which has a limited history of operations and limited revenue to date. This revenue has been comprised mainly of the sale of our confectionary products, although the Company has recognized $600,000 relating to upfront license fees for the signing of license and distribution agreements for Generex Oral-lyn™. Additionally, the Company has several product candidates that are in various research or early stages of pre-clinical and clinical development. There can be no assurance that the Company will be successful in obtaining regulatory clearance for the sale of existing or any future products or that any of the Company’s products will be commercially viable.

Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has experienced negative cash flows from operations since inception and has an accumulated deficit of approximately $358 million and a working capital deficiency of approximately $8 million at October 31, 2012. The Company has funded its activities to date almost exclusively from debt and equity financings, as well as the recent sales of non-essential real estate assets in fiscal 2012 and the beginning of fiscal 2013.

The Company will continue to require substantial funds to continue research and development, including pre-clinical studies and clinical trials of its product candidates, and to commence sales and marketing efforts, if the U.S. Food and Drug Administration or other regulatory approvals are obtained. Management’s plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common stock, preferred stock offerings, issuances of debt and convertible debt instruments. Management will be limited in the financing activities that the Company undertakes in the near future as the securities purchase agreements that the Company entered into on January 31, 2012 and August 8, 2012 with certain investors prohibit the Company from (i) issuing additional equity securities until 60 days after the effective date of a registration statement covering the resale of the common stock issuable upon exercise of the warrants and conversion of the preferred stock sold in those transactions and (ii) issuing additional debt or equity securities with variable conversion or exercise prices until February 1, 2013 and August 8, 2013, respectively. Management is also actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and strategic partners. Management has sold, and is also seeking further sales of, non-essential real estate assets which are classified as Assets Held for Investment to augment its cash position.

These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. There are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence. The Company’s inability to obtain required funding in the near future or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan, its liquidity, financial condition and business prospects will be materially and adversely affected, and the Company may have to cease operations.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 2 – Effects of Recent Accounting Pronouncements:

Recently Adopted Accounting Pronouncements

In May 2011, the FASB issued further guidance on fair value measurements and disclosures which requires the categorization by level for items that are only required to be disclosed at fair value and information about transfers between Level 1 and Level 2. In addition, the update provides guidance on measuring the fair value of financial instruments managed within a portfolio and the application of premiums and discounts on fair value measurements. The guidance requires additional disclosure for Level 3 measurements regarding the sensitivity of fair value to changes in unobservable inputs and any interrelationships between those inputs. The guidance was effective for the Company’s interim period ended April 30, 2012. The adoption of this new accounting guidance did not have a material impact on the Company’s consolidated financial statements.

Recently Issued Accounting Pronouncements

In June 2011, the FASB issued guidance regarding the presentation of Comprehensive Income within financial statements. The guidance will be effective for the Company’s annual fiscal period ended July 31, 2013 and subsequent interim periods. The Company does not expect the adoption of this new accounting guidance to have a material impact on its consolidated financial statements.

Note 3 – Stock-Based Compensation:

As of July 31, 2012, the Company had three stockholder-approved stock incentive plans under which shares and options exercisable for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 2,000,000 shares of common stock are reserved for issuance under the 2000 Stock Option Plan (the 2000 Plan), a total of 12,000,000 shares of common stock are reserved for issuance under the 2001 Stock Option Plan (the 2001 Plan) and 30,000,000 shares of common stock are reserved for issuance under the 2006 Stock Plan (the 2006 Plan). At October 31, 2012, there were 2,000,000, 4,124,444 and 8,354,823 shares of common stock reserved for future awards under the 2000 Plan, 2001 Plan and 2006 Plan, respectively. The Company issues new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and issuance of restricted shares.

The 2000, 2001 and 2006 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Board.

The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options which are not ISOs, i.e. “Non-Qualified Options.” The options granted by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides for restricted stock grants.

The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model which takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option.

In the case of restricted stock grants under the 2006 Plan, fair market value of the shares is established as the market price on the date of the stock grant.

The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plans for the three months ended October 31, 2012:

			Weighted
			Average
			Exercise		Aggregate
			Price		Intrinsic
	Options		Share		Value

Outstanding, August 1, 2012		10,979,634	$	0.257
Granted		—		n/a
Forfeited or expired		—		n/a
Exercised		—		n/a
Outstanding, October 31, 2012		10,979,634	$	0.257	$	277,615
Exercisable, October 31, 2012		10,893,384	$	0.254	$	277,615

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The 10,979,634 outstanding options at October 31, 2012 had a weighted average remaining contractual term of 3.92 years.

The following is a summary of the non-vested common stock options granted, vested and forfeited under the Plan for the three months ended October 31, 2012:

				Weighted Average
				Grant Date
	Options			Fair Value

Outstanding, August 1, 2012		172,500		$	0.46
Granted		—			0.00
Vested		(86,250	)		0.46
Forfeited		—			0.00
Outstanding, October 31, 2012		86,250		$	0.46

As of October 31, 2012, the Company had $37,367 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plans. That cost is expected to be recognized over a weighted-average period of 0.94 years.

Note 4 – Comprehensive Income and Loss:

Comprehensive loss, which includes net loss and the change in the foreign currency translation account, for the three months ended October 31, 2012, was $668,679. Comprehensive income, which includes net income and the change in the foreign currency translation account, for the three months ended October 31, 2011, was $275,644.

Note 5 – Accounts Payable and Accrued Expenses:

Accounts payable and accrued expenses consist of the following:

	October 31, 2012		July 31, 2012
Accounts Payable & Accruals – General and Administrative	$	3,971,015	$	3,556,160
Accounts Payable & Accruals – Research and Development		2,822,961		2,691,192
Accounts Payable & Accruals – Selling and Marketing		311,329		290,534
Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9)		416,286		402,300
Executive Compensation and Directors’ Fees Payable		256,141		75,466
Total	$	7,777,732	$	7,015,652

Note 6 – Pending Litigation:

In February 2001, a former business associate of the former Vice President of Research and Development (“VP”) of the Company and an entity known as Centrum Technologies Inc. (“CTI”) commenced an action in the Ontario Superior Court of Justice against the Company and the VP seeking, among other things, damages for alleged breaches of contract and tortious acts related to a business relationship between this former associate and the VP that ceased in July 1996. The plaintiffs’ statement of claim also seeks to enjoin the use, if any, by the Company of three patents allegedly owned by CTI. The three patents are entitled Liquid Formulations for Proteinic Pharmaceuticals, Vaccine Delivery System for Immunization, Using Biodegradable Polymer Microspheres, and Controlled Releases of Drugs or Hormones in Biodegradable Polymer Microspheres. It is the Company’s position that the buccal drug delivery technologies which are the subject matter of the Company’s research, development, and commercialization efforts, including Generex Oral-lyn™ and the RapidMist™ Diabetes Management System, do not make use of, are not derivative of, do not infringe upon, and are entirely different from the intellectual property identified in the plaintiffs’ statement of claim. On July 20, 2001, the Company filed a preliminary motion to dismiss the action of CTI as a nonexistent entity or, alternatively, to stay such action on the grounds of want of authority of such entity to commence the action. The plaintiffs brought a cross motion to amend the statement of claim to substitute Centrum Biotechnologies, Inc. (“CBI”) for CTI. CBI is a corporation of which 50 percent of the shares are owned by the former business associate and the remaining 50 percent are owned by the Company. Consequently, the shareholders of CBI are in a deadlock. The court granted the Company’s motion to dismiss the action of CTI and denied the plaintiffs’ cross motion without prejudice to the former business associate to seek leave to bring a derivative action in the name of or on behalf of CBI. The former business associate subsequently filed an application with the Ontario Superior Court of Justice for an order granting him leave to file an action in the name of and on behalf of CBI against the VP and the Company. The Company opposed the application. In September 2003, the Ontario Superior Court of Justice granted the request and issued an order giving the former business associate leave to file an action in the name of and on behalf of CBI against the VP and the Company. A statement of claim was served in July 2004. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

On May 20, 2011, Ms. Perri filed a statement of claim (subsequently amended) in the Ontario Superior Court of Justice, naming as defendants the Company and certain directors of the Company, Mr. Barratt, Ms. Masterson, Mr. McGee, and Mr. Fletcher. In this action, Ms. Perri has alleged that defendants engaged in discrimination, harassment, bad faith and infliction of mental distress in connection with the termination of her employment with the Company. Ms. Perri is seeking damages in this action in excess of $7,000,000 for, among other things, breach of contract, breach of fiduciary duty, violations of the Ontario Human Rights Code and aggravated and punitive damages. On September 20, 2011, the defendants filed a statement of defense and counterclaim, also naming Time Release Corp., Khazak Group Consulting Corp., and David Khazak, C.A. as defendants by counterclaim, and seeking damages of approximately $2.3 million in funds that the defendants allege Ms. Perri wrongly caused the Company to pay to third parties in varying amounts over several years and an accounting of certain third-party payments, plus interests and costs. The factual basis for the counterclaim involves payments made by the Company to third parties believed to be related to Ms. Perri. The Company intends to defend this action and pursue its counterclaim vigorously and is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.

On June 1, 2011, Golden Bull Estates Ltd. filed a claim (subsequently amended) in the Ontario Superior Court of Justice, naming the Company, 1097346 Ontario, Inc. and Generex Pharmaceuticals Inc. as defendants. The plaintiff, Golden Bull Estates, is controlled by Ms. Perri. The plaintiff alleges damages in the amount of $550,000 for breach of contract, $50,000 for punitive damages, plus interest and costs. The plaintiff’s claims relate to an alleged contract between the plaintiff and the Company for property management services for certain Ontario properties owned by the Company. The Company terminated the plaintiff’s property management services in April 2011. Following the close of pleadings, the Company served a motion for summary judgment. The plaintiff responded by amending its statement of claim to include a claim to the Company’s interest in certain of its real estate holdings. The plaintiff moved for leave to issue and register a Certificate of Pending Litigation in respect of this real estate. The motion was not successful in respect of any current real estate holdings of the Company. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.

In August 2011, the estate of Antonio Perri, the late father of Ms. Perri, commenced an action against Generex Pharmaceuticals, Inc., the law firm of Brans, Lehun, Baldwin LLP and William Lehun in the Ontario Superior Court of Justice claiming that the estate is entitled to the proceeds of sale (approximately $1,730,000) received by the Company on its sale of two properties to Golden Bull Estates Ltd., a company controlled by Ms. Perri. The suit alleges that no consideration was received when the Company purchased the two properties from Antonio Perri in 1998. The Company has responded to this statement of claim and intends to defend this action vigorously. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.

In December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc., in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in addition to costs and further interest. The Company responded to this statement of claim and also asserted a counterclaim in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs. On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following the spinout of its subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such spinout. Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each parties counsel until payment of the settlement amount. Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without costs will be filed with the court. If the Company fails to make the payment following completion of any post-spinout financing related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus interest of 3% per annum and costs fixed at $25,000.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company is involved in certain other legal proceedings in addition to those specifically described herein. Subject to the uncertainty inherent in all litigation, the Company does not believe at the present time that the resolution of any of these legal proceedings is likely to have a material adverse effect on the Company’s consolidated financial position, operations or cash flows.

With respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses its position both with respect to accrued liabilities and other potential exposures.

Note 7 – Commitments:

On December 7, 2009, the Company entered into a long-term agreement with sanofi-aventis Deutschland GmbH (“sanofi”). Under this agreement, sanofi-aventis will manufacture and supply recombinant human insulin to the Company in the territories specified in the agreement. Through this agreement, the Company will procure recombinant human insulin crystals for use in the production of Generex Oral-lyn™. The terms of the supply agreement require the Company to make certain minimum purchases of insulin from sanofi through the period ended December 31, 2011. To date, the Company has not met the minimum purchase commitments under this agreement. After December 31, 2011, sanofi may terminate the agreement due to the Company’s failure to meet such purchase commitments. Upon termination, the Company would be obligated to pay sanofi for all materials and components that it has acquired or ordered to manufacture insulin based on the Company’s forecasts or minimum purchase commitments, all related work-in-progress (at cost) and all finished insulin in inventory. To date, the Company has not provided forecasts to sanofi for the purchase of insulin and sanofi has not terminated the agreement.

Note 8 – Net (Loss)/Income Per Share (“EPS”):

Basic EPS and Diluted EPS for the three-month period ended October 31, 2012 have been computed by dividing the net loss available to common stockholders for the period by the weighted average shares outstanding during that period. All outstanding stock options, non-vested restricted stock, warrants and common stock underlying convertible preferred stock, representing 162,146,167 incremental shares at October 31, 2012, have been excluded from the respective computations of Diluted EPS as they are anti-dilutive, due to the loss generated during that period.

Basic EPS and Diluted EPS for the three-month period ended October 31, 2011 have been computed by dividing the net income available to common stockholders for the period by the weighted average shares outstanding and the diluted weighted average shares outstanding during that period, respectively. Per the treasury method of calculating Diluted EPS, 5,424 shares representing outstanding stock options which have an exercise price lower than the average market price for the quarter ended October 31, 2011 are included in the calculation of EPS. All remaining outstanding stock options and warrants which have out-of-the-money exercise prices and common stock underlying convertible preferred stock, representing 110,086,551 incremental shares in aggregate, have been excluded from the October 31, 2011 computation of Diluted EPS, as they are anti-dilutive.

Note 9 – Stockholders’ Deficiency:

Common Stock

During the three months ended October 31, 2012, the Company issued or committed to issue 1,366,666 shares of common stock to various consultants for services rendered in the amount of $114,250. The shares were valued at an average of $0.08 per share.

During the three months ended October 31, 2012, the Company issued 8,727,498 shares of common stock in conjunction with the conversion of 698 shares of the Series B 9% Convertible Preferred Stock and 6,005,443 shares of common stock as make-whole payments on Series B 9% Convertible Preferred Stock.

Stock option expense related to executive and employee options granted in October 2009, resulting in a charge to operations during the three-month period ended October 31, 2012 of $9,993.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The stockholders’ deficiency transactions as described above are summarized below:

					Additional			Change to
	Common Stock				Paid-In			Stockholders’
	Shares		Amount		Capital			Equity

Issuance of common stock on conversion of convertible preferred stock		8,727,498	$	8,727	$	(8,727	)	$	—
Issuance of common stock as make whole payments on convertible preferred stock		6,005,443		6,005		182,509			188,514
Issuance of common stock for services		1,366,666		1,367		112,883			114,250
Amortization of stock options as employee compensation		—		—		9,993			9,993
Total		16,099,607	$	16,099	$	296,658		$	312,757

Warrants

The following is a summary of warrants issued, forfeited or expired and exercised for the three months ended October 31, 2012:

	Warrants
Outstanding, August 1, 2012		74,264,078
Issued		57,629,955
Outstanding, October 31, 2012		131,894,033

The outstanding warrants at October 31, 2012 have a weighted average exercise price of $0.19 per share and have a weighted average remaining life of 3.54 years.

As of October 31, 2012, the Company has 7,499,999 warrants with a current exercise price of $0.08 and an expiry date of January 25, 2016, 54,426,222 warrants with a current exercise price of $0.08 and an expiry date of March 31, 2016, 6,249,995 warrants with a current exercise price of $0.08 and an expiry date of July 11, 2016, 10,227,270 warrants with a current exercise price of $0.08 and an expiry date of September 30, 2016, 24,999,999 warrants with a current exercise price of $0.08 and an expiry date of February 2, 2017 and 9,375,000 warrants with a current exercise price of $0.08 and an expiry date of August 10, 2017 (112,778,485 warrants in total), which have price protection provisions that allow for the reduction in the current exercise price upon the occurrence of certain events, including the Company’s issuance of common stock or securities convertible into or exercisable for common stock, such as options and warrants, at a price per share less than the exercise price then in effect. For instance, if the Company issues shares of its common stock or options exercisable for or securities convertible into common stock at an effective price per share of common stock less than the exercise price then in effect, the exercise price will be reduced to the effective price of the new issuance. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased proportionately, so that after such adjustment the aggregate exercise price payable for the adjusted number of warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment.

The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants described above that were issued in connection with the March 2008 private placement: (a) shares of common stock or standard options to the Company’s directors, officers, employees or consultants pursuant to a board-approved equity compensation program or other contract or arrangement (up to an aggregate amount of 5,608,926, representing 5% of the common stock issued and outstanding immediately prior to March 31, 2008); (b) shares of common stock issued upon the conversion or exercise of any security, right or other instrument convertible or exchangeable into common stock (or securities exchangeable into common stock) issued prior to March 31, 2008; (c) the shares of common stock issued upon exercise of the warrants issued in March 2008; and (d) shares of common stock and warrants in connection with strategic alliances, acquisitions, mergers, and strategic partnerships, the primary purpose of which is not to raise capital, and which are approved in good faith by the Company’s board of directors (up to an aggregate number of 11,217,852, representing 10% of the shares of common stock issued and outstanding immediately prior to March 31, 2008). On August 10, 2012, the Company’s triggering of the price protection features of the warrants that were issued in March 2008 resulting in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 34,481,866 to 64,653,492.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on January 25, 2011 and in March and April 2011: (I) (a) shares of common stock or options to employees, officers, or directors of the Company pursuant to plans approved by a majority of the non-employee directors of the Company or pursuant to independent contractors pursuant to other agreements or arrangements in existence as of January 24, 2011, (b) securities issued upon the exercise or exchange of or conversion of any securities issued under the Securities Purchase Agreement dated January 24, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on January 24, 2011, provided that such securities have not been amended since their issue date through the date of conversion, exercise or exchange to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (except certain adjustments to warrants expiring in March 2016 and September 2016 are not prohibited), and (c) shares of common stock or warrants to trade vendors of the Company approved by a majority of the non-employee members of the Board of Directors; provided that (II) (i) the shares issued under paragraphs I(a) and I(c) shall not, in the aggregate exceed 1,500,000 shares in each 30-day period during the first 90 days after January 24, 2011, (ii) there is a reasonable relationship between the value of the common stock or options issued pursuant to paragraphs I(a) and I(c) and the value of services rendered or goods provided and (iii) the Company does not rely in whole or in part on the exemptions provided in Sections 3(a)(9) or 3(a)(10) of the Securities Act. On August 10, 2012, the Company’s triggering of the price protection features of the warrants that were issued on January 25, 2011 and in March and April 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 4,000,000 to 7,499,999.

The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on July 8, 2011: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated July 8, 2011, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreement dated July 8, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on July 8, 2011, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in July 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 3,333,331 to 6,249,995.

The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on February 2, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011 and January 31, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on February 2, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in February 2012 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 13,333,333 to 24,999,999.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on August 10, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011, January 31, 2012 and August 8, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on August 8, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.

The Company accounts for the warrants with price protection provisions in accordance with FASB ASC Topic 815 as described in Note 10 - Derivative Liabilities below. As of October 31, 2012, there were a total of 112,778,485 warrants with an estimated fair value of $4,347,710, which are identified on the consolidated balance sheet under the caption “Derivative Warrant Liability”.

Series A 9% Convertible Preferred Stock

The Company has authorized 5,500 shares of Series A 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated July 8, 2011, the Company sold an aggregate of 2,575 shares of convertible preferred stock, as well as accompanying warrants to purchase 17,166,666 shares of common stocks. An aggregate of 17,166,666 shares of the Company’s common stock were issuable upon conversion of the convertible preferred stock which was issued at the initial closing. As of the end of our fiscal year 2012, all of the issued Series A 9% Convertible Preferred Stock had been converted to common stock. There were 17,166,666 shares of common stock which have been issued upon the conversion of the Series A convertible preferred stock and 6,129,666 shares of common stock issued as “make whole payments” on such conversions.

Series B 9% Convertible Preferred Stock

The Company has authorized 2,000 shares of Series B 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated January 31, 2012, the Company sold an aggregate of 2,000 shares of Series B convertible preferred stock, as well as accompanying warrants to purchase 13,333,333 shares of common stocks. An aggregate of 13,333,333 shares of the Company’s common stock were issuable upon conversion of the Series B convertible preferred stock which was issued at the initial closing.

Subject to certain ownership limitations, the convertible preferred stock is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $0.08 (as adjusted on August 10, 2012) per share, and will accrue a 9% dividend until February 1, 2015 and, beginning on February 2, 2015 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend is payable quarterly on September 30, December 31, March 31 and June 30, beginning on March 31, 2012 and on each conversion date in cash, or at the Company’s option, in shares of common stock. In the event that the convertible preferred stock is converted prior to February 1, 2015, the Company will pay the holder of the converted preferred stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. Such “make-whole payment” may be made in cash or, at the Company’s option, in shares of its common stock. In addition, beginning February 1, 2015, the Company will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, and if such dividends are paid. The Company will incur a late fee of 18% per annum on unpaid dividends.

The conversion price of the convertible preferred stock is subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The conversion price will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then conversion price, except in the event of certain exempt issuances. In addition, the holders of convertible preferred stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had converted all of their shares of convertible preferred stock. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the holders of convertible preferred stock will be entitled to receive, upon conversion of their shares, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. On August 10, 2012, the triggering of the price protection features of the Series B 9% Convertible Preferred Stock resulted in a decrease of the conversion price from $0.15 to $0.08.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company may become obligated to redeem the convertible preferred stock in cash upon the occurrence of certain triggering events, including the failure to provide an effective registration statement covering shares of common stock issuable upon conversion of the convertible preferred stock, material breach of certain contractual obligations to the holders of the convertible preferred stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Company’s common stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or regulated quotation services. Upon the occurrence of certain triggering events, each holder of convertible preferred stock will have the option to redeem such holder’s shares of convertible preferred stock for a redemption price payable in shares of common stock or receive an increased dividend rate of 18% on all of such holder’s outstanding convertible preferred stock.

In conjunction with the issuance of the Series B convertible preferred stock, the Company also issued 13,333,333 warrants to the investors. Subject to certain ownership limitations, the warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at an exercise price of $0.08 (as adjusted on August 10, 2012) per share of common stock. The exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares of common stock issuable upon exercise will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances. In addition, the warrant holders will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive, upon exercise of their warrants, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. These warrants have been classified as derivative liabilities and are described further in Note 10 – Derivative Liabilities.

As of October 31, 2012, 1,208 of the Series B convertible preferred stock had been converted to common stock. At October 31, 2012 and July 31, 2012, the “make whole payments” on the remaining convertible preferred stock in the amount of $213,786 and $402,300, respectively, are included in Accounts Payable and Accrued Expenses (see Note 5). The “make whole” amount was allocated as described directly below, when accounting for the initial proceeds from the Series B convertible preferred stock financing.

Accounting for proceeds from the Series B convertible preferred stock financing

The net cash proceeds from the Series B convertible preferred stock financing were $1,975,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing and second to the make whole payments. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and was reported on the Company’s consolidated statements of operations for the fiscal year ended July 31, 2012 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair values of the derivative warrant liability and the derivative additional investment rights liability are described in Note 10 – Derivative Liabilities below. The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:

Accounting allocation of initial proceeds
Net proceeds	$	1,975,000
Derivative warrant liability fair value		(1,811,746	)
Make whole payments liability		(540,000	)
Deemed dividend	$	(376, 746)

Series C 9% Convertible Preferred Stock

The Company has authorized 750 shares of Series C 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated August 8, 2012, the Company sold an aggregate of 750 shares of Series C convertible preferred stock, as well as accompanying warrants to purchase 9,375,000 shares of common stocks. An aggregate of 9,375,000 shares of the Company’s common stock were issuable upon conversion of the Series C convertible preferred stock which was issued at the initial closing.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Subject to certain ownership limitations, the convertible preferred stock is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $0.08 per share, and will accrue a 9% dividend until August 10, 2015 and, beginning on August 10, 2015 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend is payable quarterly on September 30, December 31, March 31 and June 30, beginning on September 30, 2012 and on each conversion date in cash, or at the Company’s option, in shares of common stock. In the event that the convertible preferred stock is converted prior to August 10, 2015, the Company will pay the holder of the converted preferred stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. Such “make-whole payment” may be made in cash or, at the Company’s option, in shares of its common stock. In addition, beginning August 10, 2015, the Company will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, and if such dividends are paid. The Company will incur a late fee of 18% per annum on unpaid dividends.

In conjunction with the issuance of the Series C convertible preferred stock, the Company also issued 9,375,000 warrants to the investors. Subject to certain ownership limitations, the warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at an exercise price of $0.08 per share of common stock. The exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares of common stock issuable upon exercise will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances. In addition, the warrant holders will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive, upon exercise of their warrants, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. These warrants have been classified as derivative liabilities and are described further in Note 10 – Derivative Liabilities.

As of October 31, 2012, none of the Series C convertible preferred stock had been converted to common stock. At October 31, 2012, the “make whole payments” on the remaining Series C convertible preferred stock in the amount of $202,500 are included in Accounts Payable and Accrued Expenses (see Note 5). The “make whole” amount was allocated as described directly below, when accounting for the initial proceeds from the Series C convertible preferred stock financing.

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Accounting for proceeds from the Series C convertible preferred stock financing

The net cash proceeds from the Series C convertible preferred stock financing were $725,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing and second to the make whole payments. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and was reported on the Company’s consolidated statements of operations for the quarter ended October 31, 2012 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair values of the derivative warrant liability and the derivative additional investment rights liability are described in Note 10 – Derivative Liabilities below. The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:

Accounting allocation of initial proceeds
Net proceeds	$	725,000
Derivative warrant liability fair value		(624,797	)
Make whole payments liability		(202,500	)
Deemed dividend	$	(102,297	)

Note 10 – Derivative Liabilities:

Derivative warrant liability

The Company has warrants outstanding with price protection provisions that allow for the reduction in the exercise price of the warrants in the event the Company subsequently issues stock or securities convertible into stock at a price lower than the exercise price of the warrants. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased or decreased proportionately, so that after such adjustment the aggregate exercise price payable for the adjusted number of warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment.

Accounting for Derivative Warrant Liability

The Company’s derivative warrant instruments have been measured at fair value at October 31, 2012 and July 31, 2012 using the binomial lattice model. The Company recognizes all of its warrants with price protection in its consolidated balance sheets as a liability. The liability is revalued at each reporting period and changes in fair value are recognized currently in the consolidated statements of operations. The initial recognition and subsequent changes in fair value of the derivative warrant liability have no effect on the Company’s consolidated cash flows.

The derivative warrants outstanding at October 31, 2012 are all currently exercisable with a weighted-average remaining life of 3.76 years.

The revaluation of the warrants at each reporting period, as well as the charges associated with issuing additional warrants due to the price protection features, resulted in the recognition of income of $358,714 within the Company’s consolidated statements of operations for the three months ended October 31, 2012 and income of $3,128,459 for the three months ended October 31, 2011, which is included in the consolidated statement of operations under the caption “Change in fair value of derivative liabilities”. The fair value of the warrants at October 31, 2012 and July 31, 2012 was $4,347,710 and $4,081,627, respectively, which is reported on the consolidated balance sheets under the caption “Derivative Warrant Liability”. The following summarizes the changes in the value of the derivative warrant liability from August 1, 2011 until October 31, 2012:

	Value			No. of Warrants
Balance at August 1, 2011 – Derivative warrant liability	$	8,745,508			80,234,017
Exercise of warrants classified as derivative liability		(7,230,734	)		(49,863,260	)
Additional warrants issued in February 2012 financing		1,811,746			13,333,333
Additional warrants from price protection features of existing warrants		1,548,813			11,444,440
Decrease in fair value of derivative warrant liability		(793,706	)		n/a
Balance at July 31, 2012 – Derivative warrant liability	$	4,081,627			55,148,530
Additional warrants issued in August 2012 financing		624,797			9,375,000
Additional warrants from price protection features of existing warrants		3,102,355			48,254,955
Decrease in fair value of derivative warrant liability		(3,461,069	)		n/a
Balance at October 31, 2012 – Derivative warrant liability	$	4,347,710			112,778,485

GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Fair Value Assumptions Used in Accounting for Derivative Warrant Liability

The Company has determined its derivative warrant liability to be a Level 2 fair value measurement and has used the binominal lattice pricing model to calculate the fair value as of October 31, 2012 and July 31, 2012. The binomial lattice model requires six basic data inputs: the exercise or strike price, time to expiration, the risk free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Because the warrants contain the price protection feature, the probability that the exercise price of the warrants would decrease as the stock price decreased was incorporated into the valuation calculations. The key inputs used in the October 31, 2012 and July 31, 2012 fair value calculations were as follows:

	October 31, 2012			July 31, 2012

Current exercise price	$	0.08		$	0.15
Time to expiration		3.76 years			3.9 years
Risk-free interest rate		0.54	%		0.45	%
Estimated volatility		87	%		104	%
Dividend		-0-			-0-
Stock price at period end date	$	0.056		$	0.093

Note 11 – Income from Assets Held for Investment, net:

In September 2012, the Company sold its head office real estate in Toronto for gross proceeds after real estate commissions of $1,579,189. This property had a net book value of $585,064, resulting in an accounting gain of $994,125 which is included in income from assets held for investment, net on the consolidated statement of operations. The net proceeds after commissions and other expenses were used to discharge or partially discharge the first and second mortgages on the property. The first mortgage on the property, with remaining principal of $480,951, was discharged completely upon sale. The remaining net proceeds of $1,028,780 after expenses and the discharge of the first mortgages was used to partially discharge the second mortgage and the Company did not receive any of the net proceeds from this property sale.

In August 2011, the Company sold two properties which were held for investment for gross proceeds after real estate commissions of $1,669,115. These two properties had a net book value of $1,029,435, resulting in an accounting gain of $639,680 which is included in income from assets held for investment, net on the consolidated statement of operations. The two properties had mortgages of $659,288 which were discharged upon sale, resulting in net cash proceeds to the Company of $1,009,827.

The remaining income of $48,743 in this category in the three months ended October 31, 2012, pertains to rental income from properties held for investment, net of carrying and operating expenses, compared to $72,395 in the prior year period.

Note 12 – Subsequent Events:

On November 30, 2012, the Company’s subsidiary, Generex Pharmaceuticals Inc., entered in to an agreement with a private lender for a mortgage loan of $855,000 with an annual interest rate of 9.75% and a maturity date of November 30, 2013, secured by real estate owned by the subsidiary. The prior mortgage loan of $156,596 was discharged from the proceeds and the Company received approximately $620,000, after the prior mortgage discharge, legal expenses and other fees.

The Company has evaluated subsequent events occurring after the balance sheet date through the date the interim consolidated financial statements were issued.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

As used herein, the terms the “Company,” “Generex,” “we,” “us,” or “our” refer to Generex Biotechnology Corporation, a Delaware corporation. The following discussion and analysis by management provides information with respect to our financial condition and results of operations for the three-month periods ended October 31, 2012 and 2011. This discussion should be read in conjunction with the information contained in Part I, Item 1A - Risk Factors and Part II, Item 8 - Financial Statements and Supplementary Data in our Annual Report on Form 10-K for the year ended July 31, 2012, as amended, and the information contained in Part I, Item 1 - Financial Statements and Part II, Item 1A- Risk Factors in this Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2012.

Forward-Looking Statements

We have made statements in this Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this Quarterly Report on Form 10-Q of Generex Biotechnology Corporation for the fiscal quarter ended October 31, 2012 that may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). The Act limits our liability in any lawsuit based on forward-looking statements that we have made. All statements, other than statements of historical facts, included in this Quarterly Report that address activities, events or developments that we expect or anticipate will or may occur in the future, including such matters as our projections, future capital expenditures, business strategy, competitive strengths, goals, expansion, market and industry developments and the growth of our businesses and operations, are forward-looking statements. These statements can be identified by introductory words such as “may,” "expects," “anticipates,” "plans," "intends," "believes," "will," "estimates" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Our forward-looking statements address, among other things:

our expectations concerning product candidates for our technologies;

our expectations concerning existing or potential development and license agreements for third-party collaborations, acquisitions and joint ventures;

our expectations of when different phases of clinical activity may commence and conclude;

our expectations of when regulatory submissions may be filed or when regulatory approvals may be received; and

our expectations of when commercial sales of our products may commence and when actual revenue from the product sales may be received.

Any or all of our forward-looking statements may turn out to be wrong. They may be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties. Actual outcomes and results may differ materially from what is expressed or implied in our forward-looking statements. Among the factors that could affect future results are:

the inherent uncertainties of product development based on our new and as yet not fully proven technologies;

the risks and uncertainties regarding the actual effect on humans of seemingly safe and efficacious formulations and treatments when tested clinically;

the inherent uncertainties associated with clinical trials of product candidates;

the inherent uncertainties associated with the process of obtaining regulatory approval to market product candidates;

the inherent uncertainties associated with commercialization of products that have received regulatory approval;

the further decline in our stock price;

our ability to pay dividends on our recently issued preferred stock; and

our ability to obtain the necessary financing to fund our operations and effect our strategic development plan.

Additional factors that could affect future results are set forth in Part I, Item 1A Risk Factors of our Annual Report on Form 10-K for the year ended July 31, 2012, as amended, and in Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. We caution investors that the forward-looking statements contained in this Quarterly Report must be interpreted and understood in light of conditions and circumstances that exist as of the date of this Quarterly Report. We expressly disclaim any obligation or undertaking to update or revise forward-looking statements to reflect any changes in management's expectations resulting from future events or changes in the conditions or circumstances upon which such expectations are based.

Executive Summary

Overview of Business

We are engaged primarily in the research and development of drug delivery systems and technologies. Our primary focus at the present time is our proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Through our wholly-owned subsidiary, Antigen Express, Inc. (“Antigen”), we have expanded our focus to include immunomedicines incorporating proprietary vaccine formulations.

We believe that our buccal delivery technology is a platform technology that has application to many large molecule drugs and provides a convenient, non-invasive, accurate and cost-effective way to administer such drugs. We have identified several large molecule drugs as possible candidates for development, including estrogen, heparin, monoclonal antibodies, human growth hormone and fertility hormones, but to date have focused our development efforts primarily on one pharmaceutical product, Generex Oral-lyn™, an insulin formulation administered as a fine spray into the oral cavity using our proprietary hand-held aerosol spray applicator known as RapidMist™.

Our wholly-owned subsidiary, Antigen, concentrates on developing proprietary vaccine formulations that work by stimulating the immune system to either attack offending agents (i.e., cancer cells, bacteria, and viruses) or to stop attacking benign elements (i.e., self proteins and allergens). Our immunomedicine products are based on two platform technologies and are in the early stages of development. We continue clinical development of Antigen’s synthetic peptide vaccines designed to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene for patients with HER-2/neu positive breast cancer in a Phase II clinical trial and patients with prostate cancer and against avian influenza in two Phase I clinical trials. We recently initiated an additional Phase I clinical trial in patients with either breast or ovarian cancer. The synthetic vaccine technology has certain advantages for pandemic or potentially pandemic viruses, such as the H5N1 avian and H1N1 swine flu. In addition to developing vaccines for pandemic influenza viruses, we have vaccine development efforts underway for seasonal influenza virus, HIV, HPV, melanoma, ovarian cancer, allergy and Type I diabetes mellitus. We have established collaborations with clinical investigators at academic centers to advance these technologies.

Financial Condition

We are a development stage company with a limited history of operations, and do not expect sufficient revenues to support our operation in the immediately foreseeable future. To date, we have not been profitable and our accumulated net loss available to shareholders was $358,370,276 at October 31, 2012. As of October 31, 2012, our current cash position is not sufficient to meet our working capital needs for the next twelve months. To continue operations, we will require additional funds to support our working capital requirements and any development activities, or will need to suspend operations. Management is seeking various alternatives to ensure that we can meet some of our operating cash flow requirements through financing activities, such as private placement of our common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. In addition, management is actively seeking strategic alternatives, including strategic investments and divestitures. Management has sold, and is also seeking further sales of, non-essential real estate assets which are classified as Assets Held for Investment to augment its cash position. We cannot provide any assurance that we will obtain the required funding. Our inability to obtain required funding in the near future or our inability to obtain funding on favorable terms will have a material adverse effect on our operations and our strategic development plan for future growth. If we cannot successfully raise additional capital and implement our strategic development plan, our liquidity, financial condition and business prospects will be materially and adversely affected and we may have to cease operations.

Generex Oral-lyn™

Regulatory Approvals and Clinical Trials

To date, we have received regulatory approval in Ecuador, India (subject to further study), Lebanon and Algeria for the commercial marketing and sale of Generex Oral-lyn™. We have previously submitted regulatory dossiers for Generex Oral-lyn™ in a number of other countries, including Bangladesh, Kenya, Jordan and Armenia. While we believe these countries will ultimately approve our product for commercial sale, we do not anticipate recognizing revenues in any of these jurisdictions in the next twelve months. No dossier related activities or product shipments have taken place during 2012, nor are any expected to these countries during the remainder of 2012 or first half of 2013.

In March 2008, we initiated Phase III clinical trials for this product in the U.S. with the first patient screening for such trials at a clinical study site in Texas in April 2008. Approximately 450 patients have been enrolled to date at approximately 70 clinical sites around the world, including sites in the United States, Canada, Bulgaria, Poland, Romania, Russia, Ukraine and Ecuador. The first Oral-lyn™ global Phase III trial initiated in April 2008 had a final patient visit date in August 2011. After appropriate validation, the data from approximately 450 patients was tabulated, reviewed and analyzed. Those results from the Phase III trial along with a comprehensive review and supplemental analyses of approximately 40 prior Oral-lyn™ clinical studies were compiled and submitted to the FDA in late December 2011 in a comprehensive package including a composite meta-analysis of all safety data. We are currently in ongoing discussions with the FDA with respect to the pathway for regulatory approval, including any additional clinical or pharmacological studies that might be required to support regulatory approval or enhance marketing success. We do not currently plan to expend significant resources on additional clinical trials of Oral-lyn™ until after such time that we secure additional financing.

Marketing

We have entered into licensing and distribution agreements with a number of multinational distributors to assist us with the process of gaining regulatory approval for the registration, marketing, distribution, and sale of Generex Oral-lyn™ in countries throughout the world. Under these licensing and distribution agreements, excluding one with Dong Sung Pharm Co. in South Korea, we will not receive an upfront license fee, but the distributor will bear any and all costs associated with the procurement of governmental approvals for the sale of Generex Oral-Lyn™, including any clinical and regulatory costs. We possess the worldwide marketing rights to our oral insulin product.

In India, a marketing plan has been submitted by Shreya Life Sciences Pvt. Ltd., to Generex on the marketing strategy for the distribution of Oral Recosulin™, the trademark under which Shreya will market Generex Oral-lyn™ within India. The marketing plan also includes post-approval marketing studies. Per the requirements of the regulatory approval in India, an in-country clinical study must be completed in India with Oral Recosulin™ before commercial sales can commence. The field portion of the study was completed in the third calendar quarter of 2012. Site closure, data validation and compilation, as well as analysis of the data must be completed before the study can be finalized and the results published. We have not recognized any revenues from the sale of Generex Oral-lyn™ in India through the end of the 2012 fiscal year or in the first quarter of the 2013 fiscal year.

We do not currently plan to expend significant resources on additional clinical trials or to further the commercialization of Generex Oral-lyn™ until after such time that we secure additional financing.

Cancer and Immunotherapeutic Vaccine Platforms

Our wholly-owned subsidiary Antigen Express is developing proprietary vaccine formulations based upon two platform technologies that were discovered by its founder, the Ii-Key hybrid peptides and Ii-Suppression. These technologies are applicable for either antigen-specific immune stimulation or suppression, depending upon the dosing and formulation of its products. Using active stimulation, we are focusing on major diseases such as breast, prostate and ovarian cancer, melanoma, influenza (including H5N1 avian and H1N1 swine flu) and HIV. Autoimmune diseases such as diabetes and multiple sclerosis are the focus of our antigen-specific immune suppression work.

Antigen’s immunotherapeutic vaccine AE37 is currently in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The trial is being conducted with the United States Military Cancer Institute's (USMCI) Clinical Trials Group and will examine the rate of relapse in patients with node-positive or high-risk node-negative breast cancer after two years. The study is randomized and will compare patients treated with AE37 plus the adjuvant GM-CSF versus GM-CSF alone. The Phase II trial follows a Phase I trial that demonstrated safety, tolerability, and immune stimulation of the AE37 vaccine in breast cancer patients.

Based on positive results in trials of the AE37 vaccine in breast cancer patients, we entered into an agreement in August 2006 with the Euroclinic, a private center in Athens, Greece, to commence clinical trials with the same compound as an immunotherapeutic vaccine for prostate cancer. A Phase I trial involving 29 patients was completed in August 2009, which similarly showed safety, tolerability and induction of a specific immune response. Agreements, as well as a protocol, are in place for initiation of a Phase II clinical trial once additional funding is available.

The same technology used to enhance immunogenicity is being applied in the development of a synthetic peptide vaccine for H5N1 avian influenza and the 2009 H1N1 swine flu. In April 2007, a Phase I clinical trial of Antigen’s proprietary peptides derived from the hemagglutinin protein of the H5N1 avian influenza virus was initiated in healthy volunteers in the Lebanese-Canadian Hospital in Beirut, Lebanon. We have completed the first portion of the Phase I trial. Modified peptide vaccines for avian influenza offer several advantages over traditional egg-based or cell-culture based vaccines. Modified peptide vaccines can be manufactured by an entirely synthetic process which reduces cost and increases both the speed and quantity of vaccine relative to egg- or cell-culture based vaccines. Another advantage is that the peptides are derived from regions of the virus that are similar enough in all H5N1 and H1N1 virus strains such that they would not have to be newly designed for the specific strain to emerge in a pandemic.

A Physician’s Investigational New Drug (“IND”) application for the Phase I and Phase II trials in patients with stage II HER-2/neu positive breast cancer has been filed with the FDA. The Phase I trial was completed at the Walter Reed Army Medical Center in Washington, D.C., and the Phase II trial is taking place at 13 sites, including 11 in the U.S., one in Germany and one in Greece. A Physician’s Investigational New Drug application for a Phase I trial in patients with breast or ovarian cancer also has been filed with the FDA and this Phase I trial is being conducted in Dallas, Texas at the Mary Crowley Cancer Center. Applications were filed and approvals obtained for a Phase I prostate cancer trial using AE37 in Athens, Greece from the Hellenic Organization of Drugs, and this Phase I trial was completed in August 2009. The Ministry of Health in Lebanon gave approval for Phase I trial of our experimental H5N1 prophylactic vaccine in Beirut, Lebanon following submission of an application. All other immunomedicine products are in the pre-clinical stage of development.

Other Potential Buccal Products

We have had past discussions regarding possible research collaborations with various pharmaceutical companies concerning use of our large molecule drug delivery technology with other compounds, including monoclonal antibodies, human growth hormone, fertility hormone, estrogen and heparin, and a number of vaccines. We have not expended resources to further develop any of these products during the fiscal year ended July 31, 2012 or in the first quarter of fiscal 2013 and do not currently have any plans to expend further resources on these products.

Competition

We face competition from other providers of alternate forms of insulin. Some of our most significant competitors, Pfizer, Eli Lilly, and Novo Nordisk, have announced that they will discontinue development and/or sale of their inhalable forms of insulin. Generex Oral-lyn™ is not an inhaled insulin; rather, it is a buccally absorbed formulation with no residual pulmonary deposition. We believe that our buccal delivery technology offers several advantages, including the ease of use, portability, avoidance of pulmonary inhalation and safety profile. Furthermore, insulin administered through the Generex Oral-lyn™ RapidMist™ technology is absorbed directly into the blood stream and not only acts rapidly, but returns to baseline quickly, thereby minimizing the chance of developing hypoglycemia.

In May 2009, Mannkind Corporation submitted an NDA to the FDA requesting approval to market AFREZZA(R) (insulin human [rDNA origin]) Inhalation Powder, for the treatment of adult patients with Type 1 and Type 2 diabetes for the control of hyperglycemia. In January 2011, MannKind announced that it had received a complete response letter from the FDA for AFREZZA®. In August 2011, MannKind announced that it has confirmed with the FDA the design of the two additional clinical studies which are required for AFREZZA®. In addition to other delivery systems for insulin, there are numerous products, such as sulfonylureas (Amaryl®and Glynase®), biguanides (branded and generic metformin products), thiazolidinediones (Avandia®and Actos®), glucagon-like peptide 1 (Byetta®and Victoza®), and dipeptidyl peptidase IV inhibitors (Januvia® and Onglyza™), which have been approved for use in the treatment of Type 2 diabetics in substitution of, or in addition to, insulin therapy. These products may also be considered competitive with insulin products.

Large pharmaceutical companies, such as Merck & Co., Inc., GlaxoSmithKline PLC, Novartis, Inc., MedImmune Inc. (a subsidiary of Astra-Zeneca, Inc.) and others, also compete against us in the oncology, immunomedicine and vaccine markets. These companies have competing experience and expertise in securing government contracts and grants to support research and development efforts, conducting testing and clinical trials, obtaining regulatory approvals to market products, as well as manufacturing and marketing approved products. As such, they are also considered significant competitors in these fields of pharmaceutical products and therapies. There are also many smaller companies which are pursuing similar technologies in these fields who are considered to be competitors of Generex.

Brief Company Background

We are a development stage company. From inception through the end of the quarter ended October 31, 2012, we have received only limited revenues from operations. We did not have any revenue for the three months ended October 31, 2012 and in the fiscal year ended July 31, 2012, we generated $28,651 in revenue. The revenue in each of the fiscal periods pertained primarily to the sale of our consumer/over-the-counter products. These numbers do not reflect deferred sales to customers during the respective periods with the right of return.

We operate in only one segment: the research and development of drug delivery systems and technologies for metabolic and immunological diseases.

We were incorporated in the State of Delaware in 1997. Our principal executive offices are located at 555 Richmond Street West, Suite 604, Toronto, Canada, and our telephone number at that address is (416) 364-2551. We maintain an Internet website at www.generex.com. We make available free of charge on or through our website our filings with the SEC.

Accounting for Research and Development Projects

Our major research and development projects are the refinement of our platform buccal delivery technology, our buccal insulin project (Generex Oral-lyn™) and Antigen’s peptide immunotherapeutic vaccines.

During the first three months of the current fiscal year and during the last fiscal year, we expended resources on the clinical testing and results analysis of our buccal insulin product, Generex Oral-lyn™. In July 2007, we received no objection from the FDA to proceed with our long-term multi-center Phase III study protocol for Generex Oral-lyn™. The first Oral-lyn global Phase III trial initiated in April 2008 had a final patient visit date in August 2011. After appropriate validation, the data from approximately 450 patients was tabulated, reviewed and analyzed. Those results from the Phase III trial along with a comprehensive review and supplemental analyses of approximately 40 prior Oral-lyn clinical studies were compiled and submitted to the FDA in late December 2011 in a comprehensive package including a composite meta-analysis of all safety data. We are currently in ongoing discussions with the FDA with respect to the pathway for regulatory approval, including any additional clinical or pharmacological studies that might be required to support regulatory approval or enhance marketing success. Late-stage trials involve testing our product with a large number of patients over a significant period of time. The completion of late-stage trials in Canada and the United States will require significantly greater funds than we currently have on hand. We do not currently plan to expend significant resources on additional clinical trials of Oral-lyn™ until after such time that we secure additional financing.

During the first three months of the current fiscal year and during the last fiscal year, we expended resources on research and development relating to Antigen’s peptide immunotherapeutic vaccines and related technologies. Antigen has one vaccine currently in Phase II clinical trials in the United States involving patients with HER-2/neu positive breast cancer and has completed a Phase I clinical trial for a vaccine for H5N1 avian influenza at the Lebanese-Canadian Hospital in Beirut. Antigen’s prostate cancer vaccine based on AE37 has been tested in a completed (August 2009) Phase I clinical trial in Greece.

Because of various uncertainties, we cannot predict the timing of completion and commercialization of our buccal insulin in all jurisdictions or Antigen’s peptide immunotherapeutic vaccines or related technologies. These uncertainties include the success of current studies, our ability to obtain the required financing and the time required to obtain regulatory approval even if our research and development efforts are completed and successful, our ability to enter into collaborative marketing and distribution agreements with third-parties, and the success of such marketing and distribution arrangements. For the same reasons, we cannot predict when any products may begin to produce net cash inflows.

Most of our buccal delivery research and development activities to date have involved developing our platform technology for use with insulin. Insubstantial amounts have been expended on projects with other drugs, including morphine and fentanyl, and those projects involved a substantial amount of platform technology development. As a result, we have not made significant distinctions in the accounting for research and development expenses among products, as a significant portion of all research has involved improvements to the platform technology in connection with insulin, which may benefit all of our potential buccal products. During the three months ended October 31, 2012, approximately 21% of our $653,395 in research and development expenses was attributable to insulin and platform technology development, and we did not have any research expenses related to morphine, fentanyl or other buccal projects. During the three months ended October 31, 2011, approximately 73% of our total $1,979,502 in research and development expenses was attributable to insulin and platform technology development, and we did not have any research expenses related to morphine, fentanyl or other buccal projects.

During the three months ended October 31, 2012, approximately 79%, or $514,446 of our research and development expenses was attributable to Antigen's immunomedicine compared to approximately 27%, or $534,471, of our research and development expenses for the three months ended October 31, 2011. Because these products are in initial phases of clinical trials or early, pre-clinical stage of development (with the exception of the Phase II clinical trials of Antigen HER-2/neu positive breast cancer vaccine that are underway), all of the expenses were accounted for as basic research and no distinctions were made as to particular products. Due to the early stage of development, we cannot predict the timing of completion of any products arising from this technology, or when products from this technology might begin producing revenues.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations is based on our interim consolidated financial statements which have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial statements. These principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

We consider certain accounting policies related to impairment of long-lived assets, intangible assets and accrued liabilities to be critical to our business operations and the understanding of our results of operations:

Going Concern. As shown in the consolidated interim financial statements, we have not been profitable and have reported recurring losses from operations. These factors raise substantial doubt about our ability to continue to operate in the normal course of business. The consolidated interim financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.

Revenue Recognition. Net sales of our over-the-counter confectionary products are generally recognized in the period in which the products are delivered. Delivery of the products generally completes the criteria for revenue recognition for us. In the event where the customers have the right of return, sales are deferred until the right of return lapses, the product is sold to a third party or a provision for returns can be reasonably estimated based on historical experience.

Impairment of Long-Lived Assets. Management reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss has occurred based upon expected future cash flows, the loss is recognized in the Statement of Operations.

Intangible Assets. We have intangible assets related to patents. The determination of the related estimated useful lives and whether or not these assets are impaired involves significant judgments. In assessing the recoverability of these intangible assets, we use an estimate of undiscounted operating income and related cash flows over the remaining useful life, market conditions and other factors to determine the recoverability of the asset. If these estimates or their related assumptions change in the future, we may be required to record impairment charges against these assets. In the fiscal year ended July 31, 2012, we recorded a write down of $440,780 on certain patents. There have been no patent write downs or disposals in the 2013 fiscal year to date.

Estimating accrued liabilities, specifically litigation accruals. Management's current estimated range of liabilities related to pending litigation is based on management's best estimate of future costs. While the final resolution of the litigation could result in amounts different than current accruals, and therefore have an impact on our consolidated financial results in a future reporting period, management believes the ultimate outcome will not have a significant effect on our consolidated results of operations, financial position or cash flows.

Share-based compensation. Management determines value of stock-based compensation to employees in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, Compensation – Stock Compensation. Management determines value of stock-based compensation to non-employees and consultants in accordance with and ASC 505, Equity-Based Payments to Non-Employees.

Derivative warrant liability. FASB ASC 815, Derivatives and Hedging, requires all derivatives to be recorded on the balance sheet at fair value for fiscal years beginning after December 15, 2008. As a result, certain derivative warrant liabilities (namely those with a price protection feature) are now separately valued as of August 1, 2009 and accounted for on our balance sheet, with any changes in fair value recorded in earnings. For our balance sheets as of October 31, 2012 and July 31, 2012, we used the binomial lattice model to estimate the fair value of these warrants. Key assumptions of the binomial lattice option-pricing model include the market price of our stock, the exercise price of the warrants, applicable volatility rates, risk-free interest rates, expected dividends and the instrument’s remaining term. These assumptions require significant management judgment. In addition, changes in any of these variables during a period can result in material changes in the fair value (and resultant gains or losses) of this derivative instrument.

Results of Operations

Three Months Ended October 31, 2012 Compared to Three Months Ended October 31, 2011

We had a net loss for the quarter ended October 31, 2012 of $656,199 versus net income of $336,354 in the corresponding quarter of the prior fiscal year. The loss in this year’s fiscal quarter was caused by operating expenses of $1,940,031, which were primarily offset by income from assets held for investment of $1,042,868 and a gain due to the change in fair value of the derivative liabilities of $358,714, while in the prior year operating expenses were $3,476,447 offset by income from assets held for investment of $712,075 and a gain due to the change in fair value of the derivative liabilities of $3,128,459. Our operating loss for the quarter ended October 31, 2012 decreased to $1,940,031 compared to $3,469,778 in the same fiscal quarter of 2012. The decrease in operating loss resulted from a decrease in selling and marketing expense (to $0 from $75,661), a decrease in research and development expenses (to $653,395 from $1,979,502), and a decrease in general and administrative expenses (to $1,286,636 from $1,421,284). We did not have any revenues in the quarter ended October 31, 2012, compared to $9,931 for the quarter ended October 31, 2011, reflecting our decision to discontinue sales of our over-the-counter products.

The decrease in research and development expenses in the current fiscal quarter versus the comparative quarter in the previous fiscal year is primarily due to there being no significant expenditures in this fiscal year related to the field portion of the global Phase III clinical trials of our oral insulin product and platform technology which was completed in in the first quarter of the prior fiscal year. Our efforts to significantly reduce expenses in all categories also contributed to the decrease in this category. The decrease in general and administrative expenses is related to a decrease in payroll related expenses of approximately $210,000 and a decrease in professional services expenses including legal and consulting services of approximately $68,000 in the quarter ended October 31, 2012, as compared to the previous year quarter ended October 31, 2011, as well as reductions of expenses in most other categories due to efforts to conserve cash until we complete the strategic development plan announced by management on March 30, 2011. The decrease in selling expenses for the quarter ended October 31, 2012 versus the prior year comparative quarter is associated with no longer expending resources on the over-the-counter products in the current fiscal period.

Our interest expense in the first quarter of fiscal 2013 was $117,975 compared to the previous year’s fiscal quarter at $34,921 due to the amortization of fees and costs associated with the January and February 2012 property financings, as well as penalties incurred upon the early discharge of the mortgages on the sale of our office property in September 2012. We recognized higher income from assets held for investment (net of expense) of $1,042,868 in the first quarter of fiscal 2013 compared to $712,075 in the same quarter of the previous fiscal year due to the almost $1.0 million accounting gain on the aforementioned property sale. In the prior year’s quarter, we had a gain on sale of properties held for investment of approximately $640,000. Change in fair value of derivative liabilities contributed a gain of $358,714 in the first quarter of fiscal 2013 versus a gain of $3,128,459 in the first fiscal quarter of fiscal 2012.

Our net income available to shareholders was decreased by $102,297 in the first quarter of fiscal 2013 relating to a preferred stock dividend as a result of the accounting treatment of our convertible preferred stock financing in August 2012. This amount represents a deemed dividend to the investors as a result of this financing, as further described in Note 9 to the Notes to Consolidated Financial Statements included elsewhere in this Quarterly Report. There was no preferred stock dividend in the comparable period of fiscal 2012.

Financial Condition, Liquidity and Resources

Sources of Liquidity

To date we have financed our development stage activities primarily through private placements of our common stock and securities convertible into our common stock.

As of October 31, 2012, our current cash position is not sufficient to meet our working capital needs for the next twelve months. Therefore, we will require additional funds to support our working capital requirements and any development or other activities, or will need to curtail our clinical trials and other planned activities or suspend operations.

While we have financed our development stage activities to date primarily through private placements of our common stock and securities convertible into our common stock and raised approximately $4.0 million during fiscal 2012 (including the net proceeds from mortgage financings in January and February 2012) and approximately $725,000 during fiscal 2013 to date, our cash balances have been extremely low thus far in fiscal 2013.

On March 30, 2011, our realigned management team announced its strategic development plan for Generex’s future growth. The plan included the spin-out of Antigen Express, a reverse stock split for Generex and a rights offering to Generex stockholders. As proposed, we would spin out Antigen Express as a separate DTC-eligible company, register its shares with the Securities and Exchange Commission (the “SEC”), and seek to list its shares on a national securities exchange. Management believes that the spin-out would increase value for stockholders and provide Antigen Express with ready access to capital markets to finance its on-going clinical and regulatory initiatives. Management further believes that the spin-out would benefit Generex, by allowing Generex to hold a controlling interest in a publicly-traded company while continuing to focus on maximizing opportunities for its buccal drug delivery platform. The spin-out would be accomplished by the issuance of one or more dividends of Antigen Express stock to Generex stockholders. No determination has been made as to the timing of the proposed spin-out. This Quarterly Report on Form 10-Q does not constitute an offer of any securities for sale or a solicitation of an offer to buy any securities.

Although stockholders approved a reverse stock split proposal at the June 8, 2011 annual meeting of stockholders, the reverse stock split could only be implemented in conjunction with an effort to list our common stock on a national stock exchange. The stockholder approval expired on December 7, 2012 and we will have to resubmit the matter for stockholder approval, if we wish to proceed with the reverse stock split portion of the strategic development plan. The terms of the securities purchase agreements that we entered into on January 31, 2012 and August 8, 2012 also prohibit us from undertaking a reverse or forward stock split or reclassification of our common stock except for a reverse stock split made in conjunction with a listing of the common stock on a national securities exchange.

Management may seek to meet all or some of our operating cash flow requirements through financing activities, such as private placement of our common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. The securities purchase agreements that we entered into on January 31, 2012 and August 8, 2012 with certain investors prohibits us from (i) issuing additional equity securities until 60 days after the effective date of a registration statement covering the resale of the common stock issuable upon exercise of the warrants and conversion of the preferred stock sold in each transaction and (ii) issuing additional debt or equity securities with a variable conversion or exercise price until February 1, 2013 and August 10, 2013 respectively.

Upon the filing of our Annual Report on Form 10-K on October 14, 2011, we were no longer eligible to use Form S-3 to register shares sold to investors, as the aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates was less than $75 million. As we are required under the registration rights agreements that we entered into on January 31, 2012 and August 8, 2012 with certain investors to register shares of our common stock issuable upon conversion or exercise of the securities purchased by the investors, we filed the respective registration statements on Form S-1. We incurred additional legal and accounting fees in connection with the preparation of these Form S-1 registration statements.

In addition, management is actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities, and potential strategic partners. Management has sold, and is also seeking further sales of, non-essential real estate assets which are classified as Assets Held for Investment to augment its cash position and reduce its long-term debt.

We believe that the Phase III clinical trial for Oral-lyn™ in the United States and Canada represents a significant milestone event. We believe that the successful commercial launch of Oral-lyn™ in countries where we have approval would enhance our ability to access additional sources of funding. We will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of our product candidates, further clinical trials for Oral-lyn™ and to commence sales and marketing efforts if the FDA or other regulatory approvals are obtained.

Unforeseen problems with the conduct or results of Phase III clinical trials for Oral-lyn™ or further negative developments in general economic conditions could interfere with our ability to raise additional capital as needed, or materially adversely affect the terms upon which such capital is available. We cannot provide any assurance that we will obtain the required funding. Our inability to obtain required funding in the near future or our inability to obtain funding on favorable terms will have a material adverse effect on our operations and our strategic development plan for future growth. If we cannot successfully raise additional capital and implement our strategic development plan, our liquidity, financial condition and business prospects will be materially and adversely affected and we may have to cease operations.

Proceeds from Recent Financing

On August 8, 2012, we entered into a securities purchase agreement with certain investors, pursuant to which we agreed to sell an aggregate of 750 shares of our newly designated non-voting Series C 9% Convertible Preferred Stock and warrants to purchase up to an aggregate of 100% of the shares of our common stock issuable upon conversion of the convertible preferred stock. The purchase closed on August 10, 2012. We sold the convertible preferred stock and warrants in units, with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company’s common stock issuable upon conversion of such share of convertible preferred stock. Each unit was sold at a negotiated price of $1,000, for an aggregate purchase price of $750,000. An aggregate of 18,750,000 shares of our common stock are issuable upon conversion of, or exercise of, the convertible preferred stock and warrants. We received net proceeds of approximately $725,000 from this transaction, which are reflected in the financial statements for the fiscal quarter ending October 31, 2012. We entered into this securities purchase agreement pursuant to the investors’ additional investment rights existing under the securities purchase agreement dated July 8 2011.

Subject to certain ownership limitations, the Series C convertible preferred stock will be convertible at the option of the holder at any time into shares of our common stock at an effective conversion price of $0.08 per share, and will accrue a 9% dividend until August 10, 2015 and, beginning on August 10, 2015 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend will be payable quarterly on September 30, December 31, March 31 and June 30, beginning on the first such date after the original issue date and on each conversion date in cash, or at our option, in shares of common stock. In the event that the convertible preferred stock is converted prior to August 10, 2015, we will pay the holder of the converted preferred stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. Such “make-whole payment” may be made in cash or, at our option, in shares of our common stock. In addition, beginning August 10, 2015, we will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, as and if such dividends are paid. We will incur a late fee of 18% per annum on unpaid dividends.

The conversion price of the Series C convertible preferred stock will be subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The conversion price will also be adjusted if we sell or grant any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then conversion price, except in the event of certain exempt issuances. In addition, the holders of convertible preferred stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by us pro rata to the holders of our common stock to the same extent as if such holders had converted all of their shares of convertible preferred stock. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the holders of convertible preferred stock will be entitled to receive, upon conversion of their shares, any securities or other consideration received by the holders of our common stock pursuant to the fundamental transaction.

We may become obligated to redeem the Series C convertible preferred stock in cash upon the occurrence of certain triggering events, including, material breach of certain contractual obligations to the holders of the convertible preferred stock, the occurrence of a change in control of Generex, the occurrence of certain insolvency events relating to Generex, or the failure of our common stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or regulated quotation service. Upon the occurrence of certain triggering events, each holder of convertible preferred stock will have the option to redeem such holder’s shares of convertible preferred stock for a redemption price payable in shares of common stock or receive an increased dividend rate of 18% on all of such holder’s outstanding convertible preferred stock. Late fees will apply on all redemption amounts not paid within five trading days of the payment date.

Subject to certain ownership limitations, the warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at an exercise price of $0.08 per share of common stock. The exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares of common stock issuable upon exercise will also be adjusted if we sell or grant any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances. In addition, the warrant holders will be entitled to receive any securities or rights to acquire securities or property granted or issued by us pro rata to the holders of our common stock to the same extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive, upon exercise of their warrants, any securities or other consideration received by the holders of common stock pursuant to the fundamental transaction.

The securities purchase agreement and the certificate of designation authorizing the Series C convertible preferred stock include certain agreements and covenants for the benefit of the holders of the convertible preferred stock, including restrictions on our ability to amend the certificate of incorporation and bylaws, pay cash dividends or distributions with respect to our common stock or other junior securities, repurchase more than a de minimis number of shares of our common stock or other junior securities.

With very limited exceptions, the investors will have a pro rata right of first refusal in respect of participation in any private debt or equity financings undertaken by us during the 12 months following the closing of the transaction.

We offered these securities privately pursuant to Rule 506 of Regulation D under the Securities Act of 1933. We entered into a registration rights agreement with the investors pursuant to which we agreed to file a registration statement with the SEC covering the public resale of the common stock issuable upon conversion of the preferred stock, issuable as dividends on the preferred stock, issuable upon exercise of the warrants and issued as a finders’ fee. We agreed to file the registration statement and to use our best efforts to have the registration statement declared effective within 120 days after closing. If these deadlines were not met, we would be liable for liquidated damages up to 6% of the purchase price under the securities purchase agreement. The registration statement was declared effective by the SEC on November 8, 2012.

In addition, if, during the six-month period after the issuance of the warrants and continuing until such time that all of the securities may be sold without our meeting the current public information requirement under Securities Act rule 144(c)(1), we fail to meet such requirement, we will pay liquidate damages equal to 2.0% of the purchase price paid by each investor, payable in cash every 30 days until current public information for Generex is available or is no longer required for the investors to rely on Rule 144 to transfer the securities (including underlying securities) acquired under the securities purchase agreement.

Proceeds from Warrant Exercises

We may receive additional proceeds from the exercise of warrants issued in the registered direct offerings conducted in June, August and September 2009, the sales to Seaside 88, LP in April, May and June 2010, the warrants issued in connection with the January 2011 registered direct offering and option thereunder and the warrants issued in July 2011, February 2012 and August 2012 in connection with the issuance of the Series A 9% Convertible Preferred Stock, Series B 9% Convertible Preferred Stock and Series C 9% Convertible Preferred Stock, although some of the warrants include a cashless exercise feature.

In the transaction that closed on June 15, 2009, we sold shares of common stock and warrants exercisable for up to 8,600,000 shares of our common stock to investors and issued Midtown Partners & Co., LLC, our exclusive placement agent for the transaction, a warrant to purchase up to 244,926 shares of our common stock.

In the August 6, 2009 registered direct offering, we sold shares of common stock and warrants exercisable for up to 2,995,305 shares of our common stock to investors and issued a warrant to purchase 577,666 shares of our common stock to Midtown, which acted as our exclusive placement agent for the August 2009 transaction.

In the transaction that closed on September 14, 2009, we sold an aggregate of 15,312,500 shares of our common stock and warrants exercisable for up to 5,053,125 shares of our common stock to investors and issued warrants to purchase up to 969,526 shares of our common stock to the two placement agents and a consultant in relation to the transaction.

In the closings under the common stock purchase agreement that occurred in April, May and June 2010, we sold Seaside 12,000,000 shares of our common stock and issued to Midtown, as placement agent, warrants to purchase an aggregate of 300,000 shares of our common stock.

In connection with the securities purchase agreement dated January 24, 2011 and option thereunder, we sold an aggregate of 16,056,000 shares of our common stock and issued warrants exercisable for up to 16,056,000 shares of our common stock to investors.

In connection with the securities purchase agreement dated July 7, 2011 and option thereunder, we sold an aggregate of 2,575 shares of our Series A 9% Convertible Preferred Stock and issued warrants exercisable for up to 17,166,666 shares of our common stock to investors.

In connection with the securities purchase agreement dated January 31, 2012, we sold an aggregate of 2,000 shares of our Series B 9% Convertible Preferred Stock and issued warrants exercisable for up to 13,333,333 shares of our common stock to investors.

In connection with the securities purchase agreement dated August 8, 2012, we sold an aggregate of 750 shares of our Series C 9% Convertible Preferred Stock and issued warrants exercisable for up to 9,375,000 shares of our common stock to investors.

As of December 7, 2012, all of the warrants issued in the aforementioned registered direct offerings were exercisable. At December 7, 2012, outstanding warrants issued in connection with the June, August and September 2009 registered direct offerings, the April, May and June 2010 sales to Seaside and the January to April 2011, July 2011, February 2012 and August 2012 registered direct offerings were as follows:

Date Issued	Aggregate No. of Shares Unexercised			Exercise Price		Expiration Date
June 15, 2009		8,844,926			0.76	December 15, 2014

August 6, 2009		3,572,971			0.79	February 4, 2015

September 14, 2009		6,022,651			1.00	March 15, 2015

April 8, 2010		50,000			0.4726	February 9, 2015

April 21, 2010		50,000			0.4258	February 9, 2015

April 30, 2010		50,000			0.415	February 9, 2015

May 14, 2010		50,000			0.3496	February 9, 2015

May 28, 2010		50,000			0.351	February 9, 2015

June 11, 2010		50,000			0.3543	February 9, 2015

January 25 – April 8, 2011*		7,499,999	**		0.08	January 25, 2016

July 7, 2011*		6,249,995	**		0.08	July 7, 2016

February 1, 2012*		24,999,999	**		0.08	January 31, 2017

August 10, 2012*		9,375,000			0.08	August 10, 2017

*Upon issuance of securities at a price per share of common stock less than the then applicable exercise price, the warrants are subject to anti-dilution adjustment of the exercise price and to the number of shares of common stock that may be purchased upon exercise of each warrant such that the aggregate exercise price payable upon exercise of the warrant will be the same as the aggregate exercise price in effect immediately prior to such adjustment. Due to the anti-dilution adjustment provision of these warrants, they have been reclassified on Generex’s balance sheet as a liability under the caption “Derivative Warrant Liability” with any changes in fair value at each reporting period recorded in earnings in accordance with ASC 815.

**On August 10, 2012, in connection with the issuance of the Series C convertible preferred stock, the exercise price of these warrants was adjusted down to $0.08 (from $0.15), with a corresponding increase in warrants from 4,000,000 to 7,499,999, 3,333,331 to 6,249,995 and 13,333,333 to 24,999,999, respectively warrants.

In addition, we may receive additional proceeds from the exercise of warrants issued in connection with the securities purchase agreement and related documents that we entered into on March 31, 2008 with existing institutional investors relating to a private placement of 8% secured convertible notes (the “Notes”) and warrants (the “Series Warrants”) for aggregate gross proceeds to us of $20,650,000. As of June 1, 2009, the outstanding principal balance and accrued interest on the Notes were satisfied in full.

The Series Warrants issued in connection with the March 2008 securities purchase agreement included:

(i)

Series A and A-1 Warrants, which are exercisable for a period of 7 years into an aggregate of 75% of the number of shares of our common stock initially issuable upon conversion of the Notes, with the Series A Warrants being exercisable into 5,257,729 shares immediately upon issuance and the Series A-1 warrants being exercisable into 7,541,857 shares as of October 1, 2008;

(ii)

Series B Warrants, which became exercisable on October 1, 2008 into 100% of the shares of our common stock initially issuable upon conversion of the Notes (initially 17,066,166 shares) and remain exercisable for a period of 18 months after the registration statement covering the shares of common stock issuable upon conversion or exercise of the Notes and Warrants was declared effective by the SEC; and

(iii)

Series C Warrants, which are exercisable for a period of 7 years as of October 1, 2008, but only to the extent that the Series B Warrant are exercised and only in the same percentage that the Series B Warrants are exercised, up to a maximum percentage of 75% of the number of shares of our common stock initially issuable upon conversion of the Notes (initially a maximum of 12,799,580 shares).

The initial exercise price of each Series Warrant was $1.21. The Series Warrants include a cashless exercise feature. The exercise price of the Series Warrants was subsequently reduced initially to $0.50, then to $0.33, to $0.25, to $0.15 and currently to $0.08 as a result of a price protection provision triggered by our offering of stock in private placements in May 2009, January and July 2011 and February and August 2012. This price protection feature allows for the reduction in the exercise price of the Series Warrants in the event we subsequently issue common stock or securities convertible into or exercisable for common stock, such as options and warrants, at a price per share less than the Series Warrant exercise price then in effect. In addition, with any reduction to the Series Warrant exercise price, the number of shares of common stock that may be purchased upon exercise of each Series Warrant will be increased or decreased proportionately, so that after such adjustment the aggregate Series Warrant exercise price payable for the adjusted number of shares issuable upon exercise will be the same as the aggregate Series Warrant exercise price in effect immediately prior to such adjustment. We account for these warrants with price protection in accordance with ASC 815 as described in Note 10 to the Notes to Consolidated Financial Statements included elsewhere in this quarterly report on Form 10-Q.

As of December 7, 2012, outstanding Series Warrants were as follows:

Date Issued	Aggregate No. of Shares Unexercised			Exercise Price*		Expiration Date
March 31, 2008		54,426,222	**	$	0.08	March 31, 2016

March 31, 2008		10,227,270	**	$	0.08	September 30, 2016

**On August 10, 2012, in connection with the issuance of the Series C convertible preferred stock, the exercise price of these warrants was adjusted down to $0.08 (from $0.15), with a corresponding increase in warrants from 29,027,322 to 54,426,222 and 5,454,544 to 10,227,270, respectively.

Cash Flows for the Three months ended October 31, 2012

For the three months ended October 31, 2012, we used $954,598 in cash to fund our operating activities. The use for operating activities included a net loss of $656,199, changes to working capital including a decrease of $20,769 related to deferred revenue, offset by an increase related to accounts payable and accrued expenses of $559,973 and an increase related to other current assets of $85,452,

The use of cash was offset by non-cash expenses of $117,027 related to depreciation and amortization, stock-based compensation to employees of $9,993, stock-based compensation issued in exchange for services rendered by consultants of $114,250 and common stock issued for interest on our convertible preferred stock of $188,514. There was also a year-to-date non-cash gain of $358,714 related to the fair valuation of the derivative liabilities at October 31, 2012 and an accounting gain of $994,125 related to the sale of our office property.

We had net cash provided by investing activities of $1,555,714 in the three months ended October 31, 2012, representing primarily the net proceeds after real estate commissions of $1,579,189 related to the sale of the office property, offset by costs incurred for patents of $23,475.

We had cash used in financing activities in the three months ended October 31, 2012 of $809,577, which pertained primarily to the repayment of long-term debt upon sale of our office property of $1,534,577, offset by $725,000 in net proceeds from sales of convertible preferred stock in August 2012.

Our net working capital at October 31, 2012 improved slightly to negative $8,023,397 from negative $8,054,662 at July 31, 2012, which was attributed largely to the reduction in the current portion of our long-term debt upon the sale of our office property in September 2012 and the net proceeds from the Series C convertible preferred stock financing in August 2012, offset by our cash used in operations for the three-month period ended October 31, 2012.

Conversion of Outstanding Series A, Series B and Series C 9% Convertible Preferred Stock

All outstanding shares of our Series A 9% Convertible Preferred Stock were converted into shares of our common stock prior to the end of our previous fiscal year ended July 31, 2012. A total of 17,166,666 shares of common stock have been issued upon the conversion of 2,575 shares of Series A convertible preferred stock. Upon conversion, we paid the holders of the Series A convertible preferred stock a “make whole” payment equal to $270 per $1,000 of stated value of the Series A convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. We issued 6,129,666 additional shares of common stock on such conversions of the Series A convertible preferred stock. Dividends paid on the Series A Convertible Preferred Stock were $12,383 during the fiscal year ended July 31, 2012.

As of December 7, 2012, 1,208 of the 2,000 shares of our Series B 9% Convertible Preferred Stock had been converted and no dividends had been paid through this date. A total of 15,102,500 shares of common stock have been issued upon the conversion of 1,208 shares of Series B convertible preferred stock and we have issued 4,542,887 additional shares of common stock on such conversions of the Series B convertible preferred as “make whole” payments on the conversions.

As of December 7, 2012, 100 of the 750 shares of our Series C 9% Convertible Preferred Stock had been converted and no dividends have been paid through this date. A total of 1,250,000 shares of common stock have been issued upon the conversion of 100 shares of Series C convertible preferred stock and we have issued 548,781 additional shares of common stock on such conversions of the Series C convertible preferred as “make whole” payments on the conversions.

Funding Requirements and Commitments

If we obtain necessary financing, we expect to devote substantial resources to obtaining regulatory approval of Generex Oral-lyn™ in the U.S., Canada and Europe and to commercializing Generex Oral-lyn™. We may also devote resources to obtaining approval for the importation, marketing and commercialization of Generex Oral-lyn™ in other countries where we have licensed distributors.

Under the long-term agreement that we signed with sanofi-aventis in December 2009, sanofi-aventis will manufacture and supply recombinant human insulin to us in the territories specified in the agreement. Through this agreement, we will procure recombinant human insulin crystals for use in the production of Generex Oral-lyn™. The terms of the supply agreement required us to make certain minimum purchases of insulin from sanofi-aventis through the period ended December 31, 2011, which minimum purchases we did not satisfy. Sanofi-aventis will be our exclusive supplier in certain countries and a non-exclusive supplier in some other countries. Sanofi-aventis may delete any territory from the agreement in which Generex Oral-lyn™ has not been approved for commercial sale by December 31, 2011. The prices under the supply agreement are subject to adjustment beginning after December 31, 2012. As we did not meet the minimum purchase requirements by December 31, 2011, sanofi-aventis may terminate the agreement. Upon termination, we would be obligated to pay sanofi-aventis for all materials and components that it has acquired or ordered to manufacture insulin based on our forecasts or minimum purchase commitments, all related work-in-progress (at cost) and all finished insulin in inventory. We did not provide any forecasts to sanofi-aventis and have not included any accruals related to the purchase commitments in our interim financial statements for the period ended October 31, 2012, nor has sanofi-aventis terminated the agreement.

In addition to the resources that we will dedicate to regulatory approval and commercialization of Generex Oral-lyn™, we will expend resources on further clinical development of our immunotherapeutic vaccines.

Our future funding requirements and commitments and our ability to raise additional capital will depend on factors that include:

the timing and amount of expense incurred to complete our clinical trials;

the costs and timing of the regulatory process as we seek approval of our products in development;

the advancement of our products in development;

our ability to generate new relationships with industry partners throughout the world that will provide us with regulatory assistance and long-term commercialization opportunities;

the timing, receipt and amount of sales, if any, from Generex Oral-lyn™ in India, Lebanon, Algeria and Ecuador;

the cost of manufacturing (paid to third parties) of our licensed products, and the cost of marketing and sales activities of those products;

the costs of prosecuting, maintaining, and enforcing patent claims, if any claims are made;

our ability to maintain existing collaborative relationships and establish new relationships as we advance our products in development;

our ability to obtain the necessary financing to fund our operations and effect our strategic development plan; and

the receptivity of the financial market to biopharmaceutical companies.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors, and we do not have any non-consolidated special purpose entities.

Certain Related Party Transactions

See Part III, Item 13 – Certain Relationships and Related Transactions, and Directors Independence in our Annual Report on Form 10-K for the year ended July 31, 2012, as amended, for further descriptions of our transactions with related parties during the last fiscal year.

Recently Adopted Accounting Pronouncements

In May 2011, the FASB issued further guidance on fair value measurements and disclosures which requires the categorization by level for items that are only required to be disclosed at fair value and information about transfers between Level 1 and Level 2. In addition, the update provides guidance on measuring the fair value of financial instruments managed within a portfolio and the application of premiums and discounts on fair value measurements. The guidance requires additional disclosure for Level 3 measurements regarding the sensitivity of fair value to changes in unobservable inputs and any interrelationships between those inputs. The guidance was effective for our interim period ended April 30, 2012. The adoption of this guidance did not have a significant impact on our consolidated financial statements.

Recently Issued Accounting Pronouncements

In June 2011, the FASB issued guidance regarding the presentation of Comprehensive Income within financial statements. The guidance will be effective for our annual fiscal period ended July 31, 2013 and subsequent interim periods. We do not expect the adoption of this new accounting guidance to have a material impact on our consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risks associated with changes in the exchange rates between U.S. and Canadian currencies and with changes in the interest rates related to our fixed rate debt. We do not believe that any of these risks will have a material impact on our financial condition, results of operations and cash flows.

At the present time, we maintain our cash in short-term government or government guaranteed instruments, short-term commercial paper, and interest bearing bank deposits or demand bank deposits which do not earn interest. A substantial majority of these instruments and deposits are denominated in U.S. dollars, with the exception of funds denominated in Canadian dollars on deposit in Canadian banks to meet short-term operating needs in Canada. We do not presently employ any hedging or similar strategy intended to mitigate against losses that could be incurred as a result of fluctuations in the exchange rates between U.S. and Canadian currencies.

As of October 31, 2012, we had fixed rate debt totaling $156,596. This amount consists of the following:

Loan Amount				Interest Rate per Annum
$	156,596				10.0	%

This debt instrument matures in January 2013. As our fixed rate debt instruments mature, we will likely refinance such debt at the existing market interest rates which may be more or less than interest rates on the maturing debt. Since this debt is fixed rate debt, if interest rates were to increase 100 basis points prior to maturity, there would be no impact on earnings or cash flows.

We have neither issued nor own any long-term debt instruments, or any other financial instruments, for trading purposes to which we would be subject to material market risks.

We have warrants outstanding with price protection provisions that allow for the reduction in the exercise price of the warrants in the event we subsequently issue common stock or securities convertible into or exercisable for common stock, such as options and warrants, at a price per share less than the warrant exercise price then in effect. In addition, with any reduction to the warrant exercise price, the number of shares of common stock that may be purchased upon exercise of each warrant will be increased proportionately, so that after such adjustment the aggregate warrant exercise price payable for the adjusted number of shares issuable upon exercise will be the same as the aggregate warrant exercise price in effect immediately prior to such adjustment. We account for the warrants with price protection in accordance with FASB ASC 815. We recognize the warrants with price protection in our consolidated balance sheet as liabilities. The warrant liability is revalued at each reporting period and changes in fair value are recognized currently in the consolidated statements of operations under the caption Change in fair value of derivative warrant liability. While the change in fair value of the derivative warrant liability has no effect on our cash flows, the gains or losses can have a significant impact on non-operating income and expenses and thus the net income or loss. As of October 31, 2012, there were 112,778,485 warrants outstanding subject to price protection provisions with an estimated fair value of $4,347,710 or $0.039 per warrant. If the estimated fair value of the warrants increases, there will be a corresponding non-operating expense equal to the change in the value of the liability. Likewise, if the estimated fair value of the warrants decreases, there will be a corresponding non-operating gain equal to the change in the value of the liability. There is a directly proportional relationship between the fair value of the warrants and the market price of the stock; therefore increases or decreases in the market price will lead to corresponding increases or decreases in the value of the warrant liability and result in losses or gains, respectively, on our consolidated statements of operations.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Prior to the filing of this Quarterly Report on Form 10-Q, an evaluation was performed under the supervision of and with the participation of Generex’s management, including the Chief Executive Officer (“CEO”) and acting Chief Financial Officer (“CFO”), of the effectiveness of Generex’s disclosure controls and procedures. Based on the evaluation, the CEO and CFO have concluded that, as of October 31, 2012, the Company’s disclosure controls and procedures are not effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to the Company’s management, as appropriate, to allow timely decisions regarding required disclosure.

During management’s evaluation of our disclosure controls and procedures, management identified the existence of material weaknesses in the Company’s internal controls over financial reporting, because of inadequate segregation of duties over authorization, review and recording of transactions, as well as the financial reporting of such transactions for which the Company previously engaged outside advisors. These weaknesses had also been previously identified in our review of controls for the fiscal period ended July 31, 2012.

The Company has not adopted any new accounting policies in the fiscal year ended July 31, 2012 or in the fiscal quarter ended October 31, 2012 which would have a material impact on the Company’s consolidated financial statements. Accordingly, management believes that the consolidated financial statements included in this quarterly report on Form 10-Q fairly present in all material respects the Company’s financial condition, results of operations and cash flows for the periods presented.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended October 31, 2012, there were no changes in Generex’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, Generex’s internal control over financial reporting. However, during the fiscal quarter ended July 31, 2012, the Company’s reduction in accounting personnel and the absence of available resources to engage third party consultants with financial reporting expertise, resulted in changes to the Company’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting and such weaknesses have not yet been remediated as of the current date.

Remedial Efforts to Address the Material Weaknesses

Due to the Company’s limited resources, management has not implemented a plan to mitigate the above material weaknesses. We intend to take appropriate and reasonable steps to make the necessary improvements to remediate these deficiencies when resources permit including, but not limited to, the hiring of additional accounting personnel and/or the use of third party consultants with expertise in US GAAP and financial reporting matters.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

In December 2011, a vendor of Generex commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc., in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in addition to costs and further interest. We responded to this statement of claim and also asserted a counterclaim in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs. On November 16, 2012, the parties agreed to settle this action and we have agreed to pay the plaintiff $125,000, following the spinout of our subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such spinout. Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each parties counsel until payment of the settlement amount. Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without costs will be filed with the court. If we fail to make the payment, following completion of any post-spinout financing related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment against us in the amount of the claim plus interest of 3% per annum and costs fixed at $25,000.

See Note 6 – Pending Litigation of the Notes to the Consolidated Financial Statements set forth under Item 1 of Part I of this Quarterly Report for a description of legal proceedings in which we are currently involved.

We are involved in certain other legal proceedings in addition to those specifically described in this Quarterly Report. Subject to the uncertainty inherent in all litigation, we do not believe at the present time that the resolution of any of these legal proceedings is likely to have a material adverse effect on our financial position, operations or cash flows.

With respect to all litigation matters, as additional information concerning the estimates used by us becomes known, we reassess each matter’s position both with respect to accrued liabilities and other potential exposures.

Item 1A. Risk Factors.

In addition to the other information included in this Quarterly Report on Form 10-Q, you should carefully review and consider the factors discussed in Part I, Item 1A - Risk Factors of our Annual Report on Form 10-K for the year ended July 31, 2012, as amended, certain of which have been updated below. These factors materially affect our business, financial condition or future results of operations. The risks, uncertainties and other factors described in our Annual Report on Form 10-K and below are not the only ones facing our company. Additional risks, uncertainties and other factors not presently known to us or that we currently deem immaterial may also impair our business operations, financial condition or operating results. Any of the risks, uncertainties and other factors could cause the trading price of our common stock to decline substantially.

Risks Related to Our Financial Condition

We will require additional financing to continue our operations.

As of October 31, 2012, our current cash position is not sufficient to meet our working capital needs for the next twelve months based on the pace of our planned activities. To continue operations, we will require additional funds to support our working capital requirements and any expansion or other activities, or will need to significantly reduce our clinical trials and other planned activities or suspend operations. Management is seeking various alternatives to ensure that we can meet some of our operating cash flow requirements through financing activities, such as private placement of our common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. The securities purchase agreements that we entered into on January 31, 2012 and August 8, 2012 with certain investors limits the financing activities that we may undertake in the near future as it prohibits us from (i) issuing additional equity securities until 60 days after the effective date of a registration statement covering the resale of the common stock issuable upon exercise of the warrants and conversion of the preferred stock sold in each transaction and (ii) issuing additional debt or equity securities with a variable conversion or exercise price until February 1, 2013 and August 10, 2013, respectively. In addition, management is actively seeking strategic alternatives, including strategic investments and divestitures. Management has sold, and is also seeking further sales of, non-essential real estate assets which are classified as Assets Held for Investment to augment its cash position.

We cannot provide any assurance that we will obtain the required funding. Our inability to obtain required funding in the near future or our inability to obtain funding on favorable terms will have a material adverse effect on our operations and our strategic development plan for future growth. If we cannot successfully raise additional capital and implement our strategic development plan, our liquidity, financial condition and business prospects will be materially and adversely affected and we may have to cease operations.

We have a history of losses and will incur additional losses.

We are a development stage company with a limited history of operations, and do not expect sufficient revenues to support our operation in the immediately foreseeable future. We do not expect to receive significant revenues in Ecuador, Algeria and Lebanon where we have been approved for commercial sale in the next twelve months. While we have entered into a licensing and distribution agreement with a leading Indian-based pharmaceutical company and insulin distributor, we do not anticipate recognizing revenue from sales of Generex Oral-lyn™ in India in the next twelve months, as we have to complete an in-country clinical study before the product can be offered for commercial sale in India.

To date, we have not been profitable and our accumulated net loss available to shareholders was $358,370,276 at October 31, 2012. Our losses have resulted principally from costs incurred in research and development, including clinical trials, and from general and administrative costs associated with our operations. While we seek to attain profitability, we cannot be sure that we will ever achieve product and other revenue sufficient for us to attain this objective.

With the exception of Generex Oral-lyn™, which has received regulatory approval in Ecuador, India (subject to the completion of an in-country study), Lebanon and Algeria, our product candidates are in research or early stages of pre-clinical and clinical development. We will need to conduct substantial additional research, development and clinical trials. We will also need to receive necessary regulatory clearances both in the United States and foreign countries and obtain meaningful patent protection for and establish freedom to commercialize each of our product candidates. We must also complete further clinical trials and seek regulatory approvals for Generex Oral-lyn™ in countries outside of Ecuador, India, Lebanon and Algeria. We cannot be sure that we will obtain required regulatory approvals, or successfully research, develop, commercialize, manufacture and market any other product candidates. We expect that these activities, together with future general and administrative activities, will result in significant expenses for the foreseeable future.

Our independent auditors have expressed substantial doubt about our ability to continue as a going concern as of July 31, 2012.

To date, we have not been profitable and our accumulated net loss available to shareholders was $358,370,276 at October 31, 2012, and our consolidated balance sheet reflected a stockholders’ deficiency of $8,838,409 at that date. We received a report from our independent auditors for the year ended July 31, 2012 that included an explanatory paragraph describing an uncertainty as to Generex’s ability to continue as a going concern. We must secure financing to continue our operations.

Due to material weaknesses in our internal controls over financial reporting, our internal controls were determined not to be effective for the fiscal year ended July 31, 2012. Our disclosure controls and procedures and internal controls over financial reporting may not be effective in future periods as a result of existing or newly identified material weaknesses in internal controls.

Effective internal controls are necessary for us to provide reasonable assurance with respect to our financial reports and to effectively prevent fraud. If we cannot provide reasonable assurance with respect to our financial reports and effectively prevent fraud, our reputation and operating results could be harmed. Pursuant to the Sarbanes-Oxley Act of 2002, we are required to furnish a report by management on internal control over financial reporting, including management’s assessment of the effectiveness of such control. Internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Therefore, even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. In addition, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that the control may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, or if we experience difficulties in their implementation, our business and operating results could be adversely impacted, we could fail to meet our reporting obligations, and our business and stock price could be adversely affected.

Our Chief Executive Officer and Acting Chief Financial Officer have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and have concluded that, subject to the inherent limitations identified in Item 9A of Part II of the Form 10-K filed on October 15, 2012, our disclosure controls and procedures were not effective due to the existence of material weaknesses in our internal control over financial reporting because of inadequate segregation of duties over authorization, review and recording of transactions, as well as the financial reporting of such transactions. Our independent auditors have issued an adverse attestation report regarding the effectiveness of the Company’s internal control over financial reporting. Due to our limited resources, management has not implemented a plan to mitigate the above material weaknesses.

We intend to take appropriate and reasonable steps to make the necessary improvements to remediate these deficiencies, as our resources permit. We cannot be certain that we will have adequate resources to remediate the deficiencies or that our ultimate remediation efforts will ensure that our management designs, implements and maintains adequate controls over our financial processes and reporting in the future or will be sufficient to address and eliminate the material weaknesses identified. Our inability to remedy the identified material weaknesses or any additional deficiencies or material weaknesses that may be identified in the future could, among other things, have a material adverse effect on our business, results of operations and financial condition, as well as impair our ability to meet our quarterly, annual and other reporting requirements under the Securities Exchange Act of 1934 in a timely manner, and require us to incur additional costs or to divert management resources.

Risks Related to the Market for Our Common Stock

Our stock price is below $5.00 per share and is treated as a “penny stock”, which places restrictions on broker-dealers recommending the stock for purchase.

Our common stock is defined as “penny stock” under the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act, and the rules promulgated thereunder. The SEC has adopted regulations that define “penny stock” to include common stock that has a market price of less than $5.00 per share, subject to certain exceptions. These rules include the following requirements:

broker-dealers must deliver, prior to the transaction a disclosure schedule prepared by the SEC relating to the penny stock market;

broker-dealers must disclose the commissions payable to the broker-dealer and its registered representative;

broker-dealers must disclose current quotations for the securities;

if a broker-dealer is the sole market-maker, the broker-dealer must disclose this fact and the broker-dealers presumed control over the market; and

a broker-dealer must furnish its customers with monthly statements disclosing recent price information for all penny stocks held in the customer’s account and information on the limited market in penny stocks.

Additional sales practice requirements are imposed on broker-dealers who sell penny stocks to persons other than established customers and accredited investors. For these types of transactions, the broker-dealer must make a special suitability determination for the purchaser and must have received the purchaser’s written consent to the transaction prior to sale. If our common stock remains subject to these penny stock rules these disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for our common stock. As a result, fewer broker-dealers may be willing to make a market in our stock, which could affect a shareholder’s ability to sell their shares.

The price of our common stock may be affected by a limited trading volume, may fluctuate significantly and may not reflect the actual value of our business.

There may be a limited public market for our common stock on the over the counter bulletin board market, and there can be no assurance that an active trading market will continue. An absence of an active trading market could adversely affect our stockholders’ ability to sell our common stock in short time periods, or at all. Our common stock has experienced, and is likely to experience in the future, significant price and volume fluctuations that could adversely affect the market price of our common stock without regard to our operating performance. In addition, we believe that factors, such as our sale of securities in connection with capital raising activities, changes in the overall economy and the volatility of the financial markets, could cause the price of our common stock to fluctuate substantially. Thus, the price at which shares of our common stock may trade from time to time may not reflect the actual value of our business or the actual value of our common stock.

Our recent equity financing will dilute current stockholders and could prevent the acquisition or sale of our business.

The equity financing transactions into which we have recently entered have and will dilute current stockholders. At October 31, 2012, there were 131,894,033 shares of common stock issuable upon exercise of the warrants that we issued in a private placement in March 2008, in the registered direct offerings conducted in June, August and September 2009, in connection with the sales to Seaside 88, LP in April, May and June 2010, in the registered direct offering in January to April 2011 and in the registered direct offerings in July 2011, February 2012 and August 2012. In addition, in connection with the private placement that closed on August 10, 2012, an additional 9,375,000 shares of common stock are issuable upon conversion of the recently issued Series C 9% Convertible Preferred Stock, as well as 9,897,500 shares of common stock issuable upon conversion of the remaining 792 shares of Series B 9% Convertible Preferred Stock. Together the shares of common stock issuable upon exercise or conversion of the above-mentioned warrants and preferred stock represent approximately 41% of the shares of common stock currently outstanding. Assuming the holders of the warrants convert and exercise all of the warrants into shares of common stock, the number of shares of issued and outstanding common stock will increase significantly, and current stockholders will own a smaller percentage of the outstanding common stock of Generex. The issuance of shares of common stock pursuant to the warrants will also have a dilutive effect on earnings per share and may adversely affect the market price of the common stock.

In addition, the issuance of shares of common stock upon exercise of the warrants issued in the March 2008 private placement, the registered direct offerings in June, August and September 2009 and in connection with the sales to Seaside in April, May and June 2010, in the registered direct offering in January to April 2011, the registered direct offering in July 2011 and the private placements in February 2012 and August 2012, could have an anti-takeover effect because such issuance will make it more difficult for, or discourage an attempt by, a party to obtain control of Generex by tender offer or other means. The issuance of common stock upon the exercise of the warrants will increase the number of shares entitled to vote, increase the number of votes required to approve a change of control of the company, and dilute the interest of a party attempting to obtain control of the company.

If we raise funds through one or more additional equity financings in the future, it will have a further dilutive effect on existing holders of our shares by reducing their percentage ownership. The shares may be sold at a time when the market price is low because we are in need of the funds. This will dilute existing holders more than if our stock price was higher. In addition, equity financings normally involve shares sold at a discount to the current market price. Most of our outstanding warrants have price protection provisions, which decrease the exercise price of the warrant and increase the number of shares which may be purchased upon exercise of the warrants, if we sell additional equity at an effective price per common share less than the current exercise price of the warrant. Therefore, equity financings at a low price per share will result in even more dilution to existing shareholders.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In the fiscal quarter ended October 31, 2012, we sold, or have entered into commitments to issue, common stock and other securities in transactions in reliance upon exemptions from the registration requirements of the Securities Act.

We have issued or committed to issue shares of our common stock to Seahawk Capital Partners, Inc., a consultant, pursuant to an agreement to provide us with investor relation services through September 30, 2013, as well as in relation to a finder’s fee for our February 2012 Series C convertible preferred stock financing. During the three months ended October 31, 2012, we issued or committed to issue 450,000 shares of common stock to Seahawk Capital Partners pursuant to the consulting agreement and 750,000 shares as the finder’s fee. The sale of such shares was exempt from registration under the Securities Act in reliance upon Section 4(2) thereof. We believe that Seahawk Capital Partners is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D under the Securities Act. The certificates issued for the shares of common stock included a legend to indicate that they are restricted. The sales of such securities did not involve the use of underwriters, and no commissions were paid in connection therewith.

Issuer Purchases of Equity Securities

Neither Generex nor any affiliated purchaser (as defined in Section 240.10 b-18(a)(3) of the Exchange Act) purchased any of its equity securities during the fiscal quarter ended October 31, 2012.

Item 3. Defaults Upon Senior Securities.

None.

Item 5. Other Information.

Reference is made to the disclosure set forth under Part II, Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds under the caption Unregistered Sales of Equity Securities in this Quarterly Report on Form 10-Q, which is incorporated by reference herein.

Item 6. Exhibits.

Exhibits are incorporated herein by reference or are filed with this quarterly report as set forth in the Exhibit Index beginning on page 34 hereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	GENEREX BIOTECHNOLOGY CORPORATION
	(Registrant)

Date: December 10, 2012	By:	/s/ Mark A. Fletcher
		Mark A. Fletcher
		President and Chief Executive Officer

Date: December 10, 2012	By:	/s/ Stephen Fellows
		Stephen Fellows
		Acting Chief Financial Officer

EXHIBIT INDEX

Exhibit Number		Description of Exhibit⁽¹⁾

1		Amendment dated as of April 7, 2010 to Placement Agent Agreement Placement Agency Agreement, dated June 8, 2009, by and between Generex Biotechnology Corporation and Midtown Partners & Co., LLC and amendments dated August 5, August 18, and September 11, 2009 (incorporated by reference to Exhibit 1.2 to Generex Biotechnology Corporation’s Current Report on Form 8-K filed on April 8, 2010)

2		Agreement and Plan of Merger among Generex Biotechnology Corporation, Antigen Express, Inc. and AGEXP Acquisition Inc. (incorporated by reference to Exhibit 2.1 to Generex Biotechnology Corporation’s Current Report on Form 8-K filed on August 15, 2003)

3(i)(a)		Restated Certificate of Incorporation of Generex Biotechnology Corporation (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 filed on October 26, 2009)

3(i)(b)		Certificate of Designation of Preferences, Rights and Limitations of Series A 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation’s Current Report on Form 8-K filed on July 11, 2011).

3(i)(c)		Certificate of Designation of Preferences, Rights and Limitations of Series B 9% Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Generex Biotechnology Corporation’s Current Report on form 8-K filed on February 1, 2012)

3(ii)		Amended and Restated By-Laws of Generex Biotechnology Corporation (incorporated by reference to Exhibit 3.2(ii) to Generex Biotechnology Corporation’s Report on Form 8-K filed December 5, 2007)

4.1		Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Registration Statement on Form S-1 (File No. 333-82667) filed on July 12, 1999)

4.2.1		Form of Securities Purchase Agreement entered into with Cranshire Capital, L.P.; Gryphon Partners, L.P.; Langley Partners, L.P.; Lakeshore Capital, Ltd.; LH Financial; Omicron Capital; Photon Fund, Ltd.; Howard Todd Horberg and Vertical Ventures, LLC dated May 29, 2003 (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 10-Q/A for the quarter ended October 31, 2003 filed on August 13, 2003)

4.2.2		Form of Registration Rights Agreement entered into with Cranshire Capital, L.P.; Gryphon Partners, L.P.; Langley Partners, L.P.; Lakeshore Capital, Ltd.; LH Financial; Omicron Capital; Photon Fund, Ltd.; Howard Todd Horberg and Vertical Ventures, LLC dated May 29, 2003 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 10-Q/A for the quarter ended October 31, 2003 filed on August 13, 2003)

4.2.3		Form of Warrant granted to Cranshire Capital, L.P.; Gryphon Partners, L.P.; Langley Partners, L.P.; Lakeshore Capital, Ltd.; LH Financial; Omicron Capital; Photon Fund, Ltd.; Howard Todd Horberg and Vertical Ventures, LLC dated May 29, 2003 (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 10-Q/A for the quarter ended October 31, 2003 filed on August 13, 2003)

4.3		Form of replacement Warrant issued to warrant holders exercising at reduced exercise price in May and June 2003 (incorporated by reference to Exhibit 4.13.7 to Generex Biotechnology Corporation’s Report on Form 10-K for the period ended July 31, 2003 filed on October 29, 2003)

4.4.1		Securities Purchase Agreement, dated December 19, 2003, by and among Generex Biotechnology Corporation and the investors named therein (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K/A filed on March 24, 2004)

4.4.2		Registration Rights Agreement, dated December 19, 2003, by and among Generex Biotechnology Corporation and the investors named therein (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K/A filed on March 24, 2004)

4.4.3		Form of Warrant issued in connection with Exhibit 4.4.1 (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 8-K/A filed on March 24, 2004)

4.4.4		Form of Additional Investment Right issued in connection with Exhibit 4.4.1 (incorporated by reference to Exhibit 4.4 to Generex Biotechnology Corporation’s Report on Form 8-K/A filed on March 24, 2004)

4.5.1		Securities Purchase Agreement, dated January 7, 2004, by and between Generex Biotechnology Corporation and ICN Capital Limited (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.5.2		Registration Rights Agreement, dated January 7, 2004, by and between Generex Biotechnology Corporation and ICN Capital Limited (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.5.3		Warrant issued in connection with Exhibit 4.5.1 (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.5.4		Additional Investment Right issued in connection with Exhibit 4.5.1 (incorporated by reference to Exhibit 4.4 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.6.1		Securities Purchase Agreement, dated January 9, 2004, by and between Generex Biotechnology Corporation and Vertical Ventures, LLC (incorporated by reference to Exhibit 4.5 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.6.2		Registration Rights Agreement, dated January 9, 2004, by and between Generex Biotechnology Corporation and Vertical Ventures, LLC (incorporated by reference to Exhibit 4.6 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.6.3		Warrant issued in connection with Exhibit 4.6.1 (incorporated by reference to Exhibit 4.7 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.6.4		Additional Investment Right issued in connection with Exhibit 4.6.1 (incorporated by reference to Exhibit 4.8 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.7.1		Securities Purchase Agreement, dated February 6, 2004, by and between Generex Biotechnology Corporation and Alexandra Global Master Fund, Ltd. (incorporated by reference to Exhibit 4.9 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.7.2		Registration Rights Agreement, dated February 6, 2004, by and between Generex Biotechnology Corporation and Alexandra Global Master Fund, Ltd. (incorporated by reference to Exhibit 4.10 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.7.3		Warrant issued in connection with Exhibit 4.7.1 (incorporated by reference to Exhibit 4.11 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.7.4		Additional Investment Right issued in connection with Exhibit 4.7.1 (incorporated by reference to Exhibit 4.12 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.7.5		Escrow Agreement, dated February 26, 2004, by and among Generex Biotechnology Corporation, Eckert Seamans Cherin & Mellott, LLC and Alexandra Global Master Fund, Ltd. (incorporated by reference to Exhibit 4.13 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.8.1		Securities Purchase Agreement, dated February 11, 2004, by and between Generex Biotechnology Corporation and Michael Sourlis (incorporated by reference to Exhibit 4.14 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.8.2		Registration Rights Agreement, dated February 11, 2004, by and between Generex Biotechnology Corporation and Michael Sourlis (incorporated by reference to Exhibit 4.15 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.8.3		Additional Investment Right issued in connection with Exhibit 4.8.1 (incorporated by reference to Exhibit 4.17 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.9.1		Securities Purchase Agreement, dated February 13, 2004, by and between Generex Biotechnology Corporation and Zapfe Holdings, Inc. (incorporated by reference to Exhibit 4.18 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.9.2		Registration Rights Agreement, dated February 13, 2004, by and between Generex Biotechnology Corporation and Zapfe Holdings, Inc. (incorporated by reference to Exhibit 4.19 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.9.3		Warrant issued in connection with Exhibit 4.9.1 (incorporated by reference to Exhibit 4.20 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.9.4		Additional Investment Right issued in connection with Exhibit 4.9.1 (incorporated by reference to Exhibit 4.21 Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2004)

4.10.1		Securities Purchase Agreement, dated June 23, 2004, by and among Generex Biotechnology Corporation and the investors named therein (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on July 14, 2004)

4.10.2		Registration Rights Agreement, dated June 23, 2004, by and among Generex Biotechnology Corporation and the investors (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on July 14, 2004)

4.10.3		Form of Warrant issued in connection with Exhibit 4.10.1 (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 8-K filed on July 14, 2004)

4.10.4		Form of Additional Investment Right issued in connection Exhibit 4.10.1 (incorporated by reference to Exhibit 4.4 to Generex Biotechnology Corporation’s Report on Form 8-K filed on July 14, 2004)

4.11.1		Securities Purchase Agreement, dated November 10, 2004, by and among Generex Biotechnology Corporation and the investors named therein (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on November 12, 2004)

4.11.2		Form of 6% Secured Convertible Debenture issued in connection with Exhibit 4.11.1 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on November 12, 2004)

4.11.3		Registration Rights Agreement, dated November 10, 2004, by and among Generex Biotechnology Corporation and the investors named therein (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 8-K filed on November 12, 2004)

4.11.4		Form of Voting Agreement entered into in connection with Exhibit 4.11.1 (incorporated by reference to Exhibit 4.7 to Generex Biotechnology Corporation’s Report on Form 8-K filed on November 12, 2004)

4.12		Warrant issued to The Aethena Group, LLC on April 28, 2005 (incorporated by reference to Exhibit 4.20 to Generex Biotechnology Corporation’s Quarterly Report on Form 10-Q filed on June 14, 2005)

4.13.1		Amendment No. 4 to Securities Purchase Agreement and Registration Rights Agreement entered into by and between Generex Biotechnology Corporation and the Purchasers listed on the signature pages thereto on January 19, 2006 (incorporated by reference herein to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on January 20, 2006)

4.13.2		Form of Additional AIRs issued in connection with Exhibit 4.13.1 (incorporated by reference herein to Exhibit 4.4 to Generex Biotechnology Corporation’s Report on Form 8-K filed on January 20, 2006)

4.14		Form of Warrant issued by Generex Biotechnology Corporation on January 23, 2006 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on January 24, 2006)

4.15.1		Agreement to Amend Warrants between Generex Biotechnology Corporation and Cranshire Capital L.P. dated February 27, 2006 (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on February 28, 2006).

4.15.2		Agreement to Amend Warrants between Generex Biotechnology Corporation and Omicron Master Trust dated February 27, 2006 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on February 28, 2006).

4.15.3		Agreement to Amend Warrants between Generex Biotechnology Corporation and Iroquois Capital L.P. dated February 27, 2006 (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 8-K filed on February 28, 2006).

4.15.4		Agreement to Amend Warrants between Generex Biotechnology Corporation and Smithfield Fiduciary LLC dated February 27, 2006 (incorporated by reference to Exhibit 4.4 to Generex Biotechnology Corporation’s Report on Form 8-K filed on February 28, 2006).

4.15.5		Form of Warrant issued by Generex Biotechnology Corporation on February 27, 2006 (incorporated by reference to Exhibit 4.26 to Generex Biotechnology Corporation’s Report on Form 10-K filed on October 16, 2006)

4.16.1		Agreement to Amend Additional Investment Right between Generex Biotechnology Corporation and Cranshire Capital, L.P. dated February 28, 2006 (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2006).

4.16.2		Agreement to Amend Additional Investment Right between Generex Biotechnology Corporation and Omicron Master Trust dated February 28, 2006 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2006).

4.16.3		Agreement to Amend Additional Investment Right between Generex Biotechnology Corporation and Iroquois Capital LP dated February 28, 2006 (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2006).

4.16.4		Agreement to Amend Additional Investment Right between Generex Biotechnology Corporation and Smithfield Fiduciary LLC dated February 28, 2006 (incorporated by reference to Exhibit 4.4 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 1, 2006).

4.16.5		Form of Additional AIR Debenture issued by Generex Biotechnology Corporation on February 28, 2006 (incorporated by reference to Exhibit 4.31 to Generex Biotechnology Corporation’s Report on Form 10-K filed on October 16, 2006)

4.16.6		Form of Additional AIR Warrant issued by Generex Biotechnology Corporation on February 28, 2006 (incorporated by reference to Exhibit 4.32 to Generex Biotechnology Corporation’s Report on Form 10-K filed on October 16, 2006)

4.17.1		Form of Agreement to Amend Warrants between Generex Biotechnology Corporation and the Investors dated March 6, 2006 (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 7, 2006).

4.17.2		Form of Warrant issued by Generex Biotechnology Corporation on March 6, 2006 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on March 7, 2006)

4.18		Warrant issued by Generex Biotechnology Corporation on April 17, 2006 to Zapfe Holdings, Inc. (incorporated by reference to Exhibit 4.33 to Generex Biotechnology Corporation’s Report on Form 10-Q filed on June 14, 2006)

4.19		Form of Warrant issued by Generex Biotechnology Corporation on April 17, 2006 to certain employees (incorporated by reference to Exhibit 4.34 to Generex Biotechnology Corporation’s Report on Form 10-Q filed on June 14, 2006).

4.20.1		Securities Purchase Agreement entered into by and between Generex Biotechnology Corporation and four Investors on June 1, 2006 (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on June 2, 2006)

4.20.2		Form of Warrant issued by Generex Biotechnology Corporation on June 1, 2006 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on June 2, 2006)

4.21.1		Form of Amendment to Outstanding Warrants (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 8-K filed on June 2, 2006)

4.21.2		Form of Warrant issued by Generex Biotechnology Corporation on June 1, 2006 in connection with Exhibit 4.39 (incorporated by reference to Exhibit 4.4 to Generex Biotechnology Corporation’s Report on Form 8-K filed on June 2, 2006)

4.22.1		Securities Purchase Agreement, dated as of March 31, 2008 among the Registrant and each of the purchasers named therein (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on April 2, 2008)

4.22.2		Form of 8% Secured Convertible Note, as amended (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Registration Statement (333-150562) on Form S-3 filed on October 31, 2008)

4.22.3		Form of Series A Warrant, as amended (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Registration Statement on Form S-3 (333-150562) filed on October 31, 2008)

4.22.4		Form of Series A-1 Warrant, as amended (incorporated by reference to Exhibit 4.4 to Generex Biotechnology Corporation’s Registration Statement on Form S-3 (333-150562) filed on October 31, 2008)

4.22.5		Form of Series B Warrant, as amended (incorporated by reference to Exhibit 4.5 to Generex Biotechnology Corporation’s Registration Statement on Form S-3 (333-150562) filed on October 31, 2008)

4.22.6		Form of Series C Warrant, as amended (incorporated by reference to Exhibit 4.6 to Generex Biotechnology Corporation’s Registration Statement on Form S-3 (333-150562) filed on October 31, 2008)

4.22.7		Registration Rights Agreement, dated March 31, 2008, among Registrant and each of the purchasers under Securities Purchase Agreement (incorporated by reference to Exhibit 4.7 to Generex Biotechnology Corporation’s Report on Form 8-K filed on April 2, 2008)

4.22.8		Security Agreement (incorporated by reference to Exhibit 4.8 to Generex Biotechnology Corporation’s Report on Form 8-K filed on April 2, 2008)

4.22.9		Form of Guaranty (incorporated by reference to Exhibit 4.9 to Generex Biotechnology Corporation’s Report on Form 8-K filed on April 2, 2008)

4.23.1		Form of Securities Purchase Agreement, dated May 15, 2009, entered into between Generex Biotechnology Corporation and each investor in the offering (incorporated by reference to Exhibit 1.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on May 18, 2009)

4.24.1		Form of Securities Purchase Agreement, dated June 15, 2009, entered into between Generex Biotechnology Corporation and each investor in the offering (incorporated by reference to Exhibit 10.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on June 16, 2009)

4.24.2		Form of Warrant issued in connection with Exhibit 4.24.1 (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on June 16, 2009)

4.24.3		Form of Warrant issued to Midtown Partners & Co., LLC in connection with Exhibit 4.24.1 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on June 16, 2009)

4.25.1		Form of Securities Purchase Agreement, dated August 6, 2009, entered into between Generex Biotechnology Corporation and each investor in the offering (incorporated by reference to Exhibit 10.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on August 6, 2009)

4.25.2		Form of Warrant issued in connection with Exhibit 4.25.1 (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on August 6, 2009)

4.25.3		Form of Warrant issued to Midtown Partners & Co., LLC in connection with Exhibit 4.25.1 (incorporated by reference to Exhibit 4.28 to Generex Biotechnology Corporation’s Report on Form 8-K filed on August 6, 2009)

4.26.1		Form of Securities Purchase Agreement, dated September 11, 2009, entered into between Generex Biotechnology Corporation and each investor in the offering (incorporated by reference to Exhibit 10.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on September 15, 2009)

4.26.2		Form of Warrant issued in connection with Exhibit 4.26.1 (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on September 15, 2009)

4.26.3		Form of Warrant issued to Midtown Partners & Co., LLC in connection with Exhibit 4.26.1 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on September 15, 2009)

4.27.1		Common Stock Purchase Agreement dated April 7, 2010 by and between Generex Biotechnology Corporation and Seaside 88, LP. (incorporated by reference to Exhibit 10.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on April 8, 2010)

4.27.2		First Amendment to Common Stock Purchase Agreement dated April 28, 2010 by and between Generex Biotechnology Corporation and Seaside 88, LP. (incorporated by reference to Exhibit 10.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on April 29, 2010)

4.27.3		Form of Warrant issued to Midtown Partners & Co., LLC in connection with the Placement Agency Agreement and in connection with Exhibit 4.27.1 hereto (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on April 8, 2010)

4.28.1		Form of Securities Purchase Agreement, dated January 24, 2011, entered into between Generex Biotechnology Corporation and each investor in the offering (incorporated by reference to Exhibit 10.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on January 25, 2011)

4.28.2		Form of Warrant issued in connection with Exhibit 4.28.1 (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Report on Form 8-K filed on January 25, 2011)

4.28.3		Amendment to Purchase Agreement dated March 25, 2011 (incorporated by reference to Exhibit 10.1 to Generex Biotechnology Corporation’s Current Report on Form 8-K filed on March 30, 2011).

4.28.4		Second Amendment to Purchase Agreement dated April 13, 2011 (incorporated by reference to Exhibit 10.1 to Generex Biotechnology Corporation’s Current Report on Form 8-K filed on April 14, 2011).

4.29.1		Form of Securities Purchase Agreement, dated July 8, 2011, by and among Generex Biotechnology Corporation and the purchaser(s) listed on the signature pages thereto (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Current Report on Form 8-K filed on July 11, 2011).

4.29.2		Form of Common Stock Warrant issued in connection with Exhibit 4.29.1 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Current Report on Form 8-K filed on July 11, 2011).

4.30.1		Form of Securities Purchase Agreement, dated January 31, 2012, by and among Generex Biotechnology Corporation and the purchaser(s) listed on the signature pages thereto (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Current Report on Form 8-K filed on February 1, 2012).

4.30.2		Form of Common Stock Warrant issued in connection with Exhibit 4.30.1 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on February 1, 2012).

4.30.3		Form of Registration Rights Agreement by and among Generex Biotechnology Corporation and the purchaser(s) listed on the signature pages thereto (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 8-K filed on February 1, 2012)

4.31.1		Form of Securities Purchase Agreement, dated August 8, 2012, by and among Generex Biotechnology Corporation and the purchaser(s) listed on the signature pages thereto (incorporated by reference to Exhibit 4.1 to Generex Biotechnology Corporation’s Current Report on Form 8-K filed on August 8, 2012).

4.31.2		Form of Common Stock Warrant issued in connection with Exhibit 4.30.1 (incorporated by reference to Exhibit 4.2 to Generex Biotechnology Corporation’s Report on Form 8-K filed on August 8, 2012).

4.31.3		Form of Registration Rights Agreement by and among Generex Biotechnology Corporation and the purchaser(s) listed on the signature pages thereto (incorporated by reference to Exhibit 4.3 to Generex Biotechnology Corporation’s Report on Form 8-K filed on August 8, 2012)

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(1)

In the case of incorporation by reference to documents filed by the Registrant under the Exchange Act, the Registrant’s file number under the Exchange Act is 000-25169.

EX-31.1 2 v328917_ex31-1.htm EX-31.1

Exhibit 31.1

CERTIFICATION

I, Mark A. Fletcher, certify that:

	1.		I have reviewed this Quarterly Report on Form 10-Q for the period ended October 31, 2012 of Generex Biotechnology Corporation;

	2.		Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.		Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.		The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)		Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)		Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)		Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)		Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)		All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)		Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

DATE: December 10, 2012	By: /s/ Mark A. Fletcher
	Mark A. Fletcher
	President & Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 v328917_ex31-2.htm EX-31.2

Exhibit 31.2

CERTIFICATION

I, Stephen Fellows, certify that:

	1.		I have reviewed this Quarterly Report on Form 10-Q for the period ended October 31, 2012 of Generex Biotechnology Corporation;

	2.		Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.		Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.		The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)		Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)		Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)		Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)		Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a)		All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)		Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

DATE: December 10, 2012	By: /s/ Stephen Fellows
	Stephen Fellows
	Acting Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32 4 v328917_ex32.htm EX-32

Exhibit 32

CERTIFICATIONS

Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. ss. 1350, as adopted), Mark A. Fletcher, Chief Executive Officer and President of Generex Biotechnology Corporation (the "Company"), and Stephen Fellows, Acting Chief Financial Officer of the Company, each hereby certifies that, to the best of their knowledge:

1. The Company's Quarterly Report on Form 10-Q for the period ended October 31, 2012 to which this Certification is attached as Exhibit 32 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the end of the period covered by the Report.

DATE: December 10, 2012	By: /s/ Mark A. Fletcher
	Mark A. Fletcher
	President & Chief Executive Officer
	(Principal Executive Officer)

DATE: December 10, 2012	By: /s/ Stephen Fellows
	Stephen Fellows
	Acting Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-101.INS 5 gnbt-20121031.xml XBRL INSTANCE DOCUMENT 0001059784 2004-08-01 2005-07-31 0001059784 gnbt:StockOptionPlan2006Member 2009-07-31 0001059784 2011-02-01 2011-04-30 0001059784 gnbt:EmploymentTerminationMember 2011-05-20 0001059784 gnbt:BreachOfContractMember 2011-06-01 0001059784 gnbt:PunitiveDamageMember 2011-06-01 0001059784 gnbt:SeriesaConvertiblePreferredStockMember 2011-07-08 0001059784 gnbt:SeriesaConvertiblePreferredStockMember 2011-05-01 2011-07-31 0001059784 2011-07-31 0001059784 us-gaap:WarrantMember 2011-07-31 0001059784 2011-08-31 0001059784 2011-08-01 2011-08-31 0001059784 gnbt:SeriesaConvertiblePreferredStockMember 2011-07-01 2011-09-30 0001059784 2011-09-01 2011-09-30 0001059784 2011-08-01 2011-10-31 0001059784 gnbt:RevaluationOfWarrantsMember 2011-08-01 2011-10-31 0001059784 2011-10-31 0001059784 gnbt:SeriesBConvertiblePreferredStockMember 2011-10-31 0001059784 gnbt:SeriesCConvertiblePreferredStockMember 2011-10-31 0001059784 2011-12-01 2011-12-31 0001059784 gnbt:VendorsBreachOfContractMember 2011-12-01 2011-12-31 0001059784 gnbt:SeriesBConvertiblePreferredStockMember 2011-11-01 2012-01-31 0001059784 gnbt:SeriesBConvertiblePreferredStockMember 2012-01-31 0001059784 gnbt:InvestmentRightsLiabilityStockMember 2012-02-02 0001059784 2011-08-01 2012-04-30 0001059784 gnbt:SeriesaConvertiblePreferredStockMember 2012-05-01 2012-07-31 0001059784 gnbt:SeriesBConvertiblePreferredStockMember 2012-05-01 2012-07-31 0001059784 us-gaap:CommonStockMember 2012-05-01 2012-07-31 0001059784 2011-08-01 2012-07-31 0001059784 gnbt:WarrantsIsssuedFebruary2012Member 2011-08-01 2012-07-31 0001059784 gnbt:AdditionalWarrantsMember 2011-08-01 2012-07-31 0001059784 gnbt:WarrantFairValueMember 2011-08-01 2012-07-31 0001059784 gnbt:WarrantExercisedMember 2011-08-01 2012-07-31 0001059784 2012-07-31 0001059784 gnbt:StockOptionPlan2006Member 2012-07-31 0001059784 gnbt:RevaluationOfWarrantsMember 2012-07-31 0001059784 gnbt:SeriesAconvertiblePreferredStockMember 2012-07-31 0001059784 gnbt:SeriesBConvertiblePreferredStockMember 2012-07-31 0001059784 gnbt:SeriesCConvertiblePreferredStockMember 2012-07-31 0001059784 us-gaap:WarrantMember 2012-07-31 0001059784 gnbt:StockOptionPlan2000Member 2012-07-31 0001059784 gnbt:StockOptionPlan2001Member 2012-07-31 0001059784 2012-09-01 2012-09-30 0001059784 2012-08-01 2012-10-31 0001059784 gnbt:WarrantTwoMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantsIsssuedJuly2011Member 2012-08-01 2012-10-31 0001059784 gnbt:SeriesBConvertiblePreferredStockMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantAgreementDateJanuaryMarchAnd2011AprilMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantFiveMember 2012-08-01 2012-10-31 0001059784 us-gaap:AdditionalPaidInCapitalMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantThreeMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantAgreementDate2012FebruaryMember 2012-08-01 2012-10-31 0001059784 us-gaap:WarrantMember 2012-08-01 2012-10-31 0001059784 us-gaap:ConvertiblePreferredStockMember 2012-08-01 2012-10-31 0001059784 gnbt:RevaluationOfWarrantsMember 2012-08-01 2012-10-31 0001059784 gnbt:ChangeToStockholderEquityMemberMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantAgreementDate2012AugustMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantSixMember 2012-08-01 2012-10-31 0001059784 gnbt:AdditionalWarrantsMember 2012-08-01 2012-10-31 0001059784 gnbt:SeriesCConvertiblePreferredStockMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantAgreementDate2011JulyMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantAgreementDate2008MarchMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantFairValueMember 2012-08-01 2012-10-31 0001059784 gnbt:SeriesaConvertiblePreferredStockMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantFourMember 2012-08-01 2012-10-31 0001059784 us-gaap:CommonStockMember 2012-08-01 2012-10-31 0001059784 gnbt:WarrantOneMember 2012-08-01 2012-10-31 0001059784 2012-10-31 0001059784 gnbt:StockOptionPlan2006Member 2012-10-31 0001059784 gnbt:SeriesBConvertiblePreferredStockMember 2012-10-31 0001059784 gnbt:SeriesCConvertiblePreferredStockMember 2012-10-31 0001059784 us-gaap:WarrantMember 2012-10-31 0001059784 gnbt:SeriesAconvertiblePreferredStockMember 2012-10-31 0001059784 gnbt:StockOptionPlan2000Member 2012-10-31 0001059784 gnbt:StockOptionPlan2001Member 2012-10-31 0001059784 gnbt:WarrantOneMember 2012-10-31 0001059784 gnbt:WarrantTwoMember 2012-10-31 0001059784 gnbt:WarrantThreeMember 2012-10-31 0001059784 gnbt:WarrantFourMember 2012-10-31 0001059784 gnbt:WarrantFiveMember 2012-10-31 0001059784 gnbt:WarrantSixMember 2012-10-31 0001059784 us-gaap:WarrantMember 2012-10-31 0001059784 1995-11-02 2012-10-31 0001059784 2012-10-01 2012-11-01 0001059784 us-gaap:WarrantMember 2012-07-31 0001059784 us-gaap:WarrantMember 2012-10-31 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure iso4217:CAD GENEREX BIOTECHNOLOGY CORP 0001059784 --07-31 Accelerated Filer gnbt 10-Q false 2012-10-31 Q1 2013

2798797

1069503

246309

37031

200552

116256

446861

153287

704678

118776

858377

852832

2634458

2561090

4644374

3685985

7015652

7777732

263125

242356

1222746

156596

8501523

8176684

441415

4081627

4347710

13024565

12524394

354161

370261

348099813

348396471

357611780

358370276

777615

765135

-8380191

-8838409

4644374

3685985

1000

5500

750

2000

5500

2000

750

5500

2575

750

2000

1490

792

750

1490

792

0.001

750000000

354161297

370260904

354161297

370260904

0.09 0.09 0.09 0.09 0.09 0.09 0.09

9931

5110784

3262

1620375

6669

3490409

1979502

653395

132629359

0 0 220218

75661

9333214

1421284

1286636

149088792

0 0 314328

3476447

1940031

291585911

-3469778

-1940031

-288095502

686303

712075

1042868

5377125

519

225

7782118

34921

117975

69126657

3128459

358714

-357263

-14134068

336354

-656199

-357867944

-3038185

336354

-656199

-354829759

102297

3540517

336354

-758496

-358370276

0.001

-0.002

0.001

-0.002

313342608

364310359

313348032

364310359

163703

117027

10025567

0 0 -423882 0 0 391103

3406196

88582

1353976

639680

994125

2985275

11783

9993

4011938

22690 9993 3421219 48195 114250 14621529 0 0 138375

45390

7956723

0 0 21437909 0 0 100 0 0 138000 0 0 -2405629

38345592

212490 188514 1431218

22190

0 0 353506 0 0 113274 0 0 3198604

-6774

15047

-43812

-216011

20091

-28949

-85452

97496

-13908

559973

15583913

-6471

-20769

236563

-110317

-2652987

-954598

-217553996

2416

4809439

1669115

1579189

6532514

39621

23475

2863521

-512539

195242918

82232

0 0 32000

1126157

-652071

0 0 91103

2222390

-89683

1627078

1555714

-4579713

325179

347369

5567297

684673

1534577

8597276

83002

154541

45728281

5003793

3038185

1975000

725000

17030000

100

40704930

0 0 722750

5142424

483869

120576242

497522

-684673

-809577

222254136

-18712

-817

-83396

-1729294

-209278

37031

Note 1 – Basis of Presentation:   The accompanying unaudited interim consolidated financial statements (“interim statements”) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by generally accepted accounting principles for complete financial statements are not included herein. The interim statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s latest Annual Report on Form 10-K. The results for the three months ended October 31, 2012 may not be indicative of the results for the entire year.   Interim statements are subject to possible adjustments in connection with the annual audit of the Company’s accounts for fiscal year 2013. In the Company’s opinion, all adjustments necessary for a fair presentation of these interim statements have been included and are of a normal and recurring nature.   The Company is a development stage company, which has a limited history of operations and limited revenue to date. This revenue has been comprised mainly of the sale of our confectionary products, although the Company has recognized $600,000 relating to upfront license fees for the signing of license and distribution agreements for Generex Oral-lyn™. Additionally, the Company has several product candidates that are in various research or early stages of pre-clinical and clinical development. There can be no assurance that the Company will be successful in obtaining regulatory clearance for the sale of existing or any future products or that any of the Company’s products will be commercially viable.   Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has experienced negative cash flows from operations since inception and has an accumulated deficit of approximately $358 million and a working capital deficiency of approximately $8 million at October 31, 2012. The Company has funded its activities to date almost exclusively from debt and equity financings, as well as the recent sales of non-essential real estate assets in fiscal 2012 and the beginning of fiscal 2013.   The Company will continue to require substantial funds to continue research and development, including pre-clinical studies and clinical trials of its product candidates, and to commence sales and marketing efforts, if the U.S. Food and Drug Administration or other regulatory approvals are obtained.  Management’s plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common stock, preferred stock offerings, issuances of debt and convertible debt instruments.  Management will be limited in the financing activities that the Company undertakes in the near future as the securities purchase agreements that the Company entered into on January 31, 2012 and August 8, 2012 with certain investors prohibit the Company from (i) issuing additional equity securities until 60 days after the effective date of a registration statement covering the resale of the common stock issuable upon exercise of the warrants and conversion of the preferred stock sold in those transactions and (ii) issuing additional debt or equity securities with variable conversion or exercise prices until February 1, 2013 and August 8, 2013, respectively. Management is also actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and strategic partners.  Management has sold, and is also seeking further sales of, non-essential real estate assets which are classified as Assets Held for Investment to augment its cash position.   These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. There are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence. The Company’s inability to obtain required funding in the near future or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan, its liquidity, financial condition and business prospects will be materially and adversely affected, and the Company may have to cease operations.

Note 2 – Effects of Recent Accounting Pronouncements: Recently Adopted Accounting PronouncementsIn May 2011, the FASB issued further guidance on fair value measurements and disclosures which requires the categorization by level for items that are only required to be disclosed at fair value and information about transfers between Level 1 and Level 2. In addition, the update provides guidance on measuring the fair value of financial instruments managed within a portfolio and the application of premiums and discounts on fair value measurements. The guidance requires additional disclosure for Level 3 measurements regarding the sensitivity of fair value to changes in unobservable inputs and any interrelationships between those inputs. The guidance was effective for the Company’s interim period ended April 30, 2012. The adoption of this new accounting guidance did not have a material impact on the Company’s consolidated financial statements. Recently Issued Accounting PronouncementsIn June 2011, the FASB issued guidance regarding the presentation of Comprehensive Income within financial statements. The guidance will be effective for the Company’s annual fiscal period ended July 31, 2013 and subsequent interim periods. The Company does not expect the adoption of this new accounting guidance to have a material impact on its consolidated financial statements.

Note 3 – Stock-Based Compensation: As of July 31, 2012, the Company had three stockholder-approved stock incentive plans under which shares and options exercisable for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 2,000,000 shares of common stock are reserved for issuance under the 2000 Stock Option Plan (the 2000 Plan), a total of 12,000,000 shares of common stock are reserved for issuance under the 2001 Stock Option Plan (the 2001 Plan) and 30,000,000 shares of common stock are reserved for issuance under the 2006 Stock Plan (the 2006 Plan). At October 31, 2012, there were 2,000,000, 4,124,444 and 8,354,823 shares of common stock reserved for future awards under the 2000 Plan, 2001 Plan and 2006 Plan, respectively. The Company issues new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and issuance of restricted shares. The 2000, 2001 and 2006 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Board. The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options which are not ISOs, i.e. “Non-Qualified Options.” The options granted by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides for restricted stock grants. The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model which takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. In the case of restricted stock grants under the 2006 Plan, fair market value of the shares is established as the market price on the date of the stock grant. The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plans for the three months ended October 31, 2012:<table style="width: 78%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.6in;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Weighted</td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Average</td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Exercise</td><td> </td><td> </td><td style="text-align: center;" colspan="2">Aggregate</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Price</td><td> </td><td> </td><td style="text-align: center;" colspan="2">Intrinsic</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Options</td><td style="padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Share</td><td style="padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Value</td><td style="padding-bottom: 1pt;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; width: 55%;">Outstanding, August 1, 2012</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;"> </td><td style="text-align: right; width: 12%;">10,979,634</td><td style="text-align: left; width: 1%;"> </td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 12%;">0.257</td><td style="text-align: left; width: 1%;"> </td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;"> </td><td style="text-align: right; width: 12%;"> </td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Granted</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">—</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">n/a</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify;">Forfeited or expired</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">—</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">n/a</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt;">Exercised</td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">n/a</td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="text-align: right; padding-bottom: 1pt;"> </td><td style="text-align: left; padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2.5pt;">Outstanding, October 31, 2012</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;"> </td><td style="border-bottom: black 2.5pt double; text-align: right;">10,979,634</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">0.257</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">277,615</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2.5pt;">Exercisable, October 31, 2012</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;"> </td><td style="border-bottom: black 2.5pt double; text-align: right;">10,893,384</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">0.254</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">277,615</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td></tr></table> The 10,979,634 outstanding options at October 31, 2012 had a weighted average remaining contractual term of 3.92 years. The following is a summary of the non-vested common stock options granted, vested and forfeited under the Plan for the three months ended October 31, 2012:<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 1in;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Weighted Average</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Grant Date</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Options</td><td style="padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Fair Value</td><td style="padding-bottom: 1pt;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; width: 64%;">Outstanding, August 1, 2012</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;"> </td><td style="text-align: right; width: 15%;">172,500</td><td style="text-align: left; width: 1%;"> </td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">0.46</td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Granted</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">—</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">0.00</td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify;">Vested</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">(86,250</td><td style="text-align: left;">)</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">0.46</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 1pt;">Forfeited</td><td style="padding-bottom: 1pt;"> </td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="text-align: right; padding-bottom: 1pt;">—</td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">0.00</td><td style="text-align: left; padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2.5pt;">Outstanding, October 31, 2012</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;"> </td><td style="border-bottom: black 2.5pt double; text-align: right;">86,250</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">0.46</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td></tr></table> As of October 31, 2012, the Company had $37,367 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plans. That cost is expected to be recognized over a weighted-average period of 0.94 years.

Note 5 – Accounts Payable and Accrued Expenses:   Accounts payable and accrued expenses consist of the following:   <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 45pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: justify;" colspan="2" nowrap="nowrap">October 31, 2012</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: justify;" colspan="2" nowrap="nowrap">July 31, 2012</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 70%;">Accounts Payable & Accruals – General and Administrative</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">3,971,015</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">3,556,160</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accounts Payable & Accruals – Research and Development</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,822,961</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,691,192</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Accounts Payable & Accruals – Selling and Marketing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">311,329</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">290,534</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">416,286</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">402,300</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Executive Compensation and Directors’ Fees Payable</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">256,141</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">75,466</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.36in;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">7,777,732</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">7,015,652</td> </tr> </table>

Note 6 – Pending Litigation:   In February 2001, a former business associate of the former Vice President of Research and Development (“VP”) of the Company and an entity known as Centrum Technologies Inc. (“CTI”) commenced an action in the Ontario Superior Court of Justice against the Company and the VP seeking, among other things, damages for alleged breaches of contract and tortious acts related to a business relationship between this former associate and the VP that ceased in July 1996. The plaintiffs’ statement of claim also seeks to enjoin the use, if any, by the Company of three patents allegedly owned by CTI. The three patents are entitled Liquid Formulations for Proteinic Pharmaceuticals, Vaccine Delivery System for Immunization, Using Biodegradable Polymer Microspheres, and Controlled Releases of Drugs or Hormones in Biodegradable Polymer Microspheres. It is the Company’s position that the buccal drug delivery technologies which are the subject matter of the Company’s research, development, and commercialization efforts, including Generex Oral-lyn™ and the RapidMist™ Diabetes Management System, do not make use of, are not derivative of, do not infringe upon, and are entirely different from the intellectual property identified in the plaintiffs’ statement of claim. On July 20, 2001, the Company filed a preliminary motion to dismiss the action of CTI as a nonexistent entity or, alternatively, to stay such action on the grounds of want of authority of such entity to commence the action. The plaintiffs brought a cross motion to amend the statement of claim to substitute Centrum Biotechnologies, Inc. (“CBI”) for CTI. CBI is a corporation of which 50 percent of the shares are owned by the former business associate and the remaining 50 percent are owned by the Company. Consequently, the shareholders of CBI are in a deadlock. The court granted the Company’s motion to dismiss the action of CTI and denied the plaintiffs’ cross motion without prejudice to the former business associate to seek leave to bring a derivative action in the name of or on behalf of CBI. The former business associate subsequently filed an application with the Ontario Superior Court of Justice for an order granting him leave to file an action in the name of and on behalf of CBI against the VP and the Company. The Company opposed the application. In September 2003, the Ontario Superior Court of Justice granted the request and issued an order giving the former business associate leave to file an action in the name of and on behalf of CBI against the VP and the Company. A statement of claim was served in July 2004. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.   On May 20, 2011, Ms. Perri filed a statement of claim (subsequently amended) in the Ontario Superior Court of Justice, naming as defendants the Company and certain directors of the Company, Mr. Barratt, Ms. Masterson, Mr. McGee, and Mr. Fletcher. In this action, Ms. Perri has alleged that defendants engaged in discrimination, harassment, bad faith and infliction of mental distress in connection with the termination of her employment with the Company. Ms. Perri is seeking damages in this action in excess of $7,000,000 for, among other things, breach of contract, breach of fiduciary duty, violations of the Ontario Human Rights Code and aggravated and punitive damages. On September 20, 2011, the defendants filed a statement of defense and counterclaim, also naming Time Release Corp., Khazak Group Consulting Corp., and David Khazak, C.A. as defendants by counterclaim, and seeking damages of approximately $2.3 million in funds that the defendants allege Ms. Perri wrongly caused the Company to pay to third parties in varying amounts over several years and an accounting of certain third-party payments, plus interests and costs. The factual basis for the counterclaim involves payments made by the Company to third parties believed to be related to Ms. Perri. The Company intends to defend this action and pursue its counterclaim vigorously and is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.   On June 1, 2011, Golden Bull Estates Ltd. filed a claim (subsequently amended) in the Ontario Superior Court of Justice, naming the Company, 1097346 Ontario, Inc. and Generex Pharmaceuticals Inc. as defendants. The plaintiff, Golden Bull Estates, is controlled by Ms. Perri. The plaintiff alleges damages in the amount of $550,000 for breach of contract, $50,000 for punitive damages, plus interest and costs. The plaintiff’s claims relate to an alleged contract between the plaintiff and the Company for property management services for certain Ontario properties owned by the Company. The Company terminated the plaintiff’s property management services in April 2011. Following the close of pleadings, the Company served a motion for summary judgment. The plaintiff responded by amending its statement of claim to include a claim to the Company’s interest in certain of its real estate holdings. The plaintiff moved for leave to issue and register a Certificate of Pending Litigation in respect of this real estate. The motion was not successful in respect of any current real estate holdings of the Company. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.   In August 2011, the estate of Antonio Perri, the late father of Ms. Perri, commenced an action against Generex Pharmaceuticals, Inc., the law firm of Brans, Lehun, Baldwin LLP and William Lehun in the Ontario Superior Court of Justice claiming that the estate is entitled to the proceeds of sale (approximately $1,730,000) received by the Company on its sale of two properties to Golden Bull Estates Ltd., a company controlled by Ms. Perri. The suit alleges that no consideration was received when the Company purchased the two properties from Antonio Perri in 1998. The Company has responded to this statement of claim and intends to defend this action vigorously. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.   In December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc., in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in addition to costs and further interest.  The Company responded to this statement of claim and also asserted a counterclaim in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs. On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following the spinout of its subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such spinout.  Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each parties counsel until payment of the settlement amount.  Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without costs will be filed with the court.  If the Company fails to make the payment following completion of any post-spinout financing related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus interest of 3% per annum and costs fixed at $25,000.   The Company is involved in certain other legal proceedings in addition to those specifically described herein. Subject to the uncertainty inherent in all litigation, the Company does not believe at the present time that the resolution of any of these legal proceedings is likely to have a material adverse effect on the Company’s consolidated financial position, operations or cash flows.   With respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses its position both with respect to accrued liabilities and other potential exposures.

<div>Note 7 – Commitments: On December 7, 2009, the Company entered into a long-term agreement with sanofi-aventis Deutschland GmbH (“sanofi”). Under this agreement, sanofi-aventis will manufacture and supply recombinant human insulin to the Company in the territories specified in the agreement. Through this agreement, the Company will procure recombinant human insulin crystals for use in the production of Generex Oral-lyn™. The terms of the supply agreement require the Company to make certain minimum purchases of insulin from sanofi through the period ended December 31, 2011.To date, the Company has not met the minimum purchase commitments under this agreement. After December 31, 2011, sanofi may terminate the agreement due to the Company’s failure to meet such purchase commitments. Upon termination, the Company would be obligated to pay sanofi for all materials and components that it has acquired or ordered to manufacture insulin based on the Company’s forecasts or minimum purchase commitments, all related work-in-progress (at cost) and all finished insulin in inventory. To date, the Company has not provided forecasts to sanofi for the purchase of insulin and sanofi has not terminated the agreement.</div>

Note 8 – Net (Loss)/Income Per Share (“EPS”):   Basic EPS and Diluted EPS for the three-month period ended October 31, 2012 have been computed by dividing the net loss available to common stockholders for the period by the weighted average shares outstanding during that period. All outstanding stock options, non-vested restricted stock, warrants and common stock underlying convertible preferred stock, representing 162,146,167 incremental shares at October 31, 2012, have been excluded from the respective computations of Diluted EPS as they are anti-dilutive, due to the loss generated during that period.   Basic EPS and Diluted EPS for the three-month period ended October 31, 2011 have been computed by dividing the net income available to common stockholders for the period by the weighted average shares outstanding and the diluted weighted average shares outstanding during that period, respectively. Per the treasury method of calculating Diluted EPS, 5,424 shares representing outstanding stock options which have an exercise price lower than the average market price for the quarter ended October 31, 2011 are included in the calculation of EPS. All remaining outstanding stock options and warrants which have out-of-the-money exercise prices and common stock underlying convertible preferred stock, representing 110,086,551 incremental shares in aggregate, have been excluded from the October 31, 2011 computation of Diluted EPS, as they are anti-dilutive.

Note 9 – Stockholders’ Deficiency:   Common Stock During the three months ended October 31, 2012, the Company issued or committed to issue 1,366,666 shares of common stock to various consultants for services rendered in the amount of $114,250. The shares were valued at an average of $0.08 per share.   During the three months ended October 31, 2012, the Company issued 8,727,498 shares of common stock in conjunction with the conversion of 698 shares of the Series B 9% Convertible Preferred Stock and 6,005,443 shares of common stock as make-whole payments on Series B 9% Convertible Preferred Stock.   Stock option expense related to executive and employee options granted in October 2009, resulting in a charge to operations during the three-month period ended October 31, 2012 of $9,993.   The stockholders’ deficiency transactions as described above are summarized below:   <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 45pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Additional</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Change to</td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6" nowrap="nowrap">Common Stock</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1pt;" colspan="2" nowrap="nowrap">Paid-In</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1pt;" colspan="2" nowrap="nowrap">Stockholders’</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Shares</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Amount</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Capital</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Equity</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td> </td> <td style="text-align: justify;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: justify;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: justify;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: justify;" colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; text-indent: -0.12in; padding-left: 0.12in; width: 48%;">Issuance of common stock on conversion of convertible preferred stock</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 10%;">8,727,498</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">8,727</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">(8,727</td> <td style="text-align: left; width: 1%;">)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">—</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; text-indent: -0.12in; padding-left: 0.12in;">Issuance of common stock as make whole payments on convertible preferred stock</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6,005,443</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6,005</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">182,509</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">188,514</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Issuance of common stock for services</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,366,666</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,367</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">112,883</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">114,250</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt; text-indent: -0.12in; padding-left: 0.12in;">Amortization of stock options as employee compensation</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">—</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">—</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">9,993</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">9,993</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">16,099,607</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">16,099</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">296,658</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">312,757</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   Warrants The following is a summary of warrants issued, forfeited or expired and exercised for the three months ended October 31, 2012:   <table style="width: 60%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 45pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Warrants</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 82%;">Outstanding, August 1, 2012</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 15%;">74,264,078</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Issued</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">57,629,955</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">Outstanding, October 31, 2012</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">131,894,033</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   The outstanding warrants at October 31, 2012 have a weighted average exercise price of $0.19 per share and have a weighted average remaining life of 3.54 years.   As of October 31, 2012, the Company has 7,499,999 warrants with a current exercise price of $0.08 and an expiry date of January 25, 2016, 54,426,222 warrants with a current exercise price of $0.08 and an expiry date of March 31, 2016, 6,249,995 warrants with a current exercise price of $0.08 and an expiry date of July 11, 2016, 10,227,270 warrants with a current exercise price of $0.08 and an expiry date of September 30, 2016, 24,999,999 warrants with a current exercise price of $0.08 and an expiry date of February 2, 2017 and 9,375,000 warrants with a current exercise price of $0.08 and an expiry date of August 10, 2017 (112,778,485 warrants in total), which have price protection provisions that allow for the reduction in the current exercise price upon the occurrence of certain events, including the Company’s issuance of common stock or securities convertible into or exercisable for common stock, such as options and warrants, at a price per share less than the exercise price then in effect. For instance, if the Company issues shares of its common stock or options exercisable for or securities convertible into common stock at an effective price per share of common stock less than the exercise price then in effect, the exercise price will be reduced to the effective price of the new issuance. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased proportionately, so that after such adjustment the aggregate exercise price payable for the adjusted number of warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment.   The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants described above that were issued in connection with the March 2008 private placement: (a) shares of common stock or standard options to the Company’s directors, officers, employees or consultants pursuant to a board-approved equity compensation program or other contract or arrangement (up to an aggregate amount of 5,608,926, representing 5% of the common stock issued and outstanding immediately prior to March 31, 2008); (b) shares of common stock issued upon the conversion or exercise of any security, right or other instrument convertible or exchangeable into common stock (or securities exchangeable into common stock) issued prior to March 31, 2008; (c) the shares of common stock issued upon exercise of the warrants issued in March 2008; and (d) shares of common stock and warrants in connection with strategic alliances, acquisitions, mergers, and strategic partnerships, the primary purpose of which is not to raise capital, and which are approved in good faith by the Company’s board of directors (up to an aggregate number of 11,217,852, representing 10% of the shares of common stock issued and outstanding immediately prior to March 31, 2008). On August 10, 2012, the Company’s triggering of the price protection features of the warrants that were issued in March 2008 resulting in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 34,481,866 to 64,653,492.   The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on January 25, 2011 and in March and April 2011: (I) (a) shares of common stock or options to employees, officers, or directors of the Company pursuant to plans approved by a majority of the non-employee directors of the Company or pursuant to independent contractors pursuant to other agreements or arrangements in existence as of January 24, 2011, (b) securities issued upon the exercise or exchange of or conversion of any securities issued under the Securities Purchase Agreement dated January 24, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on January 24, 2011, provided that such securities have not been amended since their issue date through the date of conversion, exercise or exchange to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (except certain adjustments to warrants expiring in March 2016 and September 2016 are not prohibited), and (c) shares of common stock or warrants to trade vendors of the Company approved by a majority of the non-employee members of the Board of Directors; provided that (II) (i) the shares issued under paragraphs I(a) and I(c) shall not, in the aggregate exceed 1,500,000 shares in each 30-day period during the first 90 days after January 24, 2011, (ii) there is a reasonable relationship between the value of the common stock or options issued pursuant to paragraphs I(a) and I(c) and the value of services rendered or goods provided and (iii) the Company does not rely in whole or in part on the exemptions provided in Sections 3(a)(9) or 3(a)(10) of the Securities Act. On August 10, 2012, the Company’s triggering of the price protection features of the warrants that were issued on January 25, 2011 and in March and April 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 4,000,000 to 7,499,999.   The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on July 8, 2011: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated July 8, 2011, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreement dated July 8, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on July 8, 2011, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in July 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 3,333,331 to 6,249,995.   The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on February 2, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011 and January 31, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on February 2, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in February 2012 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 13,333,333 to 24,999,999.   The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on August 10, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011, January 31, 2012 and August 8, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on August 8, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.   The Company accounts for the warrants with price protection provisions in accordance with FASB ASC Topic 815 as described in Note 10 - Derivative Liabilities below. As of October 31, 2012, there were a total of 112,778,485 warrants with an estimated fair value of $4,347,710, which are identified on the consolidated balance sheet under the caption “Derivative Warrant Liability”.   Series A 9% Convertible Preferred Stock The Company has authorized 5,500 shares of Series A 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated July 8, 2011, the Company sold an aggregate of 2,575 shares of convertible preferred stock, as well as accompanying warrants to purchase 17,166,666 shares of common stocks. An aggregate of 17,166,666 shares of the Company’s common stock were issuable upon conversion of the convertible preferred stock which was issued at the initial closing. As of the end of our fiscal year 2012, all of the issued Series A 9% Convertible Preferred Stock had been converted to common stock. There were 17,166,666 shares of common stock which have been issued upon the conversion of the Series A convertible preferred stock and 6,129,666 shares of common stock issued as “make whole payments” on such conversions.   Series B 9% Convertible Preferred Stock The Company has authorized 2,000 shares of Series B 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated January 31, 2012, the Company sold an aggregate of 2,000 shares of Series B convertible preferred stock, as well as accompanying warrants to purchase 13,333,333 shares of common stocks. An aggregate of 13,333,333 shares of the Company’s common stock were issuable upon conversion of the Series B convertible preferred stock which was issued at the initial closing.   Subject to certain ownership limitations, the convertible preferred stock is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $0.08 (as adjusted on August 10, 2012) per share, and will accrue a 9% dividend until February 1, 2015 and, beginning on February 2, 2015 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend is payable quarterly on September 30, December 31, March 31 and June 30, beginning on March 31, 2012 and on each conversion date in cash, or at the Company’s option, in shares of common stock. In the event that the convertible preferred stock is converted prior to February 1, 2015, the Company will pay the holder of the converted preferred stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. Such “make-whole payment” may be made in cash or, at the Company’s option, in shares of its common stock. In addition, beginning February 1, 2015, the Company will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, and if such dividends are paid. The Company will incur a late fee of 18% per annum on unpaid dividends.   The conversion price of the convertible preferred stock is subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The conversion price will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then conversion price, except in the event of certain exempt issuances. In addition, the holders of convertible preferred stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had converted all of their shares of convertible preferred stock. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the holders of convertible preferred stock will be entitled to receive, upon conversion of their shares, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. On August 10, 2012, the triggering of the price protection features of the Series B 9% Convertible Preferred Stock resulted in a decrease of the conversion price from $0.15 to $0.08.   The Company may become obligated to redeem the convertible preferred stock in cash upon the occurrence of certain triggering events, including the failure to provide an effective registration statement covering shares of common stock issuable upon conversion of the convertible preferred stock, material breach of certain contractual obligations to the holders of the convertible preferred stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Company’s common stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or regulated quotation services. Upon the occurrence of certain triggering events, each holder of convertible preferred stock will have the option to redeem such holder’s shares of convertible preferred stock for a redemption price payable in shares of common stock or receive an increased dividend rate of 18% on all of such holder’s outstanding convertible preferred stock.   In conjunction with the issuance of the Series B convertible preferred stock, the Company also issued 13,333,333 warrants to the investors. Subject to certain ownership limitations, the warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at an exercise price of $0.08 (as adjusted on August 10, 2012) per share of common stock. The exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares of common stock issuable upon exercise will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances. In addition, the warrant holders will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive, upon exercise of their warrants, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. These warrants have been classified as derivative liabilities and are described further in Note 10 – Derivative Liabilities.   As of October 31, 2012, 1,208 of the Series B convertible preferred stock had been converted to common stock. At October 31, 2012 and July 31, 2012, the “make whole payments” on the remaining convertible preferred stock in the amount of $213,786 and $402,300, respectively, are included in Accounts Payable and Accrued Expenses (see Note 5). The “make whole” amount was allocated as described directly below, when accounting for the initial proceeds from the Series B convertible preferred stock financing.   Accounting for proceeds from the Series B convertible preferred stock financing   The net cash proceeds from the Series B convertible preferred stock financing were $1,975,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing and second to the make whole payments. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and was reported on the Company’s consolidated statements of operations for the fiscal year ended July 31, 2012 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair values of the derivative warrant liability and the derivative additional investment rights liability are described in Note 10 – Derivative Liabilities below. The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:   <table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 65pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; font-weight: bold;">Accounting allocation of initial proceeds</td> <td style="padding-bottom: 1pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0px; width: 82%;">Net proceeds</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 15%;">1,975,000</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0px;">Derivative warrant liability fair value</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,811,746</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0px;">Make whole payments liability</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(540,000</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0px;">Deemed dividend</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(376, 746)</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   Series C 9% Convertible Preferred Stock The Company has authorized 750 shares of Series C 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated August 8, 2012, the Company sold an aggregate of 750 shares of Series C convertible preferred stock, as well as accompanying warrants to purchase 9,375,000 shares of common stocks. An aggregate of 9,375,000 shares of the Company’s common stock were issuable upon conversion of the Series C convertible preferred stock which was issued at the initial closing.   Subject to certain ownership limitations, the convertible preferred stock is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $0.08 per share, and will accrue a 9% dividend until August 10, 2015 and, beginning on August 10, 2015 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend is payable quarterly on September 30, December 31, March 31 and June 30, beginning on September 30, 2012 and on each conversion date in cash, or at the Company’s option, in shares of common stock. In the event that the convertible preferred stock is converted prior to August 10, 2015, the Company will pay the holder of the converted preferred stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. Such “make-whole payment” may be made in cash or, at the Company’s option, in shares of its common stock. In addition, beginning August 10, 2015, the Company will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, and if such dividends are paid. The Company will incur a late fee of 18% per annum on unpaid dividends.   The conversion price of the convertible preferred stock is subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The conversion price will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then conversion price, except in the event of certain exempt issuances. In addition, the holders of convertible preferred stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had converted all of their shares of convertible preferred stock. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the holders of convertible preferred stock will be entitled to receive, upon conversion of their shares, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction.   The Company may become obligated to redeem the convertible preferred stock in cash upon the occurrence of certain triggering events, including the failure to provide an effective registration statement covering shares of common stock issuable upon conversion of the convertible preferred stock, material breach of certain contractual obligations to the holders of the convertible preferred stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Company’s common stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or regulated quotation services. Upon the occurrence of certain triggering events, each holder of convertible preferred stock will have the option to redeem such holder’s shares of convertible preferred stock for a redemption price payable in shares of common stock or receive an increased dividend rate of 18% on all of such holder’s outstanding convertible preferred stock.   In conjunction with the issuance of the Series C convertible preferred stock, the Company also issued 9,375,000 warrants to the investors. Subject to certain ownership limitations, the warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at an exercise price of $0.08 per share of common stock. The exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares of common stock issuable upon exercise will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances. In addition, the warrant holders will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive, upon exercise of their warrants, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. These warrants have been classified as derivative liabilities and are described further in Note 10 – <div style="text-align: justify; margin: 0pt 0px 0pt 45pt; font: 10pt times new roman, times, serif;">Derivative Liabilities.</div> <div style="text-align: justify; margin: 0pt 0px 0pt 45pt; font: 10pt times new roman, times, serif;"> </div> As of October 31, 2012, none of the Series C convertible preferred stock had been converted to common stock. At October 31, 2012, the “make whole payments” on the remaining Series C convertible preferred stock in the amount of $202,500 are included in Accounts Payable and Accrued Expenses (see Note 5). The “make whole” amount was allocated as described directly below, when accounting for the initial proceeds from the Series C convertible preferred stock financing.   Accounting for proceeds from the Series C convertible preferred stock financing   The net cash proceeds from the Series C convertible preferred stock financing were $725,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing and second to the make whole payments. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and was reported on the Company’s consolidated statements of operations for the quarter ended October 31, 2012 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair values of the derivative warrant liability and the derivative additional investment rights liability are described in Note 10 – Derivative Liabilities below. The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:   <table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 65pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; font-weight: bold;">Accounting allocation of initial proceeds</td> <td style="padding-bottom: 1pt;"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0px; width: 82%;">Net proceeds</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 15%;">725,000</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0px;">Derivative warrant liability fair value</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(624,797</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0px;">Make whole payments liability</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(202,500</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: 0px; padding-left: 0px;">Deemed dividend</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(102,297</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>

Note 10 – Derivative Liabilities:   Derivative warrant liability   The Company has warrants outstanding with price protection provisions that allow for the reduction in the exercise price of the warrants in the event the Company subsequently issues stock or securities convertible into stock at a price lower than the exercise price of the warrants. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased or decreased proportionately, so that after such adjustment the aggregate exercise price payable for the adjusted number of warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment.   Accounting for Derivative Warrant Liability The Company’s derivative warrant instruments have been measured at fair value at October 31, 2012 and July 31, 2012 using the binomial lattice model. The Company recognizes all of its warrants with price protection in its consolidated balance sheets as a liability. The liability is revalued at each reporting period and changes in fair value are recognized currently in the consolidated statements of operations. The initial recognition and subsequent changes in fair value of the derivative warrant liability have no effect on the Company’s consolidated cash flows.   The derivative warrants outstanding at October 31, 2012 are all currently exercisable with a weighted-average remaining life of 3.76 years.   The revaluation of the warrants at each reporting period, as well as the charges associated with issuing additional warrants due to the price protection features, resulted in the recognition of income of $358,714 within the Company’s consolidated statements of operations for the three months ended October 31, 2012 and income of $3,128,459 for the three months ended October 31, 2011, which is included in the consolidated statement of operations under the caption “Change in fair value of derivative liabilities”. The fair value of the warrants at October 31, 2012 and July 31, 2012 was $4,347,710 and $4,081,627, respectively, which is reported on the consolidated balance sheets under the caption “Derivative Warrant Liability”. The following summarizes the changes in the value of the derivative warrant liability from August 1, 2011 until October 31, 2012:   <table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 65pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Value</td> <td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">No. of Warrants</td> <td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 70%;">Balance at August 1, 2011 – Derivative warrant liability</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">8,745,508</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 12%;">80,234,017</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Exercise of warrants classified as derivative liability</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(7,230,734</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(49,863,260</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Additional warrants issued in February 2012 financing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,811,746</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">13,333,333</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Additional warrants from price protection features of existing warrants</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,548,813</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">11,444,440</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Decrease in fair value of derivative warrant liability</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(793,706</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">n/a</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Balance at July 31, 2012 – Derivative warrant liability</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">4,081,627</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">55,148,530</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Additional warrants issued in August 2012 financing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">624,797</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">9,375,000</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Additional warrants from price protection features of existing warrants</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,102,355</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">48,254,955</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Decrease in fair value of derivative warrant liability</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(3,461,069</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">n/a</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">Balance at October 31, 2012 – Derivative warrant liability</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">4,347,710</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">112,778,485</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   Fair Value Assumptions Used in Accounting for Derivative Warrant Liability The Company has determined its derivative warrant liability to be a Level 2 fair value measurement and has used the binominal lattice pricing model to calculate the fair value as of October 31, 2012 and July 31, 2012. The binomial lattice model requires six basic data inputs: the exercise or strike price, time to expiration, the risk free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Because the warrants contain the price protection feature, the probability that the exercise price of the warrants would decrease as the stock price decreased was incorporated into the valuation calculations. The key inputs used in the October 31, 2012 and July 31, 2012 fair value calculations were as follows:   <table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 85pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: left;" colspan="2" nowrap="nowrap">October 31, 2012</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: left;" colspan="2" nowrap="nowrap">July 31, 2012</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 74%;">Current exercise price</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">0.08</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">0.15</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Time to expiration</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3.76 years</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3.9 years</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Risk-free interest rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.54</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.45</td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Estimated volatility</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">87</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">104</td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Dividend</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-0-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-0-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Stock price at period end date</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.056</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.093</td> <td style="text-align: left;"> </td> </tr> </table>

Note 11 – Income from Assets Held for Investment, net:   In September 2012, the Company sold its head office real estate in Toronto for gross proceeds after real estate commissions of $1,579,189. This property had a net book value of $585,064, resulting in an accounting gain of $994,125 which is included in income from assets held for investment, net on the consolidated statement of operations. The net proceeds after commissions and other expenses were used to discharge or partially discharge the first and second mortgages on the property. The first mortgage on the property, with remaining principal of $480,951, was discharged completely upon sale. The remaining net proceeds of $1,028,780 after expenses and the discharge of the first mortgages was used to partially discharge the second mortgage and the Company did not receive any of the net proceeds from this property sale.   In August 2011, the Company sold two properties which were held for investment for gross proceeds after real estate commissions of $1,669,115. These two properties had a net book value of $1,029,435, resulting in an accounting gain of $639,680 which is included in income from assets held for investment, net on the consolidated statement of operations. The two properties had mortgages of $659,288 which were discharged upon sale, resulting in net cash proceeds to the Company of $1,009,827.   The remaining income of $48,743 in this category in the three months ended October 31, 2012, pertains to rental income from properties held for investment, net of carrying and operating expenses, compared to $72,395 in the prior year period.

Note 12 – Subsequent Events:   On November 30, 2012, the Company’s subsidiary, Generex Pharmaceuticals Inc., entered in to an agreement with a private lender for a mortgage loan of $855,000 with an annual interest rate of 9.75% and a maturity date of November 30, 2013, secured by real estate owned by the subsidiary. The prior mortgage loan of $156,596 was discharged from the proceeds and the Company received approximately $620,000, after the prior mortgage discharge, legal expenses and other fees.   The Company has evaluated subsequent events occurring after the balance sheet date through the date the interim consolidated financial statements were issued.

The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plans for the three months ended October 31, 2012:<table style="width: 78%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.6in;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Weighted</td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Average</td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Exercise</td><td> </td><td> </td><td style="text-align: center;" colspan="2">Aggregate</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Price</td><td> </td><td> </td><td style="text-align: center;" colspan="2">Intrinsic</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Options</td><td style="padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Share</td><td style="padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Value</td><td style="padding-bottom: 1pt;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; width: 55%;">Outstanding, August 1, 2012</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;"> </td><td style="text-align: right; width: 12%;">10,979,634</td><td style="text-align: left; width: 1%;"> </td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 12%;">0.257</td><td style="text-align: left; width: 1%;"> </td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;"> </td><td style="text-align: right; width: 12%;"> </td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Granted</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">—</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">n/a</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify;">Forfeited or expired</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">—</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">n/a</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt;">Exercised</td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">n/a</td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="text-align: right; padding-bottom: 1pt;"> </td><td style="text-align: left; padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2.5pt;">Outstanding, October 31, 2012</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;"> </td><td style="border-bottom: black 2.5pt double; text-align: right;">10,979,634</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">0.257</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">277,615</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2.5pt;">Exercisable, October 31, 2012</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;"> </td><td style="border-bottom: black 2.5pt double; text-align: right;">10,893,384</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">0.254</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">277,615</td><td style="text-align: left; padding-bottom: 2.5pt;"></td></tr></table>

The following is a summary of the non-vested common stock options granted, vested and forfeited under the Plan for the three months ended October 31, 2012:<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 1in;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Weighted Average</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2">Grant Date</td><td> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Options</td><td style="padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Fair Value</td><td style="padding-bottom: 1pt;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; width: 64%;">Outstanding, August 1, 2012</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;"> </td><td style="text-align: right; width: 15%;">172,500</td><td style="text-align: left; width: 1%;"> </td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">0.46</td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Granted</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">—</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">0.00</td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify;">Vested</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">(86,250</td><td style="text-align: left;">)</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">0.46</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 1pt;">Forfeited</td><td style="padding-bottom: 1pt;"> </td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="text-align: right; padding-bottom: 1pt;">—</td><td style="text-align: left; padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">0.00</td><td style="text-align: left; padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2.5pt;">Outstanding, October 31, 2012</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;"> </td><td style="border-bottom: black 2.5pt double; text-align: right;">86,250</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">0.46</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td></tr></table>

Accounts payable and accrued expenses consist of the following:   <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 45pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: justify;" colspan="2" nowrap="nowrap">October 31, 2012</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: justify;" colspan="2" nowrap="nowrap">July 31, 2012</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 70%;">Accounts Payable & Accruals – General and Administrative</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">3,971,015</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">3,556,160</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accounts Payable & Accruals – Research and Development</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,822,961</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,691,192</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Accounts Payable & Accruals – Selling and Marketing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">311,329</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">290,534</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">416,286</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">402,300</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Executive Compensation and Directors’ Fees Payable</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">256,141</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">75,466</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.36in;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">7,777,732</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">7,015,652</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

The stockholders’ deficiency transactions as described above are summarized below:   <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 45pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Additional</td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Change to</td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6" nowrap="nowrap">Common Stock</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1pt;" colspan="2" nowrap="nowrap">Paid-In</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1pt;" colspan="2" nowrap="nowrap">Stockholders’</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Shares</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Amount</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Capital</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Equity</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td> </td> <td style="text-align: justify;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: justify;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: justify;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: justify;" colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; text-indent: -0.12in; padding-left: 0.12in; width: 48%;">Issuance of common stock on conversion of convertible preferred stock</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 10%;">8,727,498</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">8,727</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">(8,727</td> <td style="text-align: left; width: 1%;">)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">—</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; text-indent: -0.12in; padding-left: 0.12in;">Issuance of common stock as make whole payments on convertible preferred stock</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6,005,443</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6,005</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">182,509</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">188,514</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Issuance of common stock for services</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,366,666</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,367</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">112,883</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">114,250</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt; text-indent: -0.12in; padding-left: 0.12in;">Amortization of stock options as employee compensation</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">—</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">—</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">9,993</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">9,993</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 0.24in;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">16,099,607</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">16,099</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">296,658</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">312,757</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

WarrantsThe following is a summary of warrants issued, forfeited or expired and exercised for the three months ended October 31, 2012:<table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.6in;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Warrants</td><td style="padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="width: 82%;">Outstanding, August 1, 2012</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;"> </td><td style="text-align: right; width: 15%;">74,264,078</td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt;">Issued</td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">57,629,955</td><td style="text-align: left; padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt;">Outstanding, October 31, 2012</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;"> </td><td style="border-bottom: black 2.5pt double; text-align: right;">131,894,033</td><td style="text-align: left; padding-bottom: 2.5pt;"> </td></tr></table>

The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows: <table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.8in;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 0px; padding-left: 0px; font-weight: bold;">Accounting allocation of initial proceeds</td><td style="padding-bottom: 1pt;"> </td><td style="text-align: center;" colspan="2"> </td><td style="padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 0px; padding-left: 0px; width: 82%;">Net proceeds</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">1,975,000</td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 0px; padding-left: 0px;">Derivative warrant liability fair value</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">(1,811,746</td><td style="text-align: left;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 0px; padding-left: 0px;">Make whole payments liability</td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">(540,000</td><td style="text-align: left; padding-bottom: 1pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 0px; padding-left: 0px;">Deemed dividend</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(376,746</td><td style="text-align: left; padding-bottom: 2.5pt;">)</td></tr></table>

The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:  <table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.8in;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; padding: 0px;">Accounting allocation of initial proceeds</td><td> </td><td colspan="2"> </td><td> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; width: 82%; padding: 0px;">Net proceeds</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 15%;">725,000</td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding: 0px;">Derivative warrant liability fair value</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">(624,797</td><td style="text-align: left;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; padding: 0px;">Make whole payments liability</td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">(202,500</td><td style="text-align: left; padding-bottom: 1pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding: 0px;">Deemed dividend</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">(102,297</td><td style="text-align: left; padding-bottom: 2.5pt;">)</td></tr></table>

<div> The following summarizes the changes in the value of the derivative warrant liability from August 1, 2011 until October 31, 2012:</div>   <table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 65pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Value</td> <td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">No. of Warrants</td> <td style="text-align: center; padding-bottom: 1pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 70%;">Balance at August 1, 2011 – Derivative warrant liability</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">8,745,508</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 12%;">80,234,017</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Exercise of warrants classified as derivative liability</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(7,230,734</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(49,863,260</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Additional warrants issued in February 2012 financing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,811,746</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">13,333,333</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Additional warrants from price protection features of existing warrants</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,548,813</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">11,444,440</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Decrease in fair value of derivative warrant liability</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(793,706</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">n/a</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Balance at July 31, 2012 – Derivative warrant liability</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">4,081,627</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">55,148,530</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Additional warrants issued in August 2012 financing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">624,797</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">9,375,000</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Additional warrants from price protection features of existing warrants</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,102,355</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">48,254,955</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Decrease in fair value of derivative warrant liability</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(3,461,069</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">n/a</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">Balance at October 31, 2012 – Derivative warrant liability</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">4,347,710</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">112,778,485</td> </tr> </table>

The key inputs used in the October 31, 2012 and July 31, 2012 fair value calculations were as follows: <table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 1in;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">October 31, 2012</td><td style="padding-bottom: 1pt;"> </td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">July 31, 2012</td><td style="padding-bottom: 1pt;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;"> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; width: 76%;">Current exercise price</td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%;">0.08</td><td style="text-align: left; width: 1%;"> </td><td style="width: 1%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 9%;">0.15</td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Time to expiration</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">3.76 years</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">3.9 years</td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left;">Risk-free interest rate</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">0.54</td><td style="text-align: left;">%</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">0.45</td><td style="text-align: left;">%</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Estimated volatility</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">87</td><td style="text-align: left;">%</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">104</td><td style="text-align: left;">%</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left;">Dividend</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-0-</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-0-</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Stock price at period end date</td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">0.056</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;">$</td><td style="text-align: right;">0.093</td><td style="text-align: left;"> </td></tr></table>

600000

8000000

10979634

10893384

0.257

0.254

277615

172500

86250

-86250

0.46

0.00

0.46

0.00

10000000

30000000

2000000

12000000

8354823

2000000

4124444

37367

P3Y10M3D

P11M9D

275644

668679

3556160 3971015 2691192 2822961

290534

311329

402300 416286 202500

75466

256141

7000000

550000

50000

429000 2300000 200000

1730000

162146167

110086551

110086551 5424

-8727

8727

8727498

182509

188514

6005

6005443

112883

114250

1367

1366666

16099

296658

312757

16099607

16503340

80234017

112778485

55148530

131894033

9375000

112778485

7499999

54426222

6249995

10227270

24999999

9375000

74264078

131894033

-49863260 13333333 11444440 48254955 9375000 57629955 48254955

1975000

725000

-1811746

4081627

-624797

-540000 -202500 -376746 -102297

17166666

13333333

6129666

17166666

0.15 0.15

0.09

3 3

270

1000

18 18 9

8745508

2000000

4347710

4081627

3102355

4347710

2575

17166666

3400001

6129666

2575

510

402300

540000

12383

-7230734

1811746

1548813

-793706

-7230734

624797

3102355

-3461069

-49863260

0.15

0.08

P3Y10M28D

P3Y9M3D

0.0045

0.0054

1.04

0.87

0.00

0.093

0.056

P3Y9M4D

3128459

358714

1029435 585064 659288 480951 1009827 1028780

0.08

0.19

2016-03-31 2017-02-02 2016-07-11 2017-08-10 2016-09-30 2016-01-25 4,000,000 to 7,499,999. 13,333,333 to 24,999,999. 3,333,331 to 6,249,995. 34,481,866 to 64,653,492. The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on January 25, 2011 and in March and April 2011: (I) (a) shares of common stock or options to employees, officers, or directors of the Company pursuant to plans approved by a majority of the non-employee directors of the Company or pursuant to independent contractors pursuant to other agreements or arrangements in existence as of January 24, 2011, (b) securities issued upon the exercise or exchange of or conversion of any securities issued under the Securities Purchase Agreement dated January 24, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on January 24, 2011, provided that such securities have not been amended since their issue date through the date of conversion, exercise or exchange to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (except certain adjustments to warrants expiring in March 2016 and September 2016 are not prohibited), and (c) shares of common stock or warrants to trade vendors of the Company approved by a majority of the non-employee members of the Board of Directors; provided that (II) (i) the shares issued under paragraphs I(a) and I(c) shall not, in the aggregate exceed 1,500,000 shares in each 30-day period during the first 90 days after January 24, 2011, (ii) there is a reasonable relationship between the value of the common stock or options issued pursuant to paragraphs I(a) and I(c) and the value of services rendered or goods provided and (iii) the Company does not rely in whole or in part on the exemptions provided in Sections 3(a)(9) or 3(a)(10) of the Securities Act. On August 10, 2012, the Company's triggering of the price protection features of the warrants that were issued on January 25, 2011 and in March and April 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 4,000,000 to 7,499,999. The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on February 2, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011 and January 31, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on February 2, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in February 2012 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 13,333,333 to 24,999,999. The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on August 10, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011, January 31, 2012 and August 8, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on August 8, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on July 8, 2011: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated July 8, 2011, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreement dated July 8, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on July 8, 2011, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in July 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 3,333,331 to 6,249,995. The Company's issuance of the following securities will not trigger the price protection provisions of the warrants described above that were issued in connection with the March 2008 private placement: (a) shares of common stock or standard options to the Company's directors, officers, employees or consultants pursuant to a board-approved equity compensation program or other contract or arrangement (up to an aggregate amount of 5,608,926, representing 5% of the common stock issued and outstanding immediately prior to March 31, 2008); (b) shares of common stock issued upon the conversion or exercise of any security, right or other instrument convertible or exchangeable into common stock (or securities exchangeable into common stock) issued prior to March 31, 2008; (c) the shares of common stock issued upon exercise of the warrants issued in March 2008; and (d) shares of common stock and warrants in connection with strategic alliances, acquisitions, mergers, and strategic partnerships, the primary purpose of which is not to raise capital, and which are approved in good faith by the Company's board of directors (up to an aggregate number of 11,217,852, representing 10% of the shares of common stock issued and outstanding immediately prior to March 31, 2008). On August 10, 2012, the Company's issuance of common stock triggered the price protection features of the warrants that were issued in March 2008 resulting in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 34,481,866 to 64,653,492.

-34921

-117975

includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to October 31, 2012" column. See Note 10 - Derivative Liabilities.

0.09

Note 4 – Comprehensive Income and Loss:   Comprehensive loss, which includes net loss and the change in the foreign currency translation account, for the three months ended October 31, 2012, was $668,679. Comprehensive income, which includes net income and the change in the foreign currency translation account, for the three months ended October 31, 2011, was $275,644.

698

0001059784gnbt:RevaluationOfWarrantsMember2012-10-31

4347710

00010597842012-12-07 372059685 00010597842012-11-142012-11-16

125000

amount of the claim plus interest of 3% per annum

25000

0001059784gnbt:MortgageLoanMember2012-10-31

855000

0.0975

0001059784gnbt:MortgageLoanMember2012-08-012012-10-31

2013-11-30

620000

EX-101.SCH 6 gnbt-20121031.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - DOCUMENT AND ENTITY INFORMATION link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 006 - Document - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Effects of Recent Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Pending Litigation link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Commitments link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Net (Loss)/Income Per Share ("EPS") link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Stockholders' Deficiency link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Derivative Liabilities link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Income from Assets Held for Investment, net: link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Stockholders' Deficiency (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Derivative Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Basis of Presentations (Details Textual) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Comprehensive Income and Loss (Details Textual) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Pending Litigation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Net Loss per Share (Details Textual) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Stockholders' Deficiency (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Stockholders' Deficiency (Details 1) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Stockholders' Deficiency (Details 2) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Stockholders' Deficiency (Details 3) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Stockholders' Deficiency (Details Textual) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Derivative Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Derivative Liabilities (Details 1) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Derivative Liabilities (Details Textual) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Income from Assets Held for Investment, net (Details Textuals) link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Comprehensive Income and Loss link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Subsequent Events (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 gnbt-20121031_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 gnbt-20121031_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 gnbt-20121031_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Class Of Stock [Axis] Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series Aconvertible Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Assets [Abstract] ASSETS Cash and Cash Equivalents, At Carrying Value Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Other Assets, Current Other current assets Other current assets Assets, Current Total Current Assets Total Current Assets Property, Plant and Equipment, Net Property and Equipment, Net Property and Equipment, Net Property and Equipment, Net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Long-Term Investments Assets Held for Investment, Net Finite-Lived Intangible Assets, Net Patents, Net Patents, Net Assets Identifiable Assets TOTAL ASSETS TOTAL ASSETS Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIENCY Accounts Payable and Accrued Liabilities, Current Total Accounts payable and accrued expenses (Note 5) Total Deferred Revenue, Current Deferred revenue Deferred Revenue, Current, Total Long-Term Debt, Current Maturities Less Current Maturities of Long-Term Debt Current maturities of long-term debt Current maturities of long-term debt Liabilities, Current Total Current Liabilities Total Current Liabilities Long-Term Debt, Excluding Current Maturities Total Long-Term Debt Long-Term Debt, Net Long-Term Debt, Net Derivative Liabilities, Noncurrent Derivative Warrant Liability (Note 10) Liabilities Total Liabilities Total Liabilities Commitments and Contingencies Commitments and Contingencies (Notes 6 and 7) Stockholders Equity Attributable To Parent [Abstract] Stockholders' Deficiency (Note 9): Preferred Stock, Value, Issued Preferred Stock Value Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Common Stock, Value, Issued Common stock, $.001 par value; authorized 750,000,000 shares at October 31, 2012 and July 31, 2012, respectively; 370,260,904 and 354,161,297 shares issued and outstanding at October 31, 2012 and July 31, 2012, respectively Additional Paid In Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Development Stage Enterprise, Deficit Accumulated During Development Stage Deficit accumulated during the development stage Deficit accumulated during the development stage Accumulated Other Comprehensive Income (Loss), Net Of Tax Accumulated other comprehensive income Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance Stockholders Equity Attributable To Parent Total Stockholders' (Deficiency)/Equity Total Stockholders' Deficiency Balance Balance Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY)/EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY)/EQUITY Consolidated Balance Sheets [Parenthetical] [Abstract] Consolidated Balance Sheets [Parenthetical] [Abstract] Preferred Stock, Par Or Stated Value Per Share Convertible preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Convertible preferred stock, shares authorized Preferred Stock, Shares Issued Convertible preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Outstanding Convertible preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Convertible Preferred Stock Percentage Of Interest Convertible preferred stock, cumulative percentage of interest Cumulative percentage of interest on convertible preferred stock. Income Statement [Abstract] Income Statement [Abstract] Sales Revenue, Goods, Net Revenue Revenues, net Revenues, net Cost Of Goods Sold Cost of Goods Sold Cost of Goods Sold Gross Profit Gross profit Gross profit Operating Expenses [Abstract] Operating Expenses: Research and Development Expense Research and development Research and development Research and Development - Related Party Research and development - related party The aggregate costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process related to related party. Selling and Marketing Expense Selling and marketing Selling and marketing General and Administrative Expense General and administrative General and administrative General and Administrative - Related Party General and administrative - related party General and administrative - related party The aggregate total of expenses of managing and administering the affairs of an entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line related to related party. Operating Expenses Total Operating Expenses Total Operating Expenses Operating Income (Loss) Operating Loss Operating Loss Operating Loss Nonoperating Income (Expense) [Abstract] Other Income (Expense): Other Nonoperating Income (Expense) Miscellaneous income Rental Income, Nonoperating Income from assets held for investment, net (Note 11) Investment Income, Interest Interest income Interest Expense Interest expense Interest expense Interest expense Derivative, Gain (Loss) On Derivative, Net Change in fair value of derivative liabilities (Note 10) Change in fair value of derivative liabilities Gains (Losses) On Extinguishment Of Debt, Before Write Off Of Deferred Debt Issuance Cost Loss on extinguishment of debt Loss on extinguishment of debt Loss on extinguishment of debt Net Income (Loss), Including Portion Attributable To Noncontrolling Interest Net Loss Before Undernoted Net Income/(Loss) Before Undernoted Net Income (Loss) Attributable To Noncontrolling Interest Minority Interest Share of Loss Minority Interest Share of Loss Minority Interest Share of Loss Minority Interest Share of Loss Net Income (Loss) Attributable To Parent Net income/(loss) Net income/(loss) Net income/(loss) Net Loss Preferred Stock Dividends, Income Statement Impact Preferred Stock Dividend (Note 9) Net Income (Loss) Available To Common Stockholders, Basic Net Loss Available to Common Stockholders Net Income/(Loss) Available to Common Stockholders Earnings Per Share [Abstract] Net Income/(Loss) Per Common Share (Note 8) Earnings Per Share [Abstract] Earnings Per Share, Basic Basic Basic Earnings Per Share, Diluted Diluted Diluted Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Shares used in computing earnings/(loss) per share (Note 8) Shares used in computing earnings/(loss) per share (Note 8) Weighted Average Number Of Shares Outstanding, Basic Basic Basic Weighted Average Number Of Shares Outstanding, Diluted Diluted Diluted Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities [Abstract] Cash Flows From Operating Activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net income/(loss) to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Depreciation and amortization Reduction Of Notes Receivable Common Stock Exchange For Services Rendered Reduction of notes receivable - common stock in exchange for services rendered The fair value of reduction in notes receivable and common stock granted for services rendered. Reduction of notes receivable - common stock in exchange for services rendered Write Off Of Uncollectible Notes Receivable Common Stock Write-off of uncollectible notes receivable - common stock The total amount of write-off in uncollectible notes receivable in relation to common stock during the reporting period. Write Off Of Deferred Debt Issuance Cost Write-off of deferred offering costs Amortization Of Intangible Assets Write-off of abandoned patents Amortization of Intangible Assets, Total Gain (Loss) On Sale Of Property Plant Equipment (Gain)/Loss on disposal of property and equipment Loss on disposal of property and equipment (Gain)/Loss on disposal of property and equipment Stock Or Unit Option Plan Expense Common stock issued as employee compensation Amortization Of Options and Option Modifications As Employee Compensation Amortization of options and option modifications as stock compensation The total amount of amortization of options and option modifications as employee compensation during the reporting period. Common Stock Issued For Services Rendered Common stock issued for services rendered The noncash expense that accounts for the value of common stock distributed to employees for services rendered. Amortization Of Prepaid Services In Conjunction With Common Stock Issuance Amortization of prepaid services in conjunction with common stock issuance The total amortization of prepaid services in conjunction with common stock issuance by the entity during the reporting period. Allocated Share-Based Compensation Expense Non-cash compensation expense Allocated Share-based Compensation Expense, Total Issuance Of Stock and Warrants For Services Or Claims Stock options and warrants issued for services rendered Issuance Of Warrants Additional Exercise Right Inducement Issuance of warrants as additional exercise right inducement The non cash expenses incurred for issuance of warrants as additional exercise right inducement during the reporting period. Preferred Stock Issued For Services Rendered Preferred stock issued for services rendered The noncash expense that accounts for the value of preferred stock issued for services rendered. Treasury Stock Redeemed For Non Performance Of Services Treasury stock redeemed for non-performance of services The value of treasury stock redeemed for non performance of services during the reporting period. Treasury stock redeemed for non-performance of services Amortization Of Deferred Debt Issuance Costs Loan Origination Fees Amortization of deferred debt issuance costs and loan origination fees Amortization of deferred debt issuance costs and loan origination fees during the reporting period. Amortization of deferred debt issuance costs and loan origination fees Amortization Of Debt Discount (Premium) Amortization of discount on convertible debentures Common Stock Issued As Interest Payment On Convertible Debentures Common stock issued for interest on convertible debentures & preferred stock Common stock issued as interest payment on convertible debentures during the reporting period. Interest and Debt Expense Interest on short-term advance Interest and Debt Expense, Total Founders Shares Transferred For Services Rendered Founders' shares transferred for services rendered Founders' shares transferred for services rendered during the reporting period. Fees In Connection With Refinancing Of Debt Fees in connection with refinancing of debt The total amount of Fees incurred in connection with refinancing of debt by the entity during the reporting period. Warrant Repricing Costs Warrant repricing costs The non cash expenses incurred for repricing the warrants by the entity during the reporting period. Increase (Decrease) In Operating Capital [Abstract] Changes in operating assets and liabilities (excluding the effects of acquisition): Increase (Decrease) In Accounts Receivable Accounts receivable Accounts receivable Increase (Decrease) In Other Receivables Miscellaneous receivables Miscellaneous receivables Increase (Decrease) In Inventories Inventory Inventory Inventory Increase (Decrease) In Other Current Assets Other current assets Other current assets Increase (Decrease) In Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Accounts payable and accrued expenses Accounts payable and accrued expenses Increase (Decrease) In Deferred Revenue Deferred revenue Increase (Decrease) In Other Operating Assets and Liabilities, Net Other, net Other, net Other, net Other, net Net Cash Provided By (Used In) Operating Activities Net Cash Used in Operating Activities Net Cash Used in Operating Activities Net Cash Provided By (Used In) Investing Activities [Abstract] Cash Flows From Investing Activities: Payments To Acquire Property, Plant, and Equipment Purchase of property and equipment Purchase of property and equipment Purchase of property and equipment Proceeds From Sale Of Property, Plant, and Equipment Proceeds from sale of property and equipment Payments To Acquire Intangible Assets Costs incurred for patents Costs incurred for patents Increase (Decrease) In Restricted Cash Change in restricted cash Increase (Decrease) in Restricted Cash, Total Change in restricted cash Proceeds From Maturities, Prepayments and Calls Of Short-Term Investments Proceeds from maturity of short term investments Payments To Acquire Short-Term Investments Purchases of short-term investments Purchases of short-term investments Cash Acquired From Acquisition Cash received in conjunction with merger Advances To Antigen Express Advances to Antigen Express, Inc. The cash outflow from the payment of advances to antigen express during the reporting period. Advances to Antigen Express, Inc. Increase (Decrease) Due From Officers and Stockholders Increase in officers' loans receivable Increase in officers' loans receivable Increase (Decrease) In Deposits Change in deposits Change In Notes Receivable - Common Stock Change in notes receivable - common stock The cash outflow from the payment of change in notes receivable common stock during the reporting period. Change in notes receivable - common stock Repayments Of Related Party Debt Change in due from related parties Change in due from related parties Payments For (Proceeds From) Other Investing Activities Other, net Other, net Other, net Other, net Net Cash Provided By (Used In) Investing Activities Net Cash (Used in) Provided By Investing Activities Net Cash Provided by/(Used in) Investing Activities Net Cash Provided By (Used In) Financing Activities [Abstract] Cash Flows From Financing Activities: Proceeds From Short-Term Debt Proceeds from short-term advance Proceeds from short-term advance Repayments Of Short-Term Debt Repayment of short-term advance Repayment of short-term advance Repayment of short-term advance Proceeds From Issuance Of Long-Term Debt Proceeds from issuance of long-term debt Proceeds from issuance of long-term debt Repayments Of Long-Term Debt Repayment of long-term debt Repayment of long-term debt Repayment of long-term debt Repayments Of Debt and Capital Lease Obligations Repayment of obligations under capital lease Repayment of obligations under capital lease Proceeds From Related Party Debt Change in due to related parties Proceeds From Warrant Exercises Proceeds from exercise of warrants Proceeds From Stock Options Exercised Proceeds from exercise of stock options Proceeds From Noncontrolling Interests Proceeds from minority interest investment Proceeds From Issuance Of Preferred Stock and Preference Stock Net proceeds Proceeds from issuance of preferred stock Payments For Repurchase Of Preferred Stock and Preference Stock Redemption of SVR preferred stock Redemption of SVR preferred stock Proceeds From Convertible Debt Proceeds from issuance of convertible debentures, net Payment Of Costs Associated With Convertible Debentures Payment of costs associated with convertible debentures The cash outflow from the payment of costs associated with convertible debentures by the entity during the reporting period. Payment of costs associated with convertible debentures Repayments Of Convertible Debt Repayments of convertible debentures Repayments of convertible debentures Payments For Repurchase Of Other Equity Purchase of treasury stock Purchase of treasury stock Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock, net Payments For Repurchase Of Common Stock Purchase and retirement of common stock Purchase and retirement of common stock Purchase and retirement of common stock Purchase and retirement of common stock Net Cash Provided By (Used In) Financing Activities Net Cash Provided by Financing Activities Net Cash (Used in)/Provided by Financing Activities Effect Of Exchange Rate On Cash and Cash Equivalents Effect of Exchange Rates on Cash Effect of Exchange Rates on Cash Cash and Cash Equivalents, Period Increase (Decrease) Net (Decrease) Increase in Cash and Cash Equivalents Net (Decrease)/Increase in Cash and Cash Equivalents Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information [Abstract] Interest Paid Interest Interest Paid Income Taxes Paid, Net Income taxes Income Taxes Paid, Net Organization, Consolidation and Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Text Block] Accounting Changes and Error Corrections [Text Block] Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Pending Litigation Disclosure [Abstract] Pending Litigation Disclosure [Abstract] Pending Litigation Disclosure [Text Block] Pending Litigation Disclosure [Text Block] The entire disclosure for pending litigation during the reporting period. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Earnings Per Share [Text Block] Earnings Per Share [Text Block] Equity [Abstract] Equity [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments and Hedging Activities Disclosure [Text Block] Income From Assets Held For Investment Net [Abstract] Income From Assets Held For Investment Net [Abstract] Incomefromassetsheldforinvestmentnet [Text Block] Incomefromassetsheldforinvestmentnet [Text Block] Subsequent Events [Abstract] Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events [Text Block] Schedule Of Stock Options Roll Forward [Table Text Block] Schedule of Stock Options Roll Forward [Table Text Block] Non Vested Common Stock Options Granted Vested and Forfeited [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Schedule Of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule Of Stockholders Equity [Table Text Block] Schedule of Stockholders Equity [Table Text Block] Schedule Of Stockholders' Equity Note, Warrants Or Rights [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule Of Servicing Liabilities At Fair Value [Table Text Block] Schedule of Servicing Liabilities at Fair Value [Table Text Block] Schedule Of Changes In Value Of Derivative Warrant Liability [Table Text Block] Schedule Of Derivative Warrant Liability [Table Text Block] The tabular disclosure of change in the value of derivative warrant liability for the period. Schedule Of Derivative Liabilities At Fair Value [Table Text Block] Schedule of Derivative Liabilities at Fair Value [Table Text Block] License and Services Revenue License and Services Revenue Working Capital Deficiency Working Capital Deficiency This element represents the amount working capital deficiency as of balance sheet date. Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding, August 1, 2012 Outstanding, October 31, 2012 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Options Granted Granted EX-101.PRE 10 gnbt-20121031_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Textual) (USD $)			3 Months Ended
Subsequent Events (Details Textual) (USD $)	Oct. 31, 2012	Jul. 31, 2012	Oct. 31, 2012 Mortgage Loan [Member]
Debt Instrument, Face Amount			$ 855,000
Debt Instrument, Interest Rate, Stated Percentage			9.75%
Debt Instrument, Maturity Date			Nov. 30, 2013
Long-Term Debt, Current Maturities	156,596	1,222,746
Proceeds from Issuance of Debt			$ 620,000

XML 12 R33.htm IDEA: XBRL DOCUMENT

Stockholders' Deficiency (Details 3) (USD $)	3 Months Ended	12 Months Ended
Stockholders' Deficiency (Details 3) (USD $)	Oct. 31, 2012	Jul. 31, 2012
Net proceeds	$ 725,000	$ 1,975,000
Derivative warrant liability fair value	(624,797)	(1,811,746)
Make whole payments liability	(202,500)	(540,000)
Deemed dividend	$ (102,297)	$ (376,746)

- Definition

Fair value of derivative liability, presented on a gross basis even when the derivative instrument is subject to master netting arrangements and qualifies for net presentation in the statement of financial position.

+ References+ Details

- Definition

The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.

+ References+ Details

XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Textual) (USD $)	1 Months Ended	3 Months Ended
Stock-Based Compensation (Details Textual) (USD $)	Nov. 01, 2012	Oct. 31, 2012	Jul. 31, 2012	Oct. 31, 2012 Stock Option Plan 2000 [Member]	Jul. 31, 2012 Stock Option Plan 2000 [Member]	Oct. 31, 2012 Stock Option Plan 2001 [Member]	Jul. 31, 2012 Stock Option Plan 2001 [Member]	Oct. 31, 2012 Stock Option Plan 2006 [Member]	Jul. 31, 2012 Stock Option Plan 2006 [Member]	Jul. 31, 2009 Stock Option Plan 2006 [Member]
Common Stock, Capital Shares Reserved for Future Issuance				2,000,000	2,000,000	4,124,444	12,000,000	8,354,823	30,000,000	10,000,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized		$ 37,367
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	11 months 9 days	3 years 10 months 3 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		10,979,634	10,979,634

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References+ Details

XML 15 R37.htm IDEA: XBRL DOCUMENT

Derivative Liabilities (Details Textual) (USD $)	3 Months Ended
Derivative Liabilities (Details Textual) (USD $)	Oct. 31, 2012	Oct. 31, 2011	Jul. 31, 2012
Derivative warrant liability fair value	$ (624,797)		$ (1,811,746)
Revaluation Of Warrants [Member]
Derivative, Average Remaining Maturity	3 years 9 months 4 days
Derivative Instruments, Gain Recognized in Income	358,714	3,128,459
Derivative warrant liability fair value	$ 4,347,710		$ 4,081,627

- Definition

+ References+ Details

- Definition

The amount of gain recognized in income during the period on derivative instruments designated and qualifying as hedging instruments in fair value hedges and related hedged items designated and qualifying in fair value hedges, on derivative instruments designated and qualifying as hedging instruments in cash flow hedges, and on derivative instruments not designated as hedging instruments.

+ References+ Details

XML 16 R9.htm IDEA: XBRL DOCUMENT

Comprehensive Income and Loss

3 Months Ended

Oct. 31, 2012

Stockholders' Equity Note [Abstract]

Comprehensive Income (Loss) Note [Text Block]

Note 4 – Comprehensive Income and Loss:

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14-26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Reclassification Adjustments

-URI http://asc.fasb.org/extlink&oid=6522872

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e709-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669619-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e689-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 17

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e716-108580

+ Details

ZIP 17 0001144204-12-067267-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-12-067267-xbrl.zip M4$L#!!0````(`).*BD&'/^S1XH8``/=*!0`1`!P`9VYB="TR,#$R,3`S,2YX M;6Q55`D``S5@QE`U8,90=7@+``$$)0X```0Y`0``[%WK/)Y MG"#>9-.91NU?SM*^&7L#%(1F#\Z.KJ M3D#2^9V'CHZD(W'VC_?AH/4&4>@%_J*6TB:DX_!_%WRY#)P MXB'TH]97#*SGX;(_O.B5T/_9@S\@:OT\08"I'VO')FGJ&GFN_?'WUB5TX/`% MEY&,O[<22$`Z591366UUOD[HO+^@@7=*_FUA/ M'\=]PCI\/W:"8<(7D!1P-"D\\/S?4X5)0\SHDM-_U"2LL"RK)/D[:QHZ&45Q(V"DU^_WCTYKW!HMST_C&S?26'Q M3B8O$\VT)=">Z\:)$<+VO*K>Y&U&11=ZV77P MBXSB\-UYS2Y/WF14\/PW&$;95<;O,BKYMN>$V7625Z0*2%<)/2>[`GZ153P: MH17E\9N,"G'8[MOV:%:G9X!_DV,^O=Y11QQ'*,1O\]HCT7M(- M3L/$P!]AKY5TB].)3>5WGI,1"D8011X,Z6Z:-!!]C'#MT!N.!K-GKPCV/AT1 MY]">.H'C]]`].IDZLHO`C^![U'J"3D3\4=''_'?/)4^P\T.MA-TBS#5,].%BN3 M!D^R*6!)>($[_QUW?11A?PWQ(PQ.;4LF5N2\/OU^!MJ=5]#:DH'53A.4[\ZM=D"*A' MNA/AP#X9L:8/7$P2.S;/\:(QEI;KX??C47?254YI+H[.B9F=KN3E["2S64J4 M%`)&A8^]?336GK6HO?E;!NWEZD_YBHU>:G=&B'0CT&"C)]Y.YC%Z4D%M*U)5 M1B]+[:_V1R(V;.>X7:+BBX$=AMU>8BM)#[C"3BOX(*^>(1IZ>#3%]K,=?6`E M4Y,.D<-:U5V"Z%;#HE^S2Q3J5B(.S2_2[6<$;>>UVR-U<1P=[89:L[FJ0Z-Z MJGMO0J,/L>]%WAN\M(=V'^Z&/K-XVGIMFI.`(U>;3Y@"#&U<]8U$EB\#^("C M1H@G&FY2:#?TR\9E'1HW<%A:69`"#AK?O,:70S*--R2K91[2L$AVN:.L'8; ML%F)#"[B,`J&C17"LO/C6H19EILHYS>9Q#_!T6%\;-KX:/":B%7)DL6T:\VM MI.%=RVJ&W":A9]>)MD%HO/X(2-7YH[G05H4AC_#-'L3)JE&W-QG&P^WP0*N" MDL3]Y/!5C\]IB!G,0II&]IZ%D&9!!IR35SXY%`[0G_=B@"[BLH9@OHS6A6K\ M8B\T7L3E]FI\/G6YA$[SG-W2&`%XM])PA2K&B&6YY725GS'5`(6[N>V2RUPM M<4.M-L$20/YD)QLV\F&\W-AXN6PD@,M()OE&51C)?+GS8":;-I/4(+ND<\%[ M?W+[&KZ,-;YB9GF;9.T1'AZ]_FL4WGGVBS?`'&R1LG.GF"P,UJ%G\G?M25.. MIJU46I+<[%B*<[XMETI+XMHJ+7:)AZ7@FD9.F7>K5*YJJY371`ZCYL%$5IK( M13`Z7[5!K\[@V]M0BM(/$BO`W#,(8N#F-1;*,/4F4[>D]N M4%K(71-W/S9M$AW7]7]@XY/%4& M,9O2:M':3\?9A[6?(B[W2>.'U;Y]T_@A]6C7-'XX]K/%RBL(DZ7M4!]3F"SM MG?;`#FD/;(7V->%:CD7(W^? M!"R3H:R+DEP>>JA^_A%LA\-8R4EZ47#&3ST[J@U5.]OF(!Y2R-;9EHP8/!N# M:<[VVA0.L_'FY-YLG8E,NE6GCV!2@)#_R?;)GOM7&SFO'=\EW:PS0MY@-\R% MG^.]-IW"^.(:^^OML`S&`&/.T$'QF8J?9V8\V)Y[ZU_8(R^RM\0]Y!C!M$@N M?P>;R)ULO&*ONO6&D)INS#G::]7SA1"DRC1W;SO,89VP89G+@XD0YJ[^B#%' M%\%P%/CXUW#[=@YR6:EQ`V'[=)^1W;^KL\]YKO]AYLFY3G5(^=DO,U@=.%Z\ MVGX?/@=)AWD-!BY$8Y\[%L]VV$11+,G$Y%X;"']XV8G[<;AMX01G<$GSN-?F M43CQ?/+>M\,4&*>=,W[V6NV'\TY[;@"'O,--Y1WN@(FL&%4!V3O>#?,HYO!@ M&ARF(9G)#N`NVT:*Q;TVCL-1VCU6_N%*H^9<:=10$RE.?`CB'5F>6F+HH/CL MMK-.GNP<'*EIOOE#YRMUAYAWM2&G)/2E,"JL,Q_&W6WI8< MJFS8,?S:M'>8R>^%%@^GVW="BX=C0SNBR<.FR([H\7"J=R?T>,B+W04M;KT* M=VQQ9_[%T49N(-'[:L"RM.2#B]0WUC:V[S:1FP3:]\%;L^4V%0/G?F7ZRY:5 M709_.&M;N>NH^KK'P['I[1@%_M9NM[[Y7M1Z@@Y9,FNUVNWI\[_^Y?8_X'^N M?W[X`M_AI:8;YF^/\`_O_-=OM_\ACW_[X;TYJJHZFJ8YS__W>JZ??;DZ4V]N MP/67LU-@7NL:N+[^\E_@]-,7[=/-F7YCZ;>3]L=`8D*9V$_X:B.(93AY/H1V M&"-X/I%0\G(*?OIN^CMI(Z/%;T^72\UY8:#*P#C%[_A;^X[%^/V)0)FUZWIO MV+;.J<+W\1`B.PK0FJ27ZI.'E]`/AIZ?U2RK@%)-G*31YW,^BBF&TV3)*TXY M7G16:P6_*VJ-6.75(.F#*8,]I5TFT?8]\*(=$"R+MR:F/HC[.7/5KZ_-M]_GJXLM]]ZY[\UOKHOOX<':RJF4"9_[N`I)OD0]N?1>^_Q-^ ML)&E/=7*IJ9T+F*$()GHA8X]^`W:Z&H\^K*1:H\=_IC.JJ;2+%U[`X@N\.-^ M@!@9ZC@.'!#[A6XKJ4[SE6IO2NH9V:[G]Y\^AB_!@(T(F2^-VTU5/D^N8R6/ M+P,G)A;R_#%BE`[VH/\:-TG7G6+LX`7@]L/ML#?;L00C'+:9JGR]`?$@\ M,Y?D$S-5`Q*61E42H%@$HFIR:8B M,X.X]G!3\,Y[@^ZMCR=Q?9)&-+8R,98CZXJJ:I3IY%,4A8U)5MBC`,F2UL$V M?BC"M>BJJACJ8A?GI<4VN.BF9IE:+BW'"6)L(P_VATUX]UW\!,70O?/L%V_@ M121!5)A?-22@Z?3(PD&^$M1,8C3('Z4\ZLM)LMXC?(-^#`6.U[H"9$K-V83* M0F'K8JJLT.-V,92IP[J$+Y$XD0!9E@U57_:+%)E2*!B'=,#7C"`]P1R=":*UB>9G6PI), M.M^=8[&@_-D!QKZ<@?"\%@8*3ZQ@.R5W$9(^P;%VL(L3U#!\`P4V-C65QU!>$9%&@VWNVWT5,A0VL."TU MI^1!4!EXMAFQK@%%#'CJ1M]PG/0@0+AM4S$E8%%=>YE,&1!,0FJ;&(5*[T+D M@Z`B.AQ.52*7I<6G(IKB\*VW8,6#+SWP/]BHBY*8PTU&P0>(DLR*')22.=NP M*W^_58I-*K%C<4=-6AFZK.)`*,_4UI_@$',W>.:+2AO-\T^V7\54HMD\5S/_ MVPV>]U'/.]2?Q5U&^G#DM=A)XY>`^3]"=WZXZ])XF^:24U;S>0B M9"',511H93+77,XXNF4F9X96.V]5A$V9O,DY_:XRYBJ(CQK3WZH(A+9/LHI`I7)GM\3Q MU*#H0R!3=44=S>.HK)J`:C6/J8I#C!E'XGQ$]8HR++EFO]>`F&(#/#7"173C MB)R()D<%MV/0I0`+XZTI7GVCO%7OWS?*7L6>O@K>FN/Q-\K=+FMN,PZ%2@LK MMVG%LBZO8)3'DI2=YL>R*E\:;78"1_5HUUL68PAEQG\R(>8M(JP-+4.`54/C MB?*+8(VS7.740?5L>J4AL4HJR7R5+$DM!XE[F!0AJF*GLJ:W%"&T!7#)_8$K MQP_3,\$T0N"LO`$A?]9-_?8UET5>M M9)$0!H3Y[.<*%/ST,VY4S8.@`2`9](G<(B`701AU>\F;IV"0'<#Q*$.1=9F. M0%*MER/,+/R25#E%#G194NC]O1SR-R@(PP<4]+SR9J_K.G4&@6IY?8+,$EZ3 M&J=D%16'LU(QDX\PA.3C[1W?I0X#7;V/H!^RW(U6<#N695B:1!EU+CF1N/*E MHVN*8FFUP.+M$<0)6(IF<8!+1I?L4H\P.8'T8*,5AU%XM"E-!K)B4F)1%7:M MFE!QJE*6)1F87.AF(P\<#/!$$Q?^:J/?(3E$+JI+&II.GXQ=34D8'O:!OPHL MG$JS%$61@JRD"F8Y,"@F*Q%5W$8.JZ MHM>&C=>CXI'0-%,[$0P`DTZ[JEPE7I6%F&AD;)ZU'F2\`0Y0%=GD1#@U@.Z( MW)<[[\HL=Z86Q.ZJH:LJM;JY1*(L_0(KMU0I=6VF`/J\XYT%-%.S0`&(A=GD MK,C\3'1I9;055;<,^K+&#"JBH!2<>%ZMF!04;A"]2DF(8J>L'60#-KR<=E\M=Q^31E0:HV>0J*H*0 M%$V)M`J1<"H)#Q`R`"8OH/$S45Y042T9T!!2S9>C7'1QL&$9FC#2O"[-`K*N M:P83_?G5=C>VYY-QJNO/GXE8!U?([(I>="DD*1I?X6T_!CTKK0$>GT*3[XS< M1G#X'9#X2S-D75D3+BD2DC(0E[IZ)VXR]L)7TB^[/7(AY&?8"Q#\!7D1[/9Z MY-EX,X6\([D-MN]`LI`L,D01!FI3G+*O3V\?I[RQ,%"!HDITP%`)T^/5=B$S M&D71%8WJ__.FUR98("-=TX%EE:3(JQCL-TS=L-1"3K'+F$]:.E&$O)T([:L\="O$ M6S1_E5.9D1L#S;L&JZF2!M8'GMC2&\31BL3S2D0T(2@&DR@Q98#Z!9*OC$.W\P:1W8?W,"+L^=U50%2*F5%-/B)CMC2_]>1O2G1'[/A1%$M M`P+ES\+`)1PAW+I-+OW&/P\@^8%LK`X#%'E_)L_+IS/HY"-_]/I0,=$*0!8N MD$KISW_4!)(WP0&[-TW3UT`ZR4QRX^2;OMW>?1"1A%<'>F]DU*7&W*MWY]7V M^_`Z0$\0O7D.*>?C87B=X6-E`E*,U559,4Q;-VGQ)[1N. M^P8#\GUIW,KJ1H79&S?E2C&S6=2F,?-.$"T`B)]?'_ML1*MUM9]OG;?>]?E: ML'%GFTLZH">B?"#I<2DY`I/Z[&1IQ9JF9M*?*LRE)A07LU(KQ<2=@JXI%CTG M9PZO=3':&=?HBT`V8G[#"B23U.2DY8JO3#%\Y`6IXO@>OU/,<>/PVOAJ-! M\`%)4$I:$;/X(YP/]W["?+ M*+]XT>M"TV2F)&RQHS226GEB6PQI.D_<\RXS.0LOCK?9!&XP"!Q[NO+_V0ZA M2_NC"DYTL%&L!"/[G+M.C+Q1#9Z"EX(Z-8/I?2:^.PGX0LI?=1$.!KUA^146 M"BH7X2H1,]O!!A'SGEBP--V0E1+0$]\RKS4M/9]_7;U#Y'@A3&8%M[X;.U#( M,LC49Z]!NV+<;&--$W#S+CH`53&LV?5#93A(YW55%ZM.I`U03XC:([Q1!JB7H"&$U3I@'35KDYX%]A^%WE]ST]*7D.!=K(^A'JX6&?6T@0NN(^2JY*FR]G+ M(;S\9.\QD=J77N@$L1]A-S;TXJ'0V4D1,='(UMP'K`09[]J7J:B:9JWBHB;PH]B),!ER$!6K97+2JPP:F&DP'F;ID8. M?C:2$>Z5-`7,;\0JQ'D6JT78:>RZ=EA)@4A&-AGJ"(Q<-]B!BPF*(E2 MK[$;(,GYXQ339SS-",?C096S!1ZB52%E&_LW@Y3[5(^B27HIQ'"R1NG#V1(E M)H:'?M_Q_/YXT!"G?A9JPK$Q*KPF;+R>&"BRH:Z%<;)X\`A'R".OD^!.7$YF M5NNE:3/F5@JBS7V1F67JDEH$8NZ`'3*%P^/A^/];O^,DP1>50UG^`BW=,%3: MZ1?3K``CQ_A8$S[>;J9)JB$29G+QT[RPV(7[0FK"L950<`78N//A%1/(XC"2 MVX?\*"!7SI?OOS+0)0#RP%'D1.(JH5)AB'@C7$FRQ(@J4?A%C,,C/Q*4N]R6 M34NU"JTL1;0"D`5=P=14K;@KB`?)>[FOD3HM71[FU'_C"2OIX>2(E>,@/)>] M\^P7;^!%0CHS4"S)9!E&\F#4PDC!K7B:91E*0QGA'MHU4[%`Q=Q,5U,G'Z$0 M$->I1JZK6R`H&EW1PK)DZ+F^3C@\WJ%"T34]5^=<"!-W,[N%=9+T+.(ZN^+0 M*8-J95C+AGG58N6^/`Q("LB-ZEE`XU\O[/#U`07DCA3W\\>W$+JXZK16!T_% MWP2-'[*NR99)068G7AGD`B%;.*"PS`TCYMX7`X:F*=;"A2QKX)ZL?X?/0.(N.-)L@HHN.R$*X/+["PV@I4WC<^4+%6Q2H-&@0.A&UZC8)AQ M7H@#-=/9.J#K%@#4:24.^B)A\]TH40ISZK"=*'$SGK@#FF$!T_K_]MZTN6TD M21C^_$S$_@>\7O>\<@0H$R#!P][I"/GJT6Z[[B-$S8-W28[N*O?9CP`='4-]4&OXVQ-P&63[@N+D\@;)VR"ZGR_ M]GE^KH;AVL$6;QBNNM:58]E.9ZUWN!I`?9M_=),T(I.+;E5PMH"-_M;U?6S_ M>1-&2<*B>58-OM$P^XZ@'!:KZL;8:6-5-[@S=.RN/=1[`S2)8%$4T0O?]LAR M52;@$^8?^CKU&+A/KK5M73],<--4;R>X'FIK+ M-[!MO;#?!J!X/NOD%I-6<7F#Q)LQO%T5L0;J1*L$X!43-`%!Q13D1B&HF^]@ M9]GHZP!9I>??I0R7[M-TZHU9A')7KPJ[3]-L_<(B%G:0R6'>SS!F"I:Y/W'+N]Z4`I`XJG_5*ME.O@``7^ M-D_5+%35A._^H:I[*J[5Z*L&G%SN+\KZ_3356VTVE=Y999X&X:F\]_8&3^W< M;#!OAEL`)DW8#V&D.S9T<,6-V&:/H$I,_8I3[Q?JV@[*D:"N*Y<'PYY>U6L' MZ%<<8.V#2:R>W6_W-Q_Z'1+BC4D@3JXMVU$@KIVWZ/2'?3US93NH5FGE)$U!LI5F;@B2VK7"^AT] MB:D21/I29G4:?@V#V;XW5?ELC<.VU3;;&VQUN_EBU95\?Z8Z0.HX2F;NC/&?9SK87J`H2_452?\K=^17_VT\CW9KRT MW[[DY_I9]P;K5A+V8+#67?I.KN//=B#KFWR?SNVZ>1J$9RL)W"@\M3.LNT[7 MV@TN<9M.EC?:VT%N<9X&X=EJW1J%IW;INKX]L`D$8>KMUM8@JQ(>&?8>.#G>#8Y^8-.6+'0F' M86XU-B5&/)S5V%!5TSYA1.H:3?TVV+X-8Y-%C\&23J/Q#1K-A]TEVX%P&"RV M.40X!2RV*2S9)"H:8[[-U7G:FWM5F*8Y:+:R`QJ$IG;/C'Z[.^Q4AXO7$Q55 MN:94D^0JCD-L,*\P52\0>&>:ZI:5MN^_L!'M9M&6/ M^WK--,U!LU54K$%HZOII5M>&_ZL-U@II3N?#O)'1`92Y-EOCL.VJHIN%K?8E MPLZ@5W*'L"*,I?9?P^E6E2=K&K(=SY4:A:RN/66WG7X/]NNV0):SP;Y6=N-L MC<.VZZ9M%K:ZFQ;<8]O>%L85&1D?9$V^)JL#%$\1J\^]-X@W93>UA[F3QJ-` MO$6JGM.U.IMK`VP`^_UTRL9@FLG>VE_`,/L4T,6&@.Z]H0JX=?U&+A&UK$%? MKW%69_(]`KV)/_3R'$<#N7;.7J>C5X[8%N[R)SZSR`LGQ?3L!OBC;P_MH69Q MUIE^CV!O+#0TM/5,PZ-!73=LWV]WK-W!_A3-W$!4<`=(XM#W)O2!1VQB&$54 M=Q?"R/6_PC?4$R;&8N]^&(/;]PTP>.-75>8__]5/7B^,.+GWV=^>X2,MU_=F MP2OCGT`$;WK_VIB[T&U,8:Q7AH6?$V\.DCA@=P881VY@\B], M(P9LIZ^?_766O,8)1O*/%/_`-';#,O[JSA>O_W-@6]9KXXT;>[$13@T=T5?X MQLM4OOM2C?)R@7_]QU_V#SN!:/7:NTU+_]MU%DG=^;_=,,,=C\/YP@WN0?D` M%[KIQ`.GW_!@/2./F@D(3H$OIY(Q`#K)&<:%)+3=?BW?RGY6/UJO7Q@W[BTS M1HP%Q@+OT&+I:K"*T.0%<$,#?!DC2K%2IQM,C(C-4E^DATS#"#XOL`4!0!D& M!EA4__>-,;@[+I>`.!35Q.Z48B#313_QC`0OPMHC.Z- M&0M8Y/K^/=*!+1!)EQ=PPXD6D0?H+A`BA``)Y3-@KE(Z`#I&$"8P]=A/0;4; MX)DQ+[@TD,K+A#'BFS#U`0C`F;E(<*2U[.]GW'G)#1%D\P(@?@%>W<#G(P:$ M5"#`H#C&6[[":D?T7\<&YE+$B7$5!"D,]X6(JU/V?SC@0+#43SC^.%1R$S%F M@/F:W,0&E@"?&+#9PQ&+C(YE&KCI@3WOB1(CQ'M";5%AW6'W)24#`@JP&,8] M0%Z*T]$_P1C`C;$(XQA#.(8[P=GY,YQA1/GNC%]:"V7#+_)`7S@'*SI@A9+MIW-UXXQN@,3[F>W.2\3<>V"&P6D#>D-HK",YAR M7D4&643A)!TG,3)1`H)P=J.S&XT,BQS.P&"!49_WVFVSW6[#=SY54$.`TL4T M`G(!K&-J>S%E+),J,5"<5,54_2[40!)YHY3KA5G$!._A:[^@*F`_C$^@#UK^ M?2!XOCNP7X.245WS4,L408V!(/"6Q,H8PUPDL5$DNPGQ,&S76Q=LM!0QBV&C MP7+`K/`'T(L6BPP4V"ZML0\;;"QX77W0%I=$,XP)\Z"0#4+#C4&W44]:FE`' M\,Z#;3I">3+&[3E-?80E'*&>1!()/8N,,/8!'!I%T5&L(/OAQ5SWPL:&0:`@6<,\?L(5+!MQY>.WRBFUG9L;^$2&;(R5&'FXV8Q:*]Q$O8X06N11+Y$F`;25V#%E$OG!52/CS$E&X'3A3 M)EX\= M@UG%9MQX&6-!HZD?WH&L`&+I\A+&&>/V1O-1FILD9P.D7#I/*6L5MN_4&W.5 M["Y@'_P`!R]AP/7/.\[`F,-^D"^[QET8?2=B\81E\2Z`=%_RNO9RLF2++:,W M3I/$\!*N0_0`-'`/B,`'A.\'#*@2.\1,.U2@$)3AL9X:F M@%R[,>D?U^<2+0B#%A`:[3Q`!5?68,0N$(]"Z<&K48@+J30/% M"7PIMY7\$E2HZ]/:(A%$UC(@!;[R1EQ^? MI-:%]X)H2!@J"T[*,`UD]/=]H]<&(7@/G#1-F'!.*1Z+"H"D(_DAP'P92RJ] M!ZMR2\LFG5QA.'$7/EMOOJ:X=.D"OF,B=UH^>B>Z-&L+'6>.TQ*O@"H6BQG" M&`DVZN)JD0]PX943@+@&C<\E0A")T4Z5W7`4`%$&*W8I4D3[P$81K1Q?N,[R MPG5,I,>"$]*_O]09$]T6/PXY_Z&VH7@0@IO9%C@@$1P(/T9_`>P'TLJQ+K:R M)SRM&!@W^NE*,^6LX!L3``V-W=#WW5$H%E+;`/GYP())P#%8M;/(_(=5X#)/ MHA,S1@I\FD8DL*0R-#=K0VX1H3`;^_"5-_70$8X-42;S[PQ6'*WSK.P8RBXW MG7%ZHGA!H44%6`"Q)VI-?Z,H`]J(*"$B%]E65XV3,(4M`%O9I=#AZB@)&9;W M.25*/G3.FI7^&`\!9LZ8D'M<(V3;#_4ROBVELCN^\4`73X3IX^(R\A_)9^/R M&E=6B-S,^.3FW6:;?!+JH4GRTO3`C>Y6"Q,.I9E$GBM_SHQC993C0Q%%:9`S M#7?.PTGH(,H_\Z8Y83;'9O/DM*I@D0B$ZM(;?D\#$D$ZX;V`^Z%H4N0,V]R2 M`?[9HG&#(`OY2M*7*#(`W$O*7Y=O`>)3]Q9$!D'&HKEP9,GE<0VTR".26!,4 MFU)]X&N:62&%AFD7A77)S:5SGG&HTMG!!,Y\>1"?G&>.?62#CYG'4$- M_$3T8$)8ZOA@R)BHB.M-!V<:DVQ]%8?0V M!-W+]>L#.0:S<\=@_'B9-N87[J5EJ!J?HS"`OX6MNN%P[+B:9-O9+SM;!F8\ M_(.3#-CX:A+22=%*XA&DWK$H=AV`@7*/EI?%0Y4?KKZ^(3.0!""W2&:PORG2 M1S+-B\#H\T'$SF'OI1'3C:?LX(R;)D*6B-4>^DU^_O'D#(A%- MPEM4;8A<-C7*7"[H4"^F03@";N+],+U@D0I.H%,&]-JXM0`R\,9;9$O!71#^ M?`'^.XRJ*4]*AI;+=3<_%EI0-H,X7[P"?P-P:^L1+1>WH'*,/+XCM)-;-??$ MH\/1)14-^M#EJGD5+!NMJLL5F_M@DJ_)T'->PO'>[#L(N`9EV7^G`5LAS+0= MHG-Z\<@15S=B-\C_P`37`?CC3&[?TH4ML*\P:ZJQL#A_%0'+'"/_=^JK``?W MD]$E@:2C\A:`[;V:^T51T,J\K14HKX#73^A6\AOP`Z]F"5V0OZKQK%T]`)R(M),X*];9X8%9%JO!\)*#-PP.O%%04%D5, M;>9I0W"6CF6LB700[C;Q"`"2"Z9E9TWP#/H0(_28P,?G%@:>*87W#!&:>,B3 M801_(KNG?J+";."?>#'\3E<5_5T!E(&3#TWPQ#P"O"+%2 M2D86*U`4I[B+;'@B)JMHAYRL@/DFUDOT?28*16A\5*JV?"^LY,QBX972V4BX] MI+20$7HE2J0!/`$3>Y+BB10,?W=#A\5B)2,F_!XIH\0YV81A,,D+&`]*I7/< M)H".8";^3I8/EH5/>`Q*0,)]@UB>%8A9B]A3M#U'`C27QI$W8C`NJ-J)2+&* MQQ[.0C/H`4*)C<0AXW!:I4N>2),ERI!A`W,D638FD@W\*76`CWN,O#/]K(,O MO\@W*4Z*@H-/[,72E,.7T"V"J;1A"//'L$4X/803R]UJ2174?$(!BKS+:Z5N M=2T`V^+ZZR?82!K%P&.4A^Q?12YAU[8E]2@W,:`$49[S]3:5-MNJ*21%LE,4)`B?V+L$R+5D MY=]@TO\+&Y4?L0@*76H)R[1SBIR7$SDE.9B46)$SS>72D9XKGW0Y9J$D(-^Q M*G;!,Z$S#4"K2[`]"CV0#\`P%Y/D."DE_6&_XVG>G)P5X;[3;_R(%J/2W`M\ MX[M@F7\=@SV*+,I'P:-+?&`.;.P++I%'VWB,QGT:/.(12Z<-30?"N3-0GA%# M+AG#I,DIRPM?OI1CWEI>O"(>(.'EW_.32[*R`IZ4HX:[#5'F^A2$5U^2F:(J3U,4$;PST9]G;(,WS(#YTIA%YRF,W7C*.M*U1M%2Y MP4?,QA-2,I[3C#C.:N"#>/$-/X0E@U[P M^IDQ9KX?+UR4?GBKC#XO4.?PSPJR2()%.49CUY?G%*,P2<)YADTR67>:4<:H MR21[=\//94./*6<(40D1D^!OS^P=9VD0B#\8'FRSR1%!V':6ETET7OW=@+C" M;(D9.R_^4UQ\6?_TF/PWF^$12%(3AO/B[PS$9S0#CS@_..B1%\3>^.177KXK MC(X6'QTL&K!+J[XKS"/YZ@A=/!S`H/.KUT85B@F?>R_P'1LW.C9[E)C]COY9 M@]"=1=_3!J)T_4?`F+,H!)\4/;`P>F7\YW@\G8['KXW=6,,0/I[C_,1?^90F MF(N,3&O*;'GAUJXDAQC#^JGRQM-!06]0P;'E&!'Z.-D@MAC%:IO#_M#L=;I[ MA60/^#_?!>WVI>WT:\_]'W\Y,L[-K/E>(:FX.>]NO(15V9KXUR\\*-6$+")D MMJ>E]N;`MNP&YSP2+L%+]\'CT/R4A]4P]-B'DGCK:1'XS/"G@L/1&+ZRU-YH MW*O&,T?W6FHM2)V!=]U`QD/P^0Y!O5I;]FA4:Q:2$C/NV,`=V.TJ`FA3W8=E M#ZQXM%AY<;4!M^5=&H(NI/JLZ7VQ>FQM:VSEONU&B".1<;6[MSWUZGJ!9\*) M,>U^W^Q9SIY)MR^CI*ZX>9\EM)_%S6#8,3N#L[C94MR<"?<0Q,U+2O*1GPZ; MG73Z=PXQM2PS/(PPL\:R=/GE*R-TU\@U[D2RC>'RO`LC8G-1S1`OAT7N.,$[ M>#+;L7,YM*FVZ`@3^++,OGP"7Q/Y>WLO ML[@A#\_92QZ>=<[".V`6GAINJ\RL\^'PSD#0<4LVUKN'D)MT*KD.CSE#Y8/K M1=E4YZR.D]NX#RNAHM=]3`D5,CO$ZMNFTV[O%8Q3R:9P5#9%M[<'A`\9_\D4 MW],^=OV/O^P+F_9EG5UQ2D<1]-COY$"="FM<#'JF[=2EYXM3`;^>P#@=*;'Z MU$RE;^S%>COVV>+YY'J[D^MZ,N]\)OLH#DGJBN9SG'\[M;"G(/\CCB?S=_IFI]>G(#,5MTH#K:/36"N5!A^P3@&O_H;%/+2`--W$;XVHO%KN M':J3/Q.%+E>6HOF&55)H>$^KK,#KZ6C08+%K[5BA)8\51/4^0*%].>PN'2%D MM?!V+&E74GPXAH>0M:Z""7P3I6SR:U9*N_ENG'PS[*<&L9,KF"?Q,P2"O%\` M1]%X_P-)QS95'UY32;X91$IV6-TYM]]@DD`+C4"N(!`3!*)B.%ZL.ORI$YY7 ME2`^8+W_LB.687LO1RP$>*4S%@%:I1"A>':]=P2=+NE%'3@NX+5.3K=L#:&JQ/4J@UX6F%SW\HJ[3AUSV+?, M=BYYI#8,E3`Y3>P=IV<"$'O"OC);5XB^;(1K*T;^HG=->YF`INA7#?06+A5IV`;]]E`WS3FMM M.I9E=NSAX^&U8=MT0D?W>_,^`,+'QK2U\1*=6^UQH&?52&+TUJ9KM4S[4'OT7!:MVV;G78M;7IB,FUUC/G]#S9.J>SL MVURP!O6FK.JJ!%W_M?$!"\`*H5C7>MZ+X5]SB;<,Z=MH4'5K*>J:TCVH^N-^MUD#4-QHX/ MV/\$6[VQ*&LJZ<9Q./:TJLKB@=^QZ#+V=\0JV`EO9%CNG!L7=:,(2ZC+?B7\9HQH.@&**DQC MA##6S][<;`WT/F]:FS5!Z?`J36<-CC?2@6/B`([#3- MF8%9%VV$$QZ99VV4J?T%"_X9"B*F,:.6\4`:4Q;CEZ2B=<5[)PL8C]H$<#H` M"+"FO'@_K!<'I?`D-A1`!O#A,=P+U-WL5^J#:GP`?%-!#*+OYPCVO!=X8^/S MC1O-W3%+2>]KC=',;)3?W?$8FWN\8SZ8QL#U7^]CP)>W<9[/4]G'U#3^0=7K MWWCAA,TB=T*Q@L^A?X_4_NB-L=,J=K[(38.T5U.AQ(Q"'Y'XPGQHJ[J>R7;36:/W43K&!F@3F-F82,03?2ME/1JH M;+IH;S)WDX1W/UDU5R1VO*DWKS5%BPC8?!%V+Y,=*=D4J)SD.H537)K],#Y% M8*CY]X$8O#NP7RM&_N(NO,E'+T[T']^!FF,)0*[U_^9+:V6(4V=4!+6SB MWSN70RT:U_`.EO2*&)G:1'/!J\%3E#D@#\,4^T^[!C)YK"'#.]_P^OU+P@B! MQ.;A7I*"L)-Z`?:/SL]FB6YXD]<-N.%)_L`/_"K>.(P6L@4]XDE;PFECYL%8 M@*`U)*`VJE*0:5JQ1&VJCA#J9J0VZM(X8L$O,40D&A+*]CTT->_I1DN!H./[ MU/ITPMP)6FVR#SFJ,]5_;<7VK<1`V"B5!9X8IIR?P1RRPZC]AF_.V MA^M)E'`%`S:C:#P]HCZPKKY?\PH\`"ZAUEP1\NB(W;C^5-"$4V#U9%FG1U_M MJR#7*):ZQU0S$TC%8\,P3'B/@-\"I"A><8MD"D0A0J[T"!CGC`Q1YH45W MOB-:N%A0V]Y"MUMJ9/.5+6`#X8DQ2)2.61$GG6VPX2WV+I&MSSBQ!+K>K>K6 MNY+:^R3#59F$P!:WHN.;IT1JNUML(T>"7_:U!U8%1N43I3YO:8,7H:D]J6SJ M"?8+E_5CQDA["?4J>IR2>8W\B$:2:(M#^,ZICPTV"\(T*>I"'*(HQL:>X'+% MF0TEM$O)7)=/TS_Y)/MGFZ+M[,?X$CRZ*/*40BSA@(O<#B=UPB8O*IO^)C(E MK6\,\F<*;XNF(/9<4G"(?_H8K.\&&T,_.WC M^!?&N+F!'S_X+`$/(:*=2US`MXJ.]8VK+&ENWVD`LF!&W;`))FPCAV8"'P`4 M!^Q(;IR-W`FVVTEN9&MOD!A2X.,3O*-U$N$V+FFJ)7L7B;'Q+71]>,LP6@?U MF-JG&?Q>+#TGY21Y.63Q(_LQQLEAY.=]U1%S2A9+B;/%'2O=K=*_FWJ3%`01 M6$N3%-LWW7JA]![$C) M;-.EK&14:D64K4TIM]+O,1/FYR"2[\AF)%>!``5[2X-(W_N7'_ M[7XW?@$;:D&&`@HM>%;\3/ZW>PON$G_0--Y>7ET6^!GLC<*DV`6YL#@HF;%[ M[`\29[";GMN7'6/N^;Y8JRG9AVXG M>!&0V8TP@H43W,+:T6:YR# M3N!,,&/26#7FDCWM8MEO>BJJ5HS`FA M$5CO[%9+?%7>OJ)305'!E$3A4-`VMUDX2T:@ED7W:`W"6V\6`G_$_KU0WF>- M]S`T'G59MZ0@^07M_,L7@*[J+`=U/M"K,1Y]<$4SX'.S M])A$>MXKY#S7!'+@.]!%O+S7&UA(^/%7=I,"U&]R47%17&(8 M@F0+OHX3L##1*I5L4A21#[)6F\6IERA%1E@%(;]&,F$B`HF;7`%X=R,4 MAP01;+[QC2NMZ`*$M%=R'("TMH;#07ZGW]`44K1R4[54I'(_<9T=FMF:9V'R M,(7).^`UX<):=`Q\"VL<%@]_ULJ*8H"$-A%8I=X$_6]SDRRI+P_T8]8T6+C> MA-PR8:3(,R9=Q1]4ZD(,@4?4GMLB!`)TH4-)=0C%URAGT"P;O"*"#WYQRO"09\8( M(]XAO<3.!0_D-S!KB!FLGGZG5#JQ[BQB'-.8)0EN[8)+FA2D3/8">?DY$^JY M93M\$:8Y0S)>>`&>(@AK+&,D%&W>C`5F1@==ZG/Q./*]L4&V-!X?@.(#DS>@ M=N.:RRT&T@X$^/$2T$_,KB_W>Z0KCR-D^##*L@33+*6`020/>H4ZRM8]M\[< M^;]A/C\FC%"-@Y9@<@:/<5\^9GA7-P%36T09U"$4T9V^X>RL`YH9Y/(MJ1PS M)VQI.;D:%:C/9&B15A.F;$EV6+N0=!9S+^*#BF/H0%#<1):GCW/D M0P0"QW25Y[$L([)5S#N&6,OT)SS%@QF#=)YM((#P!^[L!/8M,?83U2D%,T#$ MRR8Y1XO6J:B#XZ(T!L:+41ZP,;E0/A[(,XQOCV`X3([P@DM0%SQG0;!Z&HA) M\%`^N.&']QZYY8:OO*Z\:SH)&3=71)"NU/!0-BA\&?JISJ><6V)6AA&8&MYW M-$`!OAOT%%W,K@!JX:6\R2V+X#4VG9(#ES/U\H$&V)R8BTM\+W8"SB0R/DP# M;4`9W8Z,L1O?&%/85_$3Y<$_4#!)QQCC,H751]4D&,U%)QI/,64=!&2@0"HC M:6C&!H6N"P[#B*$!&_-TM3Q/@38&78__)2VF+4`MK/I8!J2&[(_3S@UE"`Y_?(40'"-^1D^'=KZLX]__Y5Q<"U\B'ZE,$T MS&\%*G))"H!R&_TPF+6H+#C9']G)8>P&X=3#PA_`C#$,FB;Q^,:GJ/-\]/=< M5@]_5D_LN33^(2J/>'$VLED0Z35)WFKLFN$WF70'X5#1389ZN!J1^>2`G4#K3(=I,J'*^2S\'\ MD0$)&DU"2?8Y)SP,(I%7M5QX*7+%-.+JOL6%&K)?$VSY+31071:+XG!%/V=< MEQ>Q(#=72`Q5R49?M$OC:HJ1W27@):-Q`U.&VO.<8$Q2MBXFC58R+C_2FK&$ M.R1EH`&O+]!:R$[C"\P4IN!A@)D>@CLTD\8RNF`"2)&?K$P1>1`ZAV$9SWD` M:\=+N!,W)G:@AH:4_\.'TS>17'A>)&B-(0,3,[!.$C)3UE'?)/BDJ7\71M]; M7M`"-I]1?L*%J"GT0OC6/EI%7GQ#^X_#0O_%71]&&)Q:QPXP[*TWX0%]`1[Z M@QFMB'DEE!JCD_#@C\FQ"L7@<4)`1T#,(GIP;>?_ZJZX#F+WCL2;L? MTA9^X\;>V`!*B2N@X+M@E2?XG.L3T:(^$7D17=+Z`SR8$9YFHJR@@4:8)0V[ M1UK,`2P=1ET-]Q;$F0P`ZTTM9"*KVEA\2F%;+_45$7FW>G>221JI8P'^-LAE MD`'Z,[G^&:9>SPS=^,BC*F3TD&G<424SE0ZB]=\@'>#?BZXFZN;V0MW<%B-$ M3#B+^*35LTVKB_4Z^AB.C)C(KI(9Q,L]54R-LNP''6).LBB7\!3PM)J3/\H,QG34U@1_A+=,7?'0VLRH+`R^6$+*I^DR-K=-K*K;Q..B;8\; M1<9D)P*=[3:7J7$@'O1\%@7^$G1R4[R/P)(;7J-O[/ICNJ4#(V@T-`W'[-I= M.5UNMZSBFS%=M$[P' M&S2Y1U.A^0NK>S9MAOFZ,AI2^DV*=VSJ@7D7C._K63$'E+]-1AS$33GB=2)) M=L_M./+_G11[E?IFY?T(<3\"(Z]DMPN'BV<$66:GUS-[O9X2MM/\)H.8P)DC)U*L(P8BTZ$)VEFE97:Q3+!(,^!0@&AD,ZJ?\0`*/;(5\ MQ#?:E^T!G6#0TT]4WS>PW@.S;_?-[G"P:F5Y%OT_TZ"01L]E>2S$:"\W`/[^ ME5%,Z8TQ_&EMP2#4%SVSW0;EVNVL`L*-*7+3NJ-:1`NM%E'%:9XH@WS5=+JL M^:J?/3)59P>7@5^#`#8J=.Q#'I#,Q$.CL$8B:9^N[XUAU69D^FEG.),"T;DO'=K2TZ*$<4/ ME%WW09`K\O_/!,FDN[OPZA5B?.P4X1'3IR++ME(>I2TF=I_J#,NIPW*X8LTJ M)I"OA]F^M&PO6*XKR[\5#GUW(#HW7,=QZF)9K6)LCR>L:K'$-:=$:^B]EY87 M6];G5L/(EB)^<7.J)<5T3]EC)4+8N]KXQVJEO8V4F^] MI!.G&,;R*48]D;?]8N\BU.A==5+3[*S'QNC18&,-;--I/YYV*M9@8#K6<=JI M-&8WK9<*^AGYB1%?GOH_'G;"5K*/!QO+-@>#QR.*11;(439[4\9"64"BM@5Q M-<>RZO]626J%U+PX.ZG7>QFOH=MC:]NRK95Y;GYSIF+35*1TE3/]3IQ^1XB6 M56S#9'=/O@W3/D;7]3[X8,.AV6O7BY2<&S*54/%,P>TI:`_!VW'JQ6C/)"RT M<[7-OG.(?;RBRQC_?)RJ`S09O^[B!:Q%W[Z2%"O#9_DF[:'!I\L*?XA[/@3& M$:\O4/5J54N)^IK(ZJK4NT7<1N*9ZUAR*YHR+^&7%MB/!=WOICQF<25IDK_V MMCX[_D&DQ_8>77KL"9J]9T>UVSW=_7D>M)1)949)E-3F+K',9C=/IFSP:WT:EU;O.PW<;E M?5I48*=H9.[;<03M)^IWQK.C$U-ZNW/I='DSE6J7QC@/G)T`?M1`ERW77Q7%LD"8 MO821NJ%6%8#:,*EB_:7+VAZHKKAHH-]3`2.JA^P&O'&O0S/V3,/IFEV[9]JV MW=`4'ZF=KT`))H"QNXB"TQ0*U))6#6^U`?:^:??;#8V?=6;JM.4D=A?7H,%U MR#HHTQ1]>FQH=OI4_K6A2:1)V19S7.#)9;\_,+L#;3&H1EWB^B],O>`$GV"! MC7+Y#60J=!7321@O^XL.H_+TP`=,OFZ*3:5Q:D<.D&_&2 M-DIN^HRZ8(IR(@6,$ZS#[P6B4BNV/L'*X"C*Q[P3\M+M\%B[CLT[-.71DY`5 M\=B`>3XGBF[V&,JOB6H3JKD.3E:;DX.1Y#25L;3W!4E%)"9L?+>B&DM$HA/U7CPCJR0 MSJOUJLT#@W+$J%H*O8I=%:@]=T#M(X"C0K%CJ/P?YZ\):A1>9YLJO8FB*D6R M+=Q[M;ST(+T'DV1H+8-"A1FQ1:8;KQ]=+9GAS>=LXO%V%PNJH"^+FF>0'D7+ MGX#AM4GZ)+GPF;8#B>>IKA_8SC-1^&B=7!6#J14M7B\G+J+Z'***Q(I6BUP# MVVTLU2%JV2_`NJ=B/J^,"_?%JKV`$@1M3#>:*"FSINBDZF)IPDA3P`O_DCD2 MO)JT5I2$>LZYO+*\"_X93-*B1BM8X9O1C9-<7H5!%1O=.8D\JF:LNA-@" M6*69-T8+Q<--BFH;ZY#R,MKP:!4SV-O@P"^O_$6HO@_8$]A<&#= MA6A1QDTDT:,&Z!*YB-F87R'C(_)'R*&2[`UPSL)0]E#-EP+/;2G:%M3G4W6( M+>/N3/R#(0QOF@/'+I;R:BO^7K]&VW`Z=?S(FY=YYR6'E)!_HLEFJ12<,A>K MP2[+P#*9I\FW0D64">-:6`Y34'A4G@R]7@=Q*A0SDD:TU.2JV_2RJJ5Q.N`X M#2QST.OA8+VNV7,ZX*W93[B$RO%4I2RC%10]7$MTHA),@Q^R1H2@#*]?;%"( MFAY4JDW7=_#(JF[..94'&AB]"2D1L"LAT/Z?(4IY9?>&04OE&*X%8&7;KV&4'-66U#EN14'OL">W"`\ MI'.?N1*TF]3>I:B%$.%2M%L](K/>)1N_BI@LNGWCC?`,^@57N6B-K-["F3() ML8331#;!6MI9-7;GG,!2([R1>ON=W+6O"RQP<8VBQLM933G.!_,#-JB[N(F- M:Q1)B->U0(Q+1]7O3/?HL%^,89F.Z/>55>HDC[73;DW`MQ75O[3:8%,O`MT] M;`-'WECV3A3_Z@"$%\,7^";]:;5?9!7XU`ZXPH#/T2REFLI0V%(&G:J/4PETTA; M.*4RN`9`KY@"(S&V`T3P>,@(^Z&97(MF$VQGV'W=U;#3H#^R49>CXTX&G;+; MJ"5,AO+QK30SB["/P-E@E%N>1I`(4492%\VK[\H1?L>.[D`G%9Y5 MOQ:M3XQ&$68"_V+O**WOW(@%;.HE)7T/&;6N$8<+,,,4MA\@,4J3S)#4NMUK MJ\?M(:1,_DB*Z%[0,SPRYL$":#UN9(P,8V)$*QX5$[R+YTW8>?L>C:XX"ZXI M/EM$ M#\DB$FY0EF?S8*RB>(59M(33<6VEXO8XVTMG>^EL+SU^>RG;]RB"CFV6HZJM54X,&ST70VFHYE-)FE%I/DT,$I&%%Y6,XFU-F$.IM01S.A MGJ;A4+Q6L^I>9='*@,TZYLI`+D[^"L,Z\P'Y"=Z.)K31Z/$/5U_?&%=?WQK? MP@7P\0!LQ%R[)7A%7:.G1HE6VV@9[QAENV(Z^:^>._)\6LGL>CUOR'1IK+E\ M$S%NX;K\3@3/L"NY-"&2T%%+>W/2-5/7B[(CZN==L]/MFWVT?+)\0$T)9UF@ M=.F2AABYOI`UV,(]TW7`U$0S:A&185,9+7B,#80#Y37!H&J-;#-":% M_-S"(_@76GM'-*VTG&U=&$N;RUU[^*A+=>#S23Z+%2"P3:?OY"RE-:UJ7>Q. M">H$:3(66C%W'1*S2"1@5M^TUC;/!"_YJ@!-Z3NK/X2&\C2ED&5DK M_#DQ8%5>N7$GL@$U/<1]"1U;ZA5&.NNWRFC<=9GPN2:65VLIQCM86O9P MW=R2F+$N/$NJ06LR$T4SV7X97$_9&M`EYZ9VGRZ!CY`EE; M7I5<#D-J&U7!YAQ@?)VZ#$6W'I6$V*80X.DXK48&PCT+WQSD^\:[=Z M"19"WA;]%P`"PX(A1IV:]>OL[]A8?`!4Y*4>?IZ8`I#X2`ZMW&5^.X>41GX* M->%=+#>^H1L1@@W*EI2S!@43RP7*I7$M8H6W_'ZL&*P:%^IWUHK+EI>H1&`@ MF4.-QBH:'?)F(0,J^W1R@:4'D*&X%J"`5T%;;`#?E->K]6N+/"B#F&3+ M*1<;E]J;%`R5,G!'#-QQ'KJ+F,]N775M4*W;I?$5QRB81_F6W[IU)*Y*SS&- M7BPYK+A9>\F+-]MIV26#ZUQ8<14SVH3Z-$6*J&6[@,FJ]5`UCF%)-2L%SQF3'?DLV_%._1X@<]AT'$"P.`U.[F: M.8%8,*)9P(65-\V+BYA""S@$EP@YRH``2?$X`EN/&U-^X&`-?B)^!6&4SG': M-"``U(!/5"E^NRG7*16$3YSI4^UJORR%(PD@3_I&ANXG*/O$!T M<0]EO0)X$-2Q#[HC8B*X*2O4YZ/@P!E2E2^BL`4ZQ,7@=Q)YHU0=J>DL)<+4 MG&F6\.8JT8]#W.Q*EQ;*5<18N9`N7XAR1/C=ZJOEJXM3D-*@F\ZQBORC76&P56/HK`Z+ M*ZYKFUJLE#_@^N)T:82':&C5X]$N.38Q2_B6R#9/&,W<0&P=3NG"?HJ;6E5S MA>.BR&26K+NJ7UF::NYZ<1G1W* M8\2DD9#4)!- MKW12V&5K9UDFFFN($W$Y4>@7]FO96Q(T#R4N1?:2BS8O":K'`!T7F%;^;H2,0+-N;G5_\(J`3T M5US-N*RPB)"QL]0GKL2Q!0.(VYN7QC]J\QTM9>:K;130%'36`A+9WM`46XY8 ME109D8BMRA7KFFE;ROTCM#]6M&HO.\OC'3T4+B2706MGD"R3O$^35%Y M35OPGVE0J(]4S(*K%C;-I46@82S,+BW:F;MHKM(B0C2RZT7B):`WPG!8'F'K3Y*:U)AHE[>P5I0:KQ]:6`SO?EK-`B[F# M%%G#_8-*#3VG>$4=M[QVD*.:Y`P_>'>L0"0<;6,ANW*"/#9'KB0#;4 MTON/RU_+FC+D_#6YWQZ$2U9CAWW+%Y3,CLG'/A"-&UN4^Z02 M?OPLMXFGR0/39:E1TS1*>*$X=7IKR!0I!:[U>F.R%/XUPC^X\3!ZNOE#J]+% M+-,&?5CG4+)*:L5524EO?C[C%\^&:Z4T\#,`6<1[@UN8/XIX;H.-TQ_PDCS/ MNVW;[+3;6&X.W0'D(*QR2OEM/,>3G/HKF1#X61C%E&U-9VP3X_T/+/.(-8)B MQCA[.B^XZBM%2L=%P(5'NUB#>$SN12X[D&?Y4J8NJ!"38N.XODV'3%71"PA,=F=B4F3ZEX M;IE#7EJ<;[+E40LO9#N+%XH26FSM7;#\,*3J&<"HKJ*4R"A*9R-A`ZIN%N32 M:&,^_@S0)F>MD%4#UF$?D9;XMT MDX;(O2K1I3VDY2IH MMP.$N:R]F3->RO*ZZQ@M,L/[6P$'Q5YXK8PG+\S!3B2[68"N$T6@G&E`CEN. M47B!UUAR37V)$/@6[TR"`_D389]E6U2( M+;&&1?W>?*^F0JNRO754.UP_)%Z_/=O: M:E9H6Z;4XRXPG$#7LNJK1T.]6R?3,_E90I3M5VZ7=G/T[H5E#BS+['=[M:=] M\2`V%@WU<=E8RM:F>4%VLDWG+IQNN_;&7$F$'1C@T#LS;Y567_`'WLGXHM/O MF09L[N6E.K>6.\`5C[\"A>[]]XO6,%0LU=[L@:CE6^ MVU'V2N-7.];B>+[:\92O=M2\N9$_G2Z[N%'RQ".XM['4Q/"AW=TH+,OYZL9# MO+I1;1'/-S?.-S?.-S?.-S?.-S?.-S?.-S=J90\]77%_O@)QO@)QO@)QO@)Q MO@+1Y!6(#<'%55<@LJ#@4[@!<;[@<+[@<+[@<"INS?F"P_F"0^D%A]4GE2`$ M#WNVNO5="X#T.&!G((Q*S)@<6,>]A!&0;5[C]'#+.Q@[W[BH!%S)U8NV335? M'^/UBO6T.%^OJ'F]HB(YCYW!<6RZ5KM>49&8XGI%WSY?KCCYRQ7B,%9^6W&^6['V;L6@?;Y;<;Y;<;Y;4?-NA="-YYL5IW^SHF=WS?ZP?[Y7\03N M50C'\GROXHGUZ>WO=K8H-*YY=IOBOEVGS? MRZ9N]QIFLK%CX5"N],"V>)!()!,YU_+*S63Y^$;FYB3Y.7'$M`P);'[+ MY`<\=PLCB@(D5(`G#L4BT1$V/\K*SH;)YU87>0J$D4D;N2K^R6&2\1HQ'*%'460E>U?`4"5$*5H1 MRVU>-6)+@>8I1OB>Z*;_5DK8O&8NW0S\$$%C"#T[2MQHY<$\-FG!XD3N3#^+ M]+TI+6SGLM^C"VY/>0'X!LT%I[-DK15[-G?/EG8BF``S'@P/QQYQ-RV#[&.L M1>S5X)-4M5M>65;?S!7*YU97MH$I#LMSGZ?&\XXS,/M6ER;VFCHT26XB;'H/ M5+V)5YV<\"M6&1RF90_,KC.L,8AEJ@[9N6/NU5*N`._:TYNW*A\Y+]C*1>[B;\_X_VX71A:#E8<(MYZA3G!3H:,=')5-_/N*P/OAL'J8=/LM MO,3M+B3(NE.H?>%WN$,%)6)D6;VV.(EZ(\0NR/V"1%L1RRN/4)W^Z9T\>`23 MHHM=QP=[.K_;,_9;'HU>K6.YHQ_!YGCJJL33R=+8LC:Y:!?G MQMC4=^^'%B5X'Z\36QW2Z`^"Z M1I?GN!A99K?;A7_U1=EI68`KR9Z%Z\(*="D7O'2;(=JI"6_-?X>C;1V'-,"!>1T'KBTKF"! M"K?]E.W/;=,P3Y6[5'F`L_%YBL9GQ\3QS7Y_8'8'M735N>'!SHF6'U!MTF&P<07>`:]B%AO_B',%%JKD8?)2(Z>1 MB$DIWA.6L&CNX:5,YTHEQ3R6$V=X1DIY>J<1,2I'%!NQ]X.*/8^Q M_I<+:[=(D_A5/F\;$\F3R/N>97!C[3"\L?QCX45N=JD]\N+O8-(SRC!G,'Q" M]>A$M7R>;R?RN[5<<'C,F_/"X2'>\NC3=L M[`*=\YE&>)?%%>^O\C9,\6LX4JLK*[!OR,V_"U-_HK++95:;#GJ6>4Z=%X)Q M&"W"R.69:2*-+4NDTVY\BP34[^Q>+`WG(8%*A>PIC7'T844MA0JWQ)>E9^G& M&UX^U-RAP<%SA[A^W#H_Y7C9+@+P#;DN1:X\&"JG3IC/1Q%X[E\/F,3JP2*.GOH`GT%KV!$Z+VNU+IW[: MVT^GAD.W?IQ^&8?#2Y?W)5[?:9%V4/\0\<28PVHWP=_'D!_O5M<8.2(]6^W6 MHU$U#>-R>`'R58NON(F\#XR!H,E>-,T6N2Y@!SNGE0>['1+#_66^EM6ZV:5L M#9:_F06CY-4UW:G$_`)>7?R&^9-I&&4E'P.6J+=.O-A-_H(,QTS<#.25T_\. MR%&D_5JA9V(YT@8JX-"7LCK4<+$<_WMH9QC7>H//%6Z?2'IC488FC7 MB[,>`%A&P:UJV M4WXCV--81Q3=OY&LX^59I_3B[(H+Q#Q('6AE%@4==-RIG0@5GV>RPC8%H?FA M2(C]+_A%<&J,X$:B/T#V-:_BBS5_M0J^\S!*9BZU"Y+A?4Y.<2&7GI]L>F/U!6Y!&$2$[QU#X3S5<,P3OU`E2N)(^!:JHP25W3[R)$81)KF6% MF"X'L2AVTK-GH]$!N6 M(YM"%.9<*3V0\89FM^-4DQ^]SM#L`9<>7GZ4(*3M;@3-&9KV8*"35]N5:BL6 M\%RNRIUOA2:)U!Z:`[O_1#D\+[RT>A1=O,/:X0>.V&P:UF\61JJ(3H4*%R:: MYGCZ&O-.+-3D1&UF_7?`.MG83=\V.T/' MR,Y\85#J6L7]!&V9_^ME?7M1+[+X514!>D]=YAZ*49E/S\JP,#@:]4S'Q[(/ M/@7&;^%MOOE[3M[GJL%@_2=OXKD16!*_L``$T@_C,XBCN3MF*;FW,5KKEZ9! M%_G%P7U(HG<6,2X)1<6A!?D\#%PHJD;".P0J/>Z'+A?/`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`\93#GFD[=>GYXE3`KRWP:7H=O MHI1-9"\0C\6-AJ'7M"O8(N@JP0=Z$_R\N`+'("LF@%?9O3A1-9QDT+I:@X4# M5A(HBQH/VWN)&GV\E M]T\=>\?IF0#$GK`_?$7?NHS\A<7,C<8WQ,GOL`57N,!R,24$V7[5MEMP/?_! M'-BV.>Q9S&;=/IU"]C?VJ"C;R$C^YW9OQQ$P*G`_B!DSJ&#?L*R+[A%7IFN!@S\XK?+F.^&#?;R/U&:](%V!37\MR;QVJ]X9#?@L3UZ^QZ@^\J77?[/?A M7Z>6/?APFUKOBXC@R)H]YQ!$W-B!8Y>@[9J*FV#Y`'7B]_]*O>3^]#..8PUF M73M.V-0;>RP8WQM)Y((R'?,<8VH>'8\C;X0)QJ,0Z^M'3&0J>__&,KG@HMZ= M0\$/)!2\;41S4X;:`2`Y@UX)]"M@.=R[Y=KZI$%_>^,&V/0CW!V0'7H%/[;# MEV7J]\JIS^^8D%8[&"+-CE:"=KDMOHD3/[O>I'5=UASV29'A:[FUL&=$SGNW MMN2D6HWK.NR>,KON@R!7RJR;"OE49J;L/M4 M9UA.'9;#1?G+FW*VVI>6[07+`4G^K7#HNP-QY'\=QREU9\&>6KFKT@$&80`V M;#K'?\W.I1;J7"K>8//N)5=BRX,=-8S,E1F8?;MO=H>#O0-S2BDC.>R?).87 M.Z->=OIZRAB7WUAHB)O^\7>^;2Z M9[;;CMGM-MJ9^_@8/1ILK`'>?GT\>3C68&`ZUG'R.27RST^N9O7H'ZZ?-3H!1+75\VMA8MCD8/!Y1;%G=PMVMPVWVIHR%LH!$ M;0OB"MN'>O_FV5(@+_(UI;`SYGSAA_>,^C&JO*HU='ML^3[;6IGGK*DS%9NF MXM`<#FO)X#/]CD"_(T3+*N;OV=V3S]_;Q^BZW@^UZD9)S)E\)%<\4 MW*%D[!"\':=>C/9,PL(](-OL.X?8QS6223_B$A)CIY\J=#UXY=7TKW3L`(/\1IQ4[RVU?++:UWZ%:6E=79KQD`]U=V1S##0%YV?E25$?M=T^YUS79_L`=(#MX. MZIHDQ='9_A!UK)R^V;/!37)VJ69_S&UU+EQ5Q7X'K`=#V)^=S@[+O$,5IIU- MH!5V%)UM`(S:U9VK!&L94P7C6@;4GU\3-V%X;/K6=^-80'CUPXO_A&E@X#?: MI69UIYD>^LCFP%H'[QX`:!JWB"?&;6.8",R3)#28.[ZAX&T8`#)DV:`M`[MI MG/HJ[HM?N90E*3]-&&`_,2;>K3=A6`@J8A@/YI95O*HKP*[=*$JN\*RTH_;3 M`:!].=AW#X#B3B)"%8(UDG:M.RJ6C\/YDVRP%/\05]>H8`.LREBMIA<`[[N^ ML8C",6,3;A&EV4YL6(M5,<[V8C\>IBIBN?A;M6A%P^XWEN37X4"6W$YEGBUS MV'?,]EZ*6Q^BCFNM):.QWH$HN*4:4=)%-'RA1>XUV;I$CVV7:WMKFZ=[@0:W M++-?N[QNL33P"6XA&NMC2?J26I`G88M?.-UVS2VX$OTM5_W@>S!G9X>O6>8-YG=%R_D$[.ZW9[M[KW;WD[#`ERUKN:TT<=2HG;U) M.#VH_BXY@P\MW1+J/4B[MV\_&JOW`=NV/;MK]HCR\:ZR3%UYYY__ZIH#='G`F?DC[%5B:686Y$<'3!`Z".)[\R`7"?M M8<+\\:)EH&GCKSC)1JC5X@@4>2+$*=9T&NS'(.T=O*:3BJ+NO^C'*5W"+S:: M/#Q6#Y-NOX67N/M+$B`.A=\1DEZ+70+>N#[=>G*3HH!3V>?6:V.=+;R&;J=T M`=;.+CMW';"P'NA5[UUOO"LRM$V[TS7;UKXN?A_Z9@\]^%YDG^5RUL88$O.F M'F:HQ;JB7\?"VZ_8+LO$[<8^+$W;[&]1WOS$:H%?=(?FH-&^6"EVXS1#LUX:VY3[G>1T'KBTKF"!"K?]E.W/Y:.IA\U=0[.SE.AW-CY/9GDZ)IZ\=)S'4S8*1)GM M=`LW3!Z@.#L;G]L;GQVSV[/,=F^W*^1G\_.1F)_KSHHUJ[1X0-E$6/^1W8GO MFIUNW^Q;]3KF/MC"`OLN%H(5!OH#LSM8UE4K:P(TE'=0GFB;O;TB`^+D.TY] M9_>@%Q.715`L%8V&W!4]J'6W=\ZH!\;;=P\A\&Y-!=O.\;*.73; MID!OR*AI*-'Z)(`X0K9WOR<.S-^F4807&V29%.YGKR3#B61Z#\6[[7U314 MALUB+OK2E6:O)0VK(X,8!93N9V0_O2Z=:<[*?3@;U;0XJ4PGY8 MB?$>[(FYB\6];D-T&$HO7QR)F(.Z%UQ.A@VL]JXF3M5V"!(,:>[U]%6XPO[)8%&&(J"9U]^%\*G8%GS4-G1AIX M_(E_?'WWS)BP,>@:/\9(R\^]-OXG@W;E3-N#4XSD-08.A3#_"*/O7C`3C2+? M90WART"YBO_\-*U&FU;OV<^#M@!G[4RY$"AV-'WCQFSR5FM#<(41U!D5"WAS MGSWRF=^WO+ISH\DGWLE`J_WV6XI5`FJC$5-/U0)9K?:P/^QUNAI7-@WH$:E0 MPEF/@0J_T#G_=?"9Y/XO41C'-?=7*17:S:%?`F&3!/C`*]YB"@0(@/?*F58S MGA@Y-L*;(PXJ=UZQ\UT:`0/Q1WA+9/I1C/I>E?=M&-O:`#2YMF)0U'C-;O'! ML-,9-+C%EP#=DZ#[@XI\L,D56(WNC$FB?R;K;PM=]B>8BW_2Y#J).L`"E[;3 MWXL(7(?"R5&MW!QYQ%33&/F@5-O/7CP"KUT'"8C)V!O_S@]WZ].I(*SL?K]G M.7MAJCRL2P09;9YDM'D-\I-8^Z+(7H!MA$=X`>#K($ZBE"JG?$IN6/3MQ@W$ M_+]A";`8V+118[YO.^TFS):ZX)\@S:K:!8,>T.S1DBQOAY^*55P3[,.0ZG=: MG"9)U3H8;^5A/PR]/LBN(P^.NY8@/[#X*E@HQ.SOW(2I<%]S5KV-EE:W=U#Y MMA&]AT7N.H;M$R9W7F1O1_.U\>`U%#^,S5,3PV-HK<.2_3",7A/#@RH_#.@] M1E:O@YY.\+?4JYU"A.(PA`<-OS!LVLXF,.Z'%(=5#=XK:+KV\,_/OAO\YLX9 M+Z*<12#Q>WB@)^HF;PP!M@N'2+7AW3NREMT0LIU'@6R[&K+V8\#5JLC%)XVL M*H+>#!-JZ/@8FKXEJ1B;N6W87_-(3K^_G"#^\9$YD`Y7I1&+;L.QN&$S"4?Z4Z$X1@X^"O\.8\$V4LHF6#?<+"\`!\?&WR=P+//!=*&%.7N+9 M,:D+);7C]*R>S.EJ`*;#X5=-$PW[5AO/T(Z"'RIR-QK?P(_OV"WSPP5UR&EL M]>S>T+*&=@WLUD)T*-RJ'7X.;'O8LYK$3>YX\>I'-_K.L(H,JHNXP549MAT] MK6[==,V`56TK6%;''E8'2]*]0&7LD/$'-L@0P97X4["RM5-S-.VV[4Y;$U.[ M`W5(%"NM3]?JV8/>0T=Q]T9@:[=6FQ_V-TNCHNWYA?EX^4@;N#E&[CO=7F_9 MW%TY98/P51.[8`]TK2T!_#6,8YP6I`F:3%\P)OMI^AF^1?KCKQ]!H\[3^1I` M[7;KHWM/]N\:7N)@X4_?6`1JFBRQ"@S4+\8;*H.\!D]Y72W_WAHL"EY;HD5RHO#T=<#H M>?'86E<5=LT[-MZ$SN\LF(11O,5Z=<%64/)L`YP*G[=H"8'+XKM>^4:2P+=; M7]EB@R?9?,"+9!D*^942[S9]&'[D,4SK^Z>&?H"W-]6&U8 MB`U`7*6SS4!8_4Z>K]9-F+/48)$FGI\B#W]EXS0B@?C^Q]A/)VR";Z,_"8X? M2J5/T_=N%,"BQI]91/&,*]XYLH'4$3`9K"XX<%JPK1'8CH+LFAU6W68H)Y/5 M;@]ZCF/M@4S$P5JNJ7Y7H&:09Q/LZZ9J`)2-W.9T[>YF*#;,9%6 M6]ML(78.CVV^VE$-D$-B9/\I&%\4&?L4?<%S:-H!69W4SZXWN0[$@4$%'=,: M].W^(Z,&K\_V+208P."?L(B?[W-Z5*#*8^,/[2RI`O:'90E^JM7TGM_I1M=I MH;7MPI8?'\/:=H>#`Q*"&(5^DP4;CB;LK('MM(?56#L'\3'0W%V*68.!8W4? M"KJU1%2OW7;VB)C.]_\`*`XK?Q&Y;K=37P03J%5QY%]_""-9+>!XV]*R!X.* MZ"Y!?2QT&]B>5C=_&>)!H%V+DZU'^)_3QN;;75AQ MOW>[=L^V[1-'YR9B%9>G9^/ZG#BS?0C3BH:4U;;MOMT_KAC8C`](B(I&,-\] M)[Y]OGH_3EY(*[6O%!$WT_'`,`PP[:B^K.Z#,.BV^X/34*R[X[.EI<`K2XJ> M?MRVKUG3L[PH17>N2(QBW1I85E^OR%!U\I_W!O`JAO_"L`F:R"9:R?-EB>\#JZ"Z!T#N3]9>RY;1WBU M.OT>[:.2P>O,64?HM-#!0D99,:?DG^M@')&2HRN>�FO9"_6ZL#D4@-Z@6`;UX-:_(R"U?=?]'O;NZT.\>Y<3ZBD?JQFI5\)O%=P_;?@_X9N:J_J#4(5\`],\L MPMZ-[JQ2/:HFT5VD976LAKJ-O1GH[/Y>=OK]`'#%4VAY1:\6X,?$M\:A4:/X M9K5@,E'&8:,;!MRQ+;^CE+/PVD[5=.?U,^T(TY8I^@>$J6FIME26XU31VNWB M;:-H"4A.8L&L0OFI#0`?'KN=UFT+[$B094(*P00>;XJY5 M<2D/^*G8D8J^_<:2#%H7ZVD2Z?;[UM'A6]W!E\3GM\W$A6+_K3M MCN,<$[X&B+P+IRS9/'J2?EW':M.=P_63[0A6S:N0MM-W#@O9 MKM'P#IU062>'7>VD_:6P]\Z(U/*MFMDB%7V_.O`=;*.%+#QSY+I>T[^LW8=<`NG?J!P_R.\?^]#DK[J>^>&M`'5NOK MY2PKSKPG8)O(N"SSP@N)1*>)9(6LN1+*WU89;\KE/$[=M-ERGV[/:O>%6 MJ.42=M>W<6]J8]6Z#%#:V%U1YPH8?)[O`-]P,W*5"%%Y[@8!K=^3:]`HH`LV M!@,=:[E6LEA$9PU[\&X3%-G`.P-1UMYCF.ONL2L(7[SX^X>(87=F!HR;?%E5 MZ'*U!5<\8^GR!FK=#7Q5-G-CT*Y.EEL!K=XEO2EHY3K\'F+;!@P9-D!=8`+K MLKT!VO*9&X2W.GUIZP[Z^X17/[+;G;KYYG]5YVT,UIJ4W156$K4-JY4.SSS3 MBR^I6;:9NXZFX',[Q9:92W-G^EUT7/S"YJZ'!5<_HK8'#JR62K'%W0LNQ+OO MR@X75@)3#KO66_(7>"%K/70=\(XR54*63=\?Z5CVH.L,R]#;"._^T&S\FDS' M&?3U0G@UL21#\$T8?A?W4SY'(3!TR)R878#Y.:/MWG"JN`#=07NHZCGOB).,WQ8+ER\-MJ8. M=VUF;@\'=E]%8BM.K2U`,^!6I#;LO4%_T-X"W/7WZW,>3B:LQ*_KFB3LZF]M M`\YAT&DX5^KATV.KZC=/`_.R2CE/!//2HCI/`_?2`CQ/!/6R6CU/`_6RLCY/ M`_.Z%^$VU6>J@+9'F:.OL@32+,*]\"+RK=Y5#'C4D>(_PPN]5KO3ZH!I6Q&& M@X.K[4&$M]]JV_#?TX575Q6"P/V6=<($SG:ZH.^@A2DZIPJNIHX$>8>MS@G# MFYF+`ERK93NUP,U=M[@.&KH)(8:YFD6,'L#9_ML-,`7CH^C)BG[EU2+R9-'F MG[MFN]W&?T82&GVS.QR:P^'PLG`C)`/QL-#C*S*+1$)L=P*`,LO M2"V"1Y\PZM0-?]UZ<=7^5PWS][<;9F!-+C>X__]CPQ,7>HQP:B3PRS3T_?`. MB_/%6:N8.\_WC2!,C"3R9C,6T9,+"LHO%%+XI\1*#'8G5\GCE;G@(0&=83NF M@:`9;C`QO,`@<.D#`4N_O3(NKE\8%^X+@Y^8X[!C2O8U8LJ2"R,C%'W$8&68 MZ`D:F_#@%("+\*_(F'@10!A&"BR!O;%((T0^P9<7O@NCN`M$`B`=W1NN,7?_ M&6)@7;X7A$%+3K)Z5)A1']@+)FS!X/^)L!&V8,2W]&="[/5NN'(58QR#2#<3 MGX%`#-8[P0M6ADM3*D)V.2%-XV+T0E\T0?-T`>1"^)@PT7!P]F-,5=UQ(/@X M5AFJ^`4B43(.H,`77NLA]#F%50/6-Q0'&A/LQ[H$':[L2UPNPE0;74"%^:$Z M8/1YBB](Z"@V`X0`IOTR8<PU`AO0C>:X(=W^+K#`Q36*&N\%/2Y@S7'^PHU@ M@[J+F]BX1I&$>%T+Q+AT-)%"^+H[@]TP0U9`$L,(END(DT*.#/O9!4IVVJV) M"X*(6@08$^H7P,6P%\6),6P#1]V#6)HF`$')CO>`M@X^0..1E'QH,L)>U725.!>4Y`KL(?_\@-',MV*!'NFPCE?F3,PG`2 M9S0GKO`$^&J!)R&\A1P$T-\CD>XP=QI?A[\!@,3(9)DXN\Z&A$>^HG'#TW$P-BGKPD,*91.#>>8[H6KMAS#%<@;W&N MHY'=(),[@ELST:.@IG'6V\$;+9NCVD!E5O)Q[1X)C6%S)B/;9A?3IK)E0^H\ M/R99.R!N8).Y$_@*0$1=2QH"7EV$,6B5!H0LV3%+8VBON82TER2,%F*%@07. M(\@T+[XIA9/,GK46`>J5FTRK8(Y+XDT])3,J6S,=2TH(L7>XX/;&8"/031=@ MG@1!3&ZX6/9`_Y..R";9SA[[NJT]%DL4<+$'FL`IXG1<"ZVX/7:TT)0AEMR` M8LR6\_AFES"()F6F>F[7CO^5@E#A$@!Y'BRCA,V`U>"/(':%HEMO$DU@!)&+ M"(^LDA9%6I/`0*B5C.0F3A@`"XW(=G61\\'4,"XXG8@\5.V9-X@2FYL_]`+4 MN$?#P;Y)8N83CTNS&7L&PD"&7CT[2:\1+SRJO#[NX`O%_P-:@`V M&ZG%40IXLA@&NH??9^`H`9WN/+X+LU^+YB0L!,=,X"\Q40^H-'M`.V!3CWMB M\FOYN*?"6SC#%#8F(#%*D\PR1*;#!MX`JK9ZW,!!RNB3>IP="IH(V&D.Y($% MF(9"#7'YAU-&+JXST(IW'Q.\"R1".0?<`%84Y]HY[C!%#IR)0!?&?3;=:JNH M45O(T_<]BJ#C&3N;0FBG;^[PY3H-8Z?`.F=;YVSK',O6,4L-'1]X(I?H(A%'I0@/J@1A) M;4QY#(Z+1Q?Z&)H>8T+NU8:$%5(<9%%D=E#^O%&).SV/19E*0EPCSQ$..=EK MC-!8:2GARD4;R2(&NU?28Q:YX&47`!P\G)_O3UX\;J"+:1, M$-W.B#2#))?6`IHCPA3&C`:>NHZ9LP>*)@/9![GY48_D[(UU3[]0"K,;8`!',^)5 MTD_J>3RW!^6&B0BQ*;E1<#Z&Z:M#H!AZ56&LL%W MF'130SJK/^P[56;%:^/?W!\LQI]^8^775+=LA;(\^LYSK\=[T]PP^__7:AD? MPC`!F<%D[H_1:B%@OA=\?S45O_T*'XP?]%5ROV!_>P:PD-_U3'P;A3Y\>Y,D MBUJF:$TBL%,1UU-`8*=^'=41H&\_$4=_ MAFV&M7^"N&Z9H;4`E,^PN16@WC9'*KG:Y0I6=KBK/W>^[/0@.%VC_(0'VFYOC<+7ADHR;SI_6L#[.*9!U^T M%PG\^_$:'%]T*2W\G'AS3(]E=P9(+#YDMGUX4??V&:KKH_OYKOO>&^MWP*C7?T0SR M7@G8#6^R1;>2M37$Q`0\F"H_J6,B<,_&-T"0G&46L_'E++Q]^?;Z?T!PMMM6 MVQGV!]W_>EE\60X7LQD5-J>/$YCLQ\+WQIY(1`+/>XY+'`9_>[9<`TO'Y-G/ M)*#7X,-A6)KB9PF;@N1E&=K\6$L1(4`//<'+JG;+:M/=\/PO\K-\[V5NL6#U M_L^>VM@W78)L39>:]>!6X=!VO_6.C85VVR^[U5Y5N]7N;[&J$^:]>D^3:'U% M^.[]I`5V5J^E3I--'57Z-B#<&X!W7VW:]6O2!HEG]5K@RYS*B@#<$87[Q9I8 M+4L-E?VFP)SD'^UE4_!?:FQ*M&60+D`T5&GOW#G8=O%7/+E+5EOM10JN[Y#@ MY/J8;9Q16<"%)]6?B5XXMGJ]WRPF3ZK==[VYL?!3#.,*(QI^ZOQ$$3DW"-*Y M(:SARG#HRKCP$G7TCO#QU+DA<'<;U>V:Y/NIYQ]3=,04EV!ZTVE9%):AOKRV48!YA M62>X&UL550)``,U8,90-6#&4'5X"P`!!"4.```$.0$``-U=6W/;MA)^[TS_ M@X[[6EFVTYXFF:8=Q9>,9^S((SM)WSH0N9)P0H$J0,IV?_T!0-*B)!(7B:8` M31_J4%AP]_L`$%@L%K__^32+.@N@#,?DP]'I\;CJOCWZ M\X\??_C]/]WN7Q^'-YV+.$AG0)+.+2\SQA!V'G$R[5S^V_V*X1%HYVM65X=7 M=?SK\=L.__.*XA`]_]RY@`!F(U[FY+>?.V=TY/W;]Z\/_NET[_M=+OB M/1$FWT>(08?K1=B'HVF2S-_W>H^/C\=/(QH=QW32.SLY>=,K"AYE)=\_,;Q2 M^O%-4?:T]]?MS7TPA1GJ8L(21(*EE*BF2N[TW;MW/?DK+\KP>R;E;^(`)1(I MK5Z=VA+B7]VB6%<\ZIZ>==^<'C^Q\$A@0.,(AC#NR->_3Y[G\.&(X=D\$FK+ M9U,*XP]'$S)*N@+'TY-,^J?[!"4@Z!F,KS#AAF(4W<4,"YW/(\28I.RH(][P M97B]8L8$"%!X.@[B64_\WC.LK"=4#E`4I)'$YH8KN*(Z/"5`0O':[*FHO)$W MR_82!RLOBP1#,5T%*G^7I&&,V$ARD;+N!*%Y3P#8@RAAQ1,):??D-*?DI_SQ MWWW&(&'G*:53'Z=]#Y=-1#1H'@'_W.#\=4.D9?HL70VD[5U,:>_D!_3>*8" MN'AOO(T=G9B&0/G`Q\>]E'$EX[E0`$5'G4?`DVG"?VJ=PD$R!6K:VBH*NT]. ME84Y$V)L)W-)X#39[O(D02WE]%7YV+H?\S MJ%J]4LQ9-M3&FG6`-LFYBCLFBR`)4)155^H*NTL%96FY0R\<8VQJ]39M?"=M8''O*WH!8^#*A4-8`$E! M3V"-@!=@$ELXR(T4FZS9#6;O<&K/LD#KY/XXCKQ<12 M,7E6L%-1N%UMS^/9+"92#:V/<;WH'IM./<@;'L4-`]T;;?MAB#,=[A#F*ZAS M-,<)BDJJJV;U>F$OB#(!P<6!>0%1+-U!]PF:P"5)@,XI9L`GO#C`"5^1I#.! M/(07*<5DLBZA'+MWKMP+ZIL`4?\AZ+;>K9=:2]R;F,?*I#+O6Y40/Z2EG<#/U$^B-S1>(Q5RZ1RJ;;W M*^]1!"SWBWV*XU"S25!9?*^[QQ40;W2;2AM=W,<_CQEOJU+'>][-E0NBU9*N M<[!AF7[JOE M]OA5K`5_O2UI+&]RC;WYP1-/:C08@IQ0WB%:.?LRE729`F/KW5LMWT/$ZYQP MI6\1_0XE*U7?NWHAEVDRL=D][^4G,7]#D=A*#6>88)90Z7[5TZ23]($KK?5- M+D%KQK4Z'4Q&-B-9EXFP0""GXE=W^DXV^Q(^"W4,7%&H7>U>L%^Z5DQF5J72 M>VPXF]!N!*=6F>>>JU]ZNC[')%Y55S^\:@3=YD9CM'L3E2&?3*$H4[.LN'). M7R/B-#7UAKHW-UE&?6;Z7HMM`OY$04JMB-.DU!OJG@N\T$T_@JV7=)R"-;/T MTXW6]Y>6P1&?$";"F@%9/E,[$?6R3M-C8'I.V'_=Z2I"529T!:[MY9,89E/, MIIES7,0@?81Q3.$;Y>@,QF/Q+(N9%+]=,Y:*,Y#"B:=:A37V#J?Y;Q#*O)W\ MYDX[XP/XX7"$>9":40HWQC]R-B.#!F6%^3*_R:&ZUL`2YV MX#N:C_#2I`N\P"&0D&5*OVQ"7\_F*%`?4;2HQG]:[5`S[=.*0(=FPAS$^?"K M*'[DBH:8@M#--N)ALXK7#7[8?%_+^ZJ\Q0@=^&=8D!Q^?/["Q&F]%[]9/^!3 M9]TY"XM*VMXWWG;6M,<]>WM*&AF6V^7E`N:\N6.)!_\[`@DS"?NSF";X7_E< MN5`U$/><13.(7$RUL.]IL]>T;S^KUCAE3=M`;61%F`:BWL'XZ`+'(AR_.M(H2IDJIEZ/>6[(5#UOE^K:*T:\IQ;5^1S_1N`9O9!G:[X_E.OD*P5U-T*"C5"'I.IPX6,]=PR^'L+_L=(J1Z,%[)3O22FDBS0V!0@>?4FL*4 M4_S6J1!HWS:*O&\IS6XEO7.J,=4EU>J7 M)E-#G#O+_LJR\F9):EF?7<[F4?P,8K8HE*SSD#14L:>\-@5KP7]#/K,:_DL3 M?S%D0&BQ;#:2]9E%,W`*HAKR?QEUU#L* MH]J@HVY3L<\4-P!KP7]#OJ^&%E:1K!S"^RFB\!%Q4,K#B_YC:UB!I]S;PE1P MK(EO;)?CH@D.QK)%\L_+-T0I7T:PTC@UH.<1PC/56MJN'L\9MP2M(+XA9UC- MX+Y4JE!FF73F\@EH@!D,Q=NN29@&4+.0WKHJ3RG='KJ"U89\836LKL8P6$^O M3,5]9L\8HH*QAEQ>-8P]4$`LI<]2FR&$P-N+T.8R))74,_K#C7ZS/`N0!9J#D_9V@*L@L#7#:82GV?IX"+PXM\:PCB[((U,LH&_ MECDC8:\I,X.GX*HAQU!=[%.VM!W"G&+Q=CG=JHUOJBSL,QZS_7"!T?M)CP%L6X%+&UJ+E)8$/XV]7$BM=S!T;D"2L&D6QZ; MFC:87U6CC1CFIX3B])G>H;?7)559X<$W`#,:B43CFYUDW9NVN M-BOZUV4/CND-<`I2G3J85S-(O5B>WZZB7BA95')P--?#5?"MNVK$B>/=62JQ M'8]W5U72RJRPSJ*2_69VL"1R(ZF#!5CZ$^.MIVGA MV@8`(;OBT%0UF]F]=`X>.O5YJ=TR`VF M.$@@%(!8S3?61+VF4P^,X0GO?0W&MRA)J311!G!GC9./+^]4L]=M86=8'Z4N[R4+&@@, MCW3OB@ M^"R#87@*>[K=S7-O6Y#71UK`9')W>1S+N*ABNBLC/7?8K MJBK9HP^[6.1I1J9Z&?=:JX(FI7]Z%0KWLHB7QU!3WNIEO.9-`86#N?W+K6QY M5ODF)A/+GEO>_&VN2U5P\_(N?/0#^8YT3>L<*#X9X&Q`;W5%HW-W))WXI M#:9BCK=3@]BR1K];Q+8PNKB+46[>J\E!3&?0ZU)^W),JKYS.['\ M89#[8B(&/GFV_Y26A;UFTP0<@RRLCCCVU4$;YK)^4ZJ'QC`#JP.]U)!1O;#? ME!J`8Y"C=3_QP40>8Q"#R0)%PHH[H#@.U^.^=`'#IM7LD>AMS*VX_='XT*KA M1OD!PJ&*9]&M`PX0CLJAQ+VMV\OQ&`*^'BCNLQSRU<"`5..B&`ZLJO&<<#O( M]!N_ZHO8=[B&O3;319X9DUU`@G#$#*]D-Z[N%:YG-WYWVVF3#9*)Y.EF%+W' MII;=DX`;O.R3P!]%XK=PA@EF"94)Z>I-::SJO::GV(+.U:,N36#;[-7P.[2" M(3#@"$YE/MT%1+$\FMY`&U!7?/`M0(.KB[?'YT;<(OH=DB+AJ-'`5B_F*\]F MF+1R__NFSK?H.WR;E*)O/5G1=]3VZ@*&>KSR>./+1X(FV^?/O/O<,OD\.]R9>?CHY^.CS>FW[?V]^GWPF#Z(\G-T%[ MA*XH^?G3?8SP_./SRY>B@;/BI:/G3>Q(T6K\=E6TG M!__[_?K!>T8+=S^(DM2-O%4O.DQ;O\F//_YXD/^5-$V"GY*\_W7LN6G.*2%= M>\P6]+_VRV;[]*?]R>'^T>3S>^)7=)$V?EI]IC[`R4'QQT^472[VS3; M6_[SU_NKS6Y!E![XP>)@V>;`#4/R)4K#3^G'"_KY4Q(L7D)4_O:,T8P)L?P^ MI?R$TOP7.MI!#VK(OU%$)\V^CV9N%J8::=L<6Q.E\<(-(C.$%D/WHC,?8G^1 M+S>=1#;&[4/A,R$&>]D3VJ^`:Z2S;?0^U$9Q.M6Z9)8#YC25!(D>=/=(3) MX>1+L5G\I=R,IY%_$:5!^G$5S6*\R+>H3WOKZ"A5_'B($?&':(G M>0^IFR(Z^.WL,HC(MANXX5V))_%41*'Y+A*D7_J MAO2H>'A&*$WN7$R^_8S2P'-#29(E!]/'Y2MRJT[0Y1&_R8N^/YSCTB8)RCF:!%Q!%Y^/1?0I1(DT>9XB>Y-WBN1L% M?^8+CRS&TRP)(I20SZ1N$":/Z#W-I">>W%@Z^'E*5!C_+%Z\D$TV_]SR&Q,5 MCK(',4FB#@J-$J@FN^.BQ>,GNF!^HJ*3<.-_.NXFEK2&Z-HG)Z$3CTO MSB*ZT7[0Q4G6`/D%9\B_>*>L08KT2@_7D^P[%-&+US4YU.9KXB/2DZ56-$I/ M(F]02B5UA_##,SG'.DU6_AA&-OJ+?V9$N^FP]@4CF2>VPSX@-Z`1TG5PV"AO MEX,?Z:#PJ#>)"`(/>9.\C@E$,$BFKL_#',$B@V@R0&:DGL<71?8GCQ31) MR+WF;RCT+V-\1>9;DE(UGNSSS2_*[@M=1L[!^&2)1OFE\)I0WL!$VI&3D5XX MBU_IAWIPU/A%2^V",6XT"N4%@YB9/N54@2_;GKOMR0/EY@,(T*7_) M.;S_9;(T"/YE^;-378T(+G1%_IF47PG=)Q3FWW;8C9TO!7]L4)Q?D&2HS1LZ MDW5)3G&39A=[Y6A+`XV2Q7-&9I4$N\I/Q@)B]V),SH:?/Y$>64(HB5\HS729 M%D:?G[PX2LG*YX?\A%U]$_CF! MPF`\J[ES/`#>8SY4[[1TCD9`-/;Z2[Y?;QE?C]B MEU[Y'SX63W'(X'2CC?-U`#Q>I[CD[HF=+3Q>+.(HOSCE1HOD-DNI,YF2R-_/ M.1V=;P.0@Q2,4CA?MRR<4D=_),,RQ%!OXOPP`(:O$5RR]MN663LE-/B4CLO0 M94WQ1AOGQP$P=YWBDKL_6)JX=^2>'OM\_:2UK3/Y,@!V,TDO^?ZC);X7^E)! MUB7YK>T^S6WO3(S<5`WQOY7\U:7(JA"HTBHO@JJU,QG"?91#?,7^]DOI^O_^ M>M"T;FFW=TG&6(R6K]'R!<7RI4%(^6:[?0]D)I=ZWW,6,8X07(<45;B M$8BQ!0-3HML63IVV\T:H98M4-AL;LIDQHC\YLFCC<;M86D'LCCR<\WKXK3&Y M-..'C0FF0J-!0)MN-?J+LW3@>BSG[?>&>E*3@D)OJ^;-]@G?E($:%M/".&5Z MTF6$(>IMU>RI*`P)+#K\+5QIG/62AJBW50.IHC0DL.CVPW0_20I__O2).N>\ ME'.*-!N"-Y0RR=;M>.QQB+O)\S3RZ?_1>+!7-R20DFEZYF+\$43SW]PPX]U6 MI/I;-;!N,I]QIDLB`:-_W:;/"!?HENX^CIPV&ULUS,H*I95L.*M'EOM-!%9M MM+*=\:;BX M1Z\HRI!8J.T=G(E-2X$&^;%AP;D+E;K0.7I*Q8)J:>U,;)H)-$B)@0G.QJFT M/[9M#39-!CH$U`H)WJV)3J";./*45M&J@W-HT\"@>2$U8<&Y6;6FTDD)3=#3 M.;1IBM!R6`GQP;EWU4B4VPN=0YN&";V;(,4"YX9&@\F#PHA"[?!QE`;1'$4> M7S2<7LZA32N%!E$)L.F.`>\3-]7A.LUAR:%-*X<&P?&AZ8XN[V-)KWN&1;Z^ MEM;.H5U3!Y?-+"-Z*PHP=]Y:3HW0^;K6U#FTF\+501IM$.#<::>^'Q2?OG,# M_RHZ/[CO?HJPRDG-H-S6NR^I71PCGQKZ)6$DY=8X&;E5IAZ0[Y<9!U.+HG>\*N/*8*!$R>V4>E2ZLCB]()?J$P2 M!*P`L@:APK.*T<-N>ELOV:P`P(D.4ZR2*]/-;AY<+PFMH=`1#,:XZ3(O=F2+ M]0CU[AS1=_Y21*AJ"]13'P1^YELW3`(GZ19K,"Z?91R=:*,3;0><:&Z(DF5. MVR]Q[`MRTMN:@W]^1$`\'+O,69R0_24G[2$.^5I3HR7XQTC8=,,QM?R"Z=N' M.)X%O!50:P7^&9)VFN%83VY?$'9I0D7Y8*=$R@*S#_CW2600P+&4W*,$$2;0 M>ERUX-$ER1SY5L7L9-6ETF'!<)$`.NKI]'ML#8XU@?E]GE9/K:]:&H;G2RB."H"!L(5=0VNXZ2 M#DNE%0$<[TA%WBH'1$8,Q/U&V'Q:X#I8^\>(C@ MW)!6A5H+2CG>+U$7NT4!^XB*APC.-:FD2KP%KK6T6^VOGV`V@,"QEZ[*.OU" M^$#UGMMH]1O?2ZVBF: MQ1C]CH,4W*%;U=1 M&<9NU<+NP?=B5'#JWC7W@UHF@2>]B0I'LEO9L/.BE`,& MIY3,A8LCLILG92Z!A.F3U<5VA4-YB?$0:'_479]L1"NLM;W=2H=<3LL)IT(! MQHJY3N%Y$&8I-WN"T<-N54,-LJGA@&.Y;)U`-"ZE(#8WEY\'"8WGS;!4,%O' M$6V7+.R^(2H`K.1N7_"_HV#^3,B=OI++SQS=9)1!M[.-9!+1/JHTCMW:A'T$ MUSX5E,&#V989E"]9H9)/I3B2W7J'6YL"//B"W7^+:3_T5=K+,'XCERL_P(CL MZV,&D"S%8P80W`P@@5Y<$& MDSW4"1HWFH5E M2H"LL`,I=H#9:NPZ+FT:"[<[+[KPQF"QQ7OD9QX=['9V$Z MAN1>2VMRL"EE30?E@:RFMFU1_ET8`R?DL%<4FD1LE4T;YW:/!2EFP(E2K&LQ M>24>LCW1>3M-$I3R+I#\CG9S\K8K<3$GX(05KB)G:964VQEA`(&%OPG=>4&L)OUMUWQRW,$3G#CP&*3;=H.MS^9M#$-3G!?KO#&[Q:W*Q>`GC#T1U6DH; MRZRD9V"[Z95;O$=HX92.^$!FJ/W('U>HY@>-7+KOIRYA2WUW$A_]<@/833W=\@53FB/5/`"05+R M8A@9N@YE-WMUBX=%1]Y4DN]C;V1(OIF:I*P22G:WF]^Z10DK\*.2:A^S(D.J MCQBY288_QF_BZ13EW84PE\#X& M1*F;`,NJE%S';G2+@WD0Y2TO$5OTW4>TFT]K3?=795$U'>S;]]:!/*4T8CS. MHI3L9XL@6T@[DEKZVDW3M>E+8C"C$KR1ETS6K!+3I(Q?N7,_RF`6_Y#L?DP"H6 M2/\:OR3["4TG+S)Q'LD](BE.'@6]764,NRG$6US)JDRIA&P@'I!J";GY,$*5 M]?">\I^H%013<;@PI2O3V6[V\3;%*LN-2IXF(OB*"_\]>L$!_6JN&3*C]-H: MVTTGWF8H'@M])1_[`7=F:_Q9S2G>=GB^!#,JP=L/N"-,H%=_HL85_U^#?>:^ M!*D;2N3WR`]B-[=XV]J4"E>J.6$_*F^3\*F77_IJD<-*LV&SNW-DT["F*!E9 M\;;#!).)TX*:)M.OJ.7ZO82=G2.;9C)#(FT#"2>S;I->6N$Y(E\+%(59Z^<< MV;1O&9+C&CY(Q:Y;I]Q91NYI42H,>Y?I[AS9M%R97)@;,.%DL+!/ASOW@VXE M-&73\W"&_.O`?0K"7*GH=*KR!G2.;%JO#)^S(N!PTEHV,93>E>7#L$J"7^OK M'-FT9QF2<0M&.&DKC.UH'3C_VBP_B'-DT[)E<@-G@(63F2)?Z($C:?E!G*/= MMXEUXTJEL8&=$\7C*II*%W$&$.RW9D[(2EQ_%.;;ZL()6 MD:NAAF-$V9BK"EGGPK[.L4VCF-DUW885SN:]J7'>$]`X\%+D4Z8H:>;-KLXQ MP`)UW80J`Q6.4:6^QWQWTPSG,/,DI6)NDEWFS`W#A!;XC7&:(KQ8O7DG>+JH MS\C.,%3'_GV.K3G4;W>!9>.+88"GY)K$_G M;/[O)&!D?TOTPG3GKS__HZ!!\0=RCJV^`6I2GQ(# MA_,V5IL1_B4FVX6:6ZKLY!Q;?GO$J4B^,*.[IG`S>W*2` M%-`[6/>5*GT[NT[9: MP$O<,R1'=8Q@7'EU-4)6>LP^S@E`DU`W MZ7$Q`G+*U2;9JLK,=1S-%5=A>V?G!*!9J?]R9(.%XY>K3T!)>;*Z."<`[4;] ME^4Z1#A'8IU*2EWN"LH#]ZZI6>3V*0SF12U026GR!W%.`%J0^LM7#!J0`ZVV MNRC8*GC=G*\`[4[]]]XVF'"\9'5*E_G(98$V6;?X>C?G*T";4W\YML&$$X_< M4+Y7);F3DES>J^W"OLY7@&8E#9<4%E8XCK=&T$40Q3A(/_*J'6)7FZBK\Q6@ MS:B_4%E0X;C3VA7S9D%%H@84/R#R1Y8_I]^`SE>`H4DZKSHR#-#AHM/N,R`Z M88:]9ZK^]9H6W49TONZ.1:H[!P"Y!>NSNUE?35;37NOE?-T9JY4`I1:?(*N@ M\++FW2POVS--DI@^OHK\HOR]0N5!Y8&6CX_=$![R-\A2%*,\UHV?+JQL*4G)4AG&^V;1]J03+J**"XR%JI_$.X2#V MU^.F.6)5&<;Y-I08*%54;-JC^@FR! M`\=5])"]O(0Y/C>D=%^&\=M5E#_EDC-:')TH.8+SS::=246*"H#@^(96CR\$ M/.]>O9GSS:;E2(7+[7):QP(FJK`HA/3HOJ.$TB8L\+76V/EFT_"C0RYMB`11 M@P]MJV!14=6XV=(Q<(FX6IH;ELOR(:<%4:#0(B.$B?4"T MKO9IS?_3=+U_;R@FZWY1N=Z.S2M_^X1O<75*8S$MC+->PA#U=FQ>VQ6%(8$% M3MK+@_>,_"PL']%>:K6%TRT_*Q^)CG(:\CT?\H,X@[FXJT`:ACAIN8+RU>Q; MG+^2G?25+G=,QZI-0).P10CAY#G54.1/[071O%:>?II>N@'.K8:*0I<@F;7EH@I0HTR:'6SQWH^6SN-/(/\T2@C-)SE'J!F$^'S-"RFA[&&T/P[<] M7`<>?0265JZJG@P5/5G![&/&]F!@5^(A@*-?G!.:PCBOJ4S`S=$%M9N_X(`Z M%:DA-)UZ7K;(\L2T\PR3K76]!T>(_0HF6$8B(>LOG?JZ/GKID,SZ+%_1M[%P#6![[D_'`'P_\'3CP\XRZ MC4D^I7>N>4[OZ<>JR3+PC MF/1%]TM^P;^*BDBI7W#<6CG8X-<&H[J8P0[(C-(3WV6,9RC(TXKH$R3O+P$N MZFR4D`W.*^&WP>MCV^0$G#(WN9I'$R1*;;^@,4>8J%9=4!_,JG=%3?'I``U. MY'+?2;U$194^XXK.QK>&X[HQ@!Q.F+1&->YW1+T9R)^^(DQM$,LU;8T?@$*]M2J!EB:B/!'#\6UMDR5P(M:-:XN69F@ONIRAO-IJFTMP M*C@).9'(Z2[(^,352H@SL9GQKG6J:N<+G$)2&O5J2]NI)`7.Q&::OJ6KCH@A M@.I6:52XKZ(4!U$2>*+L4F/?=";_@@Z$318`>F1'MX&;_-G,CW'JAEN;LS*?=R:# M<:%LB1N`JK7E>)[$D)_$6G(3YT0TZXQ\U)D,RA-CC`>BNG%68_/&T+PQ-.]? M.32O2)ZZBA)"=FX7RXMY/CZ[T7)MW\3YPXO(-^?)5J5A]T/Y.G!D!T+\A*B; M5T0K4[%)PNX'`ZHS9`3M?ARE7F;M0.BEHK(#O>'.;`=29[@;_[=15GB504R_?OCERQ=!\5I6!ZMV\\V9V^2PD/1MC>K^CTX\:E MMP>!FM+>P8Q%S8C"P@0`)YI@1:+44=K6W)#91UJ/87-9))4&!C!ZC1:1`-%Q M],A&I\ZC1T;%9LL\4-J:6;4;L>9\NQ36R`;#]64!)0B_(O\RQI<95>)I[4$WXA:I4!YK.+F#G:#!D?+%XB6,/Q!:/K#0 M[B:N8M-RCW"29S?6_WX6)^E-G/X?2N^1%\^CX$]N,4YCWQQ.%J!1%L#10XW! M+$)JR-I:_D3;\3)/MTN(,QE*H-_V^;(#F0(@2NQ/=CZ^C@<=6'1_CWQN=J73 M>T1E0=]@B:/\3?C,#1\17IC,L.]`C3,95`S<]IDC"-8W'?%&L6+T3*_WK^@J M(K\C@N$ZKE[*&\/=QG"W'0AWR^-26R8[T4'(8HW.,HSI^U6/9+4G9(52:41^ M_E]AL0_X_\B2--\&T(ST>73?[V*<_R5-+Q=RV2>H:&ORVIQ&HP<`X&0*I)9,PZ)G\L?;@ MI@81Y0_>EQ#)EZ4PKZ#J;D@@P1.0029$T%J2Y4=93!%!=0P"=+^3=_>[E!NY[LF MX\W74D0S=[RTC9>VG;"9Z8WC'$[R*`\#G#BHGA&#EC-*N3QFQ-*T@=@=>8`/ MX%02S!9R3PO-+U_/""^"R.5&9HJZ6+V*MD_MEEL,'X`Y7I]BY'K/M[/2@\EG MT;F[<.>(S]NVME8O:]*<95"NP\#%X.MO1$V/ M<:(V>;F=K%ZGI#DM@@`GRHH&&E#RR&6*NO?N::S%[>R._$IM,/2OWPF?%]F" M M:"AJ*WA0A?O7I@1-8U>B6E: M29;FKK+;V86+:2I>I8Y-%]2FP0NVTC$^^!A)W6@->LMJB9:U4C5MF@:O.?@` M1P'Q`KOQ5EY*>(Y#0D-"]N_`"W(K=_XT6 M7&V8?09TM>%A`'/XMQ(IJU.W];)]V>%R74%08&\].D4%Y!ZD6V80+T1]BNX! MN/2P%@?K]K,)`8PLIKX?%)^^
FHQ$<`Q>0,Z>:4#. M8US3@0O%M_@X/[Q,JC.$@#XY<2AA@I/+FE-*:RXB_YS<<:-Y49$L]Q<5MH\D MO]_6[""KVS!74>\Q[F!RM?JBA!.SQD!2%.DT,!$D!QY,I&)OF,/8$@J;:?`: M^"CBU2Z5'F,P88PJB."$%0>)1I$RQAH.%&>ZKATQ!%J?SN!/CNW+'(F$N)&![NO M*"@+JY5^.)&$O,WB!KWE?^FZAU;][3ZYH&OO;,`1Q!/:EV"Q)?00X=H`PWEO M01Y/*<0?P?I/QPC1T8VZ.V[4"DXQQVD421S1JENR4:)M_0;D3A7A`.-?6*-/ MZ*%K;6_;C2KD=KN06%AV33A`'*=ZI03/;=KM$5*;^C)S`;1+8IUP1?O)/].R!G7;XG4SWJE'SK#Y9+3L?8 MX`,\=2*%X[]I]576@B95(TMJ7:WX8+5*J7W-2N`VMXR;@%@+LMG*BEO4H"#: M(5I^CZ#]/CI&\HY7T-VY@M;+))3O;38\T\U4%XX4%4<"_QQ!=UQP5(%SA(/7 M_&V$2S?`N=7V=K;ZL2PC_,$1J^P0X%\?Z`#(8!VBS4+K,YXTA'W`OQH@@\!@ M\:%S1`CT.>$J+:V&<7_9H%D0F&!5:SH:U:91;1K5IE%M&M6F46T:U:91;1K5 MIE)M(DL))=/(/_V1N4F.01"C*K5SJM18)FLLDZ5X%(QELL8R6=MZ4:4XEUWU M\E<*O2%D@XM?4)#&8EH8I[V$(>H-(>U;5A@26`SF?!!3"`P2)G_/PH].(*8N- M`*)/[\9=(*'MI*VYJ;1=:7,6A\\BP311@+%GZ9$*$*.6+O%LP:IU12ZJ24J7 M=A[JGE3N1(F+NTQ?N]G1S&G?-N$8##:;_G! MRS@3%!#>:.@<`K`U=>!M$X%Y3\4ET9'E6%LU=`X!F(ZZL+:!P+S_X2%XE^)L MU!%Q;%IEC['./BS-=5= MKJ-S"#W$6!X''`MID]8[%]_B'&I1[:]\S4Q::*P!G$/HKXRIXX%C?6B;<,S" M$N).SN%0ZN_S,<`IPWT5>3C'Y(;+X)1B4TA3'#QE:5XG(ZX7G);.).LYLG,X ME`+[&H`:5/^806`KBNYPX+5MI$K]G4/H]?*5XWZ)EVD`.1OY1;G M]H2SP/@=G:.A9$F+<<`);&'0NMS@.\EKU= MW$"8GLONX1P-(O^9#V!U@S81)T%433=!?I]C1VD0YPBZ;:,;IDI*$`P=;:4I MUF[[^7\A\I=BC4=^69V0J_;U&=@Y&HYAI"_.:C;8MYBTU+"H*ES MA%5##*)BO'TS1I.XHC96AX6RWM$Y'HH90XRCDI9].\;4RV=6N0SK'0[%Z]$%8R=Z$-:0Q\_Z6EQVM METICVD0$_9SC85A&)&"LG-/6EUYI'DC6#E:!9Y/7S3F&;B^115')R4"<:OD0 M0^YJ*R,7:#G.JCP":Z&(>SK'T.T6"D`J(=@W3)A\Q^5X*(8)&225S``8)MK( M;_>>-2*FB.>HM()7LZQ]#-&0I`*D$9J!FRJ7YN5LF-V,$G3)5>W^#. M"70SAUZLE;3MQQWG9SLKRFJSD7,"W2;23G/%<7-52))"7<)QBKPTC]6*7P-J MPVP[MN0Z.B?0S1KR."H)]#%K"'S/5Q'']H'$C.:5^ M;OK^)XH2MV`EH76>(SS]6#59;I?3-Q?[Q:.A5U&2XJS80]-GA!^?W>@VQU(W M(_^.J&J#_"G98MTYND>4R>1WLNFFV/5HK>]'A/GEMB'1Z9Q`MYV`9=LJ3MWZ MU+?WQ,G)4"PZ'8!5`K;TIN6FHY\H?,MW!6[0V_BFP/BFP`Z\*:"K!MMP7A-@ M`@!3:45'J2_+SPFPF2P22@/#;HD$2+4;/;+16>'&9AJ[306<->O;Y;!.]U;> M6:=1*ZWK*E6DH;V3U:<"Y-@L!<)\@9SRTV7A5MI0B?&;':V^#-"=^:U` M#-;06:6'E83P^7_U";U)O?F:.J5S MT)?B[UIKJ[7YU?F[23V<]&B3.1-6:_5KS9FHE>JWG_14FMK/46ER;S4%<20G M.8+=,O_*=23D`,$I\&(R*LCJHP!:HX)J+P*8.^W9A75:6AFJYV_*Z[DBVORI MGE1'G8B554-3I?@-<;-!M^`8M^D!F(SV_]'^/]K_1_L_5&/S:/\')Y+1_C_: M_V'9__4POKK+3XDJO"BB>AK!Z1QA"/M:]1RH*`8R2.`8.=JI?4%>BGP:8Z4L MLE57J^Z&_A)K`(%CS6@C]CY(_KC$"%T1!1.C)+UO3ZA0'<*J`Z.O`!F`X)2U MYXZNC,.M#6'7+Z!+E&B`X MGAK53)C!>%^:-`M*S]JTJ3V2X3)"R&A9&RUKHV5MM*P!->.,EC5P(ADM:VKN MQ'OT2M2S/(5K53B`'RG$Z3(`&YH$!(`K8CT/[CN=4^02)!%62Y06GS[IF,E\_Q M\KD#E\]ZOO6#&^9E86-RY4L_[D(W+SQ)\_)?&'4?.XQBYIIJ.!-=C,E@OL]I M'"_KOU84/,0A,["/T=S0=51S=!^;>#A'/=5&KN,DN8U:IH7,:I$;P.IE266A M2,,Q&#[\/<;IG#YF$Y5?KVX`=SB(O.#%#8M'A6@5[&<7SY'_ZTN<4\Q:2'W& M!']STH'08!@S>_.M*"P(8PE/>@#P-R-E.'`\9??TK:*P4*YOXH@23#1_;D(% MJ\M@+CT<`.H>-4KD/9HU<";!XF6U:;%6T4/VE*!_9H28BU=ZA5[SG.W1D7^] MO^)?BP2#'&B_APD^^%\#NG`-Y;H%X+(E=]4:^$7K.H[F-%;L'#VE[%*IO-:0 M]C^6R%I1EE52\V'T4-$$AKGKV(WX<2,M+6T& MB_!G2*L9K8X1RE1OKZ=+X4FZ<]8Z#>%DYF$N;6.R%I@#^H4G-T'D/_X?4$L# M!!0````(`).*BD$MXFI(L58``%P,!0`5`!P`9VYB="TR,#$R,3`S,5]L86(N M>&UL550)``,U8,90-6#&4'5X"P`!!"4.```$.0$``.6]?7/D-I(G_/\3\7P' MG.^)F^Z(DKME[WK&L[MS42VI/=KK5NDD>7P;CHL-BD1)7+/(&I*EE_GT#Q+@ M^PL(\`6)DN/V8MHJ9#)_0&8B`202__H_7W8!>:)QXD?AOWUS^NW';P@-WTW3_YP\?GI^?OWVY MCX-OH_CAPW_KA_WS]NDO*<&Y2*]+>"_3O)F)_"GD]/O3KX_ M_?8E\;Z!/HBC@-[0+>&?_W/ZNJ?_]DWB[_8!B,W_]AC3;;<,01Q_`/H/(7UP M4NH!_S^=L$\(_O\]^_,W!!K]?'-9<.$<#LF'0W+RX#A[P21P[FF0L_KFPU_( M`M+]".A/?ZA*]P4^VQ:QV94_UG@)(B:C"0FO:>Q'WD4X3M0&M5&9;U,G3B=( M7:$W)/==E#K!*(DKE(9DO:+C^K:@,]6GS$O3<7U:4LXH:]J64[LCRQZ$>03^ M_85]OR89?4EIZ('[$W\%2HDO%SX0Y@`^-45NC5D`DT$4UW$^A/>`Y?2[TX^9 MQX6__&<^;:Y#9O:IG[Y>AMLHWO')9'V?I+'CICDC+CIG_Y_JM!_^DH.NR1C3 M)#K$+M4"+/J]+HQSKR$,3*Z,$D((&I[\?/O-7XJPP0D](@A)A9+\FM/^WW\5 MWY\/#@MN[J-"V2U!M8[KNN3$;BX;^^<`K*S%!S=BDYYVCR6`/LY0,-TB+ZX!9T\O$TCUJR/_\GFWQ2"E+=.?>E MAZD83$]#`];1*V)3:8H&Y%?>Q+C&SR>I"2V6#WVNLM)Q1]!/-O/02_;/1$5' MR\88>EH55:(!T(SP=O@*.UUD%,UM*46O]C8U0E>#$^I^^Q`]??"H+Y27_:.I ML^Q/_RD\^PU]\,&AA^F5L^ORJKU-#>BK1,SFT&N?,N_I!EE3 M(MH2:,S6/AZ!YACJNY#HIK1X2%&JBCR@)S`>=7MZ^X^:O5W)GR]C2&= M;`K6'-[L=R(:8*CA-`E-:5[G`%=UKFMT%XY%H]TN"F_3R/WM]M%AH[,YI'"T M"&+(`U,9H=DH50ZA+_SC5(23K8@@)!5*Q`C6"![#T:V"FG6$NL,ZMI1UY-O& M=XQMCQW4FAC2^(98O1OY\#N&!D^1SY1&=@UM5?LN5T"]VI"MHV3 M*01OCJG!<\MN6I-[E:5+F_LTQ8Q&P]Z7NCZ7K5&TN2KLD#[P+4E+-'D>N7&T MN*4@_3I23;#9?O9#)W1]9G%1X@\DC6F18V0]3EUZE[]$5%>`\VCE^*%'QCL8&=;M3 MU"&E%@W1U%I#YFA(9I,:W:\6357NU8D)F?"W;,E`DS63E75SZM\'])HUIW%, M/?Z=K_R*6(>BZE";RH97!M.:^SDAJ5*2@C37%4&-DQ$_&1DY&P'-6%J\GA;6 M$N.U5'"RH7PZFV(H@]1F#44!3(\Z?3H&=5(=JPYU4ARHR>IT-DF=!JG-JI," MF!YU.ANE3@8=KVEHABU%50T[+$51!\U%V>LDH6FBL!_3:&@PNFZ)V#KTXPTL MV$H9EO3V]N+N%C-\[A[O9NC<.=@&EWY.\K@./?B?B[\?_".7'\ MZHQ`TLH5_".&L6]50#"I;Y_H@Q^&H&W1-COX6PAA69?")#XXD>]%9G2#0\?Y MM?8\-#R?.7^^21]I+.:4[!*`Q'EW-#;HJ3M%;:H1;T1$JQ7)VF'Y7PV)W>P& MB<-;X_C9V<0U:9/]"MPTP%[M-1W2#QL:FHT-C;XEAC4D)J_/DPN9>0,LTZDE<18;/I'L[%KJC,IJ1D!DUL0/RF@N3-5X03 MB(HP.ITM38X;W0+ MV]0@:'4"S4BE'9:'51,YVR/^*PT\LHWBBN"=SLFDADL4I*G8_=IA3I\_^Z&? MTB_^$_4NPY3U,9QEB.Z5QT8#A`:U?!!"4WL$P0FG("5)L06`&&!H8[EV4K'C MA193S"JR24M54_VFT2KIO>GM@<%]`?,;`KU>&V?MT2O4I<>4T=_Z3ND!<+7_^P3$:%>A[AU;HH.T:S#F_\RSE M\(8^T?!`A_U<#X%!E]8KF^8L7 M-SCPU`$;)WPI%*'H]DWO6OV/=J8WI\184WC;.&6S>,LR3:[B8__)2?TG6G%O M2JYEB-+HNGX(1'O=F5/4-R-+(KR5_@0LOS@Q?STG)WW-=O!./[:V\,RNI)64 MK+VD5M$PE*!7+=I%"G/E\:T%86W_E&E1'#M&2*3`52%B-7_Q-MKM?)%7!K?( MHC!EH1P-7;GQR*A,7K*5"M_:6RA;BQN!U?9H=VGG@R`FD83\P'_Z(^I4HJ!6 MK8N,@SIELN;>B#0,.Q(OM-(2JHWS/(MUFL;^_2'EQXUW$;EV^*H./_UB-+(_ ML(7'UF>*%+IYI/7C^S_C%NG33:ZP*)VB7L5DJ#)#5VNCUZ*ZA&U?D*B5G5F) M^@HK[';(R=/6\T6,>FV=1P--T0LRO^+!^?LL))JDN="*G_OV\_?CPE M>R/_/^31#RMY:1DXZ;1/8W)]ZXW_&I6O78WY'':"VC.J$S\DKJ###!]F M&1^_9WRLBBL61FI/P*'N/5JIH:JNP^19$ILU(GX[FNGS`[T(4QKO8S^A8IF< MKEWWL#L$3DJ]\T/,AJ!)(3UNFLSAI1L5]E61$HJG(E@ M35J$>(=;BW2+`.Y4@'L">/I(B5]C^DC#1,6>U^&;K2C7Z($KO5NMG?.BRR(U.1D]@Z1)LB. M>RJ%7HM2;C4>1#`A[X#->YX"`N]B,%Z(UW)FA!R)ZG4UR#YG@G8EYSC1Z839 M&$H;<:6U*PC'[`>+0O1QCKKC*M<(+XUY,JEU(HE[$CGI!-*>8\?>E)/ZH>.[ M\M3Q_0=!B3,;C$90`L!T]$KBH[OA*5+B'CVK'SE;5QQ#XOL&22TJAM&A*=U% M,"Q("E0%((J^R.M>O"L+7S`/^;]_OKQK%<`PXR'Q\-E4X*//$2B:TH3'GLZB M,(D"WX.P*_.1MX^4PHUZF/H?:>J[3B#)P1K#Q=3C3]K@VN>7)8,\U":"!?FU MQN3_(J9IV835V/-0XQ2W]DS4**W%RO9B,FUB_F*LQ\]QKVE\"^?9R@E@O0S0 M0""BF7X MR\`9D<4\:3PL*(\T;!@JEEVS"ERKWI39DIJF7:5$MN\Z"%6EJE#99.ER,"KF M'BT(;'3B_TPC9=5AX4(([3D&5/08*CZO[2Y0K@R,6'*K4.-<+-!:C59S0:U< M:4\"=@3K:@TME"3\6[.BKLBDL9R64>$8D=+JLVH\UJRB1X&P<)Z.MV`M/*#V@Q:+M`INR:&V!):2 M8=KMT'JQ2XD1J]+2(RL=6&BW\),;A8DZ6;+/W\;!?(MO7I+HUL"32'; M067"KPCS-@0:X2W[E62-%I55<9]NNJ1F%[.=JMI>OW;IJ3F+^BF.DN0ZCK:^ M;'JMMC)H277AFN/-?R7B9RS[49%POXR$2E8S7CZ3MM*AA$T[:6N@.1O9L%6P M`P6;+[(W21767?TT!NU')GA3%XJV)&]LP>IK&@#4*LB#2M/4\"&-,:?O-S2A M#.WC.O0J)6HRL20Z+ZP2SMRSE/0F MK5C)%)J6K&('$PXENMG?4%[7X]J).V^.JU*:.GY0`J%LIRZP3L]R>:I/X#%XLX_@ZJ"*?$\Q,W8H/P"NN[D#Z3W\+H.:#>`R7/ M?OK(R\P]1GO*_L%:)P?&M=HB",@])8>$;@_PB;RC>4EBSHZ%P-[!34&4A,9/ MODM7Y2\NO)[+?DFI^QCZ?X>-._9?C,T]%''C3.ZC0\H($O\A]+<,"!M`?\=( MG\1.$+?:"7$DFTH]Q.9W%:6B=[:7!:-N2LIFF.',*,1[/+F2%NYL\MM=&-W4.5; MV[M#^FYP2XJ&;"44,%'6WLX/?5@%P6'TL-$.49KHTV#8\ M#8M3HT':!EL0@=&-,C73:&V>*=G%A"5)WP=4%B5*M*:6)8I`-&S7AJ7)#*B< M)JIEER=2JSY23$I+KI&PZHLNWGNP5*+Y5B[[]\X)G8<\2LFATZ)*M[/=.G[, M6\):)4S]]'5%GA]]6)S&E(01+,-BZJ;!JUC_%/_E)$GD^KSGBM48^]IAZ[CI M(6;+I<0)J%CF4;&P@X\TED'\GZQ+J(5K(1WW5EL-:?@VQ.,,G6,,U.,+I5U_ M:\XJNLR4&Z8!F96BHCDE1CU:43Y2P;.ULKJRBK556F/86TW8?HNKEA`J2I M-56:PH=D9.\M2#H8@TF\+-`$@YJ`H*QC30-153"#LRCT;J]8L@E53FAR;AV" MT*U14EM!FW)UL7SU$Y<&[$\T.B0]KZL8G2V4]*DU<:@HD\DLG9`%'4*&JE32 M!)T>$J.Y.;UBMP_'H6FF]JN:+>!EY"A+GUDK:!_LD$"-YT<:>&3+-T_@F!LV M@_@=`/+N*DHI.3U%+8@SI%#M-!>I-IF\%9?WIA!&L=NZE#?TA5VM?AI'IB4L?%AX=CGF9+HQK=%+)7%9"/-#4DI0M) MJK1G@"FGWH[!=$G-^H%."\+:N.&&V) M5]"1H/(\4A89?IQQL:?[8O#2&'&?`U8TL/9KOVK693!MBLF1@""4B7+Q`I'X MP4\>(7;9;,_I??J)LJ4'_27V4[K9;N%OHKP%_`;%OZ#\#UQ'E/B4^;YA,A5K MQHYII1,`;^&8J'!-]0_`+5]@`S6DX".$?X7]=2M^RB:?/U9O:?P8&7L[N.8IYIU'QN]XJI2Q2F[.N!V%+'W449!,@M M*IL[?@Y9`!6R>!#M[1"ET?B0Q>F#4ILMG=]4\G:5_(:&&SP.IFEY&%W5V+NH MKJ\*.YOZO$P>%X\`.FCVMMOX'*"_^F$4P_/AQ28*KW8),RM>0LM1`=,+DHX8 MVIVE0VG]+.P),/,@\075 MGS-0Q/3HU@]]6!S\=/`]6'5-%-;$"S4XX?+7IG64U'Y2^M*2DHUBKS MR?$#$?G,1W56,)!4YH*TP5D`KQ2,X&@I'JBPH9IQ7AO*R8 M^4=#YAM-)=*T$ZD%,7P79`]4 M'Q)1_Y0%U/L#O\])LT]D.]WEN^C6Q=56@$>/$M2M7BF.4#9Y<\[N%^H_/#*! MUDQ/G`=Z==C=TWBS;;VL.13JZ_$QZ-AT`3;5.:$# M`>$4%I0[&@TD4@1BM/"Y@E*U2I\/:Y310WH0XCJ.('?`^_3Z,ULY789%T;*U MF_I/_-JD2JDP?69FC^KUH78=4G$MS-F03Z_D'7`BE^'[2N'*DIL%-C<+](KQ M?88B,UU8<2N0C=;ECJ/L<8ILSG#7WG\=1*60Y"ZZH=!%?D!K9_!WT7RFOB!*==D:0D8TOUG%`\^U`AQ:M',AF6>!U@22Q**7\FD)BM,Z)N/^U2(\K& M,^E527B!@;':;.'\)6&>BOI/D#%8R1>\>'%Y:9?/47PKWLEC[>!^;V8?$98>< MP/$@=$G"N\2'.A)9KVS+EQF!9*%>47P4<_9N@==;ZI62XJ*C6"^T.@H\6ZVK M'F(GA#WFSFYJO9LROI_4+M$>I_88?%ES'D_;>'=S%C<[80(I*YO\S`+;(*!, M'/;Y?FGZ9@Q]1J:FB#$06^=!U0)0-3;R&0)E"I@-\$G$`#.K/=0`#]@PCG^? M`S,X=/$(%PM`#V*O_+GH!^::!OJ!M>!/7X&O8POJFF/S#L6;73'=0P@(3PK3 MV(_:GMZ83QMM_#4G-M;R#1YZ3ZF>9U=9O%$%OFPO7S<>5.ZAO!P4^V_Q.AY_ MPASU0'AT43(+JXU55ZV;[25SQN$#&/F:E\B7[7C+"4WN70]!:&V?5@C`<$H2 M(FC0MH]UD=1,Q;EG"Y$HY.\SIK"_B;-7-&TXHH[A6!%>1`=UAUK)3%I[S2HV M8K8DK2B->^L$S`]=QW`2D+Y>L^%(+_Y^\/<0C4EL7I&!X6*R2I"Z*L56*E@# M-;B"G)YP!J3@@%G_=12^=T#Y_D->`=3SDWV4B%=H]SE&V+>@BR%4KO1:U$Y[ MDZC0A'W`>@PB/I"L0T_\ZVOD^5O?=<1?DXNL#\\J7=BW+SB=L:E]PCFZ8&@- MD7'ECCDSJAIC%LJ2G#4YDVBHD8W$Q7N$S551I4?$O\FNUB/,9H4-RPS6S";C M$OW1M>GHC.BC3K]FY[;C;+ZFM@TYEZ.9X$0K>YR7?,+1.'%7HC7E"A6!]$RY M(G80A!:=C$\#58LC+#K8'HD*W$[(;!42_K*7O9B7<%+BN"ZXH81C!+]1G&[7 MSS/\1)1[9;V11H7W210/LXWY&AV3K+D3#7N<+>RZ9C[:\;W\,Y?A613^UR'D M)\2_^.EC0Z:N*JC=/G8,8YRP:UP7#(5=&=?2$5V&I,*8`&?2\E[`W(*X:X$N MX7L$HDL*6^7W_,LN>88N<9N^;Y$N&1%[S=,GM=AKIMXA]Z_<;3(\4&7]"`*P M"5Y'$H"-=SD&3[4"SCR[5_G)2:A7#0B'-W04&9@\Y5*%U/(/.:&XX'S"26M+ M4.R=G]'0KJ+PA`\PV7`,R^*9SYJTV6^Z\ MV`KS%R>&3,ZD$B%NXK/`\7>RDW$]/B;?@]8$V'HQ.)\)H5@"GQMAWR+G45\0 M;F(B^*`]*3T1K`!8W:!YSH'JK!6-OJ(\1H%;;RR/T-X)ZZ3R<_EGUI['GX-P M@HL7&KM^0F^@?T#5VKE\F M>(/:BF6\*YC@RNJO36CO$ZN2FW)9ZG"&WA6Q;L-X#FBV;AN/QS9BYWBOT1UX M7D73,&N>1,\J)WB/NY@ZR2%^Y=^YH1YE7@F^Q-:XUS1F/;K+HK+LRWUN1)N/ M*7\R`F!+0S,6F5_)F7#/<@5I+"4?OD;).*'XF#GA"N.*<[A@7LQ03_85N,P8 MDZ7@*OF=.?!674LJ!T]ZP&O%->-[1N/FI3V*8,SACO5E-<\[TI'-=F;7=T4C M^1(YX8;%TW[(6WZF_<4SI-T$/'2Y@,"0PQ1Q/Q M!`'V97$YG-DE\Z+P+(`]]]$DVB>_DM:O>G,F2ZZ3_#GV:^>55W:%G(&\1\^+ M#E7.H%1FB)96J0%9)==R#8E-@A_)&,*MM0I+E+,G?G+E'G*3LD'VF$_T=8^5V_V1/(4_LU'03!C,-,K'@R1GF M@8?3D7H(3.8.](G<.J_+=9(_*`5Q`7)VD;[D8&F/S$1.V'_OB.,]+9(Q#WSY+F>?P^AN;*SH9H^HK=)4HATI&HI3'YRZF9HRQX7,G<7FS!BVJM`* MB8(E'K#+(E7P""Q7:ACU8I42JS"YLG?AV)J>4_&_E69>3OX=HH7S&)6-AP1LNDW">\8+.2>.5%5[N39S>^+G1T>V6S3$)+Q/A_OW@)SQ?]3WJPRSZZMQ>S6OJ,J:MKK-$Q[*X MK9:5=I"CVF`$$>J7@ED.`ZPSZ[678#?0:"^ID M#2^_EQ));_D-$^-.SFTHJI,R4%;L'N\*WQA07_W$I0'[$XT.5GQQ!ALS83I885^)'#_&:,+1BC(R8N2Z^R.1 M"0AN!L&9&<(L4<8<$"P(,3I-1C'(Z+(7&S89KIU7B'S@Y4C7C0]LB,N]H5'; M#E*&5FQ$#$#6W9K(V(GW7@5#4N%HCS<9B;\`NJ\`=3*@^4Z_+3'0<6"<:]_& M!$H[]G94W)3Z;H^"C\+TS?F-DQO*HL:#WNYODQ;5X[:!*#K7XL9>1FF/$QV& M5,@>=\N.:U`]NC5L.]V*A;Z,:9[C7%'-,\T^)OA+FFYH6@N;\F1S79[^59S= MBC"F]AB7!FS>=$7"!<0?&7H@"S_+0LT6\>\0A\""A:;$J2DN-_L]FCF/S;YY MYB2/UW'TY'O4^_3ZB7O M@`-SW.^K/KO@@N6BY\')H?FA&61*WML\+I->1=_PFEY%V^K0O0KLL"=UT11R MW$8PP_$?&9&THD5-;%MO"XK&NRP(ILS MW.SV:W(7K2&Q,*:U9Q;7H:?R]JL&$X.&J@6M5C2@]!9XAF&9])KZCJ3I+;6]B$$O&4.3#B`J84E)AIPJ,P:0*/=8NY&V9S-IB),\$\9[JA\!:ERP84EEA:ITL-4M0SI18,Q9.DDH[O(]AS6C0(2%R# M@QVZN,3@+H%AY)'1J"'Q6T/24UP'[RQIOI'!/8SIMOSA(YA.L\=90WQUTD/, M-W[XBXG"V[*HZLP)@F2SO84*4U!@2NP4\5\5UQ5C.".M-<9U@GS]4?)?5W8$!XZ3*_'SG68F6"5<@6 M,.--`G%1PZ6Z4W0"H+',OL=2RR;/LN*0SQ9,@0T98\RT%"7?_( MC&IP#22Q*'-^`B*73!X/?-NZK`8A\0XR*H,^02Y\YSEAWES,[A4"+.L?@4'< MT"V*9M6?$]_1^('&F%:BH%)-VQC6IRDOK8B:JF!X8>H_4'CSEPUH_SLJ?>V- MO9+2+W`KUS]KRF-QDA>MH2?<6F97?&]S:T7B511P#%L'@AK.B0 M;H/H683'4%ZG*)&]S2OZ961+5N9 MX^%"@:^,Z@_\31X;ZPP9@H>Y5:AFDT,;ATH&B7LQ;1^QX$OO8G!!A'P5K1!= M^0Z:H+#%2T@QE!OJ7H_8V-?.ZIJC]M'!42/5C!EYF25:EKDA%1?^,%YK&<")*;H(8<45R&YE0=JD)[;&8-) M:;G@]@.OPK9OZ6!VF,V]&J3L5>K/`ZFZ%'/S_$UQ5+'9WM``!O3:B=/7GN<" ME,@,SO4#XC$4*.\"C(11F?#9.H<[C#C#LF=DL]ZLT@O_%P=B M,I)1L8UF+*-@&.:/^SY'SL8KL!)W MKL'$RBNO'4HXXJJK_?=;93C?93?0W]<0&\$YY9K]V-&\?_U0(E9!:>==WCZW MHVV1Z![G<_X"U1R7[F7,\#V0'*JF)RJ8'<6E>SWHS4OW75AMO'2OH,N*!CNL MR$C72?.TLH&-G7X:K*NB#<$'+H:6.9R8^SFC`(C[GI:\^KPD`K1;JETV(+V3 MVF$`.%NSJN;;3X.T*3ND._4=64O,=Q2`1G(RJO5:"6#\3O+,$+#VD)7\SY`% MXX0/ETER@*[<;+]$X8-F'-%#C!10]$*11Q8Y&;@I(,3W4M-`\;G:ST$QNPD` M%#>;15Z2UHXZ%H>$%8;(;4D6CT@-"2)!@3%'9E!Q"#YZ,RL`&P,D&WV`4();[4+-" MF4-1,D&<98Y&!IR4#&EIHY!Q55_4V),!IPFCGCB61C:EC:DHE"S*QT\;JPCS MBQ/'3IA>O-#8]1-YCIB,#,DB.L276T1&0`H*&PQ"!P5?!-.L)H`,'+'QFP8966$GG@UVH@VH M92SB&D6T[PR:T%;,,+J`1,FOC(B%80)*I2*/+;8C4SAI-:]^;<,^ M@;F.L]?XN'FSE93X`V4_]EUHG,@0_:1&`;+ZZ4W!+)O*8..DY+?0G4AF(&-/ M=$:`AQ2T?<;,!OX;:8*6WCLJ>:'Y*/W[1Q,[X(9Z=,?#4[#FV[_=#%FTJ5U=1(A(5V;&V*_D MZLP(X\4)J\XB%K+&*=2514*6]-9N]&AA:\[];P>/1>Z9[ MAQA*,F/?1!O6+]F$WZU<$VJ@9':YV?+W(]9)$KD^>,%?_/2Q_K&L!SNL8"0C M4Q52QD#LF8YA^A4/;91L"/!IFD_&":5\RIQXN2$!7J?$RXN&=IL73FV5.0"K ME5K1Z`IR_\K)V7_"-HAUU56^#`<` M]6076X*8T1AZ`Q<;"J\_`*_AI:_ZVR=58OR=DCH4 MC4T148I%4%JV^3&`J?*D:@HE#@_QJY4;''/!L&`3H\-@%/(CKU:I M3HM^CB.O^]=_9(-9KG(61!U;%V490ZLV+*1:IW9.@5G/L,>F%2UHF!A_^AS0 MN/[ITPHC&H4I!P&G(#%-_9B62](%B[[JUC*S&-$LT8'5F'1KG2T.S((82,6# MJ[H\&^L-25RY!A,KZPOU)'5HUA6ROYB0$L[[5S/HIM0UT\16U#+[H(O2SG)) M??Y%VP[-^9F+[9:ZZ69[\2+*J]^P:603\D?'0OYV+ZP!GYR`RM_$U&)CT-=H MPFMJJB"'N#%G0(`#V81"@<5U0_:/"ALL=S,/U*@!-2%1N,RKYTI^QC`HDVYE MC.4U'9Y7`+O^Q(H('Z7B5!_4E MSO%88<*O/2U4OFYESHTJ^9M9@7X8!=3X>Z2:)MKY0*F>?9KS0;>'_3[@*U4G M``FA+.=EN(WB'4^T4*C5JLK!H.=1!]74SRHE*>J4D@JQ!458D>"9M#M-M6R: MG)Y.FGPO3UR!NG9\V5W06C.C;^+5Q&N_@I==X(+?\9Z.5)(1[TF^\5UH]OV] MMB:V7]QKJ:'1IR6C';US7F@"WV>!@]1@6HW-/B79%K7C"4G6B/!6?/17Y`KO M71(=D5-HA?C$Y5Q]:_AYRQ[M[7C6LEMUS9G:)GYP0O\??&H\B\(D"GQ/S)/\ M%D:29]UNMMF&G!//2?N?U:2:+F-.>SH2+W/N)VX0)8>8WM&7]%,@S]"8_5/' MXGNZNVD1-U1^BOP*'R/\:\?IDQ;HMC[WI-AM1^.K)(8YJ]OJMTIS'FSMNM$A MA/LZHK!W`5-/:]$DB)MNV!9 M%.SE3%>$LSWY!'Q)D?F-/PLOV2.12H_P)(J8R61&.PZIO1B]V>7Q:2<*+,694:ROQ_A9MM6^'V]@#"JGJL\O>L MKT=J_I2R;#3TV*K^"_N">/NF_(ID8E,F-59Z30E&:W(05*0DJZD:VE2'`,E< M:2QUA:L7PU+6MF6L039_J=-:8`\RCSR@/8BSSY&B4BLK.`[675;TCV'P2CC; M*";[#'!0`M8I"VB#+^B=,75MS>!]JVBW\U.QLQ6RI2O?+J>A6YNZ%5:+>GQ, MWKC2!-BZ!2I`(GCK7GS6%JX: MBWU_*TQJ00A&;_8/J5#K&O^`_AC4?E[Q42%(;#0TJ>=-$5N:P1M8$,1-E]2H MUG8.?4M5N\;=X'UN*,:5O40G1+F*4JH70*GS,'FG6P-8Z]ISA3:K#$R`VK:( M:2Z,?Q@#TNCU;ETM;5WPUE11@ZDK-/:?G-1_HI:I6LM+8< MIG`UF;(R"7PK,Z/@1BKL^%(@8U@I@&;7]H3U'6$T-66Z2;324B;;@]4>02F3 M;0I;NWV"-%UKM"U8,,$?0U]8[AF&,]:FV\6$`TIQG1\JG:^3A*;)7VG@?8[B MR^+)ZRN:#IW;:_$P=6"I":RG1`.OV2\8$.#`"Y"7/*!L`_:QO@U`C1WPC5'7 MVD'?"%V=;%V`P>%?>V1?VT9Q^:!\2-/!/``])F;M2QU:M][)Z?$3!-!1&K8L M357M,"T]/359./`^H7\_,#$NGA0O:_62&"T-V"MVNUA>WI2(MA:L*Q<2WVQI M/[GBM&OY2;4&3^.5ME)[:1!U7KJ-V-8:"]9-RR'`U/SA7RK/\5. MR'X0/Z]#6(1MJ0]/'@U9YER<3:V49NF$5F'R*"2"K/8"6J',&>>\#6RQ%N&4#G@8HFY!S>$/GL^#'YFQ,8V83K"WV9K,_C)A`Y7+4B`!A!%N4 M:&$4?%GHH'SO#M_Q+-T;T:R]@1-CC#>/_H!CM&V@K1EJV1ICEPLR)G@K!3FT MP45"(S/)1J.>`C,:"Q-Q1:"@K`.+@6%-M<,2(6_J%R?FD=DFOH%P3&UG:S1/ M2^QT"+BJV=:2[5A$F[$DFY@(ID=BT*/[(U+KCTBC/VRQ?"7CT'$$*I:!XA=H M_.2[_,9F$3ZL4UB!\068ID-098;C"=2A2EU`SJ86@JY3O64K@N'/`#_J@^]H MPD>R+`7&#V M7JX?\J(-3UQ?V)^]LJN>LZX*BJZ"X@_0&KNPPWSNI+:+.9LOP8B!2A%[O+G^ MGH4F2Y1X2!NVHI\XKK!HOEZ(>GOA.**C<6;0'R.-L@%S]O_%=VF8P`:J".9H M]J6A>(G!S_+.F)&M+RL8HX;:=DBO% MR!JBWSWZ":'B&66H22:>:$IX_.KLX/2)/&?HW`R=5_`C3@(SX;W#6+J4)(^4 MIL1S4HH7\PX92"V2';`.@_%I45R[FGU12;[X]-JJO\WS+K+L@BH@OHH7!QKINGCPB M$UTG5NBWJ1.G-G1?#?+Z\'!(4G*Z(N`T%H)^$0Z^(FT<^,9-(]:,?-\#W>B* M:2G'W%I*+>25CV<.$WF#EZ'(&OPICI)DP5FLZVM'-(]U=]:2,UF6UGE9IG7R MK\[NEU(:+S^7J75?(RWX6"=N-;`]((_)V4H\R-SNMM]]'(_#S5*,#[%X1_!E M[\><0P%K0?<[_.TC/Z0<5_,?DWI7]U=S.7M59&2X`>9DD!^J=\R<%A!P<15*]5G+Q0F/79[!D MOER?F>F2D+I0E_2V^7?P?>LSG*.#L+8(ZQS.,) M0C/)X7AX\9WK]K>.*,CLZB@#;@Z^M]CVJY$04J7C&EX0VAYKI*@"MS:V;VF[ MM=>;S!T2]KF2XW&\E0WC_'YV=CT[GTRN8]^5)\I9E7J<866&]TEA[?T[^')0J&H]0SY^-QE)4)X#),8S],?)??/#"S M@&E\\XBL9#E2$^V9^ALK0#/^O77T76(B474D7;*DBLATUUR%"NC ML7/B;"NED1/B6P@WZO=(4**-A@AO(MAH=2M>K-&\-_?VYM;!SC[FJV4C+=B< M;^PTW[?@&L53&*BNL2'"FW"-K6[%\+P[;GF22-E/O??E@WUX^@M M.W;:)_;5VXP']" MYBW,`Y6B@'9.`EH"OHD90'-(T$]U0-#?K^>?.%J_CP,A+?=B_*Q(Q[>8\_G7 M3$^NG!U=O_BR%P1JS0SZOX9X3;V&GPG\3GZ%%FBO)DX4TZ05=@UXTQ8Z1MN\ M1IY'.\=OO=K5@21KB*"5A8B2`1=MT#5S@J@8VED?_#[]K(W\E*?$R^JPP)H) M_O$K[;G1-D!@[.%OB,-S/15\"$Y(UCD$\&*Y+RP(B9SH+?#H$W&7J/5NAF>C=5IHM^W\GY_$QY9ZE:,N6F93S'\N-UC%'@T3L1)%).3KN^3-';< M5':6+BB^WL4.,WB7'_R&'O^O0!P#>_]U M2%)^"DR9AZ5WSLMU%/-?TC3V[P\I%/J[BZZ9.Y( M30(B1"#OOD1)\IZGDH`L)!>&5*3ACP%7Y"&E0"LB1"),)C;1"JE(52PV4Q,A M&);?>=/=?S_4_6E?]YOTE#A.INEY43S,A+.7M>M&AS!-KIU78,R$87^)#]3[ MXCOW?L#"*IK\1$,:.P'\YNW\T(=9)&7(!)@N?SL;:U/G.?-T0],H[:3/;+_W!V^W\1/>,$B:0W9N\$+W)YVA@W/K.] MO$\:L?/I`G2#]+B).0:$N8#R'W3@![\R1YI&RIZ4&&)?LEN@_\!RYK M0OS0!=X>:QY'AX=']K].UA(ZSCM0\NRGCWY(HI"R!:L3DW=L>0K,HST%Z=AW MW5<7JDW[6Q)$X0.-V3S!^`8'N*Y*@A)>^;5WP!S6N<^/OOO(_OX4L85=0AX= M-N6P@?!=)PA>V:1!0Q)3E[(^\-YSB?;9:+/IXJ$RPDZMO[Y%.P^=T1763D[G M\X,+^WDX(&(=]LA^/*=/-(CV8!DS>'DY8YM\_%`7C/?P.6?>HL+;?O\^N4\: MWKVO)^SU[;H]\'OV['%U=+VRM^SVZTJN3]NKJ_@]<[LPF7Q?G?@W"AH"NZI) MOW=7(C.XPS$@?H<7XDZX:,_W[A,T=SL>AM29WM(@`'!@;05/S&6XBI8U%\T* M*C8M]&G8Y5?G-_K+(P.5721)-N$9'$&P=3;KXFO&C()#%"DT@^'/#,P-AD"S M=$6?L=4B'F!-.._\ZEE"-G"$5K`G!?\B5PLW%EJT<[KZ(Y+V!WF74"I.(WY\ MCQ8>+=(IO^<0:0>*\,P585]1!+>B"/M"$1+H1]3@:3[GV0R@9O.[6?WZ) MOM(<_R:'0N?77.]PST_0A$\Q==S'S9:Y;IYM(%>"GM:FQK]7V.;0BX9DLR5Y MT]YA-Q.839`<+YJ0ZT9-1Z6*,4$]KP^0*_9$SYV=\T#ERMG9UI1J]@C:ND"< M-2.B';XSDG5P;80EO3MA?/]&0X_-VGI>2$YD:L2'1&]7D^+MB89O,J8%2L-0 M4P>5,3`7YT/.#(C`5H*0KW$#94@VVVOV5UB+P*]?_=#?'7:2>%^=A\&X7P=8 M4^'@5U(A7A%.#IJ7,R#09D4R'EAK@25`1JH@32X)M-6TN330U5$T"[Q(4G_' M5B]UX=2MKX<>S_)Z`0TK9$[:,CQ+[&T.:$USL\C*Y*HX8&%2/9P0]S0^U+R4R4['/L/A#ND,J-%QC3E%.$:8#6;60H$5QBDI5B^/4-&J"II_! M@2B-SP+'[XJ^VFU,Z7!#L'95`OXSX;^CZ.:`@/Q,)A/2A39DYWB4.`^.'R8I M/SO9.W'ZVMH_,+/CL93TQJRI2W%KIM.AM08+O\612ZF7?&9"WSH!FZ!NJ!.P MZ8I-5I(P2TIFLBB<7/S6MDG6G$![`@003`$)$31H%>-&XM@6."(I#J/EY!14 MJE5<;EB?3)8:ZCE^[-U.4J4T6D9H"$1[INI/2<#<6=(0M=0\Q/Y*[>($,!.J!`<"IY$',BIOMA1.'+*A*KFG,KU&O=S!=2'1P M'OXF4_QFZI!6!DZ%+RD9DYRSF`0JO&$NR+G#U7Y1-F!%Q!?04@>QNF?;[)Y( MIWN,9A_.:5*M-,49[6G"^J?RH%RE*%_75IBTN:E54;^XDI?R2+5HHO%M+6OE M5EHGJ0L.2Z;P`',?6#3/-".1J%,953")7#>>XN:$A+[0V/43R%&#@BI!]$PA MKX[]XF2/`NQX'J_X'6^U-6`FM867W$8,QIN!DR2;[2\.U+U/-_$-U*L?J`W? M3V,RQI0(WHHNH2W,L%EKLHD);X]<15X?0U1BB.08C$;'0TK4BHL'-`A9_P;S"F1-<.[YW&6:%?0>50DYG+36CPJ#,>5<[!&2-^ZB2O$O4?M+?$">`:=&;.PD31%*R\5P M.B@'5:',J[H)JG%INV,%'#LW:P%#3_;3ZHWZB9>&VAFNZ@C5T:EW?HC9HE`4 MF^1/A(E-Y(3O\%0VE,O]((DWGL;7=$W("1W0_02&8$@$Q^(U6&IA`2>ARAC?2ZAW@8Z;$%R/TD^,[Y!9'`5YYS,R+D/K$KD%3D/38A2]AIZY MH+L-[N3X;^?^D^_14/:4B3H/?&?0"6Q$>"":Y#PL,W`ED+VV["0C*@)8:,C] M.JPSTWD+_A88J9=`"='\IR1C?:J@G9>F[5\(I8K^=AH MO:KA=MBQ^//G*,[>I!AKQVT^EMAQ%\`1=IS]"$_)Y(QLM&,5M+UV#*5\DAYP MMIADK[[JF&2?LJ*;I`C49[#)/D;X1MD/<K9)>63YL#"JRU7K76 M2KD/N:+/_)>Q$V9)CV^3+4`C)DA&+AK89H"#X/@+6Q;:4K>:Z]SBZXT]'U-O'7H7V:4A[XX_ M7T=?TD_L6[]UC/M\O$TE*\[4$:T8.F-;N2.05#9_!&NX-9`QYU6+"_;DUSOQ M,B;[`N&?,.Y9C[ISC.5.SFE&M=3*&6T(^0)0Y7:>9*(8),6^"E2'H7P?:$4J MA%;="9(#NBHNEHK%)"0OWU-RS21\A`?@9X>R%RO7U(G3)>!$WU9N.27DA)RS M[SWQ5_K(:TTZL>1 MAW=]O]N@:A%.IS7A%$S+#S)K::;U(D.2T$67$U)9-360\DIKQ8EO(WF[46;* MANIKX^!>\IE9."%W;SZYM968S3&,JK!T0O*DTG>]1;O'L8#2&1M+QY(905RM3UM@2 MKNVTH0':'1XM(;VEA%0RJ4$IP8B\NJ10=R=DL6?^=*JSA4+8CO=?AR3EQL:, MJYP9^TP-"KQY-?-,(_9_D.ZRKU4:]K-8$,\VNXVA9HV=EC#ER(OU&$W6;E_T M>^XG;A`EAYBN[Q/^>E'O`9<^)V/'66-`MLYG.!-2Y=*J)%PR(K_FK)`.J>:$ M+'W0V0QF)2V%S M>#]Z(JX!-[`8,'5O=W30-)S::&Q2:,B^3M5A=/@W16\Q_?AK_1!3GCQY[J24 MX?S35X;S4>[05$@-'Y0-P.C+!"O("-`1("2<$M?>9P4E\'!HN)8^"96,"OO$ M2\6&NH[!%`QH9@/_=R<\./$K_\XZ]!C1Z7H?^_U5*<=RPC3_09"*AI/QR0P( MTM&`%>&\[/,/RZ$6@#EV^QS(6-@:3*QR+VH6/.AME,QW]NCB]+OUX>&0##SM MK42+&U^T@"@'&*??$4%JGP<9#RM#Q-'9YR+4<4G)K'(#?;:D$&9T&M+\IG[Z M[X?@=92A5RF1S;P.0MW(3PD06FGBHR!Q-)9&`*J8)$2VF7:'[:@8=MMP%IC! M/]/[F(<.H^;P!C7V+-X"HS./Y\16FOEH:`4JBV=S56P#A+:9?8]M*'T17[MOX<`)6&O(7)_ZMJ*?'HEHBWR9?]1PM\/"(^3;->E,/VI M=1W:@J'E5\Z.#E[M[VR.HN$U<64J`@W1+_;/+3>.7K=5I%^K6_HQ(7"[#)^H M2"#B=Z:2(IM-X:A:B=94T*8(I%6AKB`3MS$K>=-6''C.#PLMCM%1M5H4HZ%G MTYQ5/+C388?B*8A;MD%7O-;X=RI><_"G M*]ZM_Z*D=V4[PVI7%;!/ZU@;.Y1.0=BB";;*M4:^2^.:PVYNC_(R=&-^,N`$ MV2/8O);3.DUC__Z0\F)A4?6Y%^6:%U,Y&]SYG-X)[>V7@B/)GT471;*J3*%B M5OTQ)4NJ9*!U2%KKD&BP0TSNUVD5[[:SKA767UG7,T&3);3JERW%1>T;)Z77E&D0TX>'+K^B16ZT M6)82G':%K)JUK8H2"01(5Z0DQBN+91B8V4I9ZDK8+H^EK($3IN"UY_G@&)U@ MI,&,X6)J.M8&U_+M!8..Z_85?4.TH[<#5&FBGA-I2"7J`T&1%[B$(W>%POO#.YJ\LC,0I03L' M%+N6S&IZU2KFK*)4Z,:1Q=RC[*-"BV\B-2`Z5E(06F8HJH`B94`6V$Q;W13- MIJ5K$^+4(KQ8ICY6?6 M>1#R%Q%AI7KY*W5BO(APV`YJT=^@$4S*WW5C"L]M3%DYZC$QE]&K!ZWSS`'H M[5XVO@&8BIG,TW!"34R_P%HN#,5"\0!_3"/B.H%[".`OA=LH"NGR+>'::A// MA8RRVT96M+[18C^>4!=5_!=EOXAX)?3R%Q^D>\*3&*,_K:#1!>HO+;0V8DN^ M^5^@-DO.VZ[7%^;HD6VM1]JK8-T>,;L_/8>IJ#WLH&DG&)?EBML=15W\*YK* M%MF#I"B7Z'IA-'7X4U;0>9V*P@G?GZ[$;>K:,UUY$I9%KSIH(W2D"$V]L:;T M@-P$E')0XHT.O.?C#`/#N4PI=R']%RNE_@-QQU&D!(W8CJ\38NXU-B$H;31F M*6*6;<=K0&D'(N2='XITE.2]5=N,G3HVN,?8I6#HAC)N:[Y%BV\N^EOSF<4L MMS4OK:P]!<[/H4?CX!4V^,+B_<)#Z,.Z/<_J$LEKC36\97Y!__1A:,PL<`LC M3A]ZS,F<2:^<5DFC9XH;])69^*I_E?2;>@>E1F++?KEC_B/^0^(S1 M+`VZD@FP6UD:&2N2\1+U704W4F&'98$60#5IFU,5NFFR$[5YRCEB;1?BKU'` M7'_U5:W>T\0A.F-GBL,`!G(EB2"JOU>'<\!X)%C43AOUP62'__O,\-.HE9+V M*.`Y*3]Z3/T=WV'$?R%+U8SJAY%J-F1PYR\[L$CJD@W=+Y.2F=SQDXO?*D.5 M-U^UMZA1[WPMC#"-G"29+/-:\[$O.[1Q0N-73^A_"I' M\6.2_2H[,QO%SN3R=QSCWE$`Z59.TQ8E=*`M:J#D%2C*Q2O).*5A$T;GU$P)FQ)4\5RL]'3 M+W,S(-\^ZKMWW-'(X&Q5$ZWUSAR_:;K,)5JEO5>Y='P]L\>XOJPK'RRWQ*DF MX;F?2&;5KX_-B:>EC-/+QB2Z,F'/=:N8$^1T'!A&2F$GN(M M21:GE%2D)$.M/*.%IO(6,(NXGG-L^;X!8>:\$__)ED[WKWQSP8UV>R=\K:8Z M"R-H[3(8V1LR-8BFJ_(,&U97F9Y!JYHAC_LRE.1`]K4TG9%=$[(O'YE5@\?"6BTQQ-EZWGB"=T(8U!*UQX>P]*1_6&2ZTCLFLY07R3\F5Y/>]N9+AK0$EE22*/0#71.& M.KRG-D1G;\]0]39/9E4K?=MH;;K^;4O8WB*XK*5(.L8?<'E/=Q:9[>SFZ8.= M[W1[2H/=;&UXL-O"]@UVT=*:L>[IZ*ZQ[NYEPT5>68Q]3O-8NYWR[E/9`:(J M!]-%6Y5`]2Z3WN6T[V'%5+GYK&VK,,3"4 M6S]T0I>MU]'KQ*I;6V<]6&53FV$547BGH55#V=#T*J$J8N^JH&B$NE.*+*K6 M9K9,UJOV5A@MYN#:II@?=VR*&5]TM;2X^IFU+OCL8[;;.OD*);?0V&NM$+,@)T=MF)%,\=Y'VG$3.3/#'& M/A-IZY6:A;24"M=`;OSDM\\Q9;$O<^$T26^Z<^.T62`;3`\L5<,!<@+T)&?` M"SO99$**"*'9R1:0^#F2&#F_1U<-5>Q*HH-V3$!_BP+FR*#@P0@+ZV%BR:34 M@J8]/94KO'$#S5#2US[%=N4K6O7C-#/K11ZO[9G-MSU&-7AULRHG0=Z0W>.'_KAPUM=DJN=/BJ+OH9B[EX/;1[P/#$,?`G+#,,4*(H MZN="+RI;3D[L@E+,RF#L8)E_EA.R90`5P)L47S![Z$? ME#S+S!T![RTX`J/3>*-[E_<1P\N30/)^>O;31Q(7G;4O.BMC]/SHNX_DV4F( M5W8;?X,W84+@99',X41J[FX&#S*IOEI9^QTXECZWD$)\O,\!JC,P5W%-'9+\ MW02@KL4"I7$+#DA5V(X7GV)EMO$`P1657B6D*7@<`=G9IC2&,WD:)C3A,5'A M6B!:`O>4NRO,2FV:!MDHV:9GC8:K='R"1VC.HAT,`5>!->P5/E!0B4^O99.L MP-SZV8F]C=AG_DEME^BFAYG4`C3549,=6UG%9.3>_[2 M4O7SI/)]*%E0;9?)0+@0*[+)#WM^RK*T0R)$69%>6 MI>*URJ6;VG!!'0E.C%L3VKR1=Y96,6GAQ^-!/T?QEOKI@>G_.O3*HDW83G6: M7$?D9Z<.P)*NMR(;CXPJTFGX8\0Z5A:-R]"DQ>(Q,29YK[.F42RR1?$>+[&M M%U7ZYICFMEG<[]S3W1R^UZ(9,!F`FXN_^)0WKR`VS7%S=_&822U1G=4*88Y_ M#ENZW]4G+;3;D];T56\/6#4?+>(,M2>@)3RA13..UG*2_Q?4R+T,T]@/$]_E MYYS&-JSZOF_3_#)3AYK=IN)_X?6<22')0L]WHNQ$J??SF]N$&K#99?>?Y`9[ M/&Y0=YEAS#].%.R('.?D(;!Q]^F-.-O9Q^;WOG=BQE?/XCR.QXFW(O6[*'4" M8ZY:Z?-'Y)`5NW-)M]NY/<+%>"N>=60G'\<"?T9[G=LU:ABK.0/!&C..CMMB:GD@Y!N]^[$8VL M&/[>WFWYDIZN-1SYW`][L_L>;[8YI$G*UB5^^-`(Z8JLNK.(^3;'30].`+5Q M9'=,,:0Q'1<9[^SN,.F3/$SZE(=)GZ1A4D6BCC5HF3-;$8M7K+(R.\V2D9DG M@%UZ9(R'>SA.JC/Z0_%0$VXRP.T(R&RFO`0%)#Y7'^?MN[XP0&7JSL*@\%TO MA@D"7A!%9/'7'E=&N9MP##B4[B!H`V'+'!>8,K_C9;3@>:!8&=Q]:CX47ZF+ M^TJ=&.^^@9K9U"X9*-F,N>BN_GEQ<[1T0))`;(#08,PT"*%]CZ?QD#JGJ4V( M6%&&"2PFYV4U]6I.H4JZ-6&VJZ5%,-_#Y^/-ELW7NRB4SG@*E*9F/240?7MS M^:.115X2FSH$)>:\,0H27%IK%(B&=*N$PXJV\-0GP.(S!]Y,H:YRM=E"6=^. MX"3DXN\'/WVME`?9L`D\OGMTPM&1K^PM%;OD/(:SE84&:($UK)"T6EF'<%E9 M2.B$TU>X**]YVCI\\QYQ+&A< MKD'?@L(SO:>A^WKN[)@I)+?1@9G&4-;`,.UX;5.6:XJZP4=(Y2LKDGV'B`^M MN@_832J:ID[3Z??0S^;XY?+-:J[9IU;$24E1M$\_P\H$IL9VGX(G M2M@:YK/_@ILUI=4/`Q.:5/%,EN*]3\OEQF?'I;TEN09)QAO-D!13[`1X5Y;" M*P+L>VI0F:TJ*\?<+B$K[78LE:E."+7;CE MZM31_5CJLW[Q9?OH'8WG4I?JEV=4$_(K,$;=?NK'*5>+2O=BJ<.5LZ/G$6RU M*BM%A60NU6A+,:L?`?;D5_$!BQ2EC5JN+JV.GZ'`]Y?(Z<_X[FLY&0Q+,D5! MBD*^,%(DYP_)`O`%W'R9(=SM7!EY]PLP7QCI7]B_V?_`@2K[X?\'4$L#!!0` M```(`).*BD$.9M-2W#(``-NQ`P`5`!P`9VYB="TR,#$R,3`S,5]P&UL M550)``,U8,90-6#&4'5X"P`!!"4.```$.0$``.U]67/CMI;P^U3-?_#7\SJ] MR$MW.G5SI^0M\8S;5ME.,O/$HDE(YFV*5$#2;>?7?P`H4:2$E00)D&;=A]N1 M`?!L``[.^H__>EF&!\\`)D$<_?)N\N'3NP,0>;$?1(M?WOW^8!C`.P1V8'Y#/ M_YR^KL`O[Y)@N0HQV.2W)PCFO[Q;1(_I>TS'R:=\]G]LN#.-_(LH#=+7JV@> MPR6!^=T!7O?WNZL*\`L0`0A>/GCQ\B/^^T?N$A^;@7>?NBG`B]_.+X,(\2%P MPUF%V=H&T:+&8PC]$^/ M4$,62-G5&C,Z]KZ?HM/,/XN7*Q`E*@<.8W)#D-:HHIWUZCZ&`'$(_0(SX%^\ MX&\`60J*UVD(Z`Q$^+*]1N?60H5L^_,:GW3+99`2>4!8HJ,*RPGZK^O`?0Q" M]!EIFLFLU!#8&Y!>QTDR`_#^"9V=%[-[2=@H$W4(_U,<^DCQN?@K0S>FBN!7 M)S8$Y1S`X!D)PS-09QI];D.`\GOD$L;+:9*@>^XW$/J7,;R*GD%"!`2Q0Q(^ MJ:6:LC)[3,!?&5KLXEGAE-V;ULIQ^H#/'VF0>$NT?;22S^@Z7_/%-.[1T.)H!^0WA1OY^*)7HZEXG;;/3C5XI9?3K:1N MV8>X)PNM:!6].F$M8>6OT,_#[J`$-VK0>Q?1/5`W9G=*">C3=SM0(:[H/IS(AMQ1$ MIQ1Z_23H$"/:^34"HP(@.L^0!H\==/FO>($&SD3B[HV]RB="[&"-H>A\Q[\X MO,6GCTD*7>QFRA<*,8YD>4=ZKO,I/[FE8%Q3@5!X[B:/A,Q9\G[ANJN/&/:/ M($R3S2\$F_>?)FNO[W^L?W8*=]?:A+8'/'V@L[[=R]R;PBK4+O0VZZ%_[K&N MZJ)>C_BX(G[)]]Y3$!9"'A7!MPB_B7` M^["(GS_Z(,A9A_ZQRS'TDY.+[1U8!%A:D0;G+FE;CS74.;*#6Q4N5#G&`9W) MKRYH?H;`AFYXA2Z5E_\!KURB[XQUCGM$]7W8-V2?=$SWLPQB]"Z#Q'/#_P,N M1-KT.4*%07K6<.>D%]3G@+]AP*$1P;\,0@#/$"2+&/+%OC+2^=P+LM,AWU#\ MJ&.*/T`76YWO7Y>/<4/?8S-'>;Q7*;I3C4 M$H/(/]L$)*40V[#GIF#T;_?P!+4/],+'G/2G*`BL"&"U^-<@'KL/(\*$8[DWZ\43G@;Q], M5`;L_N\?'W?H22-E(=^?TS51*@7\03"WC=1XOW2#B<'-_L"TV5!I[Z!REXF"8E0P_V3KB MQF-%VWPC29DL3YG<;,/F6#HWJIQ3P\9F5IXR`Z=D6"F:;=BVJ\A*"6S8MG9% M7H8ZF7C6B(FBV88MQ8I,E,"&;:_OTS79U#%LB65:W3'\1=\N-,K`/.A/XAE5 M'6B?(?L+BWE[@`]#/W63)YR+BOX/1YP_NR%.U)NF9RZ$KT&T^,,-,]ZK4FJ^ M8=OY/N<8JJLD+H-@_&WZ!&!.F;4WF,/E_<&F[?6R/*5#/J0S5\R]'?3-6GYD M&;<'M#9%)RU'\7;+L1F,5TB=>YV%;AX8B(Z959'NS60@;YII)X(L/T4XL*,@ M^K0EK^-H\0#@R1DVJ+*7` MH=MBOR2,Q%-3=@EG8EWX(/,5JH+30+1<5BI_B102.K#\*L[$K#5)B<6,HT`- MVT$\:,_7D-Z!9Q!E0"P2]`G.Q*Q)2@/WV8@-XT38Z)[GX#$5LYDRVIF8-4AI MX#$#JV%X`Y1.=LJ1=FC6-J6#O52DM+V13>IU)<&]B2-/:?]N)SB'9LU8FK=P M%;%AO**IY2RD6"Z8Z1R:-7EIN:*%&`[CC5VIMRESACN'9@U@>@]OC,T07N., MRK4>GZV<66C6EJ:![7SDV$DI?>)Z-=9( M%`-`&>T)F%MDR"W%QK?,,(IUD=P;WY=5T<>?0=*)T#?G1@W9S\PR]`F'G M_I8-JB1XBE+Z&5<"O@'I[?S!?>'[7%16`< M]=Y^1T>*G0_=G]>^B#@-?.[.4>]M=S(H2]O:Q%NA18K5Y#<%D2%N]!S-JR3)E)F<3S*=\-V4PULLAG$1TW#DEY:6 MG&DZ0;PIHW=0&49></*EIAM.HU N2Z`S#S[97/5WJLN;,,IUA7I/3 M-#2&$2*]AZ3PEF;,,)U?WHBS6Q2TQ4O;Q56YRYG;+,%P(GHC_N[@83HZFNV2 MI)MQT,7B89(OP.W\"D<'@83GD91?I`_)Y_6P:C$4NN,BYGD<3]?URO.O%F!( MQ-TS9HP^;\F]P*;?V_1OU[3Q6O*2Z'F7Q@;\ MA&C-!<+TFPN_@Q*1>&HLT+$[#\$WN44=%63;M<:ZQ M3ZDX:'-"VO#ZV6:LRK!R.]I"I[+XR5,%?QA;\B:.XBI^:UF5>,\*YUKH8&9R M60J98000D,1S)KZ\C3L-X$6_;;.183L-X%F\P$A_>.R--URUOQM8]5(91 M2V=;YO57-XBPIGD;;7_CNV6%1*:T$F$8 M+X/<12MXSF\'F2ZJWH3[52R&4',9G8);"\4T36'PF*4XINDAQI7"XRA%$(:$ M5$)E4'DMTS76FXA"+62;!R3;H'!44)>5!],EUY7,.KN`#V&G5^.ISX/GP`>1 MG^R$HUXM5WS[GA.ET,5)&?P!7"0/G-1%5LLP55S)=K+TS M\>$1H+4;J^-DYC,W>;H,XQ_H_>P'$*#[R%1Z:0D6J:9B[&ECAK/J34TG(F.W MC&G.8YJS??R[`2F6X1F,L4'0/WW]/0'^552$=TZ]-'C.VS1(Q#XJ+]:C%.E: MR`U%1FKX0\R:QNMQ2\9=8KPHN!ZF3OU_97D46/(0WP$OCKP@!!54'V)]1T,; MGS.5OL MIPN;)$$&</&>W&@!+F-X#^!SX.%Q$4*'ZI?0LJ[A9/MNY$D7I9J'LC>+16+(UC9R\G=$ MM3`$'JD&R,:2)4S*"QG.X.]0>NJ0QG1NN";K=I,`:(F@7L-E`;J]T>3H,8P` M^[+N1RJ0HH,5[YEIDH"4]^CG3S1=>J!;@1'38A@1\=MT$UPW\':.B(?(E;[. M0C=*>)LVC=6V(LNY72H_AT@S=BZ(VL@TC)X"H MB;<$8+O[0K1RQ:=!B6?,FC[/J!9Y#CON3Y__Z%OO!//#<_-?D M8KD*XU>`WQ$8+Y894L_"INM(=/AZTT(K;9',NELC%&_.O%>'@O5(9J[I`A0= MBHDL.?0%/+9YULP@6+F!OT'@*CJ+HW]E$;&!_1FD3SO8X@M6[JRIL;#IXA;& MSIJ:M"HDK-]NMFE(%E]'[IVZB*3E4U6L\L@M8+K&1L`'0"Q)PAV.,KR(_\P##J%1W*=-E.CJ\YFI2IY`;4[9MAMQ470H'PH4*63"E`F;(1,/$+A)!E\)!G?`!TB*,0XW<30#`+3CU5S1=.L38 M>TN52(4P]=N6O$N$QQ3G7<59E*)S>!ED2VEW*V6NZ9HD)CVN#'(48F.9M7G/ M@C5--K%Q,_>5>%NB4L-0A!WZ">?F25L(913!MM(0[O.ETMT#N*J/7DF[@-Z]R4Y+`IO)94U3!=- MZ?`4425+(2*613ICS8J8N2-06+GOP!SI78AVT2*_4IFR(3/9=,65+H5"EAZ% M-)@R];)BDW/CT!U8P0!#3'1Q9OPQ;;#I(BI=!AFS\"^XV^]0XG;+;ANNI=)U MPI4$.0JQJ6]LM>%QBPB(S41(<<[_OT2R,W<5I&XHD2TJOXCIJBI=ZZ`J="DD MJM_1QOM(3SWRQ"_E1K[+"04>T<5ZGI<<,+F"TQ93K6Q9. M=H[,FF1;$@@:FLUS,.V4!]SF)D)?"Q1%H33/.3)K2VU)"G8P-)THV>J!<)9! M3&EA&I/,=.?(K)6TS4-A#]%A]`YBWXDS]Q4?@;CL@>?!#`$8N(]!2!2Q6MH$ M;T'GR*REM&7]0H3Z,%(D]_'?^"_O`#I0,S4E=&>NYRPT`Y M[^FIJ5XC9S'GV*S=5D/!1@%VIDL2Z1&3=2@#VFQ3[Z\L@*"238X4-9DL??E% MG&/#/>_JL9HN-VIH#\*:AC#T`/"32T192O4!67F17\4Y-MP93ZO`J.$]T!-& MH6:,<*YS;-;\VNYY0L-VJ$:X.T0P&'@((DQ0I;=0=:IS;&5!X7HB(8/L,`QP MY;/QFYMFD)"()-KFNP*=CF=N&":X[4@,TQ3`Y;9!O:#C;I.5G6,KJP1%L\TSD9@&E3`5<-Y;)L MV.-WQ=/G=GX'0@S(S(7I*R.?16::B3G1,K#9C-CP(VNL.X M$,JB+RD-K"G.B946RN9'PBZ2P_"/ES'$F!%'+0F#OL;FM]O',%CDM>XE98&_ MB//92EME<^D0H]WX8 MMTTHO@51#(/TE50I$[O"15.=SU9:)YN+!`M9TUVJVGQT5DM^(]4I_P&@/[(\ MILT6=#Y;&7"I\W$J0P+3+G3M?C6DA6?0>\(*=R.AJK>B\WE(UL_Z-!B(V[Z\ MKZI5>&5?-SNSG,\#LI`*\#3>AXK5KF-=5WE.2B1.DR3V`BQB>4LMA?K6R@LY MGP=@$*V/^D"<\&4[C_RAP)GE?!ZHC92"IP:_N@TRP+@:20@*SJY,7]5UB])D MY\N`[*)RZ&IH[F2%8%`U<7[HI_1/!(]?X0GA*SH:_W!#;GU(J?G.%[.VSN9"0$%(FT-^100, MP0C309^M5B&ACAMBK"_#^,=51!JC$C:)8_XE M5W"^F+5KJDB!`DK#\,!OVPD&O`B,\C#GBUF#I`J/Z%S>Q6809?'RHJ4/[@M( M,%["8KX[@YV?#!?+U,!5&DXMQN)_+),*'2[?=\F'?ZO0#[RDN,]>088]"BY` MA"3SY0/")/_J+5RXT;IG++J>3K,$'6))\JYCX2J#<19'21P&_@:F60GCV_GZ M@>V&Q;$KDSZF97WG4^>;KA'!8IRB0H`X2??J((=UX9"1V:;.%#>Q;:8!/RP#+[.2&*QO> MVXT9R=CMS:G2[_W/[%&T;N#>^?6\!B390.*&,ON<,\O0 M_"N0<&<3JW''\3-!6E3?CHG&34SFVSZ#77NHZ"!YE0-'XC)26L?`]20% MG\RMI+:0XIC<@Q5W)9@`2+?AB=M_UKKQP881(7(`@L0%9 M4PSLM5U09+85_`C[]WBGG``;/:+%G8%"UVP)Q%2'69)O[^S?@+RJA MN4J*7H-539@6U:&5LBLV6-:T4;$1_U@6Q6;TZ/=FSR,B2&\4TKOM-Q#ZES'< M]LK!02)-K08R'Q$9.%36T&'IR+^'1=`EWWM"WYO',"B^%X%4:/)06L2D[4.1 MNC0CB"JN_=XW]]EC`O[*T(H7SR:U!M95, M:XLMN:#5J6"XTC=#Q;F)HS_0W4PVZR8U=HW,K[C$(/#S/R-=&"$V!P'ZMU!4 M-*WLF$U(UBTZ^JC28K=M*\(7",)C#$.34U[&(5_CR%=?MH_1#`WQ'8#^MC9R MGH-YX`4@\E[-Z&]],I>OH\+SLXMG$R\/[(WA>P?H0;0M*;`Z"]TD66MRTY>` M5_6`.<>PLK+/(0$G*?`/@JEEO,[CI1MP>V#O#7;,UC;ALH<1VT##P<['QCV` MZ+X\+55TJY8!_0:6CP"R'A1RLQVSE4;HW*`\!*2QT<7*4";S+D92[*8K!C2:4/V1NR#/A`&%@U6E4B&>K:_SB+.-:5 M]?@L:<[C(S4(/8F',8YJ6;<826[A7;!XDG3/U%W3L:[T1RU)$>$XN%,$P.?` M(U'OA35DFEZZ`21E*[7=/*IGU].B/#])%D8.H"=8.7SS)U15)M2=-N MP3;B#QO0HN?.0$;EHG.0ND%(M*<,H=*G>CT#KF/43R]'RS6$!NX/[V`,D=>`81MUHK,5Y@< MB"X+<(&K5*Y@@`M08V\]KMF5+3,2HW2>0:22[,[@/FZ:+F[8_Z(B*EJ0-6W3 M83P3_XSA=UP-*^\=OHWC8#W^6.,-NV)DV"F"O^<&%7H\]5H_GHP1U:,N;$4\ M]*@$CTJP??PKBL"597V*#78+@O'IZUZ=N"F.WE^'9-]F:9*ZI+#/3<:(:VCM M6SU2NMO`79<`&N^AT90X)"\@N8KR;C._PCCAGD+ZO]8CE;X=[$WK^';(X3H? M!3?BQ=5U7U8!)"L4Y&I1*H7?[L$[I4M:M/CFZ53]0D\?W-9S\_[.\2/427%;`E8DY&I.L@-HW-=OW4\ZT+D.M3QMI%TC=ODF6Z2U9`V MZUV)GVFMR^#>M^P+OFM-!FFX:VO6-Y13\$^``Q>!/T4(8:OX^L:8P<#CFKFZ M@<"^\+\N3DP!130W&QS,8]F0*,L#X4P,MU,S]K864648?1-;?^L9DO!&<#D3 MP]6:;'JLBPBUV0<_#7L?)'*:&VA=\+4"XDPL\0#ID'3ME-F(]M=AB_9@-._) MFW1(B4BR=0Z,1HS-X]J0($M"X$S>CD-+@22%(+]M-U=IZU]%*0RB)/!(YD4W M)W#UF\[D[?BUN$0HA+.Q1VM@)@[R7^>(2YT)J]3WG4F/G&==$:00XK?M<5-] M$W>P9\Z^UJA02&@+ MWCWC.5EC2M:8DC6F9(TI66-*EE:5,R^Q5ZJY M"*4J#&\AA:L&3<;4+B'1JC9%([)$M)(&ID^2-9X8)"98W,S(JQE40WD*> MF#I)!I(NUAK!BE9<1B5Y#XH^):AU2I4WGMG62U7Y#3C/:M#DS6?(R=-LQ^58 M^.&+TJEFQ5P(WEO(P]-++FVI>V_F(6GG'E&$\2VD`+9`,VU)@@-5BJJO(CMW MBB*,;R*]L`VBO?'L0]E'%X[_LG.CJ`#X)O(1M5/LC20FCN^2024Q=D0O;:F- MM&>[\0@70UTYQD"7,=#E[02ZS$(WNG&70-"0O#RL)\$M.R`/BEO"EN/5@88# M1'8YP>>7[=W%MV4.,<3H,Y\$S:A9$PS'.NS3N\H7(?"VM0S?`W6BRIB)%8W! M:S)FHK\/>&N<^:S*F?4$PZ[HFIS9`J\M`D*5,[J:`FVZ!IZ^WKCX$2]0&^@3 M;''""A0()O##",?:HB>E4="&&_8ELADD8F@%A4%HAOF!PSQ6:<,,.[A8W*#S M;@=P4[J''F:MF_D*N5499]K+HL:O/="-*26:;2%GH9LDMW-RRPMN/^8<:UP! MLODA-`2&$40G:MT+`9Q"Y9T;^'ANC?6=.4Y!E]86Y," M?;]OQ;-XN8PC@IB0>7MC35=;4V(>%?JA7)#7]3(F;2E!IIXR6:H;UN](\))8 MKCN<$C])]IGO""R\V<7HGI+I-^>_8!W<3I_\'TCO@Q8LH^)O;4ZFU;UI82XLM MR'H2$VK=?$+GA^!_";"?U^%D(I#1-0D#R!%5Q^0"#CD M3QP#"J7WG(",(E/!H`(&Q\I8_>8?B3BGG'%(<49G?'26(30B[_4!71()$F_, MGL@G_Q7FS/+_E24IN3W`',UY<%]F,21_25,8/&8IINQ#/"/\X+FB.P6D1S6R M.B=,>W+=Q7T]];PXB]($*3`8+T0+]`O,`*X7CL@'3%W;:WB2#4!N*),DP)DU M7MBR87I<&HZW]7A;FPL?9YY6UX'[&(1!&H#D5WS$N2'^F[]$SRPLNCCN)C_Y M::>'KJ5[<$MJ1+6_$H+]3(BT3^B/Y^`9A/&*Q(`TEP_NPCTHSJ@-T6$X1-9X M?W/A=Y`2[:!-7='"\^`YHOWH""@5F2'8;O?.-[6>;`EJH@/!.%<6U(Z)$X%&5Q: M-&%W>_H+[T&IRT!VE1[5EE/#2EL)N!1[LCLVD,P`<>%<(YP6._45\--8WB[" MN+#VUR\R\#D&#]FIH]5#(/T*A'R;I@\M&1L],X10X!\$4YNF:UABWZ"QA\Y1 M*@YV&BYRQ8I(*8#+('*Y:1BB*8:-#72Z4QX9?!0LJY%P"H'K/>&Z.'G8!I\[ M]-&�#2C&%";UMYA%F&@Q6?P;F[=!>`SQ+:6,//<6F&,&`W5A.!P8X_D"H5 MPT1MJW`G&7X<2S-(A(0V.T@_,Y0L>=RJ^\)^&H@U&\?@8:%$#QT<`'&'PQAO MYS/T*[;>X;]^"Z)@F2TY?)5>P[[RW\Q<>Q699DV9!0X'9?&PU%EUAHVH`"(5 M(Z"=NGMCK*F7(&+)+M##\`'-8.P!X">7B##W;H@.B#O@ANBX0%3A!:5QIIFN MFJ!R3(KP&(;;9^H4/%72Z MWR%$L+U(\F;C+&`[/U3IP6P?8W@;K2-)I^F9"^$K^E%Q*S'FV\X^16JTU]"D M"T_I#4@QGC,`25Z>!DD0847+UZ8(:T4VR!PDF>6L^9VOJ=[++$)BA>8J6-]^V*YF>4L=.%K M9_1,J=A&J;8G;<_SAML7A[W'3@'X+>[]SCJ:K8M%G(-YX`7$(4/*1AA*1,X_ M+O-\K`P<'XVRC\9=LKVII^):95O7>[^%=[A0D."IR)S3DZ$KQIK10C9%O1[]H2CM![BDKZ8ZQ$YQ/QH4ZG)=H0%RW%1"2O3H3!VF'>BIFW>&4FR:B"FN[P[\\PRBAVQ>@)@X0G/;9$+L$"4[Y=9JP>5U@W5M"5*N ML)LE&LWP'(0*QB!"WDV@!2F27-B^X&=5,9)'=/BG4>Y."9X#'T2\/@O2:U@8 M&EWKF-E#:BBJA=S)^GL4I#IN(K*.A<'6C:^>`K%A1/_RT,Y_OHSANB]#7;G8 M6\?"B.]:T^!BF,00KM\RPG`XX3BR/TGXEL3#MM7D^" M%40X#(+!.[@)0Q6HXVV)<&>P)^AI/=UY*VM5?,09`"_Q:B-VZ`@)M&_L4+@%Z0`)\0`.N" MI^A;WUF!"#K6[D$$NDY]&'JC$?57SQ#G,55S)%L-1 MA:-T[JMC-@C1.$>WYS-I_W?I!I"X]F[GVQ\W35]>.3(ANT0/NN350,E2X\9^ M0Z\YCY?".;;8GSC,D\'!=!PC@UOG`"'G[L5ZX_/C,Z0("2G;X@L3_S-)S'5 M<%DIZ9TGAXKIJ@T*+/QO-\I<^$K@1T]R-&DR7<&`7>"QYDJ&"SXU8K`0,].E M&)2V[.1PFBVR1-!O7&:NZ2I-#7?M/C*FZR^H\7'RWUGX6HN+I9FFJRHUY>$. M*J8K*"CNQ$OP",G14FLO5F>;KH/4>#?NH]-B,00C'L+3UQLWQ29,OM6./L&: M:D8"FQT;>M.>/MWLO'&70&BTHPTW7:V(PR(13ZM(V&FXNT+/XB3%HDKR99+" M?REA*)"9:[KV$),;E,-6%I]^)X7K[1%B2V&AVDU")D.I8:Z_3,RB"B.JMHSEQX"PF9\I+?FW[ATBQG+>`< M6M*C39WU/)2&X2:@B3JSMIEXDG-H7>,UM6V^16,8ILFKR(.$(&ZX#M_*3[,T MA<%CEI("7W&YUX]TBFC#E9U#ZWJKL25%`ZZFM0-6_U56<.86FQD,/-HMH#3? M.;*N5=H^NY4Q,AU!U\8=L,G@NT,$0_>=AYFUD-<"Z-.=(^NZHLG>"VR$+(VG M*[6`KL?8&JLX1Y9D:@FWMSI>IL/M=`6I;V^G/`%J&6=1FNL[$\[VYD]TCBP) M]Y'9V&)43`?FMQ<9T_![C'-^>0K@#Y\H-A(4# MV#.<(TLL:\+SF8_#AE5?[6(5>1^X"?";W+A*BSA'/;"GU4-K:UCI]2%,+S2T M8U\B_P707_+#*?(WY;FY^G:3A9VC7EGCFJ):"%._S724FD1%Q:(;D/(N=-%4 MYZA')CL99`J6]]MRMZ>ZE`V42AI<9:)SU".[FQB5@MG]]KHQ$*VGL>_.=8Y[ M8'M3PJ;@^I`,;SFB*:)AG$!$9_NXDC+_\/CAC47=(Y[I&IK0F2A>C89H*K"/UOI`I\ MN>HHTQ`GF.<<]\8<)X%)P3U35CE-;^RU12K944@$<1"\:\;A'=C`9 M9`I>]]P.1D.U(NW;II;KORKG4PN68OL6=DQY8U?2B6PB+*<.;IKPDK`RQXECW!SDG/3#!T<$N&&9G<;@D M5T]AG`(O)9&T\7.`C?VT*UMNHG/2`RN:/"H%`RVK#;<)X[B*."$*C)'.20_L M6!S8"Y[TN\(;.2E.<2@.>A6N0)2L^8#P7!#RG+YNAZSOB>D/%_IY5[RK*$EA MEE\>Z1.`#T]N=$OH4';7_`FP1@G\*4+578`[@%-@T>_HMB'],#(W?`"0GQAJ M$YS.20],==92KM@YC4V#9NP-YCKJG?3(]T.Z@;\ MZ+HO[!:1OYOP%^@K3E%BL9S#J),"RD-JX[MI)2K)-:A,>L>&&1K*5T5 M:BUYW-4K4#N0CE(ZRM.:??>Q^2/B9P6%07"S7LD>6ZH+5_E!Y]XNY'963L21 ML3@T%E>;QU7GI3Q0B6G[$PUWAZK/ M."HJMI5?W*8/;Z#GLXLUWG#;)P4N<3"PM1+C)B-$KAQC=;3A%D_JVVHJQD=&EX*_0MV(?@0=3@Q7`W`2<@XUKBVJ[Y/!><@73G9V41$`!IW'O"[>+ M=1[X)GO_2-^C(]_\%Y%O4>BDIFA9P[VAE'@N@XRVMTR#`U]L*Z#7Y:2,,MW\ M28H_#+A-5]43L*'0[$6<*`9:TZI)FAD5T$W7N>O!86A=EDB3PW!KV&D<1$B[ M`$V[YR>C4J8;X[0O#.52US5%H;R$-9$4#25A%R?39G\SJ>;VQ4W( M9)I/6NU^8]I"_("6RQ`BHYUXM!./=N+13CS:B4<[LFV MY!<_^)HSI1<680DD1N.P_K9_Q#9\_Z%TL%XK)G-TC`[$<-@.[ M*DL:XJ\(V3O@Q8L(]Y6_BJXB]#SA*;T*J_3(<*R&U=".@<)$8W1?"#8(G4H^J:,!4VUW7X8":B`#X)_Y<)@]VY(>@3%*P#3UUGHDCX@ MN/#93:JW`*VV"`D]J@T0J8C&AC[\UL,TP5NI1UM("]>V#,8 M1%ZP,4V.5( ML5@OO8!]Q@85*2;!<;0]`)10BQE&!>D).+KZ=T!7O7WNRN^S8&SP!XC M-9@X.)_[9[>/R-C[_D0ZUR5YG>N;.)6)G!!,[+Y']!X],3S8/'0:\HM/"Z>: MW<@R_-GO$RVB!NO%U,;>O,\>$_!7AA:\>,;6ZYU`(KG]*5BDC3TJ^&2W^W0' M%ID=RIK2$[NCV7TGH#??Q"C87_TQ$MJAQ%3D1FP@Y#PXNR;_=1PM<'K'.7A, MV5VX>*.M8,">\.PR@8HG\TW0O3_Q,=UZ3R]=#S"?`'&V.F,'-D M550)``,U8,90-6#&4'5X"P`!!"4.```$.0$``.U=7W/;-A)_OYG[#CR_7#M3 M69;=I+$GR8UL28TZMN6QE*0W-S<=B(0D7"A`!4C9[J>_79"42!&D(,NY4,>^ MQ!2QN]S]+;#`XE_>_N-Q[CM+*A43_-U1Z_CDR*'<%1[CTW=''T>]QINC?[S_ MZU_>_JW1^/7R_MKI"#><4QXX-T`S8=1S'E@P<[I_-#XQ^D"E\RF2Y8"HXU?' M;QQX[$GFD:"F/3OO&:33P.\J=T3EQ M`B*G-+@E'HZGE%-)'X]=,6^BE-;)60NT]BGJU1-R MWJ$3$OK!NZ/?0^)K)8\<,).KBRD?!Q:R-'&&[N'L6,@ID)RTFK_>7`^UEHE4 MG_$O&>K'L?03^K,F%H^)H@DYEGIK-=+$KYI1X8K4+Y'[ZS4(3@ME)<2,JX!P M=ZU$3NG8Q-;Y^7E3ER:DG$Y)0+U"X>=-*7S:C,D2KE`UIH0L5EP3HL::(R[0 M<#=.6HT5X!>N"'D@G[+(*.H>3\6R&1>:V$(IH;11'0AJ;NEXA#IZKHS(6[0H(\+GW`2"/G4@]\K0`3GX=PLQ`MD M$S5N`E$#J*AD[HIO.U/,@'&'<"X"$D#D>O^6+!:,3P2^QG9P@2J.@,'!AX_W M_<((HFU)(F2;>UT>L."I#[+D7,L^Q#KWP.+CZ M>-.]'3GMVXX#?_NC?SK]V][@_J8]Z@]NWS8W)21"0T6]`7^OG\$_"L3ISV(H MB;EB$A/'6J`=O4M\-_2+/]#,P/M,O(=@@0[]@TF/<8AQC/AW0FDUKWRB5-P# M(/*6M&8?G`+P*P'P?#6X'0ZN^YWVJ-MQ+MO7[=NKKC/\T.V.AK5RP)7@2OC0 MQ4-;OR0^]C+#&:6!NB,0>8,9#1CH$3G`DM;L@#-[!SC_R@C\=ZTOS3#_6`;S<`1_,/0,G4'/&=QU[W7$J5>-3R%Y1=2LYXL'U><>@PXO MR&&=IS##_LH>]JOV$/3NQY\KA?L`SDEG/VAOP)]YV6H&*=*18@7%9K!?IWM M3R^)8LH1$^N*,<)YJN0:]IJF[G7YL1;FTB'#,Z:\Y:P0DM>A MEL)0&P,H_+IF9,Q\T#:ITC:$9LA/-R%/B:H5UKK^'K+@*=7S M9=^;$?[1V.O%G']W.D#K,IP:K!6L'2K9$KZQI+FP8"XR@_MJ$]PULY/BKA6T M4;/M23%O*T4#]8'Z7D_(OI[JQ1`)33Q"VHK2#/SK3>#C8#$!84XDS4%QSD1( M9RWP!X?3X*)6[AB&8T5_#\&2[G*=N^3>FF'.)2EK/B=BK!>6QG1CA,-859:0 MQ!1FC*W3$N>[2$Z].L"MB8<&Q3))B6C-?CA_5J923Z>DQQ#K$42N(111&!UP MFDL5BT8J]<3<."Y)0UY&8$8\ESJ:AR_UQ+M@*K5#`$\-:*/09BLY]B1FGV0 MRR6-L[#@@UB:$XNKES/,_6H,2:NL[UW1F.'/):#%O6\LZ4_@5Z!:X%X`NSDK M+8/=:?T)_`K53/2QHC2[(9>_;G=#+<,/0B'I#-"`KC%*-6$PB--4F9:PGH MGED@?U8`O3E3+H7^K&;04\DH[B6X/+\2?$EEP&"$>"?IA$I)/8V7,1SMSF=V MD?5:;\V[;.-,:8S(+7THF4Y-$9E=8+DB7-..N@S3UG;8"R;QSG+Y\Q;0Z]89 MEV&:B40VA&87Y!+E;2ZH9>"QV?&0A5O9;Y789#0[*I=)[[!S(N>]@P]?^`^> M2KVG$TFVTDQV-_`Y..'^=^0H*22PZ> M:N]OHA!_.!$1'P,L/XX*0L0"1PA4-1/ECYHO8`\`OJL]61]5RAJ?C'>U!EBH M7SE#H%[O:LA&4_@*YNP]>=Z.9L4+9\V3\O?Y`':2FY$JG2P_\/BTWUXO8[)1 M3F-`_"R'>&X7V/]3M]Y,#C[#T_HX-!1`6Q4R<+CQ.H:B>P:BFQRNA:O%E+#@ MKT;"U\!7C=9IXZQU_*B\J.GM\/U5F]WQ^PG?;M\WW]U@^>6$`3_YRN)CI377G5C!L,FUAV/,E[3LIH3@M\_1H_QFF^?W MF5J6T2?Q-51:E_*;7MIC%4B27!B`N<]O=N11`J4O?+J`=XQ/^P&=XR#NR"$Q MU;NC0(:87FDJ2&B8\$::SPME?-22,]_'C1P)K8*Q+7PTQ-*?I0@7R4<8B`?K MG)QY\?2]6S1U?Z.O^TH9:,L0F1C=_'/AB3EA_-O:>%FX/%%@XW:&RMEXM:N- MVQDJ9*/=S3.&1KDK8W6:9Z%[[JC$:Q;(E.)5,`&DTFK#XEWX8B>#AQ=1N M"?&5T>`H\0M>PMY[2*FAZYY!^.S0)?7%`@OOJ8^N`V\E)TBUD3;$:5?.!0Q/ MB'S:R;BU-Z.R<51_H(".V8O8_#/.A$#UXU[;FS/.4"5<>BBPVH[\`.R^IU[H M(OE@ M+LA_&<`^2R@:3":#R4?N"M^GKF[@Q1:G$'H&[P%4H?8-AH:JK;KSA2^>*,W?Q*(1>@%9!X!8RL-]I4+JE3@3 M%X1YB25]#OWE?T*N0\AG%LPVS(YF0PMJRK-D'0!BB;*#R6``XT[4$Y7_><]+IKB/;]\BHUCG.YE+.D/P/*XE[RG"\E0 M==WBT^-W<_D!6-;VEBA1C42;!VQ*>?<15\XS`;"0Y"#"F\XJ^]PJ#[,A/@2C MDZ`[T16QK91P&4X_1"/>\EC^#-Z#@"1W.'"U[<0P)VE%79V)R!)U<=?,I9^M MYG;DF;GE('G_3+^^0,9CL4_5X,G=V*KCTDAOW#I+M-XST!O&X6RE-S0SDV]W MY*N8DR'?^`1ZZOL&DI`;3_;\C#TL]:+B-D!V(9--^0+_3P3 M/HVS#Y69+\I.TAI1>PEY!X!;B"NG_"7)!(=565VRAJY!%5QA!J;SR"9MG MYJC3KP]ARF(0!AA/,%5/YRXIFPHI,GFLGG_^9D/R*+<8B=2%`=%U*%'5R54T M2_H*5;AU'I6LIJ[6$:.DF><6O7QYMAJ1UXA^V*7#'@^BCILNII/F2/18JGBBJD=_&\JRY0N"0B668+MSU+ M;&=T-$IOM/MFV>)Z!_5FSA"E3_?0Q:W/=V7V5^W&F$XX%N$WM#A]6NTCQVWV MAARRC*@REO2YBQN@J;>CZW;DJXR]674_Z$FV]!1&X09Y$^D!S'`DDTPZ:MQ) M$40;4N%IR=3&G*H%K5W*_S^MN7V>Z&VHGNG""NF>FOK#N3_,;3#'*>K>BN@J MU-=M:)ID,YC9;+/*1%LAR]:=5*)WSJ!BD@K9D8SQ")-ZKU/A('"3H'HVK*;^ MBVS($53/!K72T=`R4F456A6XITNH%_%QH,+&4$I5(3]<"O$EWO1W%UW,^#2$ M/CZ]!E]$\?56`U[L=,.-D,$4AYX\4?V>(MK0ZT'WSEVV('Y[C@O#.+,/]6I* MO8\+P8O<0<`$Y@EDNIIW";-"J]=O7*T,B^S,#0FN<`$$#'Z0T" M>M"NSPVGAKWI-;$MA)F,=.?+.EZR:2?A,QK(QNDQ[MPPG7RQ(:Y0LHWWK^(6 M%*ADN'>WSRD(F*-,+&FE#-M*65XYRU4KM;(`DFWIC>&6JPT;5H]!G7UKT9W6\&C_\%4$L!`AX#%``` M``@`DXJ*08<_[-'BA@``]TH%`!$`&````````0```*2!`````&=N8G0M,C`Q M,C$P,S$N>&UL550%``,U8,90=7@+``$$)0X```0Y`0``4$L!`AX#%`````@` MDXJ*08=U%`,U#@``),P``!4`&````````0```*2!+8<``&=N8G0M,C`Q,C$P M,S%?8V%L+GAM;%54!0`#-6#&4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`).*BD&NK+75ABL``!7S`@`5`!@```````$```"D@;&5``!G;F)T+3(P,3(Q M,#,Q7V1E9BYX;6Q55`4``S5@QE!U>`L``00E#@``!#D!``!02P$"'@,4```` M"`"3BHI!+>)J2+%6``!<#`4`%0`8```````!````I(&&P0``9VYB="TR,#$R M,3`S,5]L86(N>&UL550%``,U8,90=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`DXJ*00YFTU+<,@``V[$#`!4`&````````0```*2!AA@!`&=N8G0M,C`Q M,C$P,S%?<')E+GAM;%54!0`#-6#&4'5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`).*BD'E&_E04P\``.:7```1`!@```````$```"D@;%+`0!G;F)T+3(P M,3(Q,#,Q+GAS9%54!0`#-6#&4'5X"P`!!"4.```$.0$``%!+!08`````!@`& +`!H"``!/6P$````` ` end EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Y,&,W,S4V-5\R9&$R7S0R-S%?83DQ.%\V,6(U M8V,V8SDV.&0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D%C8V]U;G1S7U!A>6%B;&5?86YD M7T%C8W)U961?13PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E!E;F1I;F=?3&ET:6=A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T M;V-K:&]L9&5R#I%>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]F#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E M;%=O#I.86UE/E-T;V-K:&]L9&5R#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D1E#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-T;V-K:&]L9&5R#I7;W)K5]$971A:6PS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I!8W1I=F53:&5E M=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF M72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U M;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T M7SDP8S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^1T5.15)%6"!"24]414-(3D],3T=9($-/ M4E`\2!#96YT3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^,#`P,3`U.3'0^+2TP M-RTS,3QS<&%N/CPO6UB M;VP\+W1D/@T*("`@("`@("`\=&0@8VQA2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^,C`Q,SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$F5D(#3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`H3F]T92`Y*3H\+W-T'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,&,W,S4V-5\R M9&$R7S0R-S%?83DQ.%\V,6(U8V,V8SDV.&0-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO.3!C-S,U-C5?,F1A,E\T,C'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XW-3`\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'!E;G-E*3H\+W-T2!);G1E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2!) M;G1E65E(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%SF%T:6]N(&]F(&]P=&EO M;G,@86YD(&]P=&EO;B!M;V1I9FEC871I;VYS(&%S('-T;V-K(&-O;7!E;G-A M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T M:6]N(&]F('!R97!A:60@&5R8VES92!R:6=H="!I;F1U8V5M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%SF%T:6]N(&]F(&1E M9F5R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2\H57-E9"!I;BD@26YV97-T:6YG($%C=&EV:71I97,\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G0@;V8@6UE;G0@;V8@;V)L:6=A=&EO;G,@ M=6YD97(@8V%P:71A;"!L96%S93PO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G1S(&]F M(&-O;G9E2!&:6YA;F-I;F<@06-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'1087)T7SDP M8S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@ M;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`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`L M,#`P(')E;&%T:6YG('1O('5P9G)O;G0@;&EC96YS92!F965S(&9O"!/2P@ M=&AE($-O;7!A;GD@:&%S('-E=F5R86P@<')O9'5C="!C86YD:61A=&5S('1H M870@87)E(&EN('9A2!W:6QL(&)E M('-U8V-E&ES=&EN9R!O6QE M/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@ M-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE M3L@;6%R M9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E6EN9R!C;VYS;VQI M9&%T960@9FEN86YC:6%L('-T871E;65N=',@:&%V92!B965N('!R97!A2!H87,@97AP97)I M96YC960@;F5G871I=F4@8V%S:"!F;&]W2!O9B!A<'!R;WAI;6%T96QY("0X(&UI;&QI;VX@ M870@3V-T;V)E3L@ M;6%R9VEN.B`P<'0@,'!X(#!P="`T,"XU<'0[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE2!W:6QL(&-O;G1I;G5E('1O(')E<75I2!S96-U&5R8VES92!P2X@36%N86=E;65N="!I2!C;VQL86)O6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P M=#L@9F]N=#H@,3!P="!T:6UE2!T;R!C;VYT:6YU92!A M2!R86ES92!A9&1I=&EO;F%L M(&-A<&ET86P@86YD(&EM<&QE;65N="!I=',@2!A9F9E8W1E9"P@86YD('1H92!#;VUP86YY(&UA>2!H879E M('1O(&-E87-E(&]P97)A=&EO;G,N/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P M<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE2!! M9&]P=&5D($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+VD^/"]P/CQP('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P M<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE2`R,#$Q+"!T:&4@1D%30B!IF%T:6]N(&)Y(&QE M=F5L(&9O2!O9B!F86ER('9A;'5E('1O(&-H86YG97,@:6X@=6YO M8G-E6QE/3-$)VUA"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,&,W,S4V M-5\R9&$R7S0R-S%?83DQ.%\V,6(U8V,V8SDV.&0-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO.3!C-S,U-C5?,F1A,E\T,C'0O:'1M;#L@8VAA2!B92!G65E2X@5&AE($-O;7!A;GD@:7-S=65S(&YE=R!S:&%R97,@;V8@ M8V]M;6]N('-T;V-K(&9R;VT@=&AE('-H87)E6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UEF5D('1O('-E;&5C="!F65E2P@=&AE(&EN=&5R<')E=&%T:6]N(&%N9"!C;VYS=')U M8W1I;VX@;V8@86YY('!R;W9I6QE/3-$)VUA"`P<'0@ M-#5P=#L@9F]N=#H@,3!P="!T:6UE65E65E(&1I6QE/3-$)VUA#L@9F]N=#H@ M,3!P="!T:6UE'!E M8W1E9"!L:69E(&]F('1H92!O<'1I;VXL('1H92!C=7)R96YT('!R:6-E(&]F M('1H92!U;F1E2P@97AP96-T960@9&EV:61E;F1S(&]N('1H92!S=&]C:R!A;F0@=&AE M(')I6QE/3-$)VUA"`P<'0@ M-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W9E3LG/B8C,38P.SPO=&0^/'1D/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M M86QI9VXZ(&IU6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&-E M;G1E6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&-E M;G1E6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.@T*(#$E.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#LG/FXO83PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C.#(Q,CL\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T M9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^;B]A/"]T9#X\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CPO='(^/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)W!A9&1I M;F&5R8VES960\+W1D/CQT9"!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)A M8VMG3L@<&%D9&EN M9RUB;W1T;VTZ(#(N-7!T.R<^3W5T'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT.R<^,3`L.36QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R<^,"XR-3<\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@6QE/3-$)V)O6QE/3-$)VUA"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU3LG/B8C,38P M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C.#(Q M,CL\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[ M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0-"B!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#@V M+#(U,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T M9#X\=&0^)B,Q-C`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`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE2!H860@)#,W+#,V-R!O M9B!T;W1A;"!U;G)E8V]G;FEZ960@8V]M<&5N'!E8W1E9"!T;R!B92!R96-O9VYI>F5D(&]V97(@82!W96EG:'1E9"UA M=F5R86=E('!E'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!.;W1E(%M!8G-T'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P M="!T:6UE2!T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'`@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA M"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6%B;&4@86YD(&%C M8W)U960@97AP96YS97,@8V]N6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W!A9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`W,"4[)SY!8V-O=6YT6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^#0H\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@ M6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\ M=&0@6UE;G1S(&]N M($-O;G9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-#`R+#,P,#PO=&0^#0H\=&0@ M6QE/3-$)V)A8VMG6%B;&4\ M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R<^-RPP,34L-C4R/"]T9#X-"CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO M7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'`@2`R,#`Q+"!A(&9O2!T:&4@0V]M<&%N>2!O9B!T M:')E92!P871E;G1S(&%L;&5G961L>2!O=VYE9"!B>2!#5$DN(%1H92!T:')E M92!P871E;G1S(&%R92!E;G1I=&QE9"`\:3Y,:7%U:60@1F]R;75L871I;VYS M(&9O2!3>7-T96T@9F]R($EM;75N:7IA=&EO;BP@57-I;F<@0FEO M9&5G6UE28C.#(Q-SMS('!O6XF(S@T.#([(&%N9"!T:&4@4F%P:61- M:7-T)B,X-#@R.R!$:6%B971E2!T:&4@9F]R;65R(&)U2!T:&4@0V]M<&%N>2X@0V]N2!F:6QE9"!A;B!A<'!L:6-A=&EO;B!W:71H('1H92!/;G1A2X@02!S=&%T96UE;G0@;V8@8VQA:6T@=V%S('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU M"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE2`R,"P@,C`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`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X M(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E2P@,3`Y-S,T-B!/;G1A2!T97)M:6YA=&5D('1H92!P M;&%I;G1I9F8F(S@R,3<[2!M86YA9V5M96YT('-E2!S97)V960@82!M;W1I;VX@9F]R('-U;6UA6QE/3-$)W1E>'0M M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE&EM871E;'D@)#$L-S,P+#`P,"D@2!- M6QE/3-$)W1E>'0M86QI M9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE2!A;F0@:71S('-U8G-I9&EA2!P=6)L:6,@;W(@<')I=F%T92!F:6YA;F-I;F<@&5C=71E(&UU='5A;"!R96QE87-E6UE;G0@;V8@ M=&AE('-E='1L96UE;G0@86UO=6YT+B8C,38P.R!&;VQL;W=I;F<@<&%Y;65N M="!T;R!T:&4@<&QA:6YT:69F+"!T:&4@<&%R=&EE2!F M86EL2!P;W-T+7-P:6YO=70@9FEN86YC:6YG(')E;&%T960@=&\@06YT M:6=E;B!O2!I2!D97-C2!I;FAE3L@ M;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T M-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E'!O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^ M/&1I=CX\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@ M-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE2!I;B!T:&4@=&5R28C.#(Q-SMS(&9A:6QU2!W;W5L9"!B92!O8FQI9V%T960@=&\@<&%Y('-A;F]F:2!F;W(@ M86QL(&UA=&5R:6%L2X@5&\@9&%T92P@=&AE($-O;7!A;GD@:&%S(&YO="!P3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\Y,&,W,S4V-5\R9&$R7S0R-S%?83DQ.%\V,6(U M8V,V8SDV.&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3!C-S,U M-C5?,F1A,E\T,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@ M;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E2!D:79I9&EN9R!T:&4@ M;F5T(&QO2!A3L@;6%R9VEN M.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2!D:79I9&EN9R!T:&4@;F5T(&EN8V]M92!A=F%I;&%B;&4@=&\@8V]M M;6]N('-T;V-K:&]L9&5R2!T:&4@=V5I9VAT M960@879E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!.;W1E($1I'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@ M-#5P=#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X(#!P M="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E&5C=71I=F4@86YD(&5M<&QO>65E(&]P=&EO M;G,@9W)A;G1E9"!I;B!/8W1O8F5R(#(P,#DL(')E6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$ M)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E M6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O3PO=&0^#0H\=&0@3LG(&-O;'-P86X] M,T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU3LG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X- M"CPO='(^#0H\='(@6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`M,"XQ,FEN.R!P861D M:6YG+6QE9G0Z(#`N,3)I;CL@=VED=&@Z(#0X)3LG/DES6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@,3`E.R<^."PW,C6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^*#@L-S(W/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXI/"]T9#X-"CQT M9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^)B,X M,C$R.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PS M-C8L-C8V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^ M)B,Q-C`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`N,C1I;CLG M/E1O=&%L/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ M(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,38L,#DY M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT M.R<^,S$R+#3L@ M;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E2!O9B!W87)R86YT'!I&5R8VES960@9F]R('1H92!T M:')E92!M;VYT:',@96YD960@3V-T;V)E6QE M/3-$)W9E'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/DES M'0M86QI9VXZ(')I9VAT.R<^-36QE/3-$)V)A8VMG'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)V)O3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@ M;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M=6YD97)L M:6YE+7-T>6QE.B!D;W5B;&4[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@3L@;6%R9VEN.B`P<'0@,'!X(#!P M="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M2`R M-2P@,C`Q-BP@-30L-#(V+#(R,B!W87)R86YT&5R8VES92!P2`Q,2P@,C`Q-BP@,3`L,C(W+#(W,"!W87)R86YT'!I2`R+"`R,#$W(&%N9"`Y M+#,W-2PP,#`@=V%R2!D871E(&]F($%U9W5S="`Q,"P@ M,C`Q-R`H,3$R+#28C.#(Q-SMS(&ES&5R8VES92!P2!I&5R8VES86)L92!F;W(@;W(@&5R8VES92!P2P@&5R8VES92!P28C.#(Q-SMS(&ES28C.#(Q-SMS(&1I65E2!C;VUP96YS871I;VX@<')O9W)A;2!O&5R8VES92!O9B!A;GD@2!P=7)P;W-E(&]F M('=H:6-H(&ES(&YO="!T;R!R86ES92!C87!I=&%L+"!A;F0@=VAI8V@@87)E M(&%P<')O=F5D(&EN(&=O;V0@9F%I=&@@8GD@=&AE($-O;7!A;GDF(S@R,3<[ M28C.#(Q-SMS('1R:6=G97)I;F<@;V8@ M=&AE('!R:6-E('!R;W1E8W1I;VX@9F5A='5R97,@;V8@=&AE('=A3L@;6%R9VEN M.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2`R-2P@,C`Q,2!A;F0@:6X@36%R8V@@86YD($%P65E2!P M=7)S=6%N="!T;R!P;&%N2!A(&UA:F]R:71Y(&]F('1H M92!N;VXM96UP;&]Y964@9&ER96-T;W)S(&]F('1H92!#;VUP86YY(&]R('!U M&5R8VES92!P2!D;V5S(&YO="!R96QY(&EN M('=H;VQE(&]R(&EN('!A28C.#(Q-SMS(&ES2!A(&UA M:F]R:71Y(&]F('1H92!N;VXM96UP;&]Y964@;65M8F5R&5R8VES92!O&-H86YG M92!O9B!O2!396-U2`X+"`R,#$Q(&%N9"]O2`X+"`R,#$Q+"!P&-H86YG92!P2!A(&UA:F]R:71Y(&]F('1H92!D:7-I;G1E2P@<')O=FED960@=&AA="!A;GD@&5R8VES92!P3L@;6%R9VEN M.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2!P=7)S=6%N="!T;R!A;GD@2!A9&]P=&5D(&9O2!O9B!T:&4@;65M8F5R&5R8VES92!O&-H M86YG92!O9B!O2!396-U2`S,2P@,C`Q,B!A;F0O;W(@ M;W1H97(@&5R8VES86)L92!O&-H86YG96%B;&4@ M9F]R(&]R(&-O;G9E2!S=6-H(&ES6YE2!A;F0@2!A9&1I=&EO;F%L(&)E;F5F:71S(&EN(&%D9&ET:6]N M('1O('1H92!I;G9E2!I&5R8VES92!P28C M.#(Q-SMS(&ES2!A(&UA:F]R:71Y(&]F('1H M92!N;VXM96UP;&]Y964@;65M8F5R2!S=6-H(&ES6YE2!A;F0@2!A9&1I=&EO;F%L(&)E;F5F:71S(&EN(&%D9&ET M:6]N('1O('1H92!I;G9E2!I M3L@;6%R9VEN.B`P M<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!A8V-O=6YT6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P M="!T:6UE2!H87,@875T:&]R:7IE9"`U+#4P,"!S:&%R M97,@;V8@4V5R:65S($$@.24@0V]N=F5R=&EB;&4@4')E9F5R28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!W97)E(&ES3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X M(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE MF5D(#(L,#`P('-H87)E28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!W97)E(&ES28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A M;B!E9F9E8W1I=F4@8V]N=F5R65A2!T:&5R96%F=&5R+"!S=6-H(&1I=FED M96YD(')A=&4@=VEL;"!I;F-R96%S92!B>2!A;B!A9&1I=&EO;F%L(#,E+B!4 M:&4@9&EV:61E;F0@:7,@<&%Y86)L92!Q=6%R=&5R;'D@;VX@4V5P=&5M8F5R M(#,P+"!$96-E;6)E6UE;G0F(S@R,C$[(&UA>2!B92!M861E(&EN M(&-A2`Q+"`R,#$U+"!T:&4@0V]M<&%N>2!W:6QL('!A>2!D M:79I9&5N9',@;VX@2!W:6QL(&EN8W5R(&$@;&%T92!F964@;V8@,3@E('!E6QE/3-$)W1E>'0M86QI9VXZ M(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE2!S96-U'1E;G0@87,@:68@2!S96-U6QE/3-$)W1E M>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE2!B96-O;64@ M;V)L:6=A=&5D('1O(')E9&5E;2!T:&4@8V]N=F5R=&EB;&4@<')E9F5R28C.#(Q-SMS(&-O;6UO M;B!S=&]C:R!T;R!C;VYT:6YU92!T;R!B92!L:7-T960@;W(@<75O=&5D(&9O M6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@ M-#5P=#L@9F]N=#H@,3!P="!T:6UE2!T:&4@0V]M<&%N>2!P3L@;6%R9VEN M.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E6QE/3-$)W1E M>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE&-E6QE/3-$)W=I9'1H.B`W-24[(&)O6QE/3-$)W!A9&1I;F6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R M('-T>6QE/3-$)V)A8VMG#L@<&%D9&EN9RUL969T.B`P<'@[)SY$97)I M=F%T:79E('=A6QE/3-$)V)A8VMG#LG/DUA:V4@=VAO;&4@<&%Y;65N=',@;&EA M8FEL:71Y/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[('!A9&1I M;F6QE/3-$)V)O6QE/3-$)V)O3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E2!S;VQD(&%N(&%G9W)E9V%T92!O9B`W-3`@28C.#(Q-SMS M(&-O;6UO;B!S=&]C:R!W97)E(&ES28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A;B!E9F9E8W1I M=F4@8V]N=F5R6%B;&4@<75A2!W:6QL('!A>2!T:&4@:&]L9&5R(&]F('1H92!C;VYV97)T960@<')E9F5R M2!W:6QL('!A M>2!D:79I9&5N9',@;VX@2!W:6QL(&EN8W5R(&$@;&%T92!F964@;V8@,3@E('!E6QE/3-$)W1E>'0M86QI M9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE2!S96-U'1E;G0@87,@:68@2!S96-U6QE/3-$)W1E M>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE2!B96-O;64@ M;V)L:6=A=&5D('1O(')E9&5E;2!T:&4@8V]N=F5R=&EB;&4@<')E9F5R28C.#(Q-SMS(&-O;6UO M;B!S=&]C:R!T;R!C;VYT:6YU92!T;R!B92!L:7-T960@;W(@<75O=&5D(&9O M6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@ M-#5P=#L@9F]N=#H@,3!P="!T:6UE&5R8VES86)L92!A="!A;GD@ M=&EM92!A9G1E&5R8VES92P@87)E('-U8FIE8W0@=&\@861J=7-T;65N M="!I;B!T:&4@8V%S92!O9B!S=&]C:R!S<&QI=',L('-T;V-K(&1I=FED96YD MF%T:6]N('1R86YS86-T:6]N&5R8VES M92!P&5R8VES92!W:6QL(&%L2!S:&%R97,@;V8@ M8V]M;6]N('-T;V-K(&]R('-E8W5R:71I97,@8V]N=F5R=&EB;&4@:6YT;RP@ M;W(@&5R8VES92!P2!A;&P@87-S971S M(&%N9"!S:6UI;&%R(')E;W)G86YI>F%T:6]NF%T M:6]N2!S96-U6QE/3-$ M)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P M=#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P M<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T M-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN M.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2!A6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`P<'@[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@,34E.R<^-S(U+#`P,#PO=&0^#0H\=&0@#LG/D1E6QE/3-$)V)A8VMG M#LG/DUA:V4@=VAO;&4@<&%Y;65N M=',@;&EA8FEL:71Y/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[ M('!A9&1I;F6QE/3-$)V)O6QE/3-$ M)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE3L@;6%R M9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P M<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE&5R8VES92!P2!I2!W:71H(&%N>2!R M961U8W1I;VX@=&\@=&AE(&5X97)C:7-E('!R:6-E+"!T:&4@;G5M8F5R(&]F M('-H87)E2P@ M&5R8VES92!P6QE/3-$)W1E>'0M M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N M=#H@,3!P="!T:6UE2X@5&AE M(&QI86)I;&ET>2!I2!H879E(&YO(&5F9F5C="!O;B!T:&4@0V]M<&%N M>28C.#(Q-SMS(&-O;G-O;&ED871E9"!C87-H(&9L;W=S+CPO<#X-"CQP('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P M<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU M"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T M:6UE2`S,2P@ M,C`Q,B!W87,@)#0L,S0W+#F5S('1H92!C:&%N9V5S(&EN('1H92!V86QU92!O9B!T:&4@9&5R M:79A=&EV92!W87)R86YT(&QI86)I;&ET>2!F6QE/3-$)W=I9'1H.B`X-24[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^#0H\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M,3(E.R<^.#`L,C,T+#`Q-SPO=&0^#0H\=&0@3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@W+#(S,"PW,S0\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M*#0Y+#@V,RPR-C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXI/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU2`R,#$R(&9I;F%N8VEN9SPO=&0^ M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`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`V.3PO=&0^#0H\=&0@6QE/3-$ M)W!A9&1I;F6QE M/3-$)V)O6QE M/3-$)V)A8VMG3L@ M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^0F%L86YC92!A="!/8W1O8F5R(#,Q M+"`R,#$R("8C.#(Q,3L@1&5R:79A=&EV92!W87)R86YT(&QI86)I;&ET>3PO M=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E M>'0M86QI9VXZ(')I9VAT.R<^-"PS-#6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R<^,3$R+#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P M="!T:6UE2!H87,@9&5T97)M:6YE9"!I=',@9&5R:79A=&EV92!W87)R M86YT(&QI86)I;&ET>2!T;R!B92!A($QE=F5L(#(@9F%I"!B87-I8R!D871A(&EN M<'5T'!I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,7!T.R<@;F]W6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;F6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`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`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`@3L@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E2!H860@82!N970@8F]O:R!V86QU92!O9B`D-3@U M+#`V-"P@2!D M:60@;F]T(')E8V5I=F4@86YY(&]F('1H92!N970@<')O8V5E9',@9G)O;2!T M:&ES('!R;W!E3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P M<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X M(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X M(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E2P@1V5N97)E>"!0:&%R;6%C975T:6-A;',@26YC M+BP@96YT97)E9"!I;B!T;R!A;B!A9W)E96UE;G0@=VET:"!A('!R:79A=&4@ M;&5N9&5R(&9O2!D871E(&]F($YO=F5M8F5R(#,P+"`R,#$S+"`\9F]N="!S='EL93TS1"=C M;VQO2`D-C(P+#`P,"P@ M869T97(@=&AE('!R:6]R(&UO6QE/3-$ M)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P M=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'`@'!I&5R8VES M960@=6YD97(@=&AE(%!L86YS(&9O6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W=I9'1H.B`W."4[(&)O6QE/3-$)W9E3LG/B8C,38P.SPO M=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E M>'0M86QI9VXZ(&IU&5R8VES93PO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&IU M6QE/3-$)V)A8VMG3L@=VED=&@Z(#4U)3LG/D]U='-T86YD M:6YG+"!!=6=U6QE/3-$)W=I9'1H.B`Q M)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@,3(E.R<^,3`L.36QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$R)3LG/C`N M,C4W/"]T9#X\=&0@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/FXO M83PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#LG/B8C.#(Q,CL\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^;B]A/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R M('-T>6QE/3-$)V)A8VMG6QE/3-$)W!A9&1I;F&5R8VES960\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,7!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)A8VMG3L@<&%D9&EN9RUB;W1T;VTZ(#(N M-7!T.R<^3W5T'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT.R<^,3`L.36QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ M(')I9VAT.R<^,"XR-3<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/CQT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[ M('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M86QI9VXZ(&QE9G0[ M)SXD/"]T9#X\=&0@'0M86QI9VXZ(&QE9G0[)SXD M/"]T9#X\=&0@6UE;G0@07=A'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN M.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E6QE M/3-$)W1E>'0M86QI9VXZ(&IU3LG/B8C,38P.SPO=&0^/'1D('-T M>6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C.#(Q,CL\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q M-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XP,#PO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/CPO='(^/'1R('-T>6QE/3-$)V)A8VMG3LG/E9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@X-BPR-3`\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^/'1D/B8C,38P.SPO M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N-#8\+W1D/CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R M/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A M9&1I;F6QE/3-$ M)V)O6QE/3-$)V)O'0M86QI M9VXZ(&QE9G0[)SXD/"]T9#X\=&0@'1087)T7SDP8S'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'!E;G-E6%B;&5S(&%N9"!!8V-R=6%L6%B;&4@86YD($%C8W)U M960@3&EA8FEL:71I97,@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!M87)G:6XZ(#!P="`P<'@@,'!T(#0U<'0[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W9E6QE M/3-$)V)O3LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y/8W1O M8F5R(#,Q+"`R,#$R/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,7!T.R<@;F]W6QE/3-$)V)O3LG(&-O;'-P86X],T0R M(&YO=W)A<#TS1&YO=W)A<#Y*=6QY(#,Q+"`R,#$R/"]T9#X-"CQT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@,3(E.R<^,RPY-S$L,#$U/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`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`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R<^-RPW-S6QE/3-$)W!A9&1I;F7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA2`H5&%B;&5S*3QB'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!TF5D(&)E;&]W.CPO<#X-"CQP('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P M<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&IU6QE/3-$)W9E6QE/3-$)V)O M6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ M(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I M;F6QE/3-$)W9E3LG(&-O M;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/BD\+W1D/@T* M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`M,"XQ,FEN.R!P861D:6YG+6QE9G0Z(#`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`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^ M,CDV+#8U.#PO=&0^#0H\=&0@6QE/3-$)V)O6QE/3-$)V)O2!.;W1E+"!787)R86YT'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@@,'!T(#0U<'0[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$ M)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X(#!P="`T-7!T.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W=I9'1H.B`W-24[(&)O6QE/3-$)W9E#L@<&%D9&EN9RUL969T.B`P<'@[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M/'4^06-C;W5N=&EN9R!A;&QO8V%T:6]N(&]F(&EN:71I86P@<')O8V5E9',\ M+W4^/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)V)A8VMG M#L@<&%D9&EN9RUL969T.B`P<'@[('=I9'1H.B`X,B4[)SY.970@ M<')O8V5E9',\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[ M)SXD/"]T9#X\=&0@6QE M/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F2!F86ER('9A;'5E/"]T9#X\=&0^)B,Q-C`[ M/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#$L.#$Q+#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X\ M+W1R/CQT6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R!P861D:6YG.B`P<'@[)SX\=3Y!8V-O=6YT:6YG(&%L;&]C871I;VX@;V8@ M:6YI=&EA;"!P6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E.R<^-S(U M+#`P,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^/"]T2!F86ER('9A;'5E/"]T9#X\=&0^ M)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#8R M-"PW.3<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO M=&0^/"]T6UE M;G1S(&QI86)I;&ET>3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(')I9VAT.R<^*#(P,BPU,#`\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^ M*3PO=&0^/"]T6QE M/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F'1087)T7SDP8S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!;5&%B M;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)W9E M'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&IU3PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&IU&5R8VES92!O9B!W87)R86YT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#3LG/D%D9&ET:6]N M86P@=V%R6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^,2PX,3$L-S0V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,3,L,S,S+#,S,SPO M=&0^#0H\=&0@6QE/3-$)V)A8VMG3LG/D%D9&ET:6]N86P@=V%R6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^,2PU-#@L.#$S/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,3$L-#0T+#0T M,#PO=&0^#0H\=&0@6QE/3-$)V)A8VMG'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)A8VMG3LG/D)A;&%N8V4@870@2G5L>2`S M,2P@,C`Q,B`F(S@R,3$[($1E6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^-"PP.#$L-C(W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`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`[ M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^-#@L,C4T+#DU-3PO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O M'0M86QI9VXZ(')I9VAT M.R<^;B]A/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@ M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(&IU"`P<'0@-#5P M=#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W9E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`W-B4[)SY#=7)R96YT(&5X97)C:7-E('!R:6-E/"]T9#X\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[)SXP+C`X/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[)SXP+C$U M/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R<^,RXW-B!Y96%R6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY2:7-K M+69R964@:6YT97)E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N-30\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R<^)3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N-#4\+W1D/CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)3PO=&0^/"]T6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^.#<\+W1D/CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$P-#PO=&0^/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\+W1R/CQT6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY$:79I9&5N9#PO M=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#LG/BTP+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y,&,W,S4V-5\R9&$R7S0R-S%?83DQ.%\V,6(U8V,V8SDV M.&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3!C-S,U-C5?,F1A M,E\T,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&5R8VES86)L M92P@3V-T;V)E7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,&,W,S4V-5\R9&$R7S0R-S%?83DQ M.%\V,6(U8V,V8SDV.&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.3!C-S,U-C5?,F1A,E\T,C'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M,3$@;6]N=&AS(#D@9&%Y65A6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\Y,&,W,S4V-5\R9&$R7S0R-S%?83DQ.%\V,6(U8V,V8SDV.&0-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3!C-S,U-C5?,F1A,E\T,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'1U86PI("A54T0@)"D\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`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`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L2`R,"P@,C`Q,3QB'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!#;VYT:6YG96YT($EN=&5R97-T(%)A=&4@5&5R;3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^86UO=6YT(&]F('1H92!C;&%I M;2!P;'5S(&EN=&5R97-T(&]F(#,E('!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\Y,&,W,S4V-5\R9&$R7S0R-S%?83DQ.%\V,6(U8V,V8SDV.&0- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3!C-S,U-C5?,F1A,E\T M,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'1U86PI/&)R/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61E9"!F7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2`H1&5T86EL'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S(&]N(&-O;G9E6UE;G1S(&]N(&-O;G9E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65E(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2`H1&5T M86EL3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2`H M1&5T86EL2!F86ER('9A;'5E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,C0L-SDW*3QS<&%N/CPO M3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\Y,&,W,S4V-5\R9&$R7S0R-S%?83DQ.%\V,6(U8V,V8SDV M.&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3!C-S,U-C5?,F1A M,E\T,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!3=&]C:R!;365M8F5R73QB2!- M87)C:"!A;F0@07!R:6P@,C`Q,2!;365M8F5R73QB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4@86YD($%C8W)U960@3&EA8FEL M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S6UE;G1S(&]N($-O;G9E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M2=S(&ES2=S(&1I65E&5R8VES92!O9B!A;GD@2!P=7)P;W-E(&]F('=H:6-H(&ES(&YO="!T;R!R M86ES92!C87!I=&%L+"!A;F0@=VAI8V@@87)E(&%P<')O=F5D(&EN(&=O;V0@ M9F%I=&@@8GD@=&AE($-O;7!A;GDG2=S M(&ES'0^5&AE($-O;7!A M;GDG2`R-2P@,C`Q,2!A M;F0@:6X@36%R8V@@86YD($%P65E2!P=7)S=6%N="!T;R!P M;&%N2!A(&UA:F]R:71Y(&]F('1H92!N;VXM96UP;&]Y M964@9&ER96-T;W)S(&]F('1H92!#;VUP86YY(&]R('!U&5R8VES92!P2!D;V5S(&YO="!R96QY(&EN('=H;VQE(&]R(&EN M('!A2=S M(&ES2!A(&UA:F]R:71Y(&]F('1H92!N;VXM M96UP;&]Y964@;65M8F5R2!S=6-H(&ES6YE2!A;F0@2!A9&1I=&EO;F%L(&)E;F5F:71S(&EN(&%D9&ET:6]N('1O M('1H92!I;G9E2!I'0^5&AE($-O;7!A M;GDG2`X+"`R,#$Q.B`H22DH M82D@65E2!S=&]C:R!O2!O9B!T:&4@;F]N M+65M<&QO>65E(&UE;6)E2`X+"`R,#$Q+"!I;B!T:&4@<&5R:6]D M:6,@86UO=6YT&5R8VES86)L92!O&-H86YG96%B M;&4@9F]R(&]R(&-O;G9E&5R8VES92!P2!O9B!T:&4@9&ES:6YT97)E2!B92!T;R!A('!E6AO;&1E2!O2!B=7-I;F5S2!A(&UA:F]R:71Y(&]F('1H92!N;VXM96UP M;&]Y964@;65M8F5R2`R+"`R,#$R+"!P&-H86YG92!P2!A(&UA:F]R:71Y(&]F('1H92!D:7-I;G1E2P@<')O=FED960@=&AA="!A M;GD@2!F;W(@=&AE('!U2!W:&]S92!P'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^,S0L-#@Q+#@V-B!T;R`V-"PV-3,L M-#DR+CQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^,RPS,S,L,S,Q('1O(#8L,C0Y M+#DY-2X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Y,&,W,S4V-5\R9&$R7S0R-S%?83DQ.%\V,6(U8V,V8SDV.&0-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3!C-S,U-C5?,F1A,E\T,C'0O:'1M;#L@8VAA2!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'!I65A7,\3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'1U M86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@@8V]L65A'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'1U86PI("A5 M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$ M=&@^3V-T+B`S,2P@,C`Q,CQB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M2!$ M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,&,W,S4V-5\R9&$R7S0R-S%?83DQ M.%\V,6(U8V,V8SDV.&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.3!C-S,U-C5?,F1A,E\T,C'0O:'1M;#L@8VAA M&UL;G,Z;STS1")U'1087)T7SDP8S XML 19 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6

Net Loss per Share (Details Textual)
3 Months Ended

Oct. 31, 2012

Oct. 31, 2011

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 162,146,167

Outstanding Stock Options 5,424 110,086,551

Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 110,086,551

X

- Definition

The number of stock option outstanding which have an exercise price lower than average market price.

+ References

No definition available.

+ Details

Name: gnbt_OutstandingStockOptions

Namespace Prefix: gnbt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6

Pending Litigation (Details Textual) (USD $)
0 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended

Nov. 16, 2012

Dec. 31, 2011

Sep. 30, 2011

Aug. 31, 2011

Oct. 31, 2012

May 20, 2011

Employment Termination [Member]

Jun. 01, 2011

Breach Of Contract [Member]

Jun. 01, 2011

Punitive Damage [Member]

Dec. 31, 2011

Vendors Breach Of Contract [Member]

Loss Contingency, Range of Possible Loss, Minimum $ 7,000,000

Loss Contingency, Estimate of Possible Loss 550,000 50,000

Loss Contingency, Inestimable Loss 429,000

The counter claim made against the party. 200,000 2,300,000

Proceeds from Sale of Real Estate 1,730,000

Loss Contingency, Damages Sought, Value 125,000

Loss Contingency Contingent Interest Rate Term amount of the claim plus interest of 3% per annum

Loss Contingency Costs Fixed $ 25,000

X

- Definition

The counter claim made against the party.

+ References

No definition available.

+ Details

Name: gnbt_CounterClaim

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

A specified contingent loss cannot be made, if an entity fails to make a payment resulting in disclosure completions.

+ References

No definition available.

+ Details

Name: gnbt_LossContingencyContingentInterestRateTerm

Namespace Prefix: gnbt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: gnbt_LossContingencyInestimableLoss1

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The carrying amount as of the balance sheet date of the combined total of loss contingency liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_LossContingencyAccrualAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_LossContingencyDamagesSoughtValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14557-108349

+ Details

Name: us-gaap_LossContingencyEstimateOfPossibleLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The estimated minimum amount of possible loss from the contingency.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14557-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

+ Details

Name: us-gaap_LossContingencyRangeOfPossibleLossMinimum

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Cash received for the sale of real estate that is not part of an investing activity during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 24

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromSaleOfRealEstate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 21 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Deficiency (Details) (USD $)
3 Months Ended 204 Months Ended

Oct. 31, 2012

Oct. 31, 2011

Oct. 31, 2012

Issuance of common stock on conversion of convertible preferred stock $ 0

Issuance of common stock on conversion of convertible preferred stock (in shares) 0

Common stock issued as employee compensation 0 11,783 4,011,938

Common Stock [Member]

Issuance of common stock on conversion of convertible preferred stock 8,727

Issuance of common stock on conversion of convertible preferred stock (in shares) 8,727,498

Issuance of common stock as make whole payments on convertible preferred stock 6,005

Issuance of common stock as make whole payments on convertible preferred stock (in shares) 6,005,443

Issuance of common stock for services 1,367

Issuance of common stock for services (in shares) 1,366,666

Common stock issued as employee compensation 0

Total 16,099

Total (in shares) 16,099,607

Additional Paid-In Capital [Member]

Issuance of common stock on conversion of convertible preferred stock (8,727)

Issuance of common stock as make whole payments on convertible preferred stock 182,509

Issuance of common stock for services 112,883

Common stock issued as employee compensation 9,993

Total (in shares) 296,658

Change To Stockholder Equity [Member]

Issuance of common stock on conversion of convertible preferred stock 0

Issuance of common stock as make whole payments on convertible preferred stock 188,514

Issuance of common stock for services 114,250

Common stock issued as employee compensation $ 9,993

Total (in shares) 312,757

X

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4, 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfUnits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued to shareholders as a dividend during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockDividend

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 22 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Deficiency (Details 1)
3 Months Ended 12 Months Ended

Oct. 31, 2012

Jul. 31, 2012

No. of Warrants - Derivative warrant liability 112,778,485 16,503,340

Warrants Issued 48,254,955 (49,863,260)

No. of Warrants - Derivative warrant liability 131,894,033 112,778,485

Warrant [Member]

No. of Warrants - Derivative warrant liability 74,264,078

Warrants Issued 57,629,955

No. of Warrants - Derivative warrant liability 131,894,033

X

- Definition

Number of warrants issued during the peirod.

+ References

No definition available.

+ Details

Name: gnbt_WarrantsIssued

Namespace Prefix: gnbt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate amount of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 23 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation
3 Months Ended

Oct. 31, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Note 3 – Stock-Based Compensation:

As of July 31, 2012, the Company had three stockholder-approved stock incentive plans under which shares and options exercisable for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 2,000,000 shares of common stock are reserved for issuance under the 2000 Stock Option Plan (the 2000 Plan), a total of 12,000,000 shares of common stock are reserved for issuance under the 2001 Stock Option Plan (the 2001 Plan) and 30,000,000 shares of common stock are reserved for issuance under the 2006 Stock Plan (the 2006 Plan). At October 31, 2012, there were 2,000,000, 4,124,444 and 8,354,823 shares of common stock reserved for future awards under the 2000 Plan, 2001 Plan and 2006 Plan, respectively. The Company issues new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and issuance of restricted shares.

The 2000, 2001 and 2006 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Board.

The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options which are not ISOs, i.e. “Non-Qualified Options.” The options granted by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides for restricted stock grants.

The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model which takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option.

In the case of restricted stock grants under the 2006 Plan, fair market value of the shares is established as the market price on the date of the stock grant.

The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plans for the three months ended October 31, 2012:
Weighted
Average
Exercise Aggregate
Price Intrinsic
Options Share Value

Outstanding, August 1, 2012 10,979,634 $ 0.257
Granted — n/a
Forfeited or expired — n/a
Exercised — n/a
Outstanding, October 31, 2012 10,979,634 $ 0.257 $ 277,615
Exercisable, October 31, 2012 10,893,384 $ 0.254 $ 277,615

The 10,979,634 outstanding options at October 31, 2012 had a weighted average remaining contractual term of 3.92 years.

The following is a summary of the non-vested common stock options granted, vested and forfeited under the Plan for the three months ended October 31, 2012:
Weighted Average
Grant Date
Options Fair Value

Outstanding, August 1, 2012 172,500 $ 0.46
Granted — 0.00
Vested (86,250 ) 0.46
Forfeited — 0.00
Outstanding, October 31, 2012 86,250 $ 0.46

As of October 31, 2012, the Company had $37,367 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plans. That cost is expected to be recognized over a weighted-average period of 0.94 years.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Deficiency (Details 2) (USD $)
3 Months Ended 12 Months Ended

Oct. 31, 2012

Jul. 31, 2012

Net proceeds $ 725,000 $ 1,975,000

Derivative warrant liability fair value (624,797) (1,811,746)

Make whole payments liability (202,500) (540,000)

Deemed dividend $ (102,297) $ (376,746)

X

- Definition

The deemed dividend or net balance after adjustment of fair value of derivative liability an dpayment made to total proceeds from issuance.

+ References

No definition available.

+ Details

Name: gnbt_DeemedDividend

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The payment made on account of derivative liability.

+ References

No definition available.

+ Details

Name: gnbt_MakeWholePaymentsOfLiability

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value of derivative liability, presented on a gross basis even when the derivative instrument is subject to master netting arrangements and qualifies for net presentation in the statement of financial position.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 205G

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44C

-Subparagraph a

-Clause 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 25 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED BALANCE SHEETS (USD $)

Oct. 31, 2012

Jul. 31, 2012

ASSETS

Cash and cash equivalents $ 37,031 $ 246,309

Other current assets 116,256 200,552

Total Current Assets 153,287 446,861

Property and Equipment, Net 118,776 704,678

Assets Held for Investment, Net 852,832 858,377

Patents, Net 2,561,090 2,634,458

TOTAL ASSETS 3,685,985 4,644,374

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

Accounts payable and accrued expenses (Note 5) 7,777,732 7,015,652

Deferred revenue 242,356 263,125

Current maturities of long-term debt 156,596 1,222,746

Total Current Liabilities 8,176,684 8,501,523

Long-Term Debt, Net 0 441,415

Derivative Warrant Liability (Note 10) 4,347,710 4,081,627

Total Liabilities 12,524,394 13,024,565

Commitments and Contingencies (Notes 6 and 7)

Stockholders' Deficiency (Note 9):

Common stock, $.001 par value; authorized 750,000,000 shares at October 31, 2012 and July 31, 2012, respectively; 370,260,904 and 354,161,297 shares issued and outstanding at October 31, 2012 and July 31, 2012, respectively 370,261 354,161

Additional paid-in capital 348,396,471 348,099,813

Deficit accumulated during the development stage (358,370,276) (357,611,780)

Accumulated other comprehensive income 765,135 777,615

Total Stockholders' Deficiency (8,838,409) (8,380,191)

TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY)/EQUITY 3,685,985 4,644,374

Series A Convertible Preferred Stock [Member]

Stockholders' Deficiency (Note 9):

Preferred Stock Value 0 0

Series B Convertible Preferred Stock [Member]

Stockholders' Deficiency (Note 9):

Preferred Stock Value 0 0

Series C Convertible Preferred Stock [Member]

Stockholders' Deficiency (Note 9):

Preferred Stock Value $ 0 $ 0

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14, 17, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS115-1/124-1

-Paragraph 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7, 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FIN39-1

-Paragraph 10A, 10B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 4, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13495-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 7

-Paragraph 11

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph a(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.12)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basis of Presentation
3 Months Ended

Oct. 31, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Note 1 – Basis of Presentation:

The accompanying unaudited interim consolidated financial statements (“interim statements”) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by generally accepted accounting principles for complete financial statements are not included herein. The interim statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s latest Annual Report on Form 10-K. The results for the three months ended October 31, 2012 may not be indicative of the results for the entire year.

Interim statements are subject to possible adjustments in connection with the annual audit of the Company’s accounts for fiscal year 2013. In the Company’s opinion, all adjustments necessary for a fair presentation of these interim statements have been included and are of a normal and recurring nature.

The Company is a development stage company, which has a limited history of operations and limited revenue to date. This revenue has been comprised mainly of the sale of our confectionary products, although the Company has recognized $600,000 relating to upfront license fees for the signing of license and distribution agreements for Generex Oral-lyn™. Additionally, the Company has several product candidates that are in various research or early stages of pre-clinical and clinical development. There can be no assurance that the Company will be successful in obtaining regulatory clearance for the sale of existing or any future products or that any of the Company’s products will be commercially viable.

Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has experienced negative cash flows from operations since inception and has an accumulated deficit of approximately $358 million and a working capital deficiency of approximately $8 million at October 31, 2012. The Company has funded its activities to date almost exclusively from debt and equity financings, as well as the recent sales of non-essential real estate assets in fiscal 2012 and the beginning of fiscal 2013.

The Company will continue to require substantial funds to continue research and development, including pre-clinical studies and clinical trials of its product candidates, and to commence sales and marketing efforts, if the U.S. Food and Drug Administration or other regulatory approvals are obtained. Management’s plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common stock, preferred stock offerings, issuances of debt and convertible debt instruments. Management will be limited in the financing activities that the Company undertakes in the near future as the securities purchase agreements that the Company entered into on January 31, 2012 and August 8, 2012 with certain investors prohibit the Company from (i) issuing additional equity securities until 60 days after the effective date of a registration statement covering the resale of the common stock issuable upon exercise of the warrants and conversion of the preferred stock sold in those transactions and (ii) issuing additional debt or equity securities with variable conversion or exercise prices until February 1, 2013 and August 8, 2013, respectively. Management is also actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and strategic partners. Management has sold, and is also seeking further sales of, non-essential real estate assets which are classified as Assets Held for Investment to augment its cash position.

These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. There are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence. The Company’s inability to obtain required funding in the near future or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan, its liquidity, financial condition and business prospects will be materially and adversely affected, and the Company may have to cease operations.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6

Derivative Liabilities (Details) (USD $)
3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended

Oct. 31, 2012

Jul. 31, 2012

Aug. 31, 2011

Oct. 31, 2012

Warrant [Member]

Jul. 31, 2012

Warrant [Member]

Jul. 31, 2011

Warrant [Member]

Oct. 31, 2012

Warrants Isssued August 2012 [Member]

Jul. 31, 2012

Warrants Isssued February 2012 [Member]

Oct. 31, 2012

Additional Warrants [Member]

Jul. 31, 2012

Additional Warrants [Member]

Oct. 31, 2012

Warrant Fair Value [Member]

Jul. 31, 2012

Warrant Fair Value [Member]

Jul. 31, 2012

Warrant Exercised [Member]

Balance - Derivative warrant liability Value $ 4,347,710 $ 8,745,508 $ 4,347,710 $ 4,081,627 $ 8,745,508

Additional warrants issued in financing (7,230,734) 624,797 1,811,746 3,102,355 1,548,813 (3,461,069) (793,706) (7,230,734)

Balance - Derivative warrant liability Value $ 3,102,355 $ 4,347,710 $ 8,745,508 $ 4,347,710 $ 4,081,627 $ 8,745,508

No. of Warrants - Derivative warrant liability 112,778,485 16,503,340 112,778,485 55,148,530 80,234,017

Warrants Issued 48,254,955 (49,863,260) 9,375,000 13,333,333 48,254,955 11,444,440

Warrants Exercised (49,863,260)

No. of Warrants - Derivative warrant liability 131,894,033 112,778,485 112,778,485 55,148,530 80,234,017

X

- Definition

Number of warrants exercised during the peirod.

+ References

No definition available.

+ Details

Name: gnbt_WarrantsExercised

Namespace Prefix: gnbt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants issued during the peirod.

+ References

No definition available.

+ Details

Name: gnbt_WarrantsIssued

Namespace Prefix: gnbt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate amount of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Fair value of the gross liabilities less the gross assets of a derivative liability or group of derivative liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeLiabilityFairValueNet1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInDerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 28 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6

Basis of Presentations (Details Textual) (USD $)
3 Months Ended 12 Months Ended

Oct. 31, 2012

Jul. 31, 2012

License and Services Revenue $ 600,000 $ 600,000

Deficit accumulated during the development stage 358,370,276 357,611,780

Working Capital Deficiency $ 8,000,000

X

- Definition

This element represents the amount working capital deficiency as of balance sheet date.

+ References

No definition available.

+ Details

Name: gnbt_WorkingCapitalDeficiency

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 7

-Paragraph 11

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseAndServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 29 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6

Derivative Liabilities (Details 1) (USD $)
3 Months Ended 12 Months Ended

Oct. 31, 2012

Jul. 31, 2012

Current exercise price $ 0.08 $ 0.15

Time to expiration 3 years 9 months 3 days 3 years 10 months 28 days

Risk-free interest rate 0.54% 0.45%

Estimated volatility 87.00% 104.00%

Dividend 0.00% 0.00%

Stock price at period end date $ 0.056 $ 0.093

X

- Definition

Agreed upon price for the exchange of the underlying asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 30 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation (Details 1) (USD $)
3 Months Ended

Oct. 31, 2012

Outstanding, October 31, 2012 172,500

Granted 0

Vested (86,250)

Forfeited 0

Outstanding, October 31, 2012 86,250

Outstanding, August 1, 2012 $ 0.46

Granted $ 0.00

Vested $ 0.46

Forfeited $ 0.00

Outstanding $ 0.46

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(e)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Effects of Recent Accounting Pronouncements
3 Months Ended

Oct. 31, 2012

Accounting Changes and Error Corrections [Abstract]

Accounting Changes and Error Corrections [Text Block]
Note 2 – Effects of Recent Accounting Pronouncements:

Recently Adopted Accounting Pronouncements
In May 2011, the FASB issued further guidance on fair value measurements and disclosures which requires the categorization by level for items that are only required to be disclosed at fair value and information about transfers between Level 1 and Level 2. In addition, the update provides guidance on measuring the fair value of financial instruments managed within a portfolio and the application of premiums and discounts on fair value measurements. The guidance requires additional disclosure for Level 3 measurements regarding the sensitivity of fair value to changes in unobservable inputs and any interrelationships between those inputs. The guidance was effective for the Company’s interim period ended April 30, 2012. The adoption of this new accounting guidance did not have a material impact on the Company’s consolidated financial statements.

Recently Issued Accounting Pronouncements
In June 2011, the FASB issued guidance regarding the presentation of Comprehensive Income within financial statements. The guidance will be effective for the Company’s annual fiscal period ended July 31, 2013 and subsequent interim periods. The Company does not expect the adoption of this new accounting guidance to have a material impact on its consolidated financial statements.

X

- Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22499-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 1.N.Q3)

-URI http://asc.fasb.org/extlink&oid=6369664&loc=d3e30840-122693

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22644-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 1

-Section N

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 45

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=6368906&loc=d3e21914-107793

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 154

-Paragraph 17, 22, 25, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)

Oct. 31, 2012

Jul. 31, 2012

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 750,000,000 750,000,000

Common stock, shares issued 370,260,904 354,161,297

Common stock, shares outstanding 370,260,904 354,161,297

Convertible preferred stock, cumulative percentage of interest 9.00% 9.00%

Series A Convertible Preferred Stock [Member]

Convertible preferred stock, par value (in dollars per share) $ 1,000 $ 1,000

Convertible preferred stock, shares authorized 5,500 5,500

Convertible preferred stock, shares issued 0 0

Convertible preferred stock, shares outstanding 0 0

Convertible preferred stock, cumulative percentage of interest 9.00% 9.00%

Series B Convertible Preferred Stock [Member]

Convertible preferred stock, par value (in dollars per share) $ 1,000 $ 1,000

Convertible preferred stock, shares authorized 2,000 2,000

Convertible preferred stock, shares issued 792 1,490

Convertible preferred stock, shares outstanding 792 1,490

Convertible preferred stock, cumulative percentage of interest 9.00% 9.00%

Series C Convertible Preferred Stock [Member]

Convertible preferred stock, par value (in dollars per share) $ 1,000 $ 1,000

Convertible preferred stock, shares authorized 750 0

Convertible preferred stock, shares issued 750 0

Convertible preferred stock, shares outstanding 0 0

Convertible preferred stock, cumulative percentage of interest 9.00% 9.00%

X

- Definition

Cumulative percentage of interest on convertible preferred stock.

+ References

No definition available.

+ Details

Name: gnbt_ConvertiblePreferredStockPercentageOfInterest

Namespace Prefix: gnbt_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 34 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
3 Months Ended

Oct. 31, 2012

Subsequent Events [Abstract]

Subsequent Events [Text Block]
Note 12 – Subsequent Events:

On November 30, 2012, the Company’s subsidiary, Generex Pharmaceuticals Inc., entered in to an agreement with a private lender for a mortgage loan of $855,000 with an annual interest rate of 9.75% and a maturity date of November 30, 2013, secured by real estate owned by the subsidiary. The prior mortgage loan of $156,596 was discharged from the proceeds and the Company received approximately $620,000, after the prior mortgage discharge, legal expenses and other fees.

The Company has evaluated subsequent events occurring after the balance sheet date through the date the interim consolidated financial statements were issued.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

DOCUMENT AND ENTITY INFORMATION
3 Months Ended

Oct. 31, 2012

Dec. 07, 2012

Entity Registrant Name GENEREX BIOTECHNOLOGY CORP

Entity Central Index Key 0001059784

Current Fiscal Year End Date --07-31

Entity Filer Category Accelerated Filer

Trading Symbol gnbt

Entity Common Stock, Shares Outstanding 372,059,685

Document Type 10-Q

Amendment Flag false

Document Period End Date Oct. 31, 2012

Document Fiscal Period Focus Q1

Document Fiscal Year Focus 2013

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 36 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation (Tables)
3 Months Ended

Oct. 31, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of Stock Options Roll Forward [Table Text Block]
The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plans for the three months ended October 31, 2012:
Weighted
Average
Exercise Aggregate
Price Intrinsic
Options Share Value

Outstanding, August 1, 2012 10,979,634 $ 0.257
Granted — n/a
Forfeited or expired — n/a
Exercised — n/a
Outstanding, October 31, 2012 10,979,634 $ 0.257 $ 277,615
Exercisable, October 31, 2012 10,893,384 $ 0.254 $ 277,615

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]
The following is a summary of the non-vested common stock options granted, vested and forfeited under the Plan for the three months ended October 31, 2012:
Weighted Average
Grant Date
Options Fair Value

Outstanding, August 1, 2012 172,500 $ 0.46
Granted — 0.00
Vested (86,250 ) 0.46
Forfeited — 0.00
Outstanding, October 31, 2012 86,250 $ 0.46

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: gnbt_NonVestedCommonStockOptionsGrantedVestedAndForfeitedTableTextBlock

Namespace Prefix: gnbt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the change in stock options.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 204 Months Ended

Oct. 31, 2012

Oct. 31, 2011

Oct. 31, 2012

Revenues, net $ 0 $ 9,931 $ 5,110,784

Cost of Goods Sold 0 3,262 1,620,375

Gross profit 0 6,669 3,490,409

Operating Expenses:

Research and development 653,395 1,979,502 132,629,359

Research and development - related party 0 0 220,218

Selling and marketing 0 75,661 9,333,214

General and administrative 1,286,636 1,421,284 149,088,792

General and administrative - related party 0 0 314,328

Total Operating Expenses 1,940,031 3,476,447 291,585,911

Operating Loss (1,940,031) (3,469,778) (288,095,502)

Other Income (Expense):

Miscellaneous income 0 0 686,303

Income from assets held for investment, net (Note 11) 1,042,868 712,075 5,377,125

Interest income 225 519 7,782,118

Interest expense (117,975) (34,921) (69,126,657)

Change in fair value of derivative liabilities (Note 10) 358,714 3,128,459 (357,263) ^[1]

Loss on extinguishment of debt 0 0 (14,134,068)

Net Income/(Loss) Before Undernoted (656,199) 336,354 (357,867,944)

Minority Interest Share of Loss 0 0 3,038,185

Net income/(loss) (656,199) 336,354 (354,829,759)

Preferred Stock Dividend (Note 9) 102,297 0 3,540,517

Net Income/(Loss) Available to Common Stockholders $ (758,496) $ 336,354 $ (358,370,276)

Net Income/(Loss) Per Common Share (Note 8)

Basic $ (0.002) $ 0.001

Diluted $ (0.002) $ 0.001

Shares used in computing earnings/(loss) per share (Note 8)

Basic 364,310,359 313,342,608

Diluted 364,310,359 313,348,032

[1] includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to October 31, 2012" column. See Note 10 - Derivative Liabilities.

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line related to related party.

+ References

No definition available.

+ Details

Name: gnbt_GeneralAndAdministrativeRelatedParty

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process related to related party.

+ References

No definition available.

+ Details

Name: gnbt_ResearchAndDevelopmentRelatedParty

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net Increase or Decrease in the fair value of the derivative or group of derivatives included in earnings.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 36, 37, 38

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 11, 12, 36

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 26

-Paragraph 20, 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cost of borrowed funds accounted for as interest that was charged against earnings during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher OTS

-Name Federal Regulation (FR)

-Number Title 12

-Section 563c.102

-Paragraph 9

-Chapter V

-Subsection II

-LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 34

-Paragraph 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of Net Income (Loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=18733213&loc=SL4591551-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A1, A4, A5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A1, A4, A5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 5

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=18733213&loc=SL4591552-111686

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=18733213&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_RentalIncomeNonoperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total amount of expenses directly related to the marketing or selling of products or services.

+ References

No definition available.

+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 38 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments
3 Months Ended

Oct. 31, 2012

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]
Note 7 – Commitments:

On December 7, 2009, the Company entered into a long-term agreement with sanofi-aventis Deutschland GmbH (“sanofi”). Under this agreement, sanofi-aventis will manufacture and supply recombinant human insulin to the Company in the territories specified in the agreement. Through this agreement, the Company will procure recombinant human insulin crystals for use in the production of Generex Oral-lyn™. The terms of the supply agreement require the Company to make certain minimum purchases of insulin from sanofi through the period ended December 31, 2011.To date, the Company has not met the minimum purchase commitments under this agreement. After December 31, 2011, sanofi may terminate the agreement due to the Company’s failure to meet such purchase commitments. Upon termination, the Company would be obligated to pay sanofi for all materials and components that it has acquired or ordered to manufacture insulin based on the Company’s forecasts or minimum purchase commitments, all related work-in-progress (at cost) and all finished insulin in inventory. To date, the Company has not provided forecasts to sanofi for the purchase of insulin and sanofi has not terminated the agreement.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Pending Litigation
3 Months Ended

Oct. 31, 2012

Pending Litigation Disclosure [Abstract]

Pending Litigation Disclosure [Text Block]
Note 6 – Pending Litigation:

In February 2001, a former business associate of the former Vice President of Research and Development (“VP”) of the Company and an entity known as Centrum Technologies Inc. (“CTI”) commenced an action in the Ontario Superior Court of Justice against the Company and the VP seeking, among other things, damages for alleged breaches of contract and tortious acts related to a business relationship between this former associate and the VP that ceased in July 1996. The plaintiffs’ statement of claim also seeks to enjoin the use, if any, by the Company of three patents allegedly owned by CTI. The three patents are entitled Liquid Formulations for Proteinic Pharmaceuticals, Vaccine Delivery System for Immunization, Using Biodegradable Polymer Microspheres, and Controlled Releases of Drugs or Hormones in Biodegradable Polymer Microspheres. It is the Company’s position that the buccal drug delivery technologies which are the subject matter of the Company’s research, development, and commercialization efforts, including Generex Oral-lyn™ and the RapidMist™ Diabetes Management System, do not make use of, are not derivative of, do not infringe upon, and are entirely different from the intellectual property identified in the plaintiffs’ statement of claim. On July 20, 2001, the Company filed a preliminary motion to dismiss the action of CTI as a nonexistent entity or, alternatively, to stay such action on the grounds of want of authority of such entity to commence the action. The plaintiffs brought a cross motion to amend the statement of claim to substitute Centrum Biotechnologies, Inc. (“CBI”) for CTI. CBI is a corporation of which 50 percent of the shares are owned by the former business associate and the remaining 50 percent are owned by the Company. Consequently, the shareholders of CBI are in a deadlock. The court granted the Company’s motion to dismiss the action of CTI and denied the plaintiffs’ cross motion without prejudice to the former business associate to seek leave to bring a derivative action in the name of or on behalf of CBI. The former business associate subsequently filed an application with the Ontario Superior Court of Justice for an order granting him leave to file an action in the name of and on behalf of CBI against the VP and the Company. The Company opposed the application. In September 2003, the Ontario Superior Court of Justice granted the request and issued an order giving the former business associate leave to file an action in the name of and on behalf of CBI against the VP and the Company. A statement of claim was served in July 2004. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.

On May 20, 2011, Ms. Perri filed a statement of claim (subsequently amended) in the Ontario Superior Court of Justice, naming as defendants the Company and certain directors of the Company, Mr. Barratt, Ms. Masterson, Mr. McGee, and Mr. Fletcher. In this action, Ms. Perri has alleged that defendants engaged in discrimination, harassment, bad faith and infliction of mental distress in connection with the termination of her employment with the Company. Ms. Perri is seeking damages in this action in excess of $7,000,000 for, among other things, breach of contract, breach of fiduciary duty, violations of the Ontario Human Rights Code and aggravated and punitive damages. On September 20, 2011, the defendants filed a statement of defense and counterclaim, also naming Time Release Corp., Khazak Group Consulting Corp., and David Khazak, C.A. as defendants by counterclaim, and seeking damages of approximately $2.3 million in funds that the defendants allege Ms. Perri wrongly caused the Company to pay to third parties in varying amounts over several years and an accounting of certain third-party payments, plus interests and costs. The factual basis for the counterclaim involves payments made by the Company to third parties believed to be related to Ms. Perri. The Company intends to defend this action and pursue its counterclaim vigorously and is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.

On June 1, 2011, Golden Bull Estates Ltd. filed a claim (subsequently amended) in the Ontario Superior Court of Justice, naming the Company, 1097346 Ontario, Inc. and Generex Pharmaceuticals Inc. as defendants. The plaintiff, Golden Bull Estates, is controlled by Ms. Perri. The plaintiff alleges damages in the amount of $550,000 for breach of contract, $50,000 for punitive damages, plus interest and costs. The plaintiff’s claims relate to an alleged contract between the plaintiff and the Company for property management services for certain Ontario properties owned by the Company. The Company terminated the plaintiff’s property management services in April 2011. Following the close of pleadings, the Company served a motion for summary judgment. The plaintiff responded by amending its statement of claim to include a claim to the Company’s interest in certain of its real estate holdings. The plaintiff moved for leave to issue and register a Certificate of Pending Litigation in respect of this real estate. The motion was not successful in respect of any current real estate holdings of the Company. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.

In August 2011, the estate of Antonio Perri, the late father of Ms. Perri, commenced an action against Generex Pharmaceuticals, Inc., the law firm of Brans, Lehun, Baldwin LLP and William Lehun in the Ontario Superior Court of Justice claiming that the estate is entitled to the proceeds of sale (approximately $1,730,000) received by the Company on its sale of two properties to Golden Bull Estates Ltd., a company controlled by Ms. Perri. The suit alleges that no consideration was received when the Company purchased the two properties from Antonio Perri in 1998. The Company has responded to this statement of claim and intends to defend this action vigorously. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding.

In December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc., in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in addition to costs and further interest. The Company responded to this statement of claim and also asserted a counterclaim in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs. On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following the spinout of its subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such spinout. Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each parties counsel until payment of the settlement amount. Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without costs will be filed with the court. If the Company fails to make the payment following completion of any post-spinout financing related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus interest of 3% per annum and costs fixed at $25,000.

The Company is involved in certain other legal proceedings in addition to those specifically described herein. Subject to the uncertainty inherent in all litigation, the Company does not believe at the present time that the resolution of any of these legal proceedings is likely to have a material adverse effect on the Company’s consolidated financial position, operations or cash flows.

With respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses its position both with respect to accrued liabilities and other potential exposures.

X

- Details

Name: gnbt_PendingLitigationDisclosureAbstract

Namespace Prefix: gnbt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for pending litigation during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_PendingLitigationDisclosureTextBlock

Namespace Prefix: gnbt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock-Based Compensation (Details) (USD $)
3 Months Ended

Oct. 31, 2012

Outstanding, August 1, 2012 10,979,634

Granted 0

Forfeited or expired 0

Exercised 0

Outstanding, October 31, 2012 10,979,634

Exercisable, October 31, 2012 10,893,384

Outstanding, August 1, 2012 $ 0.257

Outstanding, October 31, 2012 $ 0.257

Exercisable, October 31, 2012 $ 0.254

Outstanding, October 31, 2012 $ 277,615

Exercisable, October 31, 2012 $ 277,615

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c), d(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph d(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounts Payable and Accrued Expenses (Tables)
3 Months Ended

Oct. 31, 2012

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
Accounts payable and accrued expenses consist of the following:

October 31, 2012 July 31, 2012

Accounts Payable & Accruals – General and Administrative $ 3,971,015 $ 3,556,160

Accounts Payable & Accruals – Research and Development 2,822,961 2,691,192

Accounts Payable & Accruals – Selling and Marketing 311,329 290,534

Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9) 416,286 402,300

Executive Compensation and Directors’ Fees Payable 256,141 75,466

Total $ 7,777,732 $ 7,015,652

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Derivative Liabilities
3 Months Ended

Oct. 31, 2012

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]
Note 10 – Derivative Liabilities:

Derivative warrant liability

The Company has warrants outstanding with price protection provisions that allow for the reduction in the exercise price of the warrants in the event the Company subsequently issues stock or securities convertible into stock at a price lower than the exercise price of the warrants. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased or decreased proportionately, so that after such adjustment the aggregate exercise price payable for the adjusted number of warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment.

Accounting for Derivative Warrant Liability

The Company’s derivative warrant instruments have been measured at fair value at October 31, 2012 and July 31, 2012 using the binomial lattice model. The Company recognizes all of its warrants with price protection in its consolidated balance sheets as a liability. The liability is revalued at each reporting period and changes in fair value are recognized currently in the consolidated statements of operations. The initial recognition and subsequent changes in fair value of the derivative warrant liability have no effect on the Company’s consolidated cash flows.

The derivative warrants outstanding at October 31, 2012 are all currently exercisable with a weighted-average remaining life of 3.76 years.

The revaluation of the warrants at each reporting period, as well as the charges associated with issuing additional warrants due to the price protection features, resulted in the recognition of income of $358,714 within the Company’s consolidated statements of operations for the three months ended October 31, 2012 and income of $3,128,459 for the three months ended October 31, 2011, which is included in the consolidated statement of operations under the caption “Change in fair value of derivative liabilities”. The fair value of the warrants at October 31, 2012 and July 31, 2012 was $4,347,710 and $4,081,627, respectively, which is reported on the consolidated balance sheets under the caption “Derivative Warrant Liability”. The following summarizes the changes in the value of the derivative warrant liability from August 1, 2011 until October 31, 2012:

Value No. of Warrants

Balance at August 1, 2011 – Derivative warrant liability $ 8,745,508 80,234,017

Exercise of warrants classified as derivative liability (7,230,734 ) (49,863,260 )

Additional warrants issued in February 2012 financing 1,811,746 13,333,333

Additional warrants from price protection features of existing warrants 1,548,813 11,444,440

Decrease in fair value of derivative warrant liability (793,706 ) n/a

Balance at July 31, 2012 – Derivative warrant liability $ 4,081,627 55,148,530

Additional warrants issued in August 2012 financing 624,797 9,375,000

Additional warrants from price protection features of existing warrants 3,102,355 48,254,955

Decrease in fair value of derivative warrant liability (3,461,069 ) n/a

Balance at October 31, 2012 – Derivative warrant liability $ 4,347,710 112,778,485

Fair Value Assumptions Used in Accounting for Derivative Warrant Liability

The Company has determined its derivative warrant liability to be a Level 2 fair value measurement and has used the binominal lattice pricing model to calculate the fair value as of October 31, 2012 and July 31, 2012. The binomial lattice model requires six basic data inputs: the exercise or strike price, time to expiration, the risk free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Because the warrants contain the price protection feature, the probability that the exercise price of the warrants would decrease as the stock price decreased was incorporated into the valuation calculations. The key inputs used in the October 31, 2012 and July 31, 2012 fair value calculations were as follows:

October 31, 2012 July 31, 2012

Current exercise price $ 0.08 $ 0.15

Time to expiration 3.76 years 3.9 years

Risk-free interest rate 0.54 % 0.45 %

Estimated volatility 87 % 104 %

Dividend -0- -0-

Stock price at period end date $ 0.056 $ 0.093

X

- Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4E

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4D

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4H

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Net (Loss)/Income Per Share ("EPS")
3 Months Ended

Oct. 31, 2012

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]
Note 8 – Net (Loss)/Income Per Share (“EPS”):

Basic EPS and Diluted EPS for the three-month period ended October 31, 2012 have been computed by dividing the net loss available to common stockholders for the period by the weighted average shares outstanding during that period. All outstanding stock options, non-vested restricted stock, warrants and common stock underlying convertible preferred stock, representing 162,146,167 incremental shares at October 31, 2012, have been excluded from the respective computations of Diluted EPS as they are anti-dilutive, due to the loss generated during that period.

Basic EPS and Diluted EPS for the three-month period ended October 31, 2011 have been computed by dividing the net income available to common stockholders for the period by the weighted average shares outstanding and the diluted weighted average shares outstanding during that period, respectively. Per the treasury method of calculating Diluted EPS, 5,424 shares representing outstanding stock options which have an exercise price lower than the average market price for the quarter ended October 31, 2011 are included in the calculation of EPS. All remaining outstanding stock options and warrants which have out-of-the-money exercise prices and common stock underlying convertible preferred stock, representing 110,086,551 incremental shares in aggregate, have been excluded from the October 31, 2011 computation of Diluted EPS, as they are anti-dilutive.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Deficiency
3 Months Ended

Oct. 31, 2012

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]
Note 9 – Stockholders’ Deficiency:

Common Stock

During the three months ended October 31, 2012, the Company issued or committed to issue 1,366,666 shares of common stock to various consultants for services rendered in the amount of $114,250. The shares were valued at an average of $0.08 per share.

During the three months ended October 31, 2012, the Company issued 8,727,498 shares of common stock in conjunction with the conversion of 698 shares of the Series B 9% Convertible Preferred Stock and 6,005,443 shares of common stock as make-whole payments on Series B 9% Convertible Preferred Stock.

Stock option expense related to executive and employee options granted in October 2009, resulting in a charge to operations during the three-month period ended October 31, 2012 of $9,993.

The stockholders’ deficiency transactions as described above are summarized below:

Additional Change to

Common Stock Paid-In Stockholders’

Shares Amount Capital Equity

Issuance of common stock on conversion of convertible preferred stock 8,727,498 $ 8,727 $ (8,727 ) $ —

Issuance of common stock as make whole payments on convertible preferred stock 6,005,443 6,005 182,509 188,514

Issuance of common stock for services 1,366,666 1,367 112,883 114,250

Amortization of stock options as employee compensation — — 9,993 9,993

Total 16,099,607 $ 16,099 $ 296,658 $ 312,757

Warrants

The following is a summary of warrants issued, forfeited or expired and exercised for the three months ended October 31, 2012:

Warrants

Outstanding, August 1, 2012 74,264,078

Issued 57,629,955

Outstanding, October 31, 2012 131,894,033

The outstanding warrants at October 31, 2012 have a weighted average exercise price of $0.19 per share and have a weighted average remaining life of 3.54 years.

As of October 31, 2012, the Company has 7,499,999 warrants with a current exercise price of $0.08 and an expiry date of January 25, 2016, 54,426,222 warrants with a current exercise price of $0.08 and an expiry date of March 31, 2016, 6,249,995 warrants with a current exercise price of $0.08 and an expiry date of July 11, 2016, 10,227,270 warrants with a current exercise price of $0.08 and an expiry date of September 30, 2016, 24,999,999 warrants with a current exercise price of $0.08 and an expiry date of February 2, 2017 and 9,375,000 warrants with a current exercise price of $0.08 and an expiry date of August 10, 2017 (112,778,485 warrants in total), which have price protection provisions that allow for the reduction in the current exercise price upon the occurrence of certain events, including the Company’s issuance of common stock or securities convertible into or exercisable for common stock, such as options and warrants, at a price per share less than the exercise price then in effect. For instance, if the Company issues shares of its common stock or options exercisable for or securities convertible into common stock at an effective price per share of common stock less than the exercise price then in effect, the exercise price will be reduced to the effective price of the new issuance. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased proportionately, so that after such adjustment the aggregate exercise price payable for the adjusted number of warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment.

The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants described above that were issued in connection with the March 2008 private placement: (a) shares of common stock or standard options to the Company’s directors, officers, employees or consultants pursuant to a board-approved equity compensation program or other contract or arrangement (up to an aggregate amount of 5,608,926, representing 5% of the common stock issued and outstanding immediately prior to March 31, 2008); (b) shares of common stock issued upon the conversion or exercise of any security, right or other instrument convertible or exchangeable into common stock (or securities exchangeable into common stock) issued prior to March 31, 2008; (c) the shares of common stock issued upon exercise of the warrants issued in March 2008; and (d) shares of common stock and warrants in connection with strategic alliances, acquisitions, mergers, and strategic partnerships, the primary purpose of which is not to raise capital, and which are approved in good faith by the Company’s board of directors (up to an aggregate number of 11,217,852, representing 10% of the shares of common stock issued and outstanding immediately prior to March 31, 2008). On August 10, 2012, the Company’s triggering of the price protection features of the warrants that were issued in March 2008 resulting in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 34,481,866 to 64,653,492.

The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on January 25, 2011 and in March and April 2011: (I) (a) shares of common stock or options to employees, officers, or directors of the Company pursuant to plans approved by a majority of the non-employee directors of the Company or pursuant to independent contractors pursuant to other agreements or arrangements in existence as of January 24, 2011, (b) securities issued upon the exercise or exchange of or conversion of any securities issued under the Securities Purchase Agreement dated January 24, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on January 24, 2011, provided that such securities have not been amended since their issue date through the date of conversion, exercise or exchange to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (except certain adjustments to warrants expiring in March 2016 and September 2016 are not prohibited), and (c) shares of common stock or warrants to trade vendors of the Company approved by a majority of the non-employee members of the Board of Directors; provided that (II) (i) the shares issued under paragraphs I(a) and I(c) shall not, in the aggregate exceed 1,500,000 shares in each 30-day period during the first 90 days after January 24, 2011, (ii) there is a reasonable relationship between the value of the common stock or options issued pursuant to paragraphs I(a) and I(c) and the value of services rendered or goods provided and (iii) the Company does not rely in whole or in part on the exemptions provided in Sections 3(a)(9) or 3(a)(10) of the Securities Act. On August 10, 2012, the Company’s triggering of the price protection features of the warrants that were issued on January 25, 2011 and in March and April 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 4,000,000 to 7,499,999.

The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on July 8, 2011: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated July 8, 2011, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreement dated July 8, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on July 8, 2011, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in July 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 3,333,331 to 6,249,995.

The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on February 2, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011 and January 31, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on February 2, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in February 2012 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 13,333,333 to 24,999,999.

The Company’s issuance of the following securities will not trigger the price protection provisions of the warrants issued on August 10, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011, January 31, 2012 and August 8, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on August 8, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.

The Company accounts for the warrants with price protection provisions in accordance with FASB ASC Topic 815 as described in Note 10 - Derivative Liabilities below. As of October 31, 2012, there were a total of 112,778,485 warrants with an estimated fair value of $4,347,710, which are identified on the consolidated balance sheet under the caption “Derivative Warrant Liability”.

Series A 9% Convertible Preferred Stock

The Company has authorized 5,500 shares of Series A 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated July 8, 2011, the Company sold an aggregate of 2,575 shares of convertible preferred stock, as well as accompanying warrants to purchase 17,166,666 shares of common stocks. An aggregate of 17,166,666 shares of the Company’s common stock were issuable upon conversion of the convertible preferred stock which was issued at the initial closing. As of the end of our fiscal year 2012, all of the issued Series A 9% Convertible Preferred Stock had been converted to common stock. There were 17,166,666 shares of common stock which have been issued upon the conversion of the Series A convertible preferred stock and 6,129,666 shares of common stock issued as “make whole payments” on such conversions.

Series B 9% Convertible Preferred Stock

The Company has authorized 2,000 shares of Series B 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated January 31, 2012, the Company sold an aggregate of 2,000 shares of Series B convertible preferred stock, as well as accompanying warrants to purchase 13,333,333 shares of common stocks. An aggregate of 13,333,333 shares of the Company’s common stock were issuable upon conversion of the Series B convertible preferred stock which was issued at the initial closing.

Subject to certain ownership limitations, the convertible preferred stock is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $0.08 (as adjusted on August 10, 2012) per share, and will accrue a 9% dividend until February 1, 2015 and, beginning on February 2, 2015 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend is payable quarterly on September 30, December 31, March 31 and June 30, beginning on March 31, 2012 and on each conversion date in cash, or at the Company’s option, in shares of common stock. In the event that the convertible preferred stock is converted prior to February 1, 2015, the Company will pay the holder of the converted preferred stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. Such “make-whole payment” may be made in cash or, at the Company’s option, in shares of its common stock. In addition, beginning February 1, 2015, the Company will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, and if such dividends are paid. The Company will incur a late fee of 18% per annum on unpaid dividends.

The conversion price of the convertible preferred stock is subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The conversion price will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then conversion price, except in the event of certain exempt issuances. In addition, the holders of convertible preferred stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had converted all of their shares of convertible preferred stock. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the holders of convertible preferred stock will be entitled to receive, upon conversion of their shares, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. On August 10, 2012, the triggering of the price protection features of the Series B 9% Convertible Preferred Stock resulted in a decrease of the conversion price from $0.15 to $0.08.

The Company may become obligated to redeem the convertible preferred stock in cash upon the occurrence of certain triggering events, including the failure to provide an effective registration statement covering shares of common stock issuable upon conversion of the convertible preferred stock, material breach of certain contractual obligations to the holders of the convertible preferred stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Company’s common stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or regulated quotation services. Upon the occurrence of certain triggering events, each holder of convertible preferred stock will have the option to redeem such holder’s shares of convertible preferred stock for a redemption price payable in shares of common stock or receive an increased dividend rate of 18% on all of such holder’s outstanding convertible preferred stock.

In conjunction with the issuance of the Series B convertible preferred stock, the Company also issued 13,333,333 warrants to the investors. Subject to certain ownership limitations, the warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at an exercise price of $0.08 (as adjusted on August 10, 2012) per share of common stock. The exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares of common stock issuable upon exercise will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances. In addition, the warrant holders will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive, upon exercise of their warrants, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. These warrants have been classified as derivative liabilities and are described further in Note 10 – Derivative Liabilities.

As of October 31, 2012, 1,208 of the Series B convertible preferred stock had been converted to common stock. At October 31, 2012 and July 31, 2012, the “make whole payments” on the remaining convertible preferred stock in the amount of $213,786 and $402,300, respectively, are included in Accounts Payable and Accrued Expenses (see Note 5). The “make whole” amount was allocated as described directly below, when accounting for the initial proceeds from the Series B convertible preferred stock financing.

Accounting for proceeds from the Series B convertible preferred stock financing

The net cash proceeds from the Series B convertible preferred stock financing were $1,975,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing and second to the make whole payments. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and was reported on the Company’s consolidated statements of operations for the fiscal year ended July 31, 2012 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair values of the derivative warrant liability and the derivative additional investment rights liability are described in Note 10 – Derivative Liabilities below. The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:

Accounting allocation of initial proceeds

Net proceeds $ 1,975,000

Derivative warrant liability fair value (1,811,746 )

Make whole payments liability (540,000 )

Deemed dividend $ (376, 746)

Series C 9% Convertible Preferred Stock

The Company has authorized 750 shares of Series C 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated August 8, 2012, the Company sold an aggregate of 750 shares of Series C convertible preferred stock, as well as accompanying warrants to purchase 9,375,000 shares of common stocks. An aggregate of 9,375,000 shares of the Company’s common stock were issuable upon conversion of the Series C convertible preferred stock which was issued at the initial closing.

Subject to certain ownership limitations, the convertible preferred stock is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $0.08 per share, and will accrue a 9% dividend until August 10, 2015 and, beginning on August 10, 2015 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend is payable quarterly on September 30, December 31, March 31 and June 30, beginning on September 30, 2012 and on each conversion date in cash, or at the Company’s option, in shares of common stock. In the event that the convertible preferred stock is converted prior to August 10, 2015, the Company will pay the holder of the converted preferred stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. Such “make-whole payment” may be made in cash or, at the Company’s option, in shares of its common stock. In addition, beginning August 10, 2015, the Company will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, and if such dividends are paid. The Company will incur a late fee of 18% per annum on unpaid dividends.

The conversion price of the convertible preferred stock is subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The conversion price will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then conversion price, except in the event of certain exempt issuances. In addition, the holders of convertible preferred stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had converted all of their shares of convertible preferred stock. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the holders of convertible preferred stock will be entitled to receive, upon conversion of their shares, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction.

The Company may become obligated to redeem the convertible preferred stock in cash upon the occurrence of certain triggering events, including the failure to provide an effective registration statement covering shares of common stock issuable upon conversion of the convertible preferred stock, material breach of certain contractual obligations to the holders of the convertible preferred stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Company’s common stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or regulated quotation services. Upon the occurrence of certain triggering events, each holder of convertible preferred stock will have the option to redeem such holder’s shares of convertible preferred stock for a redemption price payable in shares of common stock or receive an increased dividend rate of 18% on all of such holder’s outstanding convertible preferred stock.

In conjunction with the issuance of the Series C convertible preferred stock, the Company also issued 9,375,000 warrants to the investors. Subject to certain ownership limitations, the warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at an exercise price of $0.08 per share of common stock. The exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares of common stock issuable upon exercise will also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances. In addition, the warrant holders will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive, upon exercise of their warrants, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. These warrants have been classified as derivative liabilities and are described further in Note 10 –

Derivative Liabilities.

As of October 31, 2012, none of the Series C convertible preferred stock had been converted to common stock. At October 31, 2012, the “make whole payments” on the remaining Series C convertible preferred stock in the amount of $202,500 are included in Accounts Payable and Accrued Expenses (see Note 5). The “make whole” amount was allocated as described directly below, when accounting for the initial proceeds from the Series C convertible preferred stock financing.

Accounting for proceeds from the Series C convertible preferred stock financing

The net cash proceeds from the Series C convertible preferred stock financing were $725,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing and second to the make whole payments. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and was reported on the Company’s consolidated statements of operations for the quarter ended October 31, 2012 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair values of the derivative warrant liability and the derivative additional investment rights liability are described in Note 10 – Derivative Liabilities below. The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:

Accounting allocation of initial proceeds

Net proceeds $ 725,000

Derivative warrant liability fair value (624,797 )

Make whole payments liability (202,500 )

Deemed dividend $ (102,297 )

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Income from Assets Held for Investment, net:
3 Months Ended

Oct. 31, 2012

Income From Assets Held For Investment Net [Abstract]

Incomefromassetsheldforinvestmentnet [Text Block]
Note 11 – Income from Assets Held for Investment, net:

In September 2012, the Company sold its head office real estate in Toronto for gross proceeds after real estate commissions of $1,579,189. This property had a net book value of $585,064, resulting in an accounting gain of $994,125 which is included in income from assets held for investment, net on the consolidated statement of operations. The net proceeds after commissions and other expenses were used to discharge or partially discharge the first and second mortgages on the property. The first mortgage on the property, with remaining principal of $480,951, was discharged completely upon sale. The remaining net proceeds of $1,028,780 after expenses and the discharge of the first mortgages was used to partially discharge the second mortgage and the Company did not receive any of the net proceeds from this property sale.

In August 2011, the Company sold two properties which were held for investment for gross proceeds after real estate commissions of $1,669,115. These two properties had a net book value of $1,029,435, resulting in an accounting gain of $639,680 which is included in income from assets held for investment, net on the consolidated statement of operations. The two properties had mortgages of $659,288 which were discharged upon sale, resulting in net cash proceeds to the Company of $1,009,827.

The remaining income of $48,743 in this category in the three months ended October 31, 2012, pertains to rental income from properties held for investment, net of carrying and operating expenses, compared to $72,395 in the prior year period.

X

- Details

Name: gnbt_IncomeFromAssetsHeldForInvestmentNetAbstract

Namespace Prefix: gnbt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: gnbt_IncomefromassetsheldforinvestmentnetTextBlock

Namespace Prefix: gnbt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Deficiency (Details Textual) (USD $)
3 Months Ended 12 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended

Oct. 31, 2012

Oct. 31, 2011

Jul. 31, 2012

Jul. 31, 2005

Aug. 31, 2011

Jul. 31, 2011

Oct. 31, 2012

Warrant One [Member]

Oct. 31, 2012

Warrant Two [Member]

Oct. 31, 2012

Warrant Three [Member]

Oct. 31, 2012

Warrant Four [Member]

Oct. 31, 2012

Warrant Five [Member]

Oct. 31, 2012

Warrant Six [Member]

Oct. 31, 2012

Warrant [Member]

Feb. 02, 2012

Investment Rights Liability Stock [Member]

Oct. 31, 2012

Series A Convertible Preferred Stock [Member]

Jul. 31, 2012

Series A Convertible Preferred Stock [Member]

Sep. 30, 2011

Series A Convertible Preferred Stock [Member]

Jul. 31, 2011

Series A Convertible Preferred Stock [Member]

Jul. 08, 2011

Series A Convertible Preferred Stock [Member]

Oct. 31, 2012

Series B Convertible Preferred Stock [Member]

Jul. 31, 2012

Series B Convertible Preferred Stock [Member]

Jan. 31, 2012

Series B Convertible Preferred Stock [Member]

Oct. 31, 2011

Series B Convertible Preferred Stock [Member]

Oct. 31, 2012

Series C Convertible Preferred Stock [Member]

Jul. 31, 2012

Series C Convertible Preferred Stock [Member]

Oct. 31, 2011

Series C Convertible Preferred Stock [Member]

Jul. 31, 2012

Common Stock [Member]

Oct. 31, 2012

Warrant Agreement Date March 2008 [Member]

Oct. 31, 2012

Warrant Agreement Date January March and April 2011 [Member]

Oct. 31, 2012

Warrant Agreement Date August 2012 [Member]

Oct. 31, 2012

Warrant Agreement Date July 2011 [Member]

Oct. 31, 2012

Warrant Agreement Date February 2012 [Member]

Convertible preferred stock, shares authorized 5,500 2,000 2,000 2,000 0 750 0 750

Convertible preferred stock, par value (in dollars per share) $ 1,000 $ 1,000 $ 1,000 $ 1,000 $ 1,000 $ 1,000 $ 1,000 $ 1,000

Convertible preferred stock, shares issued 2,575 792 1,490 2,000 0 750 0 750

Incremental Common Shares Attributable to Conversion of Preferred Stock 6,129,666 17,166,666 17,166,666 13,333,333

Convertible Preferred Stock Conversion Price $ 0.15 $ 0.15

Preferred Stock, Dividend Rate, Percentage 9.00%

Additional Preferred Stock Dividend Rate Percentage 3 3

Conversion of Preferred Stock $ 0 $ 0 $ 270 $ 270

Conversion of Stock, Amount Converted 1,000 1,000

Percentage Of Unpaid Dividend 18

Increased Preferred Stock Dividend Rate Percentage 18 9

Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants 18

Balance at July 31, 2012 - Derivative warrant liability 3,102,355 4,347,710 8,745,508 2,000,000

Conversion of Preferred Stock (in shares) 2,575 0 17,166,666 3,400,001 6,129,666

Conversion of Stock, Shares Converted 2,575 2,575 698 510

Convertible preferred stock, shares outstanding 792 1,490 0 0 0

Accounts Payable and Accrued Liabilities 402,300

Preferred Stock Holder Whole Payment 540,000

Dividends, Preferred Stock, Stock 12,383

Number of Shares To be Purchased 131,894,033 112,778,485 16,503,340 7,499,999 54,426,222 6,249,995 10,227,270 24,999,999 9,375,000 9,375,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.08 $ 0.08 $ 0.08 $ 0.08 $ 0.08 $ 0.08 $ 0.08 $ 0.19 $ 0.08

Investment Warrants Expiration Date Jan. 25, 2016 Mar. 31, 2016 Jul. 11, 2016 Sep. 30, 2016 Feb. 02, 2017 Aug. 10, 2017

Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9) 416,286 402,300 202,500

Stock price at period end date $ 0.056 $ 0.093

Warrants Price Protection Provisions The Company's issuance of the following securities will not trigger the price protection provisions of the warrants described above that were issued in connection with the March 2008 private placement: (a) shares of common stock or standard options to the Company's directors, officers, employees or consultants pursuant to a board-approved equity compensation program or other contract or arrangement (up to an aggregate amount of 5,608,926, representing 5% of the common stock issued and outstanding immediately prior to March 31, 2008); (b) shares of common stock issued upon the conversion or exercise of any security, right or other instrument convertible or exchangeable into common stock (or securities exchangeable into common stock) issued prior to March 31, 2008; (c) the shares of common stock issued upon exercise of the warrants issued in March 2008; and (d) shares of common stock and warrants in connection with strategic alliances, acquisitions, mergers, and strategic partnerships, the primary purpose of which is not to raise capital, and which are approved in good faith by the Company's board of directors (up to an aggregate number of 11,217,852, representing 10% of the shares of common stock issued and outstanding immediately prior to March 31, 2008). On August 10, 2012, the Company's issuance of common stock triggered the price protection features of the warrants that were issued in March 2008 resulting in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 34,481,866 to 64,653,492. The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on January 25, 2011 and in March and April 2011: (I) (a) shares of common stock or options to employees, officers, or directors of the Company pursuant to plans approved by a majority of the non-employee directors of the Company or pursuant to independent contractors pursuant to other agreements or arrangements in existence as of January 24, 2011, (b) securities issued upon the exercise or exchange of or conversion of any securities issued under the Securities Purchase Agreement dated January 24, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on January 24, 2011, provided that such securities have not been amended since their issue date through the date of conversion, exercise or exchange to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (except certain adjustments to warrants expiring in March 2016 and September 2016 are not prohibited), and (c) shares of common stock or warrants to trade vendors of the Company approved by a majority of the non-employee members of the Board of Directors; provided that (II) (i) the shares issued under paragraphs I(a) and I(c) shall not, in the aggregate exceed 1,500,000 shares in each 30-day period during the first 90 days after January 24, 2011, (ii) there is a reasonable relationship between the value of the common stock or options issued pursuant to paragraphs I(a) and I(c) and the value of services rendered or goods provided and (iii) the Company does not rely in whole or in part on the exemptions provided in Sections 3(a)(9) or 3(a)(10) of the Securities Act. On August 10, 2012, the Company's triggering of the price protection features of the warrants that were issued on January 25, 2011 and in March and April 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 4,000,000 to 7,499,999. The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on August 10, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011, January 31, 2012 and August 8, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on August 8, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on July 8, 2011: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated July 8, 2011, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreement dated July 8, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on July 8, 2011, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in July 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 3,333,331 to 6,249,995. The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on February 2, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011 and January 31, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on February 2, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in February 2012 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 13,333,333 to 24,999,999.

Increase In Warrants 34,481,866 to 64,653,492. 4,000,000 to 7,499,999. 3,333,331 to 6,249,995. 13,333,333 to 24,999,999.

Net proceeds $ 725,000 $ 1,975,000

X

- Definition

The carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to make whole payments on convertible preferred stock.

+ References

No definition available.

+ Details

Name: gnbt_AccruedLiabilitiesMakeWholePaymentsOnConvertiblePreferredStockCurrent

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Additional preferred stock dividend rate percentage.

+ References

No definition available.

+ Details

Name: gnbt_AdditionalPreferredStockDividendRatePercentage

Namespace Prefix: gnbt_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of conversion price per share of preferred stock upon conversion.

+ References

No definition available.

+ Details

Name: gnbt_ConvertiblePreferredStockConversionPrice

Namespace Prefix: gnbt_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The increased percentage rate used to calculate dividend payments on preferred stock.

+ References

No definition available.

+ Details

Name: gnbt_IncreasedPreferredStockDividendRatePercentage

Namespace Prefix: gnbt_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition

Increase in number of warrants during the period.

+ References

No definition available.

+ Details

Name: gnbt_IncreaseInWarrants

Namespace Prefix: gnbt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of unpaid dividend during the year.

+ References

No definition available.

+ Details

Name: gnbt_PercentageOfUnpaidDividend

Namespace Prefix: gnbt_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount payable to preferred stock holder at the time of issuance.

+ References

No definition available.

+ Details

Name: gnbt_PreferredStockHolderWholePayment

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Disclosure of warrants issuance terms issued by the company during the period.

+ References

No definition available.

+ Details

Name: gnbt_WarrantsPriceProtectionProvisions

Namespace Prefix: gnbt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expiration date of warrants held.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 13

-Sentence Column A

+ Details

Name: invest_InvestmentWarrantsExpirationDate

Namespace Prefix: invest_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 1, 5

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(1),(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 7

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The exercise price of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 4

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate amount of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ConversionOfStockAmountIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value of the gross liabilities less the gross assets of a derivative liability or group of derivative liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeLiabilityFairValueNet1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Equity impact of stock dividends for preferred shareholders declared by an entity during the period. This element includes paid and unpaid dividends declared during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 01-6

-Paragraph 14

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 405

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

+ Details

Name: us-gaap_DividendsPreferredStockStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 40

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1930-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The percentage rate used to calculate dividend payments on preferred stock.

+ References

No definition available.

+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Derivative Liabilities (Tables)
3 Months Ended

Oct. 31, 2012

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule Of Derivative Warrant Liability [Table Text Block]
The following summarizes the changes in the value of the derivative warrant liability from August 1, 2011 until October 31, 2012:

Value No. of Warrants

Balance at August 1, 2011 – Derivative warrant liability $ 8,745,508 80,234,017

Exercise of warrants classified as derivative liability (7,230,734 ) (49,863,260 )

Additional warrants issued in February 2012 financing 1,811,746 13,333,333

Additional warrants from price protection features of existing warrants 1,548,813 11,444,440

Decrease in fair value of derivative warrant liability (793,706 ) n/a

Balance at July 31, 2012 – Derivative warrant liability $ 4,081,627 55,148,530

Additional warrants issued in August 2012 financing 624,797 9,375,000

Additional warrants from price protection features of existing warrants 3,102,355 48,254,955

Decrease in fair value of derivative warrant liability (3,461,069 ) n/a

Balance at October 31, 2012 – Derivative warrant liability $ 4,347,710 112,778,485

Schedule of Derivative Liabilities at Fair Value [Table Text Block]
The key inputs used in the October 31, 2012 and July 31, 2012 fair value calculations were as follows:

October 31, 2012 July 31, 2012

Current exercise price $ 0.08 $ 0.15
Time to expiration 3.76 years 3.9 years
Risk-free interest rate 0.54 % 0.45 %
Estimated volatility 87 % 104 %
Dividend -0- -0-
Stock price at period end date $ 0.056 $ 0.093

X

- Definition

The tabular disclosure of change in the value of derivative warrant liability for the period.

+ References

No definition available.

+ Details

Name: gnbt_ScheduleOfChangesInValueOfDerivativeWarrantLiabilityTableTextBlock

Namespace Prefix: gnbt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of derivative liabilities at fair value.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6

Comprehensive Income and Loss (Details Textual) (USD $)
3 Months Ended

Oct. 31, 2012

Oct. 31, 2011

Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent $ 668,679 $ 275,644

X

- Definition

Amount before tax, net of reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency, which is attributable to the parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 49 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
3 Months Ended 204 Months Ended

Oct. 31, 2012

Oct. 31, 2011

Oct. 31, 2012

Cash Flows From Operating Activities:

Net income/(loss) $ (656,199) $ 336,354 $ (354,829,759)

Adjustments to reconcile net income/(loss) to net cash used in operating activities:

Depreciation and amortization 117,027 163,703 10,025,567

Minority Interest Share of Loss 0 0 (3,038,185)

Reduction of notes receivable - common stock in exchange for services rendered 0 0 423,882

Write-off of uncollectible notes receivable - common stock 0 0 391,103

Write-off of deferred offering costs 0 0 3,406,196

Write-off of abandoned patents 0 88,582 1,353,976

(Gain)/Loss on disposal of property and equipment (994,125) (639,680) (2,985,275)

Loss on extinguishment of debt 0 0 14,134,068

Common stock issued as employee compensation 0 11,783 4,011,938

Amortization of options and option modifications as stock compensation 9,993 22,690 3,421,219

Common stock issued for services rendered 114,250 48,195 14,621,529

Amortization of prepaid services in conjunction with common stock issuance 0 0 138,375

Non-cash compensation expense 0 0 45,390

Stock options and warrants issued for services rendered 0 0 7,956,723

Issuance of warrants as additional exercise right inducement 0 0 21,437,909

Preferred stock issued for services rendered 0 0 100

Treasury stock redeemed for non-performance of services 0 0 (138,000)

Amortization of deferred debt issuance costs and loan origination fees 0 0 2,405,629

Amortization of discount on convertible debentures 0 0 38,345,592

Common stock issued for interest on convertible debentures & preferred stock 188,514 212,490 1,431,218

Interest on short-term advance 0 0 22,190

Founders' shares transferred for services rendered 0 0 353,506

Fees in connection with refinancing of debt 0 0 113,274

Warrant repricing costs 0 0 3,198,604

Change in fair value of derivative liabilities (358,714) (3,128,459) 357,263 ^[1]

Changes in operating assets and liabilities (excluding the effects of acquisition):

Accounts receivable 0 6,774 (15,047)

Miscellaneous receivables 0 0 43,812

Inventory 0 216,011 (20,091)

Other current assets 85,452 28,949 (97,496)

Accounts payable and accrued expenses 559,973 (13,908) 15,583,913

Deferred revenue (20,769) (6,471) 236,563

Other, net 0 0 110,317

Net Cash Used in Operating Activities (954,598) (2,652,987) (217,553,996)

Cash Flows From Investing Activities:

Purchase of property and equipment 0 (2,416) (4,809,439)

Proceeds from sale of property and equipment 1,579,189 1,669,115 6,532,514

Costs incurred for patents (23,475) (39,621) (2,863,521)

Change in restricted cash 0 0 512,539

Proceeds from maturity of short term investments 0 0 195,242,918

Purchases of short-term investments 0 0 (195,242,918)

Cash received in conjunction with merger 0 0 82,232

Advances to Antigen Express, Inc. 0 0 (32,000)

Increase in officers' loans receivable 0 0 (1,126,157)

Change in deposits 0 0 (652,071)

Change in notes receivable - common stock 0 0 (91,103)

Change in due from related parties 0 0 (2,222,390)

Other, net 0 0 89,683

Net Cash Provided by/(Used in) Investing Activities 1,555,714 1,627,078 (4,579,713)

Cash Flows From Financing Activities:

Proceeds from short-term advance 0 0 325,179

Repayment of short-term advance 0 0 (347,369)

Proceeds from issuance of long-term debt 0 0 5,567,297

Repayment of long-term debt (1,534,577) (684,673) (8,597,276)

Repayment of obligations under capital lease 0 0 (83,002)

Change in due to related parties 0 0 154,541

Proceeds from exercise of warrants 0 0 45,728,281

Proceeds from exercise of stock options 0 0 5,003,793

Proceeds from minority interest investment 0 0 3,038,185

Proceeds from issuance of preferred stock 725,000 0 17,030,000

Redemption of SVR preferred stock 0 0 (100)

Proceeds from issuance of convertible debentures, net 0 0 40,704,930

Payment of costs associated with convertible debentures 0 0 (722,750)

Repayments of convertible debentures 0 0 (5,142,424)

Purchase of treasury stock 0 0 (483,869)

Proceeds from issuance of common stock, net 0 0 120,576,242

Purchase and retirement of common stock 0 0 (497,522)

Net Cash (Used in)/Provided by Financing Activities (809,577) (684,673) 222,254,136

Effect of Exchange Rates on Cash (817) (18,712) (83,396)

Net (Decrease)/Increase in Cash and Cash Equivalents (209,278) (1,729,294) 37,031

Cash and Cash Equivalents, Beginning of Period 246,309 2,798,797

Cash and Cash Equivalents, End of Period 37,031 1,069,503 37,031

Supplemental Cash Flow Information [Abstract]

Interest 117,975 34,921

Income taxes $ 0 $ 0

[1] includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to October 31, 2012" column. See Note 10 - Derivative Liabilities.

X

- Definition

The cash outflow from the payment of advances to antigen express during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_AdvancesToAntigenExpress

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amortization of deferred debt issuance costs and loan origination fees during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_AmortizationOfDeferredDebtIssuanceCostsLoanOriginationFees

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The total amount of amortization of options and option modifications as employee compensation during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_AmortizationOfOptionsAndOptionModificationsAsEmployeeCompensation

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The total amortization of prepaid services in conjunction with common stock issuance by the entity during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_AmortizationOfPrepaidServicesInConjunctionWithCommonStockIssuance

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow from the payment of change in notes receivable common stock during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_ChangeInNotesReceivableCommonStock

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Common stock issued as interest payment on convertible debentures during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_CommonStockIssuedAsInterestPaymentOnConvertibleDebentures

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The noncash expense that accounts for the value of common stock distributed to employees for services rendered.

+ References

No definition available.

+ Details

Name: gnbt_CommonStockIssuedForServicesRendered

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The total amount of Fees incurred in connection with refinancing of debt by the entity during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_FeesInConnectionWithRefinancingOfDebt

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Founders' shares transferred for services rendered during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_FoundersSharesTransferredForServicesRendered

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The non cash expenses incurred for issuance of warrants as additional exercise right inducement during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_IssuanceOfWarrantsAdditionalExerciseRightInducement

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow from the payment of costs associated with convertible debentures by the entity during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_PaymentOfCostsAssociatedWithConvertibleDebentures

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The noncash expense that accounts for the value of preferred stock issued for services rendered.

+ References

No definition available.

+ Details

Name: gnbt_PreferredStockIssuedForServicesRendered

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The fair value of reduction in notes receivable and common stock granted for services rendered.

+ References

No definition available.

+ Details

Name: gnbt_ReductionOfNotesReceivableCommonStockExchangeForServicesRendered

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The value of treasury stock redeemed for non performance of services during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_TreasuryStockRedeemedForNonPerformanceOfServices

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The non cash expenses incurred for repricing the warrants by the entity during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_WarrantRepricingCosts

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The total amount of write-off in uncollectible notes receivable in relation to common stock during the reporting period.

+ References

No definition available.

+ Details

Name: gnbt_WriteOffOfUncollectibleNotesReceivableCommonStock

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 21

-Paragraph 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph a(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAcquiredFromAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Net Increase or Decrease in the fair value of the derivative or group of derivatives included in earnings.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The effect of exchange rate changes on cash balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 26

-Paragraph 20, 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in receivables to be collected from the reporting entity's executives and owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseDueFromOfficersAndStockholders

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 230

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3095-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Audit and Accounting Guide (AAG)

-Number AAG-DEP

-IssueDate 2006-05-01

-Chapter 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncreaseDecreaseInDeposits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities less other operating liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets and liabilities, other noncurrent assets and liabilities, or a combination of other current and noncurrent assets and liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Interest and debt related expenses associated with nonoperating financing activities of the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 34

-Paragraph 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

+ Details

Name: us-gaap_InterestAndDebtExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of Net Income (Loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=18733213&loc=SL4591551-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A1, A4, A5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3095-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3098-108585

+ Details

Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire common stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire other equity not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsForRepurchaseOfOtherEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire preferred stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Section Appendix C

-Paragraph 5

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Section Appendix C

-Paragraph 5

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow contributed by noncontrolled interest that purchase additional shares or otherwise increase their ownership stake in a subsidiary of the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromMinorityShareholders

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RepaymentsOfConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.

+ References

No definition available.

+ Details

Name: us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RepaymentsOfShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_WriteOffOfDeferredDebtIssuanceCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 50 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounts Payable and Accrued Expenses
3 Months Ended

Oct. 31, 2012

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]
Note 5 – Accounts Payable and Accrued Expenses:

Accounts payable and accrued expenses consist of the following:

October 31, 2012 July 31, 2012

Accounts Payable & Accruals – General and Administrative $ 3,971,015 $ 3,556,160

Accounts Payable & Accruals – Research and Development 2,822,961 2,691,192

Accounts Payable & Accruals – Selling and Marketing 311,329 290,534

Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9) 416,286 402,300

Executive Compensation and Directors’ Fees Payable 256,141 75,466

Total $ 7,777,732 $ 7,015,652

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6

Accounts Payable and Accrued Expenses (Details) (USD $)

Oct. 31, 2012

Jul. 31, 2012

Accounts Payable & Accruals General and Administrative $ 3,971,015 $ 3,556,160

Accounts Payable & Accruals Research and Development 2,822,961 2,691,192

Accounts Payable & Accruals Selling and Marketing 311,329 290,534

Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9) 416,286 402,300

Executive Compensation and Directors' Fees Payable 256,141 75,466

Total $ 7,777,732 $ 7,015,652

X

- Definition

The carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to general and administrative.

+ References

No definition available.

+ Details

Name: gnbt_AccountsPayableAndAccruedLiabilitiesGeneralAndAdministrativeCurrent

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to research and development.

+ References

No definition available.

+ Details

Name: gnbt_AccountsPayableAndAccruedLiabilitiesResearchAndDevelopmentCurrent

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to make whole payments on convertible preferred stock.

+ References

No definition available.

+ Details

Name: gnbt_AccruedLiabilitiesMakeWholePaymentsOnConvertiblePreferredStockCurrent

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

No definition available.

+ Details

Name: us-gaap_AccruedMarketingCostsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 91 241 1 true 38 0 false 5 false false R1.htm 001 - Document - DOCUMENT AND ENTITY INFORMATION Sheet http://www.generex.com/role/DocumentAndEntityInformation DOCUMENT AND ENTITY INFORMATION true false R2.htm 002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.generex.com/role/StatementOfFinancialPositionClassified CONSOLIDATED BALANCE SHEETS false false R3.htm 003 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://www.generex.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS [Parenthetical] false false R4.htm 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.generex.com/role/StatementOfIncome CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.generex.com/role/StatementOfCashFlowsIndirect CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 006 - Document - Basis of Presentation Sheet http://www.generex.com/role/OrganizationAndBusiness Basis of Presentation false false R7.htm 007 - Disclosure - Effects of Recent Accounting Pronouncements Sheet http://www.generex.com/role/EffectsOfRecentAccountingPronouncements Effects of Recent Accounting Pronouncements false false R8.htm 008 - Disclosure - Stock-Based Compensation Sheet http://www.generex.com/role/StockBasedCompensation Stock-Based Compensation false false R9.htm 009 - Disclosure - Comprehensive Income and Loss Sheet http://www.generex.com/role/ComprehensiveIncomeAndLoss Comprehensive Income and Loss false false R10.htm 010 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://www.generex.com/role/AccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses false false R11.htm 011 - Disclosure - Pending Litigation Sheet http://www.generex.com/role/PendingLitigation Pending Litigation false false R12.htm 012 - Disclosure - Commitments Sheet http://www.generex.com/role/CommitmentsAndContingentLiabilities Commitments false false R13.htm 013 - Disclosure - Net (Loss)/Income Per Share ("EPS") Sheet http://www.generex.com/role/NetLossPerShareEPS Net (Loss)/Income Per Share ("EPS") false false R14.htm 014 - Disclosure - Stockholders' Deficiency Sheet http://www.generex.com/role/StockholdersEquity Stockholders' Deficiency false false R15.htm 015 - Disclosure - Derivative Liabilities Sheet http://www.generex.com/role/DerivativeLiabilities Derivative Liabilities false false R16.htm 016 - Disclosure - Income from Assets Held for Investment, net: Sheet http://www.generex.com/role/IncomeFromAssetsHeldForInvestmentNet Income from Assets Held for Investment, net: false false R17.htm 017 - Disclosure - Subsequent Events Sheet http://www.generex.com/role/SubsequentEvents Subsequent Events false false R18.htm 018 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.generex.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) false false R19.htm 019 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.generex.com/role/AccountsPayableAndAccruedExpensesTable Accounts Payable and Accrued Expenses (Tables) false false R20.htm 020 - Disclosure - Stockholders' Deficiency (Tables) Sheet http://www.generex.com/role/StockholdersDeficiencyTables Stockholders' Deficiency (Tables) false false R21.htm 021 - Disclosure - Derivative Liabilities (Tables) Sheet http://www.generex.com/role/DerivativeLiabilitiesTables Derivative Liabilities (Tables) false false R22.htm 022 - Disclosure - Basis of Presentations (Details Textual) Sheet http://www.generex.com/role/OrganizationAndBusinessDetailsTextual Basis of Presentations (Details Textual) false false R23.htm 023 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.generex.com/role/StockBasedCompensationDetails1 Stock-Based Compensation (Details) false false R24.htm 024 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://www.generex.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details 1) false false R25.htm 025 - Disclosure - Stock-Based Compensation (Details Textual) Sheet http://www.generex.com/role/StockBasedCompensationDetailsTextual Stock-Based Compensation (Details Textual) false false R26.htm 026 - Disclosure - Comprehensive Income and Loss (Details Textual) Sheet http://www.generex.com/role/ComprehensiveIncomeandLossDetails Comprehensive Income and Loss (Details Textual) false false R27.htm 027 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://www.generex.com/role/AccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) false false R28.htm 028 - Disclosure - Pending Litigation (Details Textual) Sheet http://www.generex.com/role/PendingLitigationDetailsTexuals Pending Litigation (Details Textual) false false R29.htm 029 - Disclosure - Net Loss per Share (Details Textual) Sheet http://www.generex.com/role/NetLossPerShareDetailsTextual Net Loss per Share (Details Textual) false false R30.htm 030 - Disclosure - Stockholders' Deficiency (Details) Sheet http://www.generex.com/role/StockholdersDeficiencyEquityDetails Stockholders' Deficiency (Details) false false R31.htm 031 - Disclosure - Stockholders' Deficiency (Details 1) Sheet http://www.generex.com/role/StockholdersDeficiencyEquityDetailsTextual Stockholders' Deficiency (Details 1) false false R32.htm 032 - Disclosure - Stockholders' Deficiency (Details 2) Sheet http://www.generex.com/role/StockholdersDeficiencyDetails Stockholders' Deficiency (Details 2) false false R33.htm 033 - Disclosure - Stockholders' Deficiency (Details 3) Sheet http://www.generex.com/role/StockholdersDeficiencyDetails3 Stockholders' Deficiency (Details 3) false false R34.htm 034 - Disclosure - Stockholders' Deficiency (Details Textual) Sheet http://www.generex.com/role/SeriesAndB9ConvertiblePreferredStockDetailsTextual Stockholders' Deficiency (Details Textual) false false R35.htm 035 - Disclosure - Derivative Liabilities (Details) Sheet http://www.generex.com/role/DerivativeLiabilitiesDetailsNew Derivative Liabilities (Details) false false R36.htm 036 - Disclosure - Derivative Liabilities (Details 1) Sheet http://www.generex.com/role/DerivativeLiabilitiesDetails1 Derivative Liabilities (Details 1) false false R37.htm 037 - Disclosure - Derivative Liabilities (Details Textual) Sheet http://www.generex.com/role/DerivativeLiabilitiesDetailsTextual Derivative Liabilities (Details Textual) false false R38.htm 038 - Disclosure - Income from Assets Held for Investment, net (Details Textuals) Sheet http://www.generex.com/role/IncomeFromAssetsHeldForInvestmentNetDetailsTextuals Income from Assets Held for Investment, net (Details Textuals) false false R39.htm 039 - Disclosure - Subsequent Events (Details Textual) Sheet http://www.generex.com/role/SubsequentEventsDetailsTextual Subsequent Events (Details Textual) false false All Reports Book All Reports Element gnbt_CounterClaim had a mix of decimals attribute values: -5 0. Process Flow-Through: 002 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Oct. 31, 2011' Process Flow-Through: Removing column 'Jul. 31, 2011' Process Flow-Through: 003 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical] Process Flow-Through: Removing column 'Jan. 31, 2012' Process Flow-Through: Removing column 'Oct. 31, 2011' Process Flow-Through: 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS gnbt-20121031.xml gnbt-20121031.xsd gnbt-20121031_cal.xml gnbt-20121031_def.xml gnbt-20121031_lab.xml gnbt-20121031_pre.xml true true XML 53 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6

Income from Assets Held for Investment, net (Details Textuals) (USD $)
1 Months Ended 3 Months Ended 204 Months Ended

Sep. 30, 2012

Aug. 31, 2011

Oct. 31, 2012

Oct. 31, 2011

Oct. 31, 2012

Proceeds from sale of property and equipment $ 1,579,189 $ 1,669,115 $ 1,579,189 $ 1,669,115 $ 6,532,514

Book Value Of Property Sold 585,064 1,029,435

(Gain)/Loss on disposal of property and equipment 994,125 639,680 994,125 639,680 2,985,275

Mortgage On Property Remaining Principal Amount Discharged Upon Sale 480,951 659,288

Proceeds From Sale Of Property Remaining Amount 1,028,780 1,009,827

Income from assets held for investment, net (Note 11) $ 1,042,868 $ 712,075 $ 5,377,125

X

- Definition

Carrying book value of property and sold

+ References

No definition available.

+ Details

Name: gnbt_BookValueOfPropertySold

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount attributable to mortgage on the property with remaining principal amount which was discharged upon sale.

+ References

No definition available.

+ Details

Name: gnbt_MortgageOnPropertyRemainingPrincipalAmountDischargedUponSale

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The remaining net proceeds after expenses and discharge of the mortgage.

+ References

No definition available.

+ Details

Name: gnbt_ProceedsFromSaleOfPropertyRemainingAmount

Namespace Prefix: gnbt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_RentalIncomeNonoperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 54 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Deficiency (Tables)
3 Months Ended

Oct. 31, 2012

Schedule of Stockholders Equity [Table Text Block]
The stockholders’ deficiency transactions as described above are summarized below:

Additional Change to

Common Stock Paid-In Stockholders’

Shares Amount Capital Equity

Issuance of common stock on conversion of convertible preferred stock 8,727,498 $ 8,727 $ (8,727 ) $ —

Issuance of common stock as make whole payments on convertible preferred stock 6,005,443 6,005 182,509 188,514

Issuance of common stock for services 1,366,666 1,367 112,883 114,250

Amortization of stock options as employee compensation — — 9,993 9,993

Total 16,099,607 $ 16,099 $ 296,658 $ 312,757

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Warrants
The following is a summary of warrants issued, forfeited or expired and exercised for the three months ended October 31, 2012:
Warrants
Outstanding, August 1, 2012 74,264,078
Issued 57,629,955
Outstanding, October 31, 2012 131,894,033

Series B Convertible Preferred Stock [Member]

Schedule of Servicing Liabilities at Fair Value [Table Text Block]
The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:

Accounting allocation of initial proceeds
Net proceeds $ 1,975,000
Derivative warrant liability fair value (1,811,746 )
Make whole payments liability (540,000 )
Deemed dividend $ (376,746 )

Series C Convertible Preferred Stock [Member]

Schedule of Servicing Liabilities at Fair Value [Table Text Block]
The fair values assigned to each component and the calculation of the amount of the deemed dividend are as follows:

Accounting allocation of initial proceeds
Net proceeds $ 725,000
Derivative warrant liability fair value (624,797 )
Make whole payments liability (202,500 )
Deemed dividend $ (102,297 )

X

- Definition

Tabular disclosure of the activity in the balance of servicing liabilities subsequently measured at fair value (including a description of where changes in fair value are reported in the statement of income for each period for which results of operations are presented), including but not limited to, the following: beginning and ending balances, additions (through assumptions of servicing obligations, and servicing obligations that result from transfers of financial assets), disposals, changes in fair value during the period resulting from changes in inputs or assumptions used in the valuation model, other changes in fair value and a description of those changes, and other changes that affect the balance and a description of those changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 860

-SubTopic 50

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7882072&loc=d3e122625-111746

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph B9

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 140

-Paragraph 17

-Subparagraph f(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ScheduleOfServicingLiabilitiesAtFairValueTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number D-98

-Paragraph 2

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Net Loss per Share (Details Textual)	3 Months Ended
Net Loss per Share (Details Textual)	Oct. 31, 2012	Oct. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	162,146,167
Outstanding Stock Options	5,424	110,086,551
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	110,086,551

Pending Litigation (Details Textual) (USD $)	0 Months Ended	1 Months Ended			3 Months Ended				1 Months Ended
Pending Litigation (Details Textual) (USD $)	Nov. 16, 2012	Dec. 31, 2011	Sep. 30, 2011	Aug. 31, 2011	Oct. 31, 2012	May 20, 2011 Employment Termination [Member]	Jun. 01, 2011 Breach Of Contract [Member]	Jun. 01, 2011 Punitive Damage [Member]	Dec. 31, 2011 Vendors Breach Of Contract [Member]
Loss Contingency, Range of Possible Loss, Minimum						$ 7,000,000
Loss Contingency, Estimate of Possible Loss							550,000	50,000
Loss Contingency, Inestimable Loss									429,000
The counter claim made against the party.		200,000	2,300,000
Proceeds from Sale of Real Estate				1,730,000
Loss Contingency, Damages Sought, Value	125,000
Loss Contingency Contingent Interest Rate Term					amount of the claim plus interest of 3% per annum
Loss Contingency Costs Fixed					$ 25,000

Stockholders' Deficiency (Details) (USD $)	3 Months Ended		204 Months Ended
Stockholders' Deficiency (Details) (USD $)	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012
Issuance of common stock on conversion of convertible preferred stock		$ 0
Issuance of common stock on conversion of convertible preferred stock (in shares)		0
Common stock issued as employee compensation	0	11,783	4,011,938
Common Stock [Member]
Issuance of common stock on conversion of convertible preferred stock	8,727
Issuance of common stock on conversion of convertible preferred stock (in shares)	8,727,498
Issuance of common stock as make whole payments on convertible preferred stock	6,005
Issuance of common stock as make whole payments on convertible preferred stock (in shares)	6,005,443
Issuance of common stock for services	1,367
Issuance of common stock for services (in shares)	1,366,666
Common stock issued as employee compensation	0
Total	16,099
Total (in shares)	16,099,607
Additional Paid-In Capital [Member]
Issuance of common stock on conversion of convertible preferred stock	(8,727)
Issuance of common stock as make whole payments on convertible preferred stock	182,509
Issuance of common stock for services	112,883
Common stock issued as employee compensation	9,993
Total (in shares)	296,658
Change To Stockholder Equity [Member]
Issuance of common stock on conversion of convertible preferred stock	0
Issuance of common stock as make whole payments on convertible preferred stock	188,514
Issuance of common stock for services	114,250
Common stock issued as employee compensation	$ 9,993
Total (in shares)	312,757

Stockholders' Deficiency (Details 1)	3 Months Ended	12 Months Ended
Stockholders' Deficiency (Details 1)	Oct. 31, 2012	Jul. 31, 2012
No. of Warrants - Derivative warrant liability	112,778,485	16,503,340
Warrants Issued	48,254,955	(49,863,260)
No. of Warrants - Derivative warrant liability	131,894,033	112,778,485
Warrant [Member]
No. of Warrants - Derivative warrant liability	74,264,078
Warrants Issued	57,629,955
No. of Warrants - Derivative warrant liability	131,894,033

Stockholders' Deficiency (Details 2) (USD $)	3 Months Ended	12 Months Ended
Stockholders' Deficiency (Details 2) (USD $)	Oct. 31, 2012	Jul. 31, 2012
Net proceeds	$ 725,000	$ 1,975,000
Derivative warrant liability fair value	(624,797)	(1,811,746)
Make whole payments liability	(202,500)	(540,000)
Deemed dividend	$ (102,297)	$ (376,746)

CONSOLIDATED BALANCE SHEETS (USD $)	Oct. 31, 2012	Jul. 31, 2012
ASSETS
Cash and cash equivalents	$ 37,031	$ 246,309
Other current assets	116,256	200,552
Total Current Assets	153,287	446,861
Property and Equipment, Net	118,776	704,678
Assets Held for Investment, Net	852,832	858,377
Patents, Net	2,561,090	2,634,458
TOTAL ASSETS	3,685,985	4,644,374
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Accounts payable and accrued expenses (Note 5)	7,777,732	7,015,652
Deferred revenue	242,356	263,125
Current maturities of long-term debt	156,596	1,222,746
Total Current Liabilities	8,176,684	8,501,523
Long-Term Debt, Net	0	441,415
Derivative Warrant Liability (Note 10)	4,347,710	4,081,627
Total Liabilities	12,524,394	13,024,565
Commitments and Contingencies (Notes 6 and 7)
Stockholders' Deficiency (Note 9):
Common stock, $.001 par value; authorized 750,000,000 shares at October 31, 2012 and July 31, 2012, respectively; 370,260,904 and 354,161,297 shares issued and outstanding at October 31, 2012 and July 31, 2012, respectively	370,261	354,161
Additional paid-in capital	348,396,471	348,099,813
Deficit accumulated during the development stage	(358,370,276)	(357,611,780)
Accumulated other comprehensive income	765,135	777,615
Total Stockholders' Deficiency	(8,838,409)	(8,380,191)
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY)/EQUITY	3,685,985	4,644,374
Series A Convertible Preferred Stock [Member]
Stockholders' Deficiency (Note 9):
Preferred Stock Value	0	0
Series B Convertible Preferred Stock [Member]
Stockholders' Deficiency (Note 9):
Preferred Stock Value	0	0
Series C Convertible Preferred Stock [Member]
Stockholders' Deficiency (Note 9):
Preferred Stock Value	$ 0	$ 0

Derivative Liabilities (Details) (USD $)	3 Months Ended	12 Months Ended					3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended
Derivative Liabilities (Details) (USD $)	Oct. 31, 2012	Jul. 31, 2012	Aug. 31, 2011	Oct. 31, 2012 Warrant [Member]	Jul. 31, 2012 Warrant [Member]	Jul. 31, 2011 Warrant [Member]	Oct. 31, 2012 Warrants Isssued August 2012 [Member]	Jul. 31, 2012 Warrants Isssued February 2012 [Member]	Oct. 31, 2012 Additional Warrants [Member]	Jul. 31, 2012 Additional Warrants [Member]	Oct. 31, 2012 Warrant Fair Value [Member]	Jul. 31, 2012 Warrant Fair Value [Member]	Jul. 31, 2012 Warrant Exercised [Member]
Balance - Derivative warrant liability Value	$ 4,347,710		$ 8,745,508	$ 4,347,710	$ 4,081,627	$ 8,745,508
Additional warrants issued in financing		(7,230,734)					624,797	1,811,746	3,102,355	1,548,813	(3,461,069)	(793,706)	(7,230,734)
Balance - Derivative warrant liability Value	$ 3,102,355	$ 4,347,710	$ 8,745,508	$ 4,347,710	$ 4,081,627	$ 8,745,508
No. of Warrants - Derivative warrant liability	112,778,485	16,503,340		112,778,485	55,148,530	80,234,017
Warrants Issued	48,254,955	(49,863,260)					9,375,000	13,333,333	48,254,955	11,444,440
Warrants Exercised													(49,863,260)
No. of Warrants - Derivative warrant liability	131,894,033	112,778,485		112,778,485	55,148,530	80,234,017

Basis of Presentations (Details Textual) (USD $)	3 Months Ended	12 Months Ended
Basis of Presentations (Details Textual) (USD $)	Oct. 31, 2012	Jul. 31, 2012
License and Services Revenue	$ 600,000	$ 600,000
Deficit accumulated during the development stage	358,370,276	357,611,780
Working Capital Deficiency		$ 8,000,000

Derivative Liabilities (Details 1) (USD $)	3 Months Ended	12 Months Ended
Derivative Liabilities (Details 1) (USD $)	Oct. 31, 2012	Jul. 31, 2012
Current exercise price	$ 0.08	$ 0.15
Time to expiration	3 years 9 months 3 days	3 years 10 months 28 days
Risk-free interest rate	0.54%	0.45%
Estimated volatility	87.00%	104.00%
Dividend	0.00%	0.00%
Stock price at period end date	$ 0.056	$ 0.093

Stock-Based Compensation (Details 1) (USD $)	3 Months Ended
Stock-Based Compensation (Details 1) (USD $)	Oct. 31, 2012
Outstanding, October 31, 2012	172,500
Granted	0
Vested	(86,250)
Forfeited	0
Outstanding, October 31, 2012	86,250
Outstanding, August 1, 2012	$ 0.46
Granted	$ 0.00
Vested	$ 0.46
Forfeited	$ 0.00
Outstanding	$ 0.46

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Oct. 31, 2012	Jul. 31, 2012
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	370,260,904	354,161,297
Common stock, shares outstanding	370,260,904	354,161,297
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%
Series A Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Convertible preferred stock, shares authorized	5,500	5,500
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Convertible preferred stock, shares authorized	2,000	2,000
Convertible preferred stock, shares issued	792	1,490
Convertible preferred stock, shares outstanding	792	1,490
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%
Series C Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Convertible preferred stock, shares authorized	750	0
Convertible preferred stock, shares issued	750	0
Convertible preferred stock, shares outstanding	0	0
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%

DOCUMENT AND ENTITY INFORMATION	3 Months Ended
DOCUMENT AND ENTITY INFORMATION	Oct. 31, 2012	Dec. 07, 2012
Entity Registrant Name	GENEREX BIOTECHNOLOGY CORP
Entity Central Index Key	0001059784
Current Fiscal Year End Date	--07-31
Entity Filer Category	Accelerated Filer
Trading Symbol	gnbt
Entity Common Stock, Shares Outstanding		372,059,685
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Oct. 31, 2012
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2013

Commitments	3 Months Ended
Commitments	Oct. 31, 2012
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 7 – Commitments: On December 7, 2009, the Company entered into a long-term agreement with sanofi-aventis Deutschland GmbH (“sanofi”). Under this agreement, sanofi-aventis will manufacture and supply recombinant human insulin to the Company in the territories specified in the agreement. Through this agreement, the Company will procure recombinant human insulin crystals for use in the production of Generex Oral-lyn™. The terms of the supply agreement require the Company to make certain minimum purchases of insulin from sanofi through the period ended December 31, 2011.To date, the Company has not met the minimum purchase commitments under this agreement. After December 31, 2011, sanofi may terminate the agreement due to the Company’s failure to meet such purchase commitments. Upon termination, the Company would be obligated to pay sanofi for all materials and components that it has acquired or ordered to manufacture insulin based on the Company’s forecasts or minimum purchase commitments, all related work-in-progress (at cost) and all finished insulin in inventory. To date, the Company has not provided forecasts to sanofi for the purchase of insulin and sanofi has not terminated the agreement.

Stock-Based Compensation (Details) (USD $)	3 Months Ended
Stock-Based Compensation (Details) (USD $)	Oct. 31, 2012
Outstanding, August 1, 2012	10,979,634
Granted	0
Forfeited or expired	0
Exercised	0
Outstanding, October 31, 2012	10,979,634
Exercisable, October 31, 2012	10,893,384
Outstanding, August 1, 2012	$ 0.257
Outstanding, October 31, 2012	$ 0.257
Exercisable, October 31, 2012	$ 0.254
Outstanding, October 31, 2012	$ 277,615
Exercisable, October 31, 2012	$ 277,615

Stockholders' Deficiency (Details Textual) (USD $)	3 Months Ended		12 Months Ended				3 Months Ended								3 Months Ended					3 Months Ended				3 Months Ended			3 Months Ended
Stockholders' Deficiency (Details Textual) (USD $)	Oct. 31, 2012	Oct. 31, 2011	Jul. 31, 2012	Jul. 31, 2005	Aug. 31, 2011	Jul. 31, 2011	Oct. 31, 2012 Warrant One [Member]	Oct. 31, 2012 Warrant Two [Member]	Oct. 31, 2012 Warrant Three [Member]	Oct. 31, 2012 Warrant Four [Member]	Oct. 31, 2012 Warrant Five [Member]	Oct. 31, 2012 Warrant Six [Member]	Oct. 31, 2012 Warrant [Member]	Feb. 02, 2012 Investment Rights Liability Stock [Member]	Oct. 31, 2012 Series A Convertible Preferred Stock [Member]	Jul. 31, 2012 Series A Convertible Preferred Stock [Member]	Sep. 30, 2011 Series A Convertible Preferred Stock [Member]	Jul. 31, 2011 Series A Convertible Preferred Stock [Member]	Jul. 08, 2011 Series A Convertible Preferred Stock [Member]	Oct. 31, 2012 Series B Convertible Preferred Stock [Member]	Jul. 31, 2012 Series B Convertible Preferred Stock [Member]	Jan. 31, 2012 Series B Convertible Preferred Stock [Member]	Oct. 31, 2011 Series B Convertible Preferred Stock [Member]	Oct. 31, 2012 Series C Convertible Preferred Stock [Member]	Jul. 31, 2012 Series C Convertible Preferred Stock [Member]	Oct. 31, 2011 Series C Convertible Preferred Stock [Member]	Jul. 31, 2012 Common Stock [Member]	Oct. 31, 2012 Warrant Agreement Date March 2008 [Member]	Oct. 31, 2012 Warrant Agreement Date January March and April 2011 [Member]	Oct. 31, 2012 Warrant Agreement Date August 2012 [Member]	Oct. 31, 2012 Warrant Agreement Date July 2011 [Member]	Oct. 31, 2012 Warrant Agreement Date February 2012 [Member]
Convertible preferred stock, shares authorized																			5,500	2,000	2,000	2,000	0	750	0	750
Convertible preferred stock, par value (in dollars per share)																			$ 1,000	$ 1,000	$ 1,000	$ 1,000	$ 1,000	$ 1,000	$ 1,000	$ 1,000
Convertible preferred stock, shares issued																			2,575	792	1,490	2,000	0	750	0	750
Incremental Common Shares Attributable to Conversion of Preferred Stock	6,129,666														17,166,666			17,166,666				13,333,333
Convertible Preferred Stock Conversion Price																		$ 0.15				$ 0.15
Preferred Stock, Dividend Rate, Percentage																				9.00%
Additional Preferred Stock Dividend Rate Percentage																				3				3
Conversion of Preferred Stock		$ 0		$ 0																$ 270				$ 270
Conversion of Stock, Amount Converted																				1,000				1,000
Percentage Of Unpaid Dividend																				18
Increased Preferred Stock Dividend Rate Percentage																				18				9
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants																								18
Balance at July 31, 2012 - Derivative warrant liability	3,102,355		4,347,710		8,745,508									2,000,000
Conversion of Preferred Stock (in shares)		2,575		0												17,166,666					3,400,001						6,129,666
Conversion of Stock, Shares Converted		2,575														2,575				698	510
Convertible preferred stock, shares outstanding																				792	1,490		0	0	0
Accounts Payable and Accrued Liabilities																					402,300
Preferred Stock Holder Whole Payment																					540,000
Dividends, Preferred Stock, Stock																	12,383
Number of Shares To be Purchased	131,894,033		112,778,485			16,503,340	7,499,999	54,426,222	6,249,995	10,227,270	24,999,999	9,375,000												9,375,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08						$ 0.08	$ 0.08	$ 0.08	$ 0.08	$ 0.08	$ 0.08	$ 0.19											$ 0.08
Investment Warrants Expiration Date							Jan. 25, 2016	Mar. 31, 2016	Jul. 11, 2016	Sep. 30, 2016	Feb. 02, 2017	Aug. 10, 2017
Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9)	416,286		402,300																					202,500
Stock price at period end date	$ 0.056		$ 0.093
Warrants Price Protection Provisions																												The Company's issuance of the following securities will not trigger the price protection provisions of the warrants described above that were issued in connection with the March 2008 private placement: (a) shares of common stock or standard options to the Company's directors, officers, employees or consultants pursuant to a board-approved equity compensation program or other contract or arrangement (up to an aggregate amount of 5,608,926, representing 5% of the common stock issued and outstanding immediately prior to March 31, 2008); (b) shares of common stock issued upon the conversion or exercise of any security, right or other instrument convertible or exchangeable into common stock (or securities exchangeable into common stock) issued prior to March 31, 2008; (c) the shares of common stock issued upon exercise of the warrants issued in March 2008; and (d) shares of common stock and warrants in connection with strategic alliances, acquisitions, mergers, and strategic partnerships, the primary purpose of which is not to raise capital, and which are approved in good faith by the Company's board of directors (up to an aggregate number of 11,217,852, representing 10% of the shares of common stock issued and outstanding immediately prior to March 31, 2008). On August 10, 2012, the Company's issuance of common stock triggered the price protection features of the warrants that were issued in March 2008 resulting in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 34,481,866 to 64,653,492.	The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on January 25, 2011 and in March and April 2011: (I) (a) shares of common stock or options to employees, officers, or directors of the Company pursuant to plans approved by a majority of the non-employee directors of the Company or pursuant to independent contractors pursuant to other agreements or arrangements in existence as of January 24, 2011, (b) securities issued upon the exercise or exchange of or conversion of any securities issued under the Securities Purchase Agreement dated January 24, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on January 24, 2011, provided that such securities have not been amended since their issue date through the date of conversion, exercise or exchange to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (except certain adjustments to warrants expiring in March 2016 and September 2016 are not prohibited), and (c) shares of common stock or warrants to trade vendors of the Company approved by a majority of the non-employee members of the Board of Directors; provided that (II) (i) the shares issued under paragraphs I(a) and I(c) shall not, in the aggregate exceed 1,500,000 shares in each 30-day period during the first 90 days after January 24, 2011, (ii) there is a reasonable relationship between the value of the common stock or options issued pursuant to paragraphs I(a) and I(c) and the value of services rendered or goods provided and (iii) the Company does not rely in whole or in part on the exemptions provided in Sections 3(a)(9) or 3(a)(10) of the Securities Act. On August 10, 2012, the Company's triggering of the price protection features of the warrants that were issued on January 25, 2011 and in March and April 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 4,000,000 to 7,499,999.	The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on August 10, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011, January 31, 2012 and August 8, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on August 8, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.	The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on July 8, 2011: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated July 8, 2011, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreement dated July 8, 2011 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on July 8, 2011, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in July 2011 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 3,333,331 to 6,249,995.	The Company's issuance of the following securities will not trigger the price protection provisions of the warrants issued on February 2, 2012: (I)(a) shares of common stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of common stock issued to the vendors identified in Securities Purchase Agreement dated January 31, 2012, in the periodic amounts set forth therein, (c) securities upon the exercise or exchange of or conversion of any Securities issued under the Securities Purchase Agreements dated July 8, 2011 and January 31, 2012 and/or other securities exercisable or exchangeable for or convertible into shares of common stock issued and outstanding on February 2, 2012, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. On August 10, 2012, the triggering of the price protection features of the warrants that were issued in February 2012 resulted in a decrease of the exercise price from $0.15 to $0.08 per share and an increase in the number of warrants from 13,333,333 to 24,999,999.
Increase In Warrants																												34,481,866 to 64,653,492.	4,000,000 to 7,499,999.		3,333,331 to 6,249,995.	13,333,333 to 24,999,999.
Net proceeds	$ 725,000		$ 1,975,000

Comprehensive Income and Loss (Details Textual) (USD $)	3 Months Ended
Comprehensive Income and Loss (Details Textual) (USD $)	Oct. 31, 2012	Oct. 31, 2011
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent	$ 668,679	$ 275,644

Accounts Payable and Accrued Expenses (Details) (USD $)	Oct. 31, 2012	Jul. 31, 2012
Accounts Payable & Accruals General and Administrative	$ 3,971,015	$ 3,556,160
Accounts Payable & Accruals Research and Development	2,822,961	2,691,192
Accounts Payable & Accruals Selling and Marketing	311,329	290,534
Accrued Make Whole Payments on Convertible Preferred Stock (see Note 9)	416,286	402,300
Executive Compensation and Directors' Fees Payable	256,141	75,466
Total	$ 7,777,732	$ 7,015,652

Income from Assets Held for Investment, net (Details Textuals) (USD $)	1 Months Ended		3 Months Ended		204 Months Ended
	Sep. 30, 2012	Aug. 31, 2011	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012
Proceeds from sale of property and equipment	$ 1,579,189	$ 1,669,115	$ 1,579,189	$ 1,669,115	$ 6,532,514
Book Value Of Property Sold	585,064	1,029,435
(Gain)/Loss on disposal of property and equipment	994,125	639,680	994,125	639,680	2,985,275
Mortgage On Property Remaining Principal Amount Discharged Upon Sale	480,951	659,288
Proceeds From Sale Of Property Remaining Amount	1,028,780	1,009,827
Income from assets held for investment, net (Note 11)			$ 1,042,868	$ 712,075	$ 5,377,125